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Abstract 
 
The glucagon receptor (GCGR), a family B G protein-coupled receptor 
(GPCR), plays an important role in regulating blood glucose levels through its 
ability to bind the 29 amino acid peptide hormone, glucagon (GCG). 
Antagonising GCG action is a potential therapeutic option for reducing hepatic 
glucose production. However, GCG-based therapy is currently limited to 
acute emergency treatment of hypoglycemia in patients with type 1 diabetes 
(T1D) (Habegger et al., 2010). Further insight into GCGR-mediated signalling 
pathways and mechanism of activation may provide the basis for therapeutic 
development.  
We investigated the ligand stimulated GCGR signalling using multiple 
assays including those measuring cAMP accumulation, ERK1/2 
phosphorylation and intracellular Ca2+ (Ca2+i) mobilisation. Through site 
directed mutagenesis and FACS analysis for the investigation of cell-surface 
expression, we identified several important residues. They included K16812.49, 
L16912.50, H17012.51 and T1722.45 of the ICL1 region (G1651.63-T1722.45) as 
potential determinant in signalling bias at the GCGR through Gq/11-coupling, 
C1712.44 as a critical determinant of GCGR expression and R1732.46 as an 
essential residue for G protein-coupling. Helix 8 residue E4068.49 was 
implicated in maintaining GCGR in an inactive state. Finally, TM4 residues 
G2714.49, L2774.55 and V2804.58 were found to plays an important role in 
successful translation and/or trafficking of GCGR and (Ca2+i) mobilisation. 
The GCGR-mediated pERK1/2 response way found to be both Gq/11 
and β-arrestin1/2 mediated, whereas it was independent of PKA or Gβγ-
subunits. The GCG analogue TH-GCG, contrary to previous reports 
(Wakelam et al., 1986, Lenzen et al., 1990), was characterised as a partial 
agonist at the GCGR, inducing a robust cAMP response but fails to induce a 
detectable Ca2+i or IP1 response. We also identified a RAMP2-dependent 
potentiation of the GCG stimulated cAMP response at the GCGR.  
The research described in this thesis has produced novel data that 
contributes to a clearer understanding of GCGR pharmacology. 
 
 
 
 
 
 
 
	 XI 
Abbreviations 
 
A2AR  adenosine A2A receptor  
AC adenylate cyclase 
ADP adenosine diphosphate 
AKAP A-kinase-anchoring proteins  
AM adrenomedullin 
AMP ampicillin  
AMY amylin 
AP-1 activator protein 1  
APC allophycocyanin  
ATP adenosine triphosphate  
BAPTA 
1,2-Bis(2-aminophenoxy)ethane-N,N,N',N'-
tetraacetic acid tetrakis(acetoxymethyl ester) 
bp base pair 
BRET bioluminescence resonance energy transfer 
BSA  bovine serum albumin 
C-terminus carboxyl terminus 
cAMP cyclic adenosine 3’,5’-monophosphate  
cDNA  complementary DNA 
CFP  cyan  fluorescent protein  
CGRP calcitonin gene related peptide  
CGS 
21689 
2-[p -(2-carboxyethyl)phenylethylamino]-50-
ethylcarboxamidoadenosine  
CHO chinese hamster ovary  
CLR calcitonin receptor-like receptor  
CRF corticotropin-releasing factor  
CRF corticotropin-releasing factor  
CRF1R corticotropin-releasing factor receptor 1 
CRISPR clustered regularly interspaced, short palindromic repeat 
CT calcitonin 
DAG diacylglycerol 
DMEM  Dulbecco’s modified Eagle’s medium 
DMSO dimethyl sulphoxide 
DNA  deoxyribose nucleic acid 
E. coli  Escherichia coli 
ECD extracellular N-terminal domain 
ECL  extra-cellular loop 
EDTA ethylenediaminetetraacetic acid  
ELISA  enzyme-linked immunosorbent assay 
Emax  maximum level of signal 
ER endoplasmic reticulum  
ERK1/2 extracellular signal-regulated kinase 1/2 
	 XII 
FACS fluorescence activated cell sorting 
FBS  fetal bovine serum 
FFA4 free fatty acid 4 receptor  
FRET  fluorescence resonance energy transfer 
G protein guanine nucleotide-binding proteins  
GABA glutamate, y-aminobutyric acid  
GAP GTPase-activating protein 
GbR metabotripic γ-aminobutyric acid type b receptor  
GCG glucagon 
GCGR glucagon receptor 
GDP guanosine 5’-diphosphate  
GEF guanine nucleotide exchange factor 
GFP  green fluorescence protein 
GIP  gastric inhibitory polypeptide  
GIPR gastric inhibitory polypeptide  receptor 
GLP-1  glucagon-like peptide 1 
GLP-1R  glucagon-like peptide 1 receptor  
GNAS Gαs-subunit encoding guanine nucleotide binding α-stimulating 
GPCR  G protein-coupled receptor 
GRAFS Glutamate, Rhodopsin, Adhesion, Frizzled/Taste and Secretin 
GRK2 GPCR kinase 2  
GTP guanosine 5’-triphosphate  
HBSS  Hank’s balanced salt solution 
HEK  human embryonic kidney 
HTRF homogeneous time resolved fluorescence 
IBMX  3-Isobutyl-1-methylxanthine 
ICL intracellular loop 
IP1 inositol monophosphate  
IP3  inositol 1,4,5 trisphosphate 
IP3  inositol 1,4,5 trisphosphate 
JNK Jun N-terminal kinases 
KAN  kanamycin  
LANCE Lanthanide Chelate Excite 
MAP  mitogen activated protein 
MAPK  mitogen activated protein kinase 
MAPKK mitogen activated protein kinase kinase 
MAPKKK  mitogen activated protein kinase kinase kinase 
MCS  multi-cloning site 
MEK  
mitogen activated protein (MAP) extracellular signal-regulated kinases 
ERK kinase 
MEME  minimal essential medium Eagle 
mGluR metabotropic glutamate receptor 
NAD nicotinamide adenine dinucleotide 
	 XIII 
N-terminus amino terminus 
NAM negative allosteric modulator  
NECA 5’-N-Ethylcarboxamidoadenosine 
NESP55  chromagranin-like neuroendocrine secretory protein  
OPD  O-phenylenediamine dihydrochloride 
OTR oxytocin receptor  
PAM  positive allosteric modulator 
PAR2 proteinase activated receptor 2  
PBS phosphate buffered saline 
PCR  polymerase chain reaction  
pEC50  
negative logarithm of concentration of agonist required to produce a 
half-maximal response 
PH pleckstrin-homology  
PIP2 phosphatidylinositol 4,5-bisphosphate  
PKA  protein kinase A 
PKC  protein kinase C 
PLC phospholipse C 
PLL  Poly-L-lysine 
PMA  Phorbol 12-myristate 13-acetate 
PTH parathyroid hormone 
PTHR parathyroid hormone type 1 receptor  
PTX pertussis toxin 
RAMP  receptor activity-modifying protein 
RGS regulators of G protein signalling  
RhoGEF rhoGTPase nucleotide exchange factor 
RNA ribonucleic acid 
RTK receptor tyrosine kinase  
SEM standard error of the mean 
StaR thermostabilised receptor  
T4L T4-lysozyme 
TM transmembrane 
TSHR thyrotropin receptor  
V2R V2 vasopressin receptor  
VPAC vasoactive intestinal polypeptide receptor 
WT wild-type 
β2AR β2 adrenergic receptor  
	 XIV 
List of Figures 
Figure Page 
1.1 Heterotrimeric G protein activation cycle.   9 
1.2 cAMP pathway and crosstalk with MAPK/ERK pathway 17 
1.3 G protein and β-arrestin mediated ERK activation.  22 
1.4 Full-length GCGR crystal structure 29 
1.5 Schematic representation of proglucagon processing in the pancreatic 
α-cells and intestinal L-cells 
32 
2.1 G418 kill curve for HEK 293 cells 45 
2.2 pVITRO1-neo-mcs vector map 50 
2.3 Principles of the LANCE® cAMP assay kit 60 
2.4 Principles of the LANCE® Ultra cAMP assay kit 61 
2.5 Schematic of Gq–mediated signaling following GPCR activation and 
tools to measure the downstream signaling components.  
65 
3.1 Typical LANCE cAMP standard curve 76 
3.2 Forskolin stimulated cAMP response in Flp-In HEK 293T cells plated at 
various densities 
76 
3.3 cAMP response in Flp-In HEK 293T cells stably expressing the GLP-1R 
or GCGR, with or without the true basal stimulation point 
79 
3.4 cAMP response in Flp-In CHO-K1 cells stably expressing the GLP-1R 
at various time points 
82 
3.5 cAMP dose-response in Flp-In CHO-K1 cells stably expressing the 
GLP-1R at various time points 
83 
3.6 8 minutes stimulation time at 1,000 and 2,000 cells/well is optimal in 
Flp-In HEK 293T cells stably expressing the GLP-1R 
83 
3.7 cAMP response in HEK 293T cells transfected with pcDNA3.1 
containing GCGR 
85 
3.8 cAMP response in HEK 293T cells 24 or 48 hours post-transfection 
with pcDNA3.1 containing GCGR.  
87 
3.9 Influence of DNA concentration at transfection on measured cAMP 
response in HEK 293 cells 
89 
3.10 Influence of transfection reagent on cell viability in HEK 293 91 
3.11 Comparison of transfection reagents on measured cAMP response 92 
3.12 Schematic of NF449 activity at GS and predicted dose-response data 94 
3.13 Assessing NF449 as an inhibitor of GS activity 95 
3.14 YM-254890 treatment has no effect on measured cAMP response in 
HEK 293T cells 
98 
3.15 Effect of YM-254890 treatment on Ca2+i respons in HEK 293T cells 100 
3.16 Cell number and stimulation time optimisation for IP1 accumulation 
assay 
103 
3.17 Cell-surface expression of mCherry-tagged GCGR in G418 selected 
HEK 293 cells 
106 
3.18 Comparison of cAMP response in transient and stable GCGR 
expressing HEK 293 cells 
106 
	 XV 
3.19 Expression profile of receptors in Hep 3B cells 109 
3.20 Expression profile of G proteins in Hep 3B cells 110 
3.21 cAMP response to forskolin in Hep 3B at various cell densities 112 
3.22 cAMP response to GCG in Hep 3B at 10, 000 and 20, 000 cells/well 112 
3.23 cAMP response to GCG in Hep 3B at 5, 000 cells/well as measured 
using the LANCE® Ultra cAMP assay kit 
113 
3.24 Comparison of cAMP response to GCG in Hep 3B and GCGR 
transfected HEK 293 cells 
113 
3.25 Cell number directly correlates with luminescent output for CellTiter-
Glo® Luminescent Cell Viability Assay.  
117 
3.26 Measurement of cell viability in HEK 293 knockout cell lines 117 
3.27 Comparison of cell growth profiles of WT and knockout HEK 293 cell 
lines 
118 
3.28 Maximal forskolin responses in HEK 293 knockout cell lines 119 
3.29 cAMP response in ΔGs HEK 293 cells changes over passage 121 
3.30 Comparison of PMA responses in HEK 293 knockout cell lines 123 
3.31 FACS data analysis: example manual gating of untransfected HEK 293 
cells 
127 
3.32 FACS data analysis: example gating of single untransfected HEK 293 
cells 
127 
3.33 Example histograms generated from flow cytometry of untransfected 
and vector only/GCGR transfected HEK 293 cells 
128 
3.34 Example histograms generated from flow cytometry of WT or mutant 
GCGR transfected HEK 293 cells 
129 
3.35 DNA concentration at transfection and detectable cell-surface 
expression of WT and mutant GCGR, as determined by FACS analysis 
131 
4.1 cAMP response in GCGR transfected HEK 293 cells 135 
4.2 cAMP responses in GCGR transfected HEK 293T and HEK 293 cells 138 
4.3 cAMP response in HEK 293 cells transfected with pcDNA3.1 or 
pVITRO1 expressing GCGR 
142 
4.4 Ca2+i mobilization in HEK 293T cells expressing GCGR +/- YM-254890 
treatment.  
148 
4.5 Ca2+i mobilization dose-response in HEK 293T cells expressing GCGR 
+/- YM-254890 treatment 
149 
4.6 Ca2+i mobilization in GCGR stably expressing CHO-K1 cells +/- YM-
254890 treatment 
150 
4.7 Ca2+i mobilization dose-response in GCGR stably expressing CHO-K1 
cells +/- YM-254890 treatment 
151 
4.8 GCG stimulated pERK1/2 response in three alternative cell lines 155 
4.9 GCG and Oxyntomodulin stimulated pERK1/2 response in GCGR 
transfected HEK 293T cells and CHO-K1 cells stably expressing GCGR 
158 
4.10 GCG and Oxyntomodulin stimulated pERK1/2 response in HEK 239 
cells stably expressing GCGR 
161 
4.11 G protein mediated activation of extracellular signal-regulated kinase 1 163 
	 XVI 
and 2 (ERK1/2) though both α and βγ subunits 
4.12 pERK1/2 response in CHO-K1 cells stably expressing GCGR 164 
4.13 pERK1/2 response in CHO-K1 cells stably expressing GCGR +/- PKA 
inhibitor 
165 
4.14 pERK1/2 response in CHO-K1 cells stably expressing GCGR +/- Gβγ 
inhibitor 
168 
4.15 pERK1/2 response in CHO-K1 cells stably expressing GCGR +/- Gq/11 
inhibitor 
171 
4.16 GCG stimulated pERK1/2 response in WT and various knockout HEK 
239 cells lines 
174 
4.17 GCG dose-response is within the dynamic range of the cAMP assay in 
HEK 293T cells 
170 
4.18 Activity of des-His1,Glu9-GCG in GCGR transfected HEK 293T cells 180 
4.19 cAMP response to des-His1,Glu9-GCG in GCGR/vector only transfected 
HEK 293T cells 
181 
4.20 Activity of L-168,049 in GCGR transfected HEK 293T cells 185 
4.21 cAMP response to L-168,049 in GCGR/vector only transfected HEK 
293T cells 
186 
4.22 TH-GCG induces a concentration-dependent increase in cAMP 
accumulation in HEK 293T cells expressing GCGR 
190 
4.23 TH-GCG stimulated cAMP response is GCGR-dependent in HEK 293T 
cells 
191 
4.24 TH-GCG fails to induce a Ca2+i response in HEK 293T cells expressing 
GCGR 
193 
4.25 TH-GCG fails to induce a measurable IP1 response in HEK 293T cells 
or CHO-K1 cells expressing GCGR 
196 
4.26 TH-GCG fails to induce a concentration-dependent increase in cAMP 
accumulation in Hep 3B cells 
198 
4.27 Forskolin induces a concentration-dependent increase in cAMP 
accumulation in C57BL/6 hepatocytes 
200 
4.28 TH-GCG and GCG induce a concentration-dependent increase cAMP 
accumulation in C57BL/6 hepatocytes 
201 
4.29 Investigating the TH-GCG stimulated pERK1/2 response in GCGR 
transfected HEK 293T cells and CHO-K1 cells stably expressing GCGR 
204 
4.30 RAMP2 does not influence the cell-surface expression of myc-tagged 
GCGR in transfected  
209 
4.31 GCGR does not influence the cell-surface expression of FLAG-tagged 
RAMP2 in transfected HEK 293T cells 
210 
4.32 RAMP2 potentiates the GCG response at the GCGR in transfected 
HEK 293T cells 
212 
4.33 RAMP2 fails to potentiate the cAMP response in HEK 293T cells 
transfected with the pVITRO vector expressing GCGR and RAMP2 
216 
4.34 FLAG-RAMP2 cell-surface expression was elevated in HEK 293T cells 
transfected with pVITRO1 expressing RAMP2 only when compared to 
218 
	 XVII 
pVITRO1 expressing RAMP2 and GCGR 
4.35 cAMP signaling profile in Hep 3B cells 221 
4.36 The measured potency for GCG and oxyntomodulin varies across 
experimental repeats in Hep 3B cells 
223 
4.37 cAMP signaling profile in Hep 3B cells 225 
4.38 The measured potency for AM varies across experimental repeats in 
Hep 3B cells 
226 
4.39 GCG, oxyntomodulin and GLP-1(7-36)amide stimulates a pERK1/2 
response in ‘young’ Hep 3B cells 
229 
4.40 Activity of des-His1,Glu9-glucagon amide in Hep 3B 232 
4.41 Activity of L-168,049 in Hep 3B 235 
5.1 GCGR family structure-based alignment 242 
5.2 Cell-surface expression of WT and GCGR ICL1 mutants 244 
5.3 Effect of GCGR ICL1 mutants on cAMP response 246 
5.4 Effect of GCGR ICL1 mutants on pERK1/2 response 249 
5.5 Effect of GCGR ICL1 mutants on Ca2+i response 253 
5.6 Radar plot of antilog ΔΔ(Tau/KA).  255 
5.7 ICL1 region within crystal structure of full-length GCGR 258 
5.8 GCGR and A2AR structure-based alignment 261 
5.9 NECA induces a cAMP response in mock transfected HEK 293 cells 261 
5.10 NECA failed to stimulate Ca2+i mobilisation in CHO-K1 cells expressing 
A2AR 
263 
5.11 Effect of A2AR ICL1 mutants on NECA stimulated cAMP response 264 
5.12 Effect of A2AR ICL1 mutants on CGS21680 stimulated cAMP response 267 
5.13 ICL1 region within crystal structure of A2AR bound to ZM241385 273 
5.14 Comparison of polar contacts within ZM241385 bound WT and alanine 
containing A2AR crystal structure 
274 
5.15 [K/R]KLH motif and helix 8 conserved glutamate residues in crystal 
structure of full-length GCGR 
280 
5.16 Modelled S167R mutant within full-length GCGR crystal structure 281 
5.17 WT and S167R GCGR show similar cell-surface expression in HEK 
293 cells as determined by FACS analysis 
282 
5.18 cAMP response in WT and S167R GCGR mutants 282 
5.19 Cell-surface expression of WT, R173A and R173A, N174A GCGR are 
similar in transfected HEK 293 cells, as determined by FACS analysis 
285 
5.20 GCG and oxyntomodulin induced cAMP response is attenuated in 
R173A transfected HEK 293 
287 
5.21 Comparison of polar contacts within WT and modelled R173A 
containing crystal structure of full-length GCGR at position 173 
290 
5.22 GCGR family structure-based alignment of helix 8 295 
5.23 Cell-surface expression of WT and Helix 8 GCGR mutants, as 
determined by FACS analysis 
295 
5.24 cAMP response in WT and helix 8 GCGR mutant 297 
5.25 E406A, E410A GCGR mutant showed a ligand-independent elevated 298 
	 XVIII 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
basal cAMP level 
5.26 Comparison of polar contacts at position 406 within WT and modelled 
E406A mutant full-length crystal structure 
302 
5.27 GCGR family structure-based alignment of TM4 region 306 
5.28 Cell-surface expression of WT and GCGR TM4 mutants 307 
5.29 Effect of TM4 mutations on the GCGR stimulated cAMP response in 
HEK 293T cells.  
309 
5.3 Effect of TM4 mutations on the GCGR stimulated cAMP response is 
reproducible the in HEK 293 cells 
312 
5.31 Effect of GCGR TM4 mutants on pERK1/2 response 315 
5.32 Effect of GCGR TM4 mutants on Ca2+i mobilization in transfected HEK 
293T cells 
318 
6.1 GCGR-mediated ERK activation 328 
	 XIX 
List of Tables 
Table Page 
1.1 α-subunits of heterotrimeric G proteins 10 
2.1 Transfection components according to size of tissue culture plate for 
Fugene® HD and PEI 
48 
2.2 Oligonucleotides used to create GCGR mutants in ICL1, TM2, TM4 and 
helix 8 
52 
2.3 Reaction components for QuikChange (site or multi site-directed) 
mutagenesis kit 
53 
2.4 Cycle parameters for QuikChange (site or multi site-directed) 
mutagenesis kit 
53 
2.5 Oligonucleotides used to create A2AR mutants in ICL1 region, TM1, 
ICL1 and TM2  
54 
2.6 Oligonucleotides used in RT-PCR of cDNA synthesized from RNA 
extracted from HEK 293T and Hep 3B cells  
57 
2.7 Gene specific oligonucleotides to human Gα-subunits used in RT-PCR 
of cDNA synthesized from RNA extracted from Hep 3B cells 
58 
2.8 Cycling parameters for Taq DNA polymerase for 200 bp product 59 
2.9 Components Ca2+ containing and Ca2+-free of HBS 69 
3.1 Forskolin stimulated cAMP response in Flp-In HEK 293T cells plated at 
various densities 
77 
3.2 cAMP response in Flp-In HEK 293T cells stably expressing the GLP-1R 
or GCGR, with or without the true basal stimulation point 
80 
3.2 Optimising ligand stimulation time for cAMP accumulation assay 84 
3.3 cAMP response in HEK 293T cells 24 or 48 hours post-transfection 
with pcDNA3.1 containing GCGR.  
88 
3.4 Influence of DNA concentration at transfection on measured cAMP 
response in HEK 293 cells 
89 
3.5 Comparison of transfection reagents on measured cAMP response 92 
3.6 Assessing NF449 as an inhibitor of GS activity 96 
3.7 YM-254890 treatment has no effect on measured cAMP response in 
HEK 293T cells 
99 
3.8 Effect of YM-254890 treatment on Ca2+i respons in HEK 293T cells 101 
3.9 Cell number and stimulation time optimisation for IP1 accumulation 
assay 
104 
3.10 Comparison of cAMP response in transient and stable GCGR 
expressing HEK 293 cells 
107 
3.11 Optimisation of the cAMP assay in Hep 3B cells 114 
3.12 Comparison of cAMP response to GCG in Hep 3B and GCGR 
transfected HEK 293 cells 
115 
3.13 cAMP response in ΔGs HEK 293 cells changes over passage 121 
4.1 cAMP response in GCGR transfected HEK 293 cells 136 
4.2 cAMP responses in GCGR transfected HEK 293T and HEK 293 cells 139 
4.3 Size, promoter and enhancers present in three mammalian expression 140 
	 XX 
vectors.  
4.4 cAMP response in HEK 293 cells transfected with pmCherry-N1, 
pcDNA3.1 or pVITRO1 expressing GCGR 
143 
4.5 Ca2+i mobilization dose-response in GCGR expressing cell lines +/- 
YM-254890 treatment  
152 
4.6 GCG stimulated pERK1/2 response in three alternative cell lines.  156 
4.7 GCG and Oxyntomodulin stimulated pERK1/2 response in GCGR 
transfected HEK 293T cells and CHO-K1 cells stably expressing GCGR 
159 
4.8 GCG and Oxyntomodulin stimulated pERK1/2 response in HEK 239 
cells stably expressing GCGR 
162 
4.9 pERK1/2 response in CHO-K1 cells stably expressing GCGR +/- PKA 
inhibitor 
166 
4.10 pERK1/2 response in CHO-K1 cells stably expressing GCGR +/- Gβγ 
inhibitor 
169 
4.11 pERK1/2 response in CHO-K1 cells stably expressing GCGR +/- Gq/11 
inhibitor 
172 
4.12 GCG stimulated pERK1/2 response in WT and various knockout HEK 
239 cells lines 
175 
4.13 Activity of des-His1,Glu9-GCG in GCGR/Vector only transfected HEK 
293T cells 
182 
4.14 Activity of L-168,049 in GCGR/vector only transfected HEK 293T cells 187 
4.15 TH-GCG induces a concentration-dependent increase in cAMP 
accumulation in HEK 293T cells expressing GCGR 
191 
4.16 TH-GCG fails to induce a Ca2+i response in HEK 293T cells expressing 
GCGR 
194 
4.17 TH-GCG fails to induce a concentration-dependent increase in cAMP 
accumulation in Hep 3B cells 
198 
4.18 Forskolin induces a concentration-dependent increase in cAMP 
accumulation in C57BL/6 hepatocytes 
201 
4.19 TH-GCG and GCG induce a concentration-dependent increase cAMP 
accumulation in C57BL/6 hepatocytes 
202 
4.20 Investigating the TH-GCG stimulated pERK1/2 response in GCGR 
transfected HEK 293T cells and CHO-K1 cells stably expressing GCGR 
203 
4.21 RAMP2 potentiates the GCG response at the GCGR in transfected 
HEK 293T cells 
213 
4.22 RAMP2 fails to potentiate the cAMP response in HEK 293T cells 
transfected with the pVITRO vector expressing GCGR and RAMP2 
217 
4.23 cAMP signaling profile in Hep 3B cells 222 
4.24 cAMP signaling profile in Hep 3B cells 225 
4.25 Rank order of potency at the CLR with RAMP1-3.  226 
4.26 Rank order of potency at the CALCR receptor with and without 
RAMP1-3 
226 
4.27 GCG, oxyntomodulin and GLP-1(7-36)amide stimulates a pERK1/2 
response in ‘young’ Hep 3B cells 
230 
	 XXI 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
4.28 Activity of des-His1,Glu9-glucagon amide in Hep 3B.  233 
4.29 Activity of L-168,049 in Hep 3B 236 
5.1 Colour code key for structural-alignment 243 
5.2 Effect of GCGR ICL1 mutants on cAMP response 247 
5.3 Effect of GCGR ICL1 mutants on pERK1/2 response 250 
5.4 Effect of GCGR ICL1 mutants on Ca2+i response  254 
5.5 Comparison of GCGR residue polar contacts within WT and modelled 
ICL1 mutant structures 
257 
5.6 Effect of A2AR ICL1 mutants on NECA stimulated cAMP response 265 
5.7 Effect of A2AR ICL1 mutants on CGS21680 stimulated cAMP response 268 
5.8 Comparison of A2AR residue polar contacts within WT and modelled 
A2AR mutant crystal structures 
271 
5.9 cAMP response in WT and S167R GCGR mutants 283 
5.10 GCG and oxyntomodulin induced cAMP response is attenuated in 
R173A transfected HEK 293 
288 
5.11 Comparison of polar contacts at position 173 within WT GCGR and 
modelled R173A/ R173A, R174A mutant structures 
291 
5.12 cAMP response in WT and helix 8 GCGR mutant 299 
5.13 Comparison of polar contacts at position 406 and 410 within WT GCGR 
and modelled E406A/E410A/E406A, E410A GCGR mutant structures 
301 
5.14 Effect of TM4 mutations on the GCGR stimulated cAMP response in 
HEK 293T cells 
310 
5.15 Effect of TM4 mutations on the GCGR stimulated cAMP response is 
reproducible the in HEK 293 cells 
313 
5.16 Effect of GCGR TM4 mutants on pERK1/2 response 316 
5.17 Effect of GCGR TM4 mutants on Ca2+i mobilization in transfected HEK 
293T cells 
319 
5.18 Comparison of GCGR residue polar contacts within WT and modelled 
TM4 mutant structures 
321 
	 1 
Chapter 1.  Introduction 
1.1.  Membrane proteins  
 
The cell is the basic structural and functional unit of life. Surrounded by a lipid 
bilayer known as a membrane, a cell contains the organelles responsible for 
performing the individual tasks of that particular cell-type (Alberts et al., 2002, 
Lodish et al., 2000).  The membrane serves as a barrier, separating the cell’s 
internal and external environment and selectively allows the influx and efflux 
of material (Alberts et al., 2002, Lodish et al., 2000). Associated with each 
membrane is a compliment of membrane proteins, which can be classified 
into two categories; intrinsic proteins which have one or more segment 
embedded in the lipid bilayer or extrinsic proteins which either interact directly 
with the polar head groups of the lipid bilayer or indirectly with integral 
membrane proteins (Alberts et al., 2002, Lodish et al., 2000). The binding of a 
chemical signal molecule to either cell-surface or intracellular receptors 
generates a cascade of intracellular signals that control diverse biological 
functions within a cell.  
 
1.1.1. The receptor concept  
 
The receptor concept was the result of multiple complementary lines of 
evidence (reviewed in Triggle, 2000 and Rang, 2006) and provides the basic 
framework for the scientific discipline of pharmacology (Rang, 2006). In 
cellular signalling, chemical recognition is the function of receptors. Here, the 
receptor translates the information of the ligand interaction into a cellular 
response (Triggle, 2000). The linear sequence of amino acids and ultimately 
the three-dimensional representation of the sequence (receptor structure) 
provide the basis for receptor classification (Triggle 2000). Four principal 
families of chemically sensitive receptors have been described; ion channels, 
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enzyme associated, nuclear and G protein-coupled receptors (GPCRs) 
(Triggle 2000).  
1.2.  G protein-coupled receptors (GPCRs) 
 
G protein-coupled receptors (GPCRs) constitute the largest and most diverse 
family of membrane receptors in eukaryotes with approximately 1000 
members (Lefkowitz et al., 2007). These seven-transmembrane (7TM) 
receptors, as their name implies, couple to heterotrimeric guanine nucleotide-
binding proteins (G proteins) comprising of a single α-, β-, and γ-subunits, 
allowing the transduction of signals from extracellular molecules as diverse as 
hormones, neuropeptides, odours, photons and glycoproteins (Rosenbaum et 
al., 2009). 
GPCRs play an important role in a plethora of diverse physiological 
and pathological processes (Lefkowitz et al., 2007). Unsurprisingly, therefore, 
they are one of the major targets of pharmaceutical drugs, with around 30 to 
50% of currently available pharmaceutical drugs targeting only ~20% of the 
known GPCRs (Salon et al., 2011). This discrepancy between total GPCRs 
members and currently targeted GPCRs does not infer that the majority of 
this receptor family is ‘undruggable’, but likely reflects the lengthy 
pharmaceutical pipeline and lack of complete GPCR knowledge (Salon et al., 
2011).  
1.3.  GPCRs classification  
 
All GPCRs are integral membrane proteins, which share the same topology of 
a 7TM domain, an extracellular N-terminal domain (ECD) and a cytoplasmic 
C-terminus (Furness et al., 2012). Despite this apparent structural similarity, 
GPCRs are in fact extremely diverse which makes the development of GPCR 
classification systems difficult (Davies et al., 2007). The majority of GPCRs 
can be classified into three of the six families (A, B or C) of the A-F 
classification system (Kolakowski, 1994). According to the alternative GRAFS 
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(Glutamate, Rhodopsin, Adhesion, Frizzled/Taste and Secretin) classification 
system, based on phylogenetic studies, the majority of human GPCRs fall into 
five main families; Rhodopsin (Class A), Secretin (Class B), Glutamate (Class 
C), Adhesion and Frizzled/Taste (Fredriksson et al., 2003, Schioth and 
Fredriksson, 2005).  
Regardless of the classification system, most consist of three primary 
families based on sequence analysis and functional similarity (Rosenbaum et 
al., 2009). The largest sub-family, class A rhodopsin-like, comprises receptors 
for a vast array of ligands including ions, lipids, steroids, glycoproteins, 
nucleotides, biogenic amines (muscarinic and dopaminergic ect) and small 
peptides (Müller et al., 2012, Hiller et al., 2013). The class B, secretin-like 
GPCRs, form a group of 15 receptors including receptors for several peptide 
hormones such as corticotropin-releasing factor (CRF) glucagon-like peptide 
1 (GLP-1), glucagon (GCG) and calcitonin gene related peptide (CGRP)  
(Hollenstein et al., 2014, Müller et al., 2012). The class C metabotropic 
glutamate receptor (mGluR) comprise the receptors that bind glutamate, y-
aminobutyric acid (GABA), Ca2+, amino acids and taste compounds 
(Nisweder and Jeffrey, 2010). 
 
1.3.1.  Class A (Rhodopsin-like) receptors 
 
The class A rhodopsin-like receptors account for over 80% of all known 
GPCRs (Hiller et al., 2013). The first insight into the structure of GPCRs was 
from the two-dimensional crystals of bovine rhodopsin (Schertler et al., 1993). 
This GPCR can be found in the rod photoreceptor cells of the retina and 
converts photons into chemical signals allowing vertebrates to sense light 
(Zhou et al., 2012). More recently, multiple research groups have obtained 
three-dimensional crystal structures of rhodopsin leading to significant 
progress in our understanding of the entire GPCRs superfamily (Palczewski 
et al., 2000).  
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The most variable structure among the family of GPCRs is the N-
terimus, with class A GPCRs having a relatively short sequence (10-50 amino 
acids) when compared to class B and C (∼100-600) (Kobilka, 2007). A 
conserved feature among all class A GPCRs include the stretch of amino acid 
residues glutamic acid/aspartic acid-arginine-tyrosine (E3.49/D3.49 R3.50 Y3.51 
(E/DRY) motif) of TM3 and a negatively charged aspartic acid/glutamic acid 
(D/E6.30) in TM6, involved in stabilising the inactive state conformation (Vogel 
et al., 2008) (See 1.17.1). Another highly conserved motif is Asn-Pro-X-X-Tyr  
(NPXXY) (where X represents any amino acid) located in the cytoplasmic end 
of TM7 (Barak et al., 1995) and conformational changes within this motif are 
associated with GPCR activation (Rosenbaum et al., 2009). 
 
1.3.1.1.  A2A receptor; an archetype class A GPCR 
 
In the work presented in this thesis, the adenosine A2A receptor (A2AR) was 
chosen as an archetype class A Gs-coupled GPCR to investigate the 
importance of intracellular loop one (ICL1). This was due to the availability of 
multiple A2AR crystal structures (Liu et al., 2012, Lebon et al., 2011, Lebon et 
al., 2015 and Carpenter et al., 2016, to name a few) and past laboratory 
experience investigating this receptor.  
This receptor binds the purine nucleoside, adenosine, and is one of the 
four receptor subtypes which also include, A1, A2B and A3, (A1R, A2BR and 
A3R) (Sheth et al., 2014). These receptors either inhibit cyclic adenosine 3’,5’-
monophosphate (cAMP) accumulation in the case of A1R and A3R through 
coupling to Gi/o or stimulate cAMP accumulation in the case of A2AR and A2BR 
via coupling to Gs (Sheth et al., 2014). The A2AR is an attractive therapeutic 
target due to its importance in mediating vasodilation, protecting tissues from 
inflammatory damage and supporting the synthesis of new blood vessels (de 
Lera Ruiz et al., 2013).  
Similarly to other GPCRs, the signalling pathway following A2AR 
stimulation depends on the cell and tissue type, the signalling machinery that 
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particular cell possesses and the G protein to which it couples. In addition to 
elevated cAMP levels following A2AR stimulation, there is also evidence to 
suggest activation of kinases including extracellular signal-regulated kinase 
1/2 (ERK1/2) (Schulte and Fredholm, 2000, Orr et al., 2015).  On the other 
hand, A2AR has been demonstrated not to induce an intracellular Ca2+ 
response following agonism (Orr et al., 2015).  
 
1.3.2.  Class B (Secretin-like) receptors  
 
There are fifteen known receptors that form class B, the second largest family 
of GPCRs (Hollenstein et al., 2014). In comparison to the diverse ligands 
bound by class A GPCRs, class B GPCRs predominantly bind peptide 
hormones of around 30-40 amino acids including the glucagon subfamily 
(GCG, GLP-1, GLP-2, glucose dependent inulinotopic polypeptide (GIP)), 
secretin, calcitonin (CT), CGRP, amylin (AMY) and adrenomedullin (AM), to 
name a few (Pal et al., 2012). The relatively large ECD (∼100-160) containing 
three disulphide bonds is characteristic of class B GPCRs and, in combination 
with the 7TM domain, is known to be important for peptide binding (Hoare, 
2005).  
These receptors are important therapeutic targets for brain and 
metabolic diseases such as migraine, cardiovascular disease, cancer, 
obesity, diabetes, stress and anxiety, to name a few (Sexton and Wootten, 
2013).  
1.3.2.1.  Receptor activity-modifying proteins (RAMPs)  
 
Several class B GPCRs are known to form heterodimers with receptor 
activity-modifying proteins (RAMPs) (Conner et al., 2004) and have been 
reported to modulate both cell-surface expression and pharmacology 
(Magalhaes et al., 2012). 
Mammalian cells express three RAMPs (RAMP1-3) (McLatchie et al., 
1998) which share approximately 31% identity in primary amino acid 
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sequence (Qi and Hay, 2010). Despite the low sequence identity, all three 
RAMPs have a common structure: an N-terminal signal peptide between 22 
and 42 amino acids, a highly conserved single-TM domain spanning ~22 
amino acids, a long extracellular N-terminal (~90 amino acids for RAMP1 and 
RAMP3, ~102 amino acids for RAMP2) a short intracellular C-terminal tail (~ 
9 amino acids) and four conserved cysteine residues presumed to form 
disulphide bonds  (Sexton et al., 2006, Qi and Hay, 2010).  
One of the best characterised interactions between RAMPs and a 
GPCR is that observed for the class B calcitonin receptor-like receptor (CLR) 
(Conner et al., 2004). A stable heteromeric complex is formed between CLR 
and RAMPs in the ER, which is maintained through their life cycle (Sexton et 
al., 2006). The expression of CLR alone in mammalian cells renders the 
receptor unable to interact with its endogenous ligands where it remains in 
the endoplasmic reticulum (ER) (Wootten et al., 2013). The co-expression of 
CLR with RAMPs in HEK 293T cells allows the functional cell-surface 
expression of the receptor (McLatchie et al., 1998). Similarly RAMPs, 
particularly RAMP1, are retained within the ER when not associated with a 
receptor partner (McLatchie et al., 1998).  
RAMPs have not only been shown to escort CLR to the cell surface 
(Flahaut et al., 2002, Sexton et al., 2006), but also to modify the biochemical 
properties of the receptor (Watkins et al., 2014, Weston et al., 2015 (Section 
4.7)). For example, RAMPs have been shown to alter the ligand selectivity of 
CLR (McLatchie et al., 1998). While independent heterodimerisation of CLR 
with RAMP1 forms a CGRP receptor, heterodimerisation with RAMP2 or 
RAMP3 forms an adrenomedullin (AM) receptor (McLatchie et al., 1998). 
Aside from class B GPCRs, RAMPs have also been reported to 
interact with the class C calcium-sensing receptor (CaSR) where RAMP 1 
and RAMP3 enable its cell-surface expression (Desai et al., 2014, Bouschet 
et al., 2005). The ubiquitous and abundant expression of RAMPs in the 
majority of mammalian tissue suggests that they may play an important role in 
defining the functional properties of GPCRs (Christopoulos, 2003). Enhancing 
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our current knowledge of GPCRs and their interactions with RAMPs is of 
huge importance, both academically and for potential drug development.  
1.5.  G proteins  
 
GPCRs, as their name implies, couple to G proteins comprising of α-, β-, and 
γ-subunits. The α-subunit is a 37-42 kDa protein containing the guanine 
nucleotide-binding pocket and has intrinsic GTPase activity (Goldsmith and 
Dhanasekaran, 2007). 17 α-subunits have been identified to date, with those 
showing more than 50% identity in the amino acid sequence grouped into one 
of four distinct classes; Gs, Gi, Gq and G12 (Simon et al., 1991) (Table 1.1). 
The βγ-subunit is formed through the tight association of the individual 35 kDa 
β-subunit and the 8-11 kDa γ-subunit, of which 5 and 12 have been identified 
respectively (Goldsmith and Dhanasekaran, 2007). Although any 
combinations of α-, β- and γ-subunits is possible, not all are observed 
(Goldsmith and Dhanasekaran, 2007).  Efficient plasma membrane targeting 
of the G protein requires assembly of the Gα and Gβγ-subunit and post-
translational modifications on the Gα-subunit (myristic and/or palmitic acid) 
and Gγ-subunit (farnesol or geranylgeraniol) (Vogler et al., 2008).  
 
1.5.1.  G protein cycle 
 
On agonist binding, the active GPCR conformation is stabilised promoting 
interaction with the G proteins. The release of guanosine 5’-diphosphate 
(GDP) from the ‘inactive’ state α-subunit allows guanosine 5’-triphosphate 
(GTP) binding and subsequent dissociation from the GPCR and the βγ-
subunit (Gilman 1987) (Figure 1.1). In turn, both the α-subunit and βγ-subunit 
stimulate a number of distinct downstream effectors (Gilman 1987), ultimately 
leading to changes in intracellular secondary messenger levels and effectively 
connecting the external cellular environment to a plethora of internal cellular 
regulators (Hofmann et al., 2009).  
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The hydrolysis of GTP back to GDP, triggered by the intrinsic GTPase 
activity of Gα-subunit, leads to re-association of the individual G protein 
subunits, thereby completing the activation-inactivation GTPase cycle and 
allowing rebinding to the GPCR (Bourne et al., 1991). The GTPase cycle is 
highly regulated by GTPase-activating proteins (GAPs) and guanine 
nucleotide exchange factors (GEFs). Despite the intrinsic GTPase activity of 
G proteins, GTP hydrolysis is very slow and requires GAPs to accelerate the 
cleavage (Bos et al., 2007). These include regulators of G protein signalling 
(RGS) proteins which are specific for the Gα-subunit, terminating the GPCR 
signalling cascade (Wettschureck and Offermanns, 2005).  
GEFs induce the release of bound GDP through a reduction in 
nucleotide affinity and a subsequent increase in GTP-bound G protein due to 
approximately 10-fold higher cellular concentration of GTP compared to GDP 
(Bos et al., 2007). The βγ-subunit is thought to enhance efficiency of 
GTP/GDP exchange due to the preference of this subunit to bind Gα-subunit-
GDP over Gα-subunit-GTP and the GPCR itself to bind G proteins more 
tightly that to either subunit alone. Through these preferences, the reaction is 
driven towards replacing GDP for GTP (Bourne et al., 1991). 
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Figure 1.1 Heterotrimeric G protein activation cycle. In the absence of 
agonist, the G protein-GDP forms a tight inactive complex. G protein also exists 
in a nucleotide-free state and can stabilising receptor conformations that have 
high binding affinity for agonists (Yao et al., 2009). On agonist binding to GPCR 
(R*), the active GPCR conformation is stabilised. GTP binding to the G protein 
leads to dissociation from the GPCR and the Gβγ-subunit. In turn, both the Gα-
subunit and Gβγ-subunit stimulate a number of distinct downstream effectors. 
The activation cycle is terminated by the intrinsic GTPase activity of the Gα-
subunit, which allows GTP hydrolysis and reassociation with Gβγ-subunit. The 
GTPase cycle of G proteins is highly regulated by guanine nucleotide exchange 
factors (GEFs), which stimulate the exchange of GDP for GTP, and GTPase-
activating proteins (GAPs), which antagonise GEFs and accelerate GTP 
hydrolysis back to GDP. Regulators of G protein signalling (RGS) proteins are 
specific for the Gα-subunit. Image created using information from Gilman 1987 
and Denis et al., 2012. 
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1.5.1.1.  Gs family 
 
The nucleotide sequence encoding the α-subunit of the Gs protein is 20 kb; 
composed of 13 exons and 12 introns (Kozasa et al., 1988). The Gαs-subunit 
encoding guanine nucleotide binding α-stimulating (GNAS) locus is complex, 
undergoing genomic imprinting and generating multiple gene products with 
the use of four alternative first exons that splice onto a common set of 
downstream exons (Liu et al., 2000). In addition to coding for the Gαs-subunit 
itself, GNAS also encodes a chromagranin-like neuroendocrine secretory 
protein NESP55 and a larger variant of Gαs, GαsXL (Plagge et al., 2004). 
While Gαs expression is biallelic (Hayward et al., 1998), NESP55 and GαsXL 
are expressed from maternal and paternal alleles, respectively (Hayward et 
al., 1998). GαsXL-subunit is mostly identical to Gαs-subunit with the exception 
of a XL-specific N-terminus and is able to act as a fully functional Gs protein 
(Plagge et al., 2008), activating adenylyl cyclases (ACs) resulting in elevated 
cAMP levels (Wettschureck and Offermanns, 2005). 
 
1.5.1.2.  Gi/o family  
 
Of the Gi/o family members Gi1, Gi2 and Gi3 are structurally similar, widely 
expressed and are known to mediate receptor-dependent inhibition of ACs 
(Wettschureck and Offermanns, 2005). Interestingly and distinct from other G 
proteins, the effect of Go appears to be primarily mediated by the Gβγ-subunit 
where the activity of the Gαo-subunit is unclear (Wettschureck and 
Offermanns, 2005). Ggust, Gt1 and Gt2 are members of this family that show 
more restricted expression and are involved in specific sensory function 
(Table 1.1). Pertussis toxin (PTX) from Bordetella pertussis (Aktories 2011) is 
a multisubunit toxin composed of an A protomer (also known as S1) and a B 
oligomer (a pentameric ring of subunits S2, S3, two S4 and S5) and can be 
used as a tool to study the function of Gi/o family members (Carbonetti, 2011). 
Once in the cytosol, the A subunit hydrolyses nicotinamide adenine 
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dinucleotide (NAD) and transfers adenosine diphosphate (ADP)-ribose to 
cysteine residing within the C-terminus of the α-subunit of inhibitory Gi/o 
proteins (with the exception of Gαz-subunit which lacks this cysteine (Fong et 
al., 1988)), leading to the inhibition of Gi/o protein-coupled pathways (Fields 
and Casey, 1997, Kozasa et al., 1988).  
 
1.5.1.3.  Gq family  
 
The α-subunits of each of the four Gq family members, Gαq, Gα11 Gα14 and 
Gα15 are expressed from four individual genes (Offermanns et al., 2003) 
(Table 1.1). These G proteins mediate regulation of phospholipase C (PLC) β-
isoforms leading to hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2), 
generating inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), with a 
subsequent rise in intracellular calcium (Ca2+i) and activation of protein kinase 
C (PKC), respectively (Exton et al., 1994). In addition to activation of PKC, 
GPCRs coupled to the Gq/11 such as the proteinase activated receptor 2 
(PAR2) and the free fatty acid 4 receptor (FFA4) have also been implicated in 
activation of the ERK cascade (Déry et al., 1998 and Young et al., 2010 
respectively).  
Gα15/16-subunits are considered promiscuous whereby they initiate a 
specific effector response (PLCβ) following stimulation of receptors which are 
known to activate the Gq family of G proteins and receptors that normally 
couple to Gs and Gi proteins (Offermanns and Simon, 1995). 
 
1.5.1.4.  G12/13 family  
 
Although only studied in more detail relatively recently the G12/13 family 
members, G12 and G13, are being found to couple to a growing number of 
GPCRs and are amongst the most important in the context of cancer 
development (Rasheed et al., 2015). The upregulated expression of G12/13 
has been consistently reported in aggressive cancers such as prostate cancer 
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and dominantly active forms have been reported to induce both invasion and 
metastatic behaviours in a number of cell types (Dorsam and Gutkind, 2007). 
These G proteins are known to activate RhoGTPase nucleotide exchange 
factors (RhoGEFs) which are key Rho regulators; both transduce signals to 
Rho and directly activate Rho GTPase by inducing GDP exchange for GTP 
(Chikumi et al., 2004). Rho GTPase once activated, in turn regulates a 
number of downstream effectors including cytoskeletal proteins (Siehler, 
2009). 
 
1.5.2.  βγ-subunit signalling 
 
One of five β-subunits irreversibly interacts with a single 12 γ-subunits to form 
the Gβγ-subunit, a signal mediator in its own right (Smrcka, 2008). Although 
extensive detail into the unique roles and effectors of Gβγ has not been 
described in this thesis, a number of reviews exist (Smrcka, 2008, Dupré, 
2009 and Khan, 2013). 
 Ligand binding to GPCR and G protein activation is followed by the 
stimulation of a number of distinct downstream effectors both by the Gα and 
Gβγ-subunit (Gilman 1987). Unlike the Gα-subunit, Gβγ does not undergo 
significant conformational changes on GPCR activation and lacks a catalytic 
site (Smrcka 2008). It is suggested that G protein activation exposes Gβγ 
surface allowing binding and regulation of a growing list of molecules and 
effectors including inward rectifying K+ channels, GPCR kinase 2 (GRK2), AC 
and PLC-β (Smrcka 2008). In one well-characterised example, free Gβγ is 
thought to bind the pleckstrin-homology (PH) domain in GRK2 thereby 
localising it to the membrane where it is able to interact and phosphorylate 
GPCRs (Pitcher et al., 1995).  
 In addition to providing a mechanism of plasma membrane 
recruitment, Gβγ is also thought to directly activate some effectors through 
altering their enzymatic activity, such as binding the catalytic domain of PLC-β 
(Smrcka 2008).  In many cases, the activation of a particular pathway such as 
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the mitogen-activated protein (MAP) kinase (MAPK) pathway is not one 
mechanism but a number of distinct mechanisms, which likely reflect cell-
type, GPCR, and G protein of that pathway (Khan 2013). In the case of the 
MAPK pathway, three mechanisms have been described, namely the 
activation of an intracellular effector such as PLC-β, recruitment of GRK 
isoforms leading to phosphorylation of the GPCR and recruitment of β-
arrestin which in turn acts as an adaptor for Src (a non-receptor tyrosine 
kinase) and finally, transactivation of a receptor tyrosine kinase (RTK) 
activating classic MAPK signalling pathway (Khan 2013).  
1.6.  Major effectors of G proteins 
1.6.1.  Adenylyl cyclases and the cAMP pathway  
 
ACs, large transmembrane ATP-pyrophosphate lyases, represent the 
major effector of Gs-coupled GPCRs that generates cAMP and 
pyrophosphate (PPi) from ATP. A total of ten human AC isoforms have been 
identified, nine of which are membrane-bound designated AC1-9 and a tenth 
lacking a membrane span and resembling the cyanobacterial AC enzymes 
(Sadana and Dessauer, 2009). In addition to receiving stimulatory signals 
from Gs and inhibitory signals from Gi, they are also capable of responding to 
Gβγ-subunit (stimulatory or inhibitory depending on the AC isoform) (Tang 
and Gilman, 1991), Ca2+, protein kinases including protein kinase A (PKA), 
protein kinase C (PKC) and calmodulin kinases (Ca2+-CaM) (Birnbaumer, 
2007).  
Forskolin, a potent activator of AC (AC1-8 but not 9 or 10) is a useful 
tool in the investigation signalling cascades involving AC and cAMP (Seamon 
et al., 1981). This compound binds to the catalytic core of AC, opposite the 
active site and promotes the assembly of the two domains (Zhang et al., 
1997) leading to activation and subsequent elevations in cAMP (Seamon et 
al., 1981). 
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 The intracellular levels of cAMP are regulated by the activity of both 
ACs and phosphodiesterases (PDEs). Eleven different PDE families exist, 
each consisting of several different isoforms and spliced variants (Bender and 
Beavo, 2006). Similarly to ACs, PDE isoforms differ in their expression 
patterns generating cell type specific responses (Sassone-Corsi, 2012).  
Elevations in cAMP activate three main effectors; PKA, exchange protein 
activated by cAMP (epac) which is a cAMP regulated GEF and cyclin-
nucleotide-gated ion channels (Sassone-Corsi, 2012) (Figure 1.2).  
 Inactive PKA is composed of a regulatory subunit dimer and two 
reversibly associated catalytic subunits (Manni et al., 2008). Cooperative 
binding of cAMP to the four binding sites on the regulatory subunit causes 
dissociation of the catalytic subunits thus activating PKA (Manni et al., 2008). 
A-kinase-anchoring proteins (AKAPs) are known to bind various enzymes, 
including the regulatory subunit of PKA, sequestering them near to their 
specific effectors and substrates, effectively providing specificity in secondary 
messenger signal transduction (Wong and Scott, 2004).  Activated PKA in 
turn phosphorylates many different substrates including other kinases, 
transcription factors and GPCRs, in addition to regulating other signalling 
pathways (Pierce et al., 2002).  One such pathway includes the activation and 
inhibition of the MAPK pathway through the regulation of Raf (Dumaz and 
Marais, 2003). In most cell types, PKA is suggested to downregulate the 
MAPK/ERK pathway by interfering with the Ras-mediated activation of Raf-1 
(Dumaz and Marais, 2003).  On the other hand, PKA is also implicated in 
activating ERK through inhibition of various phosphatases involved in the 
downregulation of MAPK signalling (Sassone-Corsi, 2012).  
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1.6.2.  Phospholipase C (PLC) 
 
Activation of all four isoforms of PLC-β  (PLC-β1 through 4) is predominantly 
through GPCR coupled to the Gα-subunit of the Gq family. Activation of PLC-β 
can also occur through direct stimulation by Gβγ-subunits and increased 
Ca2+i (Kadamur and Ross 2013). PLC catalyses the hydrolysis of PIP2 
generating two important secondary messengers; IP3 and DAG (Exton et al., 
Figure 1.2. cAMP pathway and crosstalk with MAPK/ERK pathway.   
ACs are activated by Gs-coupled GPCRs through the binding of both the Gαs and 
Gβγ subunit (Tang and Gilman, 1991) resulting in elevated cAMP levels. The 
intracellular levels of cAMP are regulated by the balance of ACs and 
phosphodiesterases (PDEs) activity. ACs and PDEs can be activated and inhibited 
by the chemical compounds forskolin (Zhang et al., 1997) and 3-Isobutyl-1-
methylxanthine (IBMX) (Schmidt et al., 2000), respectively. PKA can be inhibited by 
Rp-8-bromo-cAMP (Rp-8-Br-cAMP) (Schwede et al., 2000). These chemicals 
provide invaluable tools for the investigation of cAMP signal transduction pathways. 
Elevations in cAMP activates three main effectors; the serine/threonine kinase, 
PKA, the guanine-nucleotide-exchange factor (GEF) EPAC and cyclin-nucleotide-
gated ion channels (Sassone-Corsi, 2012). Activated PKA in turn phosphorylates 
many different substrates including other kinases, transcription factors, GPCRs, in 
addition to regulating signalling components of other pathways such as MAPK/ERK 
pathway (Dumaz and Marais, 2003). 
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1994). Through binding to a conserved C1 domain, DAG in turn stimulates a 
number of enzymes including PKC (Colón-González and Kazanietz, 2006). In 
addition to the traditional role in PKC activation, DAG is also known to recruit 
a number of effector proteins such as protein kinase D (PKD) and DAG 
kinases (DGK) β and γ  (Griner and Kazanietz, 2007). More recently, DAG 
has also been reported to mediate regulation of the two-pore domain 
potassium channels, TASK-1 and TASK-3 (Wilke et al., 2014). The secondary 
messenger IP3 acts at Ca2+ release channels, such as the IP3 receptors 
located in the ER, allowing Ca2+ to diffuse down the electrochemical gradient 
into the cytoplasm (Foskett et al., 2007). IP3 is also the substrate for IP1 
synthesis, which in turn stimulates a number of protein kinases and 
transcription factors (Kadamur and Ross 2013).   
1.7.  β-arrestins  
1.7.1.  β-arrestins; desensitisation and internalisation  
 
Since their discovery (Kuhn, 1984), our current understanding of arrestin 
structure and function has expanded hugely with binding to the majority of 
phosphorylated GPCRs now known to be a central mechanism in regulating 
signalling (Gurevich and Gurevich, 2006). There are four mammalian arrestin 
proteins and seven GRK genes that can undergo alternative splicing (Claing 
et al., 2002). Arrestin 1 and GRK 1 regulate rhodopsin in the retinal rods 
whereas arrestin 4 and GRK 7 regulate colour opsins within the retinal cones 
(Lefkowitz and Shenoy 2005). The regulation of most GPCRs is through, the 
almost ubiquitously expressed arrestin 2 and arrestin 3 (from herein referred 
to as β-arrestin 1 and 2, respectively (β-arrestin1/2)) and GRKs 2, 3, 5 and 6 
(Lefkowitz and Shenoy 2005). For the majority of agonist bound GPCRs, 
receptor phosphorylation by GRKs is followed by β-arrestins binding to the 
phosphorylated C-terminus and subsequent receptor desensitisation and 
internalisation (Moore et al., 2007).  
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 GPCR internalisation is achieved via the bound β-arrestin acting as a 
linker to components of the endocytic machinery including clathrin (Goodman 
1996) and adaptor protein 2 (AP-2) (Laporte et al., 2002), in addition to 
mediating receptor ubiquitination, thereby targeting them to the proteasome 
for degradation (Shenoy et al., 2001). The process of endocytosis, not only 
plays a role in receptor desensitisation, internalisation and receptor 
degradation, but also in receptor resensitisation by dephosphorylation and 
recycling (Krueger et al., 1997).  
 
1.7.2.  β-arrestins; an alternative signalling system 
 
Binding of β-arrestin to the cytoplasmic surface of the receptor core has been 
suggested to result in steric hindrance of further G protein-coupling (Shukla et 
al., 2014, Kumari et al., 2016).  However, this view that β-arrestins essentially 
‘arrest’ GPCR signalling has been challenged by the observation that a 
number of GPCRs including the V2 vasopressin receptor (V2R) (Feinstein et 
al., 2013) and parathyroid hormone type 1 receptor (PTHR1) (Ferrandon et 
al., 2009) are able to maintain G protein signalling after internalisation to 
endosomes (Irannejad et al., 2013). More recent work has provided direct 
evidence for the formation of a super-complex composed of a single GPCR, 
G protein and β-arrestin (Thomsen et al., 2016). In this super-complex, β-
arrestin mediated receptor internalisation had no interference with G protein-
coupling (Thomsen et al., 2016) and may provide a physical basis for 
sustained G protein signalling within cellular compartments.  
β-arrestins are now appreciated to serve as an alternative signalling 
system where they are able to recruit multiple enzymatic effectors (Luttrell 
and Gesty-Palmer, 2010) through serving as adaptor, scaffold proteins and/or 
signal transducers (Peirce et al., 2002). Indeed, recent work has shown that 
β-arrestins remain active after GPCR dissociation allowing them to remain at 
the cell-surface, presumably signalling independently (Nuber et al., 2016).  
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Although extensive detail into the growing list of endocytic and 
signalling proteins bound by β-arrestins is beyond the scope of this work, β-
arrestins are known to bind a number of components involved in the MAPK 
pathway (Gesty-Palmer et al., 2006, Lefkowitz et al., 2006). Here, β-arrestins 
can form complexes with several signalling protein including Raf, MEK, 
ERK1/2 and JNK3, thereby stimulating the MAPK pathway (Luttrell et al., 
2001, McDonald et al., 2000).  
 
1.8.  G protein and β-arrestin mediated ERK1/2 activation 
 
One of the major cellular effectors activated by GPCRs are the MAPKs, which 
include ERK1/2 (Eishingdrelo and Kongsamut, 2013).  ERK1/2 are 
downstream components of the MAPK pathway. This conserved cascade 
consisting of MAP kinase kinase kinases (MAPKKKs) (such as Raf isoforms 
and Ste11), MAP kinase kinases (MAPKKs) (such as MAP/ERK kinase 1 and 
2 (MEK1/2)) and finally MAPKs themselves (such as ERK1/ERK2 and Jun N-
terminal kinases (JNK1-3)) (Qi and Elion 2005). ERK1 and ERK2 (ERK1/2) 
have many known targets (including transcription factors such as activator 
protein 1 (AP-1), nuclear factor (NF)-κB and Myc) and regulate a number of 
cellular processes including proliferation, differentiation and meiosis (Qi and 
Elion 2005). 
ERK1/2 activation has been reported to occur via G protein and β-
arrestin mediated pathways for a number of GPCRs (Gesty-Palmer et al., 
2006). For example, PTHR activation stimulates ERK1/2 phosphorylation is 
both G protein (involving PKA or PKC) and β-arrestins dependent (Gesty-
Palmer et al., 2006). As previously indicated, both Gα and Gβγ-subunits of 
the G protein are able to activate signal transduction pathways leading to 
ERK1/2 phosphorylation and may be via a PKA mediated pathway (Figure 
1.2). GPCRs are also reported to activate ERK1/2 through Gq-mediated 
(Eishingdrelo and Kongsamut, 2013) or β-arrestin-mediated signalling 
pathways (Wei et al., 2003, Lefkowitz et al., 2006) (Figure 1.3).  
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In order to distinguish between Gq protein or β-arrestin-mediated 
pathways, various PKC inhibitors such as GF109203X and small interfering 
(si) ribonucleic acid (RNA) (siRNA) targeted to β-arrestins have been 
employed (Gesty-Palmer, 2006). Whereas G protein mediated ERK activation 
is rapid, transient and blocked by PKC inhibitors, β-arrestin mediated 
activation is slower in onset and persists longer  (Lefkowitz and Shenoy 
2005). In addition, whereas ERK activated through G protein-dependent 
mechanisms tend to translocate to the nucleus leading to transcriptional 
regulation and cell proliferation, β-arrestin mediated activated ERK tends to 
remain in the endocytic vesicles within the cytosol (Lefkowitz and Shenoy 
2005). As an example, GLP-1 activates ERK1/2 through either PKA or β-
arrestin1 dependent mechanisms (Quoyer et al., 2010). Whereas the PKA-
dependent pathway leads to a rapid and transient ERK1/2 phosphorylation 
with translocation to the nucleus, β-arrestin1 mediated pathway produces a 
late ERK1/2 phosphorylaton that is cytoplasm restricted (Quoyer et al., 2010).  
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1.9.  Signalling bias: a relatively new field  
 
The classic view of GPCR activation is based on the idea that a receptor’s 
conformation is induced or stabilised on agonist binding leading to an ‘active’ 
conformation. Signalling bias (biased agonism or agonist receptor-trafficking) 
is the phenomenon by which the activated signalling cascade of a single 
receptor is determined by the bound ligand resulting in different physiological 
outcomes (Wisler et al., 2014, Bologna et al., 2017). Although the functional 
coupling of a single GPCR to more than one G protein has been known for 
years, it is an increasingly recognised concept that ligands can determine a 
bias towards a particular G protein (Kenakin, 1995), β-arrestin (Lefkowitz and 
Figure 1.3. G protein and β-arrestin mediated ERK activation. GPCRs are able 
to activate ERK1/2 in a G protein-dependent or β-arrestin-mediated signalling 
pathways (Wei et al., 2003). The G protein signal transduction pathways leading to 
ERK1/2 activation may be PKA (Figure 1.2) or PKC mediated (shown here) 
(Eishingdrelo and Kongsamut, 2013). Both PKC inhibitors (such as GF109203X) 
and activators (such as PMA) are useful tools for the investigation into ERK1/2 
signalling. β-arrestins are able to recruit multiple enzymatic effectors including 
components of the MAPK cascade (Luttrell and Gesty-Palmer, 2010). 
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Shenoy, 2005) or one of the G protein subunits (Gα or Gβγ) (Blättermann et 
al., 2012). 
Signalling bias can be determined, not only by the changes in second 
messenger levels or activated cascade components, but also receptor 
desensitisation, down regulation and degradation (Koole et al., 2013). A 
number of mathematical methods are used to estimate relative bias towards 
G protein or β-arrestin mediated pathways. Bias quantification can be 
achieved through fitting concentration-response curves for each agonist and 
analysing them by nonlinear regression using the operational model of 
agonism to determine the tau (τ)/KA ratio (where τ is a measure of coupling 
efficiency or efficacy and KA denotes the dissociation constant) (Black and 
Leff, 1983, Evans et al., 2010, Rajagopal et al., 2011).  
This field has seen recent growth due to its implications in drug design 
with work carried out on a number of receptors including the GLP-1 receptor 
(GLP-1R) (Wootten et al., 2013b), µ-Opioid receptor (Thompson et al., 2015) 
and free fatty acid receptor 1 (FFAR1) (Mancini et al., 2015). Unsurprisingly, 
this has been coupled to an increasing list of identified biased ligands, 
including orthosteric ligands (bind at the endogenous ligand bindings site) and 
biased allosteric modulators, which bind to a site district from the orthosteric-
binding site and modulate the efficacy/affinity of another ligand (Wisler et al., 
2014). 
1.10.  Compounds and toxins as tools for deconvoluting GPCR 
signalling  
 
The investigation of G proteins and the role they play in GPCR signalling has 
been made possible by the availability of tools and technologies to dissociate 
their coupling to downstream signalling cascades. Among these tools are 
short interfering and short hairpin RNAs (Krumins et al., 2006) and knockout 
cell lines (Alvarez-Curto et al., 2016) generated using technology such as 
clustered regularly interspaced short palindromic repeat (CRISPR)/Cas-based 
RNA-guided DNA endonucleases (Ran et al., 2013). Alternatively, chemical 
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inhibitors and toxins functionally inhibit, whilst allowing the protein to remain 
physically intact (Schrage et al., 2015).  
 Through the utilisation of pharmacological tools with activity at a 
particular G protein, functional uncoupling of a receptor of interest to a 
downstream output measure (such as cAMP) can be used to indicate G 
protein-coupling. Despite the advances in our understanding of G proteins, 
specific inhibitors have only been described against the Gi and Gq family 
(Schmitz et al., 2014) (Table 1.1). Signalling via the Gβγ-subunit of the G 
protein can also be investigated using the specific Gβγ small molecule 
inhibitor gallein (Lehmann et al., 2008).  
 Members of the Gi family, with the exception of the Gαz-subunit 
(Fong et al., 1988), are well-known targets of PTX, as previously described 
(Section 1.5.1.2) (Fields and Casey, 1997). Although not specific, the suramin 
analogue, NF449 is a selective inhibitor of the P2X1 receptor with reported 
inhibitory activity at Gs (Hohenegger et al., 1998, Halls and Cooper, 2010). 
 YM-254890, a cyclic depsipeptide isolated from Chromobacterium 
sp. QS3666, is a Gq inhibitor (Takasaki et al., 2004). This compound 
specifically inhibits the release of GDP from Gαq, Gα11 and Gα14 subunit 
through binding to a hydrophobic cavity and stabilising the GDP-bound form 
(Nishimura et al., 2010). A close structural analogue of YM-254890, 
FR900359 (also known as UBO-QIC), first isolated from the evergreen plant 
Ardisa crenata (Fujioka et al., 2001), is also a selective inhibitor of Gαq, Gα11 
and Gα14 with extraordinary stability (Schrage et al., 2015). Since the 
discovery of these compounds they have become an invaluable tool for the 
deconvolution of GPCR signalling and for the investigation of Gq-mediated 
cellular responses. The availability of YM-254890 and FR900359 to the 
scientific community has been described a restricted (Xiong et al., 2016). 
However, YM-254890 can be acquired from Wako Pure Chemical Industries 
Ltd.  
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1.11.  GPCR dimerisation  
1.11.1.  Beyond class C GPCR 
 
The growing body of evidence indicating the existence of some GPCRs 
forming homodimers, heterodimers or as part of large oligomeric complexes 
has challenged the classic view of GPCRs existing as monomeric entities 
(Terrillion and Bouvier, 2004, Milligan, 2004).  
Although the existence of dimerisation amongst GPCRs is largely 
accepted, particularly for the class C GPCRs where there is evidence of 
obligate dimerisation (Marshall et al., 1999), their functional significance 
including G protein and β-arrestin coupling, downstream signalling and 
receptor internalisation remains unclear and even controversial (Terrillion et 
al., 2004). In particular, the difficulty in analysing GPCR dimerisation in native 
cells has led to the suggestion that some experimental evidence could be 
attributed to receptor overexpression which often occurs in cellular models 
(Angers et al., 2002). Answering these fundamental questions surrounding 
receptor dimerisation could be an important step towards the development of 
GPCR targeted therapeutics.  
 
1.11.2. Dimerisation and receptor trafficking  
 
There is a growing body of evidence that GPCR dimerisation plays an 
essential role in the entire GPCR lifecycle; from ER exit to internalisation as a 
dimeric complex (Milligan, 2009). A number of heterodimers have been 
reported to co-internalise following stimulation with only one of the receptors 
cognate ligand including the α1a/α1b adrenergic and A2A adenosine/D2 
dopamine receptors (Stanasila et al, 2003 and Ginés et al, 2002, 
respectively). 
The requirement of dimerisation for cell-surface expression has been 
well established for a number of GPCRs (Terrillon and Bouvier, 2004). The 
exit from the ER requires complete and correct folding and masking of any 
ER retention signal or hydrophobic regions that would otherwise retain the 
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receptor, mostly through interaction(s) with chaperones (Reddy and Corley, 
1998). A classic example of obligate dimerisation for successful ER exit is the 
metabotripic gamma-aminobutyric acid (GABA) type b receptor (GABAB), a 
class C GPCR formed of two distinct gene products, GABAB receptor 1 
(GBR1) and GABAB receptor 2 (GBR2) (Marshall et al., 1999). Although 
GBR2 alone is able to reach the cell surface, it is non-functional and requires 
co-expression of GBR1 which itself is only able to exit the ER following 
masking of the carboxy-terminal ER retention motif by heterodimerisation with 
GBR2 (Margeta-Mitrovic et al., 2000).  
Studies looking at a number of class A GPCR truncated mutants 
including V2R (Zhu and Wess, 1998) and dopamine D3 receptor (Karpa et al, 
2000) co-expressed with their respective wild-type (WT) receptors revealed 
prevention of WT receptor cell surface expression (Milligan et al., 2010). In 
other words, the mutant acts as a ‘dominant-negative’ preventing expression 
of the co-expressed WT GPCR (Milligan et al., 2010).  
 
1.11.3.  Dimerisation and signal transduction  
 
Studies on the GABAB receptor provided the first convincing evidence that 
dimerisation has implications in signal transduction (Margeta-Mitrovic et al., 
2000). Despite GBR1 harbouring the binding site for the agonist GABA, co-
expression of GBR2 is required for both cell-surface expression of GBR1 and 
formation of a functional receptor capable of coupling to the G protein 
(Margeta-Mitrovic et al., 2000). Interestingly, selectivity for different G protein 
subfamilies by some GPCRs has been suggested to be influenced by 
heterodimerisation (Milligan, 2007). As an example, in contrast to the 
individually expressed δ- and µ- opioid receptors, known to couple to PTX 
sensitive G protein Gi, co-expression of these receptors caused a loss in Gi-
coupling but its retained ability to inhibit AC following PTX treatment 
suggesting coupling to a PTX insensitive G protein, Gz (George et al., 2000).   
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1.11.4.  Dimerisation in class B GPCRs 
 
Whilst the evidence surrounding GPCR dimerisation amongst class A and C 
continues to grow, research focused on the class B GPCRs remains sparse in 
comparison (Ng et al., 2012). Despite this, there is considerable evidence for 
homodimerisation amongst some members of this class including secretin 
receptor (Ding et al., 2002), vasoactive intestinal polypeptide receptors 
(VPAC1 and VPAC2) (Harikumar et al., 2006) and GLP-1R (Harikumar et al., 
2012). In addition, there is also evidence for some heterodimers amongst 
class B GPCRs such as the secretin receptor with GLP-1R (Harikumar et al., 
2017) and the GLP-1R with GIPR (Schelshorn et al., 2012), to name a few, 
although functional consequences have not been reported.  
The structural basis for GPCR dimerisation remains elusive, but TM4 
has been implicated to constitute the dimerisation interface (Harikumar et al., 
2007, Harikumar et al., 2012, Xue et al., 2015, Harikumar et al., 2017). In a 
secretin receptor TM peptide competition experiment, only TM4 peptide 
segment disrupted the measure of dimerisation and resulted in reduced 
signalling implicating dimerisation in receptor functionality (Harikumar et al., 
2007). One study demonstrated that double and triple substitutions within the 
hydrophopic face of TM4 within GLP-1R (L256A4.49, V259A4.55 or G252A4.49, 
L256A4.55, V259A4.58 (See Section 1.13 for details on numbering system)) had 
selective effect on signalling, suggested to be a consequence of a disturbed 
homodimerisation interface (Harikumar et al., 2012). Here, stimulation with 
peptide ligands including GLP-1(7-36)amide and oxyntomodulin showed a 
completely abolished Ca2+i mobilisation and attenuation (~10-fold) in potency 
for cAMP accumulation and ERK1/2 phosphorylation in the TM4 mutant when 
compared to WT GLP-1R (Harikumar et al., 2012). In contrast, the allosteric 
agonist compound 2 showed a completely abolished cAMP accumulation 
response and a small reduction in the ERK1/2 phosphorylation (Harikumar et 
al., 2012).  These findings suggested that dimerisation of GLP-1R plays an 
important role in the control of signal bias via altering the coupling efficiency 
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of this receptor to a number of known GLP-1R effectors such as Gs, Gq and 
potentially to β-arrestins. 
1.12.  GPCR structures 
 
The general structure of GPCRs can be divided into three regions including 
the extracellular regions consisting of the ECD and three extracellular loops 
(ECL1-3), the TM regions consisting of TM1-7 (Figure 1.4) and the 
intracellular region consisting of ICL1-3, the amphipathic helix 8 (not present 
in all GPCRs) and the C terminus (Venkatakrishnan et al., 2013). Improving 
the structural information available on GPCR through solving the crystal 
structures allow an expansion on pharmacological data and provide a 
template for the rational design of structure-based drugs.  
To date, of the approximately 1000 mammalian GPCRs (Lefkowitz et 
al., 2007), the crystal structures of 40 inactive class A GPCRs and a handful 
of agonist bound class A GPCRs have been solved, including β2AR in 
complex with the heterotrimeric Gs protein (Rasmussen et al., 2011). Of the 
15 class B GPCRs, the crystal structures of four have been solved to date; 
GCGR (Siu et al., 2013, Jazayeri et al., 2016 and Zhang et al., 2017), CRF1R 
(Hollenstein et al., 2013), CTR (Liang et al., 2017) and GLP-1R (Song et al., 
2017, Jazayeri et al., 2017, Zhang et al., 2017b). However of these class B 
structures, two of the GCGR (Siu et al., 2013 and Jazayeri et al., 2016) and 
the CRF1R (Hollenstein et al., 2013) structures lack the ECD which, in 
combination with the 7TM domain, is known to be important for peptide 
binding (Hoare, 2005).   
The ECD of class B GPCRs is stabilised by three disulphide bonds and 
contribute most of the binding affinity of the receptor for the peptide 
(Underwood et al., 2010). Using X-ray crystallography or NMR, the structure 
of a number of ECDs in combination with peptide ligands including the GLP-
1R (Runge et al., 2008, Underwood et al., 2010), GIPR (Parthier et al., 2007) 
and GCGR (Koth et al., 2012) have given insight into the mechanism of 
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peptide binding (Culhane et al., 2015). Such structures, in combination with 
ligand binding studies, employing truncated and chimeric peptide ligands, 
provided the basis of the two-step, two-domain model of activation (as 
reviewed in Pal et al., 2012). This model proposes that in the absence of a 
ligand, the ECD is mobile through flexibility in the linker connected to TM1 
and the C-terminal of the peptide forms an initial complex with the ECD, 
which in turn allows the N-terminal of the peptide to interact with the 7TM 
domain and activate the GPCR (Pal et al., 2012).   
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Figure 1.4. Full-length GCGR crystal structure: full-length GCGR in complex 
with the negative allosteric modulator (NAM) NNC0640 solved by Zhang et al., 
2017 at a resolution of 3 Å (PDB ID: 5XEZ) shown as A) cartoon representation in 
MacPyMOL. B) Figure A rotated (counterclockwise as viewed from the top) 270
o
 
along the y axis.  The mAb1 and T4L (inserted into the ICL2 between A256 and 
E260) has been removed for clarity. The ECD (Q27-D124), stalk (G125-K136) 
and TMD (M137-W418) are coloured in yellow, cyan and green, respectively. 
Labelling of TMDs was in line with residues numbering indicated in GPCRdb.org; 
TM1 (Q131-L166), TM2 (C171-R201), TM3 (S217-L255), TM4 (S262-E290), TM5 
(N300-A335), TM6 (Y343-F367), TM7 (Q374-L403), helix 8 (N404-N429).  
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1.13.  GPCR residue numbering  
There are a number of GPCR residue numbering schemes employed for the 
various classes of GPCRs. The class A Ballesteros-Weinstein number 
scheme (Ballesteros and Weinstein, 1995) consists of two numbers, the first 
of which is based on TM1-7 and the second on the position relative to the 
most conserved residue (defined as number 50) within that TM helix. As an 
example, 3.49 denote a residue located in TM3, one residue before the most 
conserved residue R3.50. A problem with this numbering system is that not all 
reference residues are conserved across all receptors within class A making 
the identification of residues not always straightforward  (Isberg et al., 2015). 
The Wootten class B GPCR numbering system (Wootten et al., 
2013c), is similar to the Ballesteros-Weinstein number scheme and denotes 
the most conserved residue in each class B GPCR TM domain as .50, 
preceded by the TM number and the absolute residue number is shown in 
superscript. As an example, G3937.50 of GCGR denotes a glycine at position 
393 within TM7 and is the most conserved in the secretin-like class B 
receptors (Siu et al., 2013). In the case of amino acids falling between two TM 
regions such as ICL1, within this thesis, the first number indicates the TM 
immediately before and after (such as ICL1 S16712.48 within GCGR).  
The class C GPCR Pin numbering system was used in the publication 
of the mGluR5 structure, whereas the class F Wang scheme was used in the 
publication of the Smoothened receptor structure  (Pin et al., 2003 and Wang 
et al., 2014, respectively). 
GPCRDB provides tools supporting alignment of all GPCR classes 
displaying the residue numbers from the various schemes; Ballesteros and 
Weinstein (A), Wootten (B), Pin (C) and Wang (F) (Isberg et al., 2017). In this 
thesis, the Wootten class B and Ballesteros and Weinstein class A GPCR 
numbering system was employed for the GCGR and A2AR, respectively.  
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1.14.  The glucagon receptor (GCGR) 
 
GCG is a 29-amino acid peptide hormone produced by the α-cells of the 
pancreatic islets through posttranscriptional processing of proglucagon 
peptide (Rouillé, 1997) (Figure 1.5). GCG binds the glucagon receptor 
(GCGR) leading to the stimulation of glycogenolysis (the enzymatic 
breakdown of glycogen) and gluconeogenesis (the synthesis of glucose from 
lactate and amino acids), effectively counteracting the consequences of 
excessive insulin and ultimately resulting in glucose release into the 
bloodstream (Quesada et al., 2008). GCGR is also stimulated by the GCG 
related 37-amino acid peptide oxyntomodulin (Pocai, 2012, Weston et al., 
2015). This peptide is mainly produced in gut endocrine L-cells (Figure 1.5) 
and is able to modulate gastric acid secretion from gastric oxyntic glands 
(Pocai, 2014). It has been described as a full agonist of the GCGR-mediated 
cAMP accumulation while showing 100-fold reduced potency when compared 
to GCG (Pocai et al., 2009, Weston et al., 2015).  
Although the GCGR is reported to mediated its effects through the 
activation of Gs, studies have highlighted the possibility of GCGR to activate 
alternative G proteins such as Gq/11, leading to a downstream increased 
intracellular DAG and IP3 via Ca2+ activated PLCβ (Xu and Xie, 2009, 
Wakelam et al., 1986). Interestingly, the GCG analogue (1-N-α-
trinitrophenylhistidine,12-homoarginine)glucagon (TH-GCG) was previously 
reported in  hepatocytes extracted from male Sprague-Dawley rats to neither 
activate AC or cause cAMP response, but was shown to fully stimulate 
glycogenolysis,  gluconeogenesis and stimulates the production of inositol 
phosphates (Wakelam et al., 1986). This was described as an alternative 
mechanism by which GCG activation may exert its effects independent of 
cAMP and that this may indicate the existence of two distinct receptors for 
GCG, one coupled to inositol phospholipid breakdown and another coupled to 
stimulate AC activity. Similar findings were reported in hepatocytes extracted 
from guinea pigs (Lenzen et al., 1990).  These early finding may be explained 
by signaling bias where the downstream signaling cascade initiated by TH-
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GCG is predominantly through Gq-coupling. However, relatively little research 
has been performed to investigate alternative G protein-coupling within the 
GCGR and to confirm these early findings. 
 
 
 
 
Figure 1.5. Schematic representation of proglucagon processing in the 
pancreatic α-cells and intestinal L-cells. Glicentrin, GLP-1, GLP-2, GCG, 
oxyntomodulin, glicentin-related pancreatic polypeptide (GRPP), major proglucagon 
fragement (MPGF), intervening peptide 1 and 2 (IP1 and IP2, respectively), are all 
processed from a single messenger RNA (mRNA) transcript expressing in the α-cells of 
the pancreatic islets, intestinal L-cells and central nervous system (CNS). This 
proglucaon mRNA is translated into a single 160 amino acid precursor protein which 
undergoes tissue-specific posttranslational processing. Partial processing is indicated 
by dashed arrows. Figure adapted from Janssen et al., 2013 and Rouillé, 1997. The 
amino acid sequence of GCG, oxyntomodulin, GLP-1 and GLP-1(7-36) are also shown.   
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1.15.  GCGR structures 
 
The first crystal structure of the 7TM domain of GCGR bound to the negative 
allosteric modulator (NAM), NNC0640, was solved to a resolution of 3.4 Å 
(Sui et al., 2013 PDB ID: 4L6R). Interestingly, a comparison between this 
structure and that of 15 known inactive class A GPCR structures revealed 
that both the position and orientation of the helices within the 7TM domain 
were conserved, but there are a number of distinct features (Sui et al., 2013). 
Such features include the long N-terminal end of helix I (the stalk) extending 
three helical turns above the extracellular membrane boundary, the 16 
residue ECL1 when compared to 4-6 residues in class A GPCRs and the 
positioning of the extracellular tips of the 7TM helices creating a wider and 
deeper cavity in the ligand-binding pocket (Sui et al., 2013).  With the CRF1R 
structure also revealing a wider and deeper ligand-binding pocket when 
compared to class A GPCRs, this appears to be a conserved feature amongst 
class B GPCRs (Hollenstein et al., 2013).  
The second crystal structure of GCGR in complex with the antagonist 
MK-0893 was solved at a resolution of 2.5 Å (Jazayeri et al., 2016 PDB ID: 
5EE7). In order to facilitate crystalisation, the GCGR ECD was removed, the 
C-terminus truncated, 11 amino acid substitutions made to creating a 
thermostabilised receptor (StaR) (such as R173A) and T4-lysozyme (T4L) 
inserted into ICL2. The conformation of the 7TM domain was found to be 
similar to the first resolved GCGR structure with the conserved disulphide 
bond between C29445.50 in ECL2 and C2243.29 stabilising the 7TM fold 
(Jazayeri et al., 2016). Within this structure, the N-terminus of TM5 unwinds 
by one helical turn allowing ECL2 to extend across the bundle forming a cap 
to the entrance of the orthosteric site and mediates interactions from TM3 
across to TM6 and TM7 (Jazayeri et al., 2016). MK-0893 was found to bind at 
an allosteric site in a position between TM6 and TM7, effectively straddling 
TM6 from within the lipid bilayer, and may restrict the outward movement of 
TM6 required for G protein-coupling (Jazayeri et al., 2016).  
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Most recently, the crystal structure of the full-length inactive GCGR 
structure in complex with the NNC0640, and antigen-binding fragment (Fab) 
of an inhibitory antibody (mAb1) was solved to a resolution of 3.0 Å (Zhang et 
al., 2017 PDB ID: 5XEZ). This full-length GCGR structure has a similar 7TM 
domain compared to the two previously solved structures (Siu et al., 2013 and 
Jazayeri et al., 2016) and a similar ECD comprising the common α-β-β-α fold 
as observed in the ECD structures of GCGR (Koth et al., 2012) and GLP-1R 
(Underwood et al., 2010). NNC0640 was found to bind to the extracellular 
surface of the 7TM domain in a cleft between TM6 and TM7, similar to the 
binding site of MK-0893 at GCGR (Jazayeri et al., 2016) and the two NAMs 
(PF-06372222 and NNC0640) at GLP-1R (Song et al., 2017). The 
identification of this novel allosteric binding site not only expands the current 
understanding of the mechanism of GCGR and indeed other class B GPCR 
activation, but also provided the opportunity for structure-based drug design 
for the class B GPCRs. 
1.16.  Insight into receptor activation; Comparison between active and 
inactive class B crystal structures  
 
Recently, the X-ray structure of peptide agonist-bound GLP-1R (Jazayeri et 
al., 2017) and cryo-EM structures of the class B salmon calcitonin (sCT) 
unmodified CTR (at a nominal resolution of 3.8 Å) and peptide-activated 
rabbit GLP-1R (nominal resolution of 3.9 Å) both in complex with 
heterotrimeric Gs were solved (Liang et al., 2017 and Zhang et al., 2017b, 
respectively). The comparison between these active structures and inactive 
GPCR structures, such as the CRF1R and GCGR, provided some insight into 
conformational changes upon class B GPCR activation. 
Relative to the inactive structures of GCGR (Jazayeri et al., 2016) and 
CRF1R (Hollenstein et al., 2013), TM6 in CTR showed a large outward 
movement at the cytoplasmic and extracellular face (15 Å and 9-11 Å, 
respectively (measured from alpha carbon (Cα) of X6.35)), with a 60o kink at 
the centre of TM6 formed around the highly conserved Pro6.47-X-X-Gly6.50 
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(PXXG) motif (CTR P3846.47-X-X-G3876.50) (Liang et al., 2017). This 
movement at the cytoplasmic face was suggested to open the bundle to 
accommodate interactions with the α5-helix of Gs (Liang et al., 2017). This 
sharp kink in the PXXG motif was also reported in the active structure of GLP-
1R and caused the intracellular half of TM6 to move outwards by 18 Å 
(measured from Cα of K3466.35) (Zhang et al., 2017b). This movement was 
indicated to allow interactions between the N-terminus of GLP-1(7-36)amide 
and the binding pocket (Zhang et al., 2017b). Given the similarities between 
both Gs bound GLP-1R and CTR structures, the outward movement of TM6 is 
likely to be a conserved mechanism of receptor activation for class B GPCRs.    
 
1.17.  Inactive receptor state; conformation stabilisation 
1.17.1.  The E/DRY motif in class A GPCRs 
 
The highly conserved E/DRY (E3.49/D3.49 R3.50 Y3.51) motif in TM3, is one of the 
mostly highly conserved sequences motifs in GPCRs (Rovati et al., 2007). 
The “ionic lock” (Vogel et al., 2008) is proposed to stabilise the inactive 
receptor conformation and involves a salt bridge between the R3.50 within the 
E/DRY motif in TM3 and a negatively charged D/E6.30 in TM6 (Audet and 
Bouvier, 2012). This R3.50-E6.30 ionic lock is consistently shown in the inactive 
rhodopsin receptor crystal structures and in a number of other class A 
GPCRs including the antagonist bound A2AR (Doré et al., 2011), D3R (Chien 
et al., 2010) and A1R (Cheng et al., 2017, Glukhova et al., 2017) suggesting 
this mechanism may be a general feature of class A GPCR.  
In some GPCRs where the ionic lock is absent, such as the β2AR, 
there are residues capable of forming strong interactions between TM3 and 
TM6 (Trzaskowski et al., 2012). Disruption of this interaction has been shown 
to lead to TM6 movement away from the TM bundle creating a crevice in the 
cytoplasmic region of the receptor (Xiaojie et al., 2006), providing a deep 
pocket for the G protein (Rasmussen et al., 2011). This is highly similar to the 
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outward movement of TM6 reported for the class B GLP-1R and CTR active 
structures (Zhang et al., 2017b and Liang et al., 2017, respectively), 
previously described. Indeed, mutations the E/DRY motif have bee shown to 
induce constitutive activity (agonist independent increase in basal activity) for 
a number of GPCRs including the β2AR, rhodopsin receptor and oxytocin 
receptor (OTR) (Rovati et al., 2007).  
In the A2AR, R1023.50 of the E/DRY motif  engages in two salt bridges, 
one with E2286.30 and another with the adjacent D1013.49 (Fanelli and Felline, 
2011). Other residues implicated to be involved in the ionic lock of the A2AR 
include Y11234.53 in the ICL2 and T412.39 in TM2, where D1013.49 forms 
hydrogen bonds with both residues (Martínez-Archundia and Correa-Basurto, 
2014). In the A2AR, R1023.50 may act to strengthen the polar interactions 
between the motif, ICL2 and TM2 and may have direct implications on G 
protein activation (Jaakola et al., 2008). 
 
1.17.2.  HETX motif in class B GPCRs 
 
Similar to the functional role of the E/DRY motif in class A GPCRs, an 
extensive polar interaction network is formed between residues H2.50, E3.50, 
T6.42 and Y7.57 known as the HETX motif (or TM2-3-6-7 network) and is 
suggested to lock class B GPCRs in an inactive conformation (Liang et al., 
2017). Interestingly, T6.42 within TM6 of class B GPCRs is suggested to mimic 
the D/E6.30 in class A GPCRs and disruption of the restraint imposed by T6.42 
facilitates the outward movement of TM6 and thus receptor activation 
(Cordomí et al., 2015). Indeed, within the inactive structure of GCGR, the side 
chain of T3516.42 forms a hydrogen-bond interaction with Y4007.57 (Siu et al., 
2013). While the H2.50-E3.50 interaction is maintained in two of the inactive 
GCGRs structures (Sui et al., 2013 and Jazayeri et al., 2016) and in the 
active CTR structure (Liang et al., 2017), the polar interactions between T6.42 
and Y7.57 are broken within the active CTR structure and form new hydrogen 
bonds with the TM6 backbone (Liang et al., 2017). This lost interaction 
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supposedly releasing the constraint on TM6 and possibly allows transition of 
TM6 away from the TM bundle  (Liang et al., 2017). Indeed, this outward 
movement of TM6 and HETX motif disruption was also found in the active 
GLP-1R structure (Zhang et al., 2017b) suggesting this conformational 
change may be conserved amongst class B GPCRs.  
Similarly as has been reported from mutations within the E/DRY motif 
(Rovati et al., 2007), mutations within the HETX motif have also been shown 
to result in constitutive receptor activity. For example mutation of T6.42 within 
GCGR to alanine led to an increased constitutive activity (Hjorth et al., 1998), 
suggesting this motif may be implicated in maintaining the receptor in an 
inactive state.  
 
1.17.3.  TM2-6-7-Helix 8 network in class B GPCRs 
 
The TM2-6-7-Helix 8 (R2.46, R/K6.37, N8.47 and E8.49) network similarly to HETX 
motif, has been implicated to form part of the class A E/DRY motif equivalent 
in class B GPCRs (Vohra et al., 2013). It should be noted that position N8.47 
has also been denoted N7.61 in the literature (Liang et al., 2017 and Zhang et 
al., 2017), and is at the TM7-helix 8 junction.  
Within GLP-1R, R1762.46, R3486.37 and helix 8 N4068.47 and E4088.49 
were implicated to be important for stabilising the inactive receptor (Wootten 
et al., 2016) and outward movement of TM6 on receptor activation breaks 
these polar interactions (Zhang et al., 2017b). The residues within this 
disrupted network may in turn form electrostatic interactions with the α5-helix 
of Gs (Zhang et al., 2017b). This outward opening of the cytoplasmic half of 
TM6 and the cytoplasmic end of TM5, TM2, TM3 and TM7 was shown to form 
the binding cavity for Gs and additional electrostatic interactions described 
between E4128.53 of helix 8 and H171 of ICL1 with Gβ of the G protein (Zhang 
et al., 2017b). 
A similar TM2-6-7-helix 8 network was also evident in the GCGR 
structure involving R1732.46, R3466.37, N4048.47 and E4068.49  (Siu et al., .2013) 
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and within the CTR structure involving R1802.46, K3406.37 N3958.47 and 
E3978.49   (Liang et al., 2017). In both the GCGR inactive structure and a CTR 
homology model, R2.46 forms tight interactions with R/K6.37 and E8.49 (Sui et al., 
2013 and Liang et al., 2017, respectively). Whilst the salt bridge between R2.46 
and E8.49 was maintained in the active CTR-Gs structure, the one between 
K6.37 and E8.49 was broken with the residues shown to be 26 Å apart, thereby 
releasing constraints on TM6 (Liang et al., 2017). These findings may 
implicate the importance of the helix 8 E8.49 for class B GPCR activity (Section 
1.18.2). 
1.18.  Intracellular GPCR domains ICL1 and Helix 8 
 
The intracellular region of GPCRs consists of ICL1-3, helix 8 and the C-
terminus which are all capable of forming interactions with GPCR effectors 
including G proteins, kinases and β-arrestins (Venkatakrishnan et al., 2013). 
A number of studies looking at class B GPCRs have proposed critical roles 
for residues within ICL1-3 including maintaining GPCR in an inactive state 
(Martínez-Archundia and Correa-Basurto, 2014), coupling to G proteins 
(Mathi et al., 1997, Conner et al., 2006 and Kleinau et al., 2010), protein 
folding and correct transport (Thomas et al., 2007). Here, we focus on 
previous research looking at the importance of ICL1 and helix 8 only.  
 
1.18.1.  The importance of ICL1 in cell-surface expression and G protein-
coupling 
1.18.1.1.  ICL1 cysteine and cell-surface expression 
 
The importance of ICL1 C2.44 has been studied in GPCRs including GLP-1R, 
PTHR1 and the CLR (Mathi et al., 1997 and Underwood et al., 2013, Thomas 
et al., 2007 and Conner et al., 2006, respectively).  Mutation within CLR 
(C149A2.44) had no influence on receptor cell-surface expression or cAMP 
response (Conner et al., 2006), whereas the similar mutation in GLP-1R 
(C174A2.44) resulted in reduced cell-surface expression and cAMP response 
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(Mathi et al., 1997 and Underwood et al., 2013). Similarly, C2172.44 of PTHR1 
was implicated as a critical determinant of cell-surface translocation and 
function (Thomas et al., 2007). Imaging of mutant PTHR1 showed 
fluorescence signal concentrated to the interior of the cell suggesting C2172.44 
has a distinctive role in protein folding and correct transport (Thomas et al., 
2007).  
 
1.18.1.2.  ICL1 and G protein-coupling 
 
Multiple studies have highlighted the importance of conserved R2.46 for G 
protein-coupling including the CGRP receptor model (R1512.46) (Vohra et al., 
2013) and in the structure of the peptide-activated rabbit GLP-1R in complex 
with heterotrimeric Gs (R1762.46) (Zhang et al., 2017b). Within this latter 
structure, it was suggested that the lost interactions for R1762.46, N4068.47 and 
E4088.39 in helix 8 on receptor activation may be stabilised through hydrogen 
bonds or electrostatic interactions with residues of the Gs α5-helix (Zhang et 
al., 2017b).  
Mutagenesis studies in combination with measurement of secondary 
messenger responses have provided additional evidence to support these 
structural findings. In one such study looking at alanine substitution mutants 
of all the conserved residues within the ICLs of the CGRP receptor, R1512.46 
of the ICL1 region (K145-R151) was found to be crucial for G protein-
coupling, as determined by the sever reduction of CGRP-mediated cAMP 
accumulation, but had no effect on cell-surface expression  (Conner et al., 
2006). Similarly, a number of residues within the ICL1 region of GLP-1R and 
CLR were implicated as important for the cAMP response, suggesting a role 
for ICL1 in Gs-coupling (Mathi et al., 1997 and Conner et al., 2006, 
respectively). The cAMP response measured in C174A2.44, R176A2.46 and 
N177A2.47 GLP-1R was significantly reduced when compared to WT, which 
was not necessarily correlated with reduced cell-surface expression (Mathi et 
al., 1997).  For example, R176A2.46 showed the lowest cAMP response with a 
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10-fold reduced GLP-1(7-36)amide potency but had no reduced cell-surface 
expression when compared to WT (Mathi et al., 1997).  In another study, 
mutation of GIPR R1692.46 to alanine resulted in a 7-fold reduction in cAMP 
potency with a small decrease in cell-surface expression (Cordomí et al., 
2015).   
The importance of ICL1 has also been implicated in class A GPCRs. In 
one such study, the ICL1 and helix 8 amino acids of the class A GPCR 
thyrotropin receptor (TSHR) were systematically investigated using site-
directed mutagenesis and cAMP and IP accumulation assays (Kleinau et al., 
2010). A number of ICL1 alanine mutants were found to reduce both cAMP 
and IP accumulation whereas some (and a single helix 8 mutant) were 
identified to impact IP but not cAMP accumulation (Kleinau et al., 2010). This 
finding was interpreted as TSHR Gq-coupling requiring more selective 
interactions when compared to Gs-coupling and was speculated to be the 
case for other GPCRs (Kleinau et al., 2010). This may implicate ICL1 as a 
mediator of G protein selectivity and therefore could be involved in signalling 
bias.  
 
1.18.2.  Helix 8 of GPCRs 
 
Within GPCRs, the structure of the cytoplasmic C-terminus is the least well-
defined domain and likely reflects the conformational plasticity (Sensoy and 
Weinstein, 2014). Within class A GPCRs, helix 8 is defined as an 
amphiphathic helix that is initiated just after the conserved NPXXY motif in 
TM7, usually oriented parallel to the membrane bilayer and perpendicular to 
the TM bundle (Gehret et al., 2010). Despite very little or no sequence 
homology between class A and B GPCRs, there is suggested to be striking 
topological similarity of helix 8 (Conner et al., 2008) (Figure 1.4). The CTR 
structure revealed a very long extended helix 8 (Liang et al., 2017) similar to 
that in the GCGR structure detailing a 20-residue helix 8 (Sui et al., 2013). 
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The conserved nature of helix 8 in both structures suggested that this might 
be a conserved feature of not only class A GPCRs but also class B GPCRs. 
Helix 8 is implicated in a range of functions including cell-surface 
expression (Timossi et al., 2004, Liang et al., 2017) and G protein-coupling 
(Delos Santos et al., 2006, Kleinau et al., 2010). Interestingly, one helix 8 
TSHR mutant was found to reduce IP but not the cAMP response, implicating 
this residue as sensitive to Gq but not Gs activation and may suggest a role 
for helix 8 in G protein-coupling specificity (Kleinau et al., 2010). 
Intramolecular links between helix 8 and the TM domains have been 
observed in a number of GPCRs structures and have been implicated to be 
important in receptor activation and deactivation for both class A (Huynh et 
al., 2009) and class B GPCRs (Zhang et al., 2017b). In particular, E8.49 is fully 
conserved in class B GPCRs and may play a role in GPCR activation 
(Kirkpatrick et al., 2012) where it has been implicated in the TM2-6-7-helix 8 
network (Section 1.17.3) and G protein-coupling (Liang et al., 2017). For 
example, helix 8 residues within the structures of CTR (A4078.59, W4138.65 and 
Q4088.60) and GLP-1R (R4198.60 (and possible further electrostatic interaction 
with E4128.53 and ICL1 H17112.49)) were predicted to interact with Gβ  (Liang 
et al., 2017 and Zhang et al., 2017b, respectively). It is possible helix 8 plays 
a crucial part of a functional activation switch. With this in mind, determining 
the interactions between helix 8 and other regions within the GPCR and how 
this might influence receptor signalling is of interest.  
1.19.  Aims of this study  
 
In order to understand how GPCRs, through multiple conformational states, 
mediate signal transduction at the molecular level, we must begin to 
understand how agonist binding leads to receptor activation and subsequent 
stimulation of downstream signalling. We hypothesise that GCGR is able to 
activate multiple downstream signalling cascades.  
Using mutagenesis, knockout cell lines and multiple assays measuring 
downstream signalling components (cAMP, pERK1/2 and Ca2+i mobilisation), 
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this work aims to explore this hypothesis and expand current knowledge on 
GCGR activity. We aim to characterise the action of two known GCGR 
agonists (GCG and oxyntomodulin) and two potential GCGR antagonists 
(des-His1,[Glu9]-glucagon amide (des-His1,[Glu9]-GCG) and L-168,049 
(Unson et al., 1989 and Cascieri et al., 1999,. respectively)) both in 
transfected and hepatocyte cell lines. We also aim to investigate the activity 
of the GCG analogue TH-GCG, previously suggested to act at a receptor 
distinct from GCG (Wakelam et al., 1986). 
We aim to investigate the ICL1 region and several other residues 
within GCGR including the helix 8 residues E4068.49 (implicated in the TM2-6-
7-helix 8 network (Section 1.17.3) and G protein-coupling (Liang et al., 2017)) 
and three TM4 residues (G2714.49, L2774.55, V2804.58) (suggested to form a 
homodimerisation interface in GLP-1R (Harikumar et al., 2012)) to determine 
their importance for both GCGR cell-surface expression and signalling. The 
A2AR, due to the availability of multiple crystal structures, was chosen as an 
archetype class A Gs-coupled receptor to further investigate the importance of 
ICL1 across GPCR classes. 
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Chapter 2.  Materials and Methods 		
2.1.  Cell culture methodology 	
2.1.1.  Cell lines  
 
Cell lines were maintained using standard subculturing routines as guided by 
the European Collection of Cell Culture (ECACC) and checked annually for 
mycoplasma infection using an EZ-PCR mycoplasma test kit from Biological 
Industries (Kibbutz Beit-Haemek, Israel).  All procedures following were 
performed in a sterile tissue culture hood using aseptic technique and 
solutions used in the propagation of each cell line were sterile and pre-
warmed to 37oC. 
The Flp-In human embryonic kidney-293 (HEK 293) cells stably 
expressing the GLP-1R and the CRISPR/Cas9 genome-edited HEK 293 cells 
were kindly gifted to us by Dr Dan Donnelly (University of Leeds) and Dr 
Asuka Inoue (Tohoku University, Japan), respectively. All HEK 293 cell lines 
and HEK 293T cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10 percent fetal bovine serum (FBS) purchased 
from Sigma-Aldrich Company Ltd (Sigma-Aldrich, F9665) (Dorset, UK) and 
placed in a humidified 5 percent CO2 incubator at 37oC. Human black 
hepatocyte carcinoma (Hep 3B) cells were purchased from ATCC (Middlesex, 
UK) and cultured in minimal essential medium Eagle (MEME) (Sigma-Aldrich, 
M5650), supplemented with 10 percent FBS and 2 mM L-glutamine (Sigma-
Aldrich). Chinese hamster ovary (CHO)–K1 cells, including the CHO-K1 cells 
stably expressing GCGR or GLP-1R (kindly gifted to us by Dr David Hornigold 
and Dr Jacqui Naylor at MedImmune Ltd, Cambridge UK) were cultured in F-
12 Nutrient Mixture (Ham) GlutaMAXTM purchased from Thermo Fisher 
Scientific (31765035) (Wilmington, Massachusetts, US) supplemented with 10 
percent FBS. All cell lines were harvested following washing with PBS using 
0.05 percent Trypsin-ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich, 
59417C). 
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2.1.2. CRISPR knockout HEK 293 cell lines 
 
The parental HEK 293 cell line and the various knockout HEK 293 cell lines 
generated through the use of CRISPR/Cas-based RNA-guided DNA 
endonucleases where kindly made and gifted to us by Dr Asuka Inoue 
(Alvarez-Curto et al., 2016). Here, the genes encoding the various G proteins 
and β-arrestin1/2 were targeted by a CRISPR-Cas9 system (Ran et al., 2013) 
with some modifications (Schrage et al., 2015). Briefly, HEK 293 cells were 
transfected with G protein/β-arrestin1/2 targeting sgRNA sequence containing 
vector(s) (pX330; Addgene plasmid 442230) and a pGreen Lantern vector 
encoding a GFP. GFP-positive cells were isolated using a cell sorter (SH800, 
Sony, Japan), and cultured in a 96-well plate for approximately 2 weeks until 
wells containing an apparent single colony were selected for passages. 
Successful introduction of the null mutation was confirmed through a 
polymerase chain reaction  (PCR) and restriction enzyme digest or Sanger 
sequencing method (FASMAC, Japan), western blot analysis for protein 
expression and through functional assays. The absence of G protein or β-
arrestin1/2 expression in each cell line, although confirmed by others (Schrag 
et al., 2015, Alvarez-Curto et al., 2016), was not re-confirmed by us.  
 
2.1.3.  GCGR stable expressing HEK 293 cell line generation 
 
The aminoglycoside antibiotic Geneticin®, or G418 (Thermo Fisher Scientific) 
was used to select for HEK 293 cells expressing pmCherry-N1 vector 
(Clontech Laboratories, 632523) (California US) containing the neo gene 
(Davies and Jimenez, 1980) and GCGR (made by a previous postdoctoral 
research associate in the Dr Ladds laboratory group, Dr Cathryn Weston). 
The optimum concentration of G418 to select for transfected cells was 
determined through performing a kill curve (Figure 2.1). Here, HEK 293 cells 
were treated with several antibiotic concentrations ranging from 100-1000 
µg/ml in a 24-well tissue culture plate and the lowest concentration at which 
100 percent death occurred over the 10 days determined as 800 µg/ml G418. 
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HEK 293 cells were seeded at 25 percent confluency in the antibiotic 
containing media 48 hours post-transfection and the media changed every 3 
days. Following selection and passage, cells were maintained in 800 µg/ml 
G418. Stably expressing HEK 293 cells were confirmed using a fluorescence 
microscope to assess cell-surface expression of the mCherry-tagged GCGR 
and measuring cAMP accumulation following stimulation with GCG using the 
LANCE® cAMP Detection Kit (PerkinElmer, Inc. (Waltham, Massachusetts, 
US) (Section 3.6).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.4.  Long-term storage and recovery 	
Cells cultured in a 75 cm2 flask at approximately 80 percent confluence were 
harvested, washed and suspended in 2 ml of freezing down media (90 
percent FBS, 10 percent dimethyl sulfoxide (DMSO)) and divided equally into 
two cryogenic vials (Greiner Bio-One, Kremsmünster, Austria) prior to 
placement in a freezing container at -80 oC for 24 hours and subsequently 
being transferred to a liquid nitrogen vessel. 
0 2 4 6 8 10
0
20
40
60
80
100
Time (Days)
C
el
l v
ia
bi
lit
y 
(%
) 200 µg/ml
400 µg/ml
600 µg/ml
800 µg/ml
1000 µg/ml
Control
Figure 2.1. G418 kill curve for HEK 293 cells. A kill curve was 
performed for HEK 293 cells to determine the optimal concentration of 
G418. This was determined as the lowest concentration required in 
order to kill 100 percent of HEK 293 cells (800 µg/ml).  
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Recovery of cells from long term storage was achieved by thawing the 
cells in a 37oC water bath with constant agitation for 2 minutes and 
transferred to a 25 cm2 flask containing 10 ml of pre-warmed growth media. 
Once healthy cells were completely adhered, the media was replaced and the 
cell lines maintained as previously described.   
 
2.2.  Hepatocyte Isolation from C57BL/6 mouse  
 
Dr Maja Wallberg performed the following procedure for the extraction of 
intact hepatocyte from C57BL/6 mice within the small laboratory animal unit of 
the Department of Pathology (University of Cambridge) in accordance with 
the UK Animals Scientific Procedures Act (1986). The following protocol was 
adapted from Mederacke et al., 2015 and Shen et al., 2012. Rather than 
using anesthetised live mice, these mice were euthanised and used for both 
islet isolation and hepatocytes isolation for same day experiments, thereby 
minimising waste. Mouse euthanasia was performed and abdomen entered 
through a midline incision. The inferior vena cava was exposed by carefully 
moving the viscera outside of the abdominal cavity. Using a 23-gauge syringe 
needle, 5 ml ice-cold collagenase P (Roche Diagnostics, 11213857001) 
solution (0.5 mg/ml) dissolved in HBSS (containing 1 mM CaCl2 and 10 mM 
HEPES (Thermo Fisher Scientific)) was injected into the inferior vena cava.  
 Once the liver appeared pale in colour and inflated, the portal vein was 
cut and the remaining collagenase P injected. The liver was then cut out of 
the mouse and placed into ice cold HBSS, supplemented as above, on ice 
prior to transfer to a 37oC water bath for 20 minutes The tissue was then 
transferred through a metal tea strainer into a falcon tube to release the 
hepatocytes before centrifuging for 2 minutes at 1000 RPM. The digested and 
mechanically separated liver was then transferred through a sterile nylon 
mesh into a 15 ml falcon tube and washed twice in unsupplemented DMEM 
with 2 minutes centrifugation at 1000 RPM. Hepatocytes were then counted 
using a hemocytometer and cell viability determined using trypan blue 
(Sigma-Aldrich) staining. Typically, hepatocytes showed a 1:1 ratio of live and 
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dead hepatocytes. Hepatocytes were delivered in DMEM culture medium 
(Thermo Fisher Scientific) to the Department of Pharmacology (University of 
Cambridge) within 15 minutes of completing the extraction for cAMP 
accumulation assay (LANCE® Ultra cAMP Detection Kit (PerkinElmer)). 
 
2.3.  Cell viability assay 
 
The quantification of ATP as a measure of cell viability was conducted using 
the CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Wisconsin, 
US). Since ATP amount is directly proportional to cell number (Section 3.8.1), 
cell number when comparing viability across cell lines was controlled for. 
Cells were harvested using 0.05 percent Trypsin-EDTA (Sigma-Aldrich) and 
washed before counting and plating in 25 µl of media (5000 cells/well) on a 
white 384-well Optiplates (PerkinElmer). 25 µl of the CellTiter-Glo® Reagent 
containing thermostable luciferase from the firefly Photuris pennsylvanica 
(Ultra-GloTM Recombinant Luciferase) was added to each well containing the 
cells and incubated at room temperature on an orbital shaker for 2 minutes to 
induce cell lysis. The amount of ATP was determined using an ATP standard 
curve where a tenfold serial dilution of adenosine 5’-triphosphate disodium 
salt hydrate (Sigma-Aldrich) (10 µM to 0.01 nM; 25 µl contains 2.5 x 10-10 to 
2.5 x 10-16 moles of ATP) was made immediately prior to addition of 25 µl 
reagent. Media without cells was used as a blank control, again with the 
addition of 25 µl of the CellTiter-Glo® Reagent. The plate was then incubated 
at room temperature for 10 minutes to allow signal stabilisation prior to 
reading the luminescence on a Mithras LB 940 (Berthold technology Ltd, Bad 
Wildbad, Germany). 
 
2.4.  Transient transfection 
 
Transfections were conducted 24 or 48 hours prior to assay using either 
Fugene® HD (Roche Diagnostics) or more commonly polyethylenimine (PEI, 
linear, MW = 25,000 g/mol) (Polysciences Inc) at a 1:3 DNA:Fugene ratio or 
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1:2 DNA:PEI ratio when cells were 60-80 percent confluent (Section 3.3). PEI 
was dissolved to a concentration of 1 mg/ml in accordance with the 
manufacturers instructions. Briefly, 100 mg of PEI was added to 90 mL of 
water (i.e. to a concentration of 1.11 mg/ml) and 12 M hydrochloric acid (HCl) 
was added to reach a pH less than 2.0. The solution was stirred continuous 
for approximately 3 hours until the solution became mostly clear prior to the 
addition of 10 M sodium hydroxide dropwise until a pH 7.0 was achieved. 
Aliquots of stock PEI were stored at -20°C. DNA concentration for transfection 
was determined for each individual cell line and expression vector but unless 
otherwise stated was conducted as shown in Table 2.1 and optomised in 
Section 3.2.3. For Fugene® HD, serum free media and Fugene® HD was 
allowed to complex for 5 minutes prior to addition of DNA and a further 15 
minutes incubation before addition to plated cells dropwise. For transfection 
with PEI, serum free media, DNA and PEI were allowed to complex for 10 
minutes prior to addition to plated cells dropwise.  
 
 
2.5.  Ligands and compounds 
 
GCG, oxyntomodulin, 1-N-α-trinitrophenylhistidine,12-homoarginine)glucagon 
(TH-GCG) (made up in DMSO), GLP-1(7-36)amide and GLP-1(9-36)amide 
and oxytocin were synthesised by Alta Biosciences (University of 
Birmingham, UK). des-His1,Glu9-glucagon amide was purchased from 
Bachem (Bubendorf, Switzerland) and L-168,049 purchased from Trocris 
Biosciences (Bristol, UK). The small molecular agonist of GLP-1R, BETP (4-
Table 2.1. Transfection components according to size of tissue culture 
plate for Fugene® HD and PEI 
 
Tissue 
culture 
plate 
Total 
media 
volume 
DNA 
amount 
DNA 
(100ng/
ul 
stock) 
Serum 
free 
media to a 
total of  
Fugene® 
HD 
PEI 
(1mg/
mL 
stock) 
96-well 100 µl 100 ng 1 µl 10 µl 0.3 µl 0.2 µl 
24-well plate 500 µl 250 ng 2.5 µl 25 µl 0.75 µl 0.5 µl 
6-well plate 1000 µl 500 ng  5 µl 50 µl 1.5 µl 1 µl 
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(3-benzyloxyphenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine) (Willard et 
al., 2012), was purchased from Tocris Biosciences and made up in DMSO. 
The potent adenosine receptor agonist 5’-N-Ethylcarboxamidoadenosine 
(NECA) was purchased from Thermo Fisher Scientific and the selective A2AR 
agonist, CGS 26180 (2-[p-(2-carboxyethyl)phenylethylamino]-50-
ethylcarboxamidoadenosine) (Jarvis et al., 1989) from Trocris Biosciences, 
both of which were made up in DMSO. Unless otherwise stated, all ligands 
were made up in deionised water, supplemented with 0.1 percent BSA 
(Sigma-Aldrich, A2153) in order to reduce adsorption to plastic or glass 
surfaces. 
Forskolin, a potent activator of AC (AC1-8 but not 9 or 10) leading to 
elevations in cAMP (Seamon et al., 1981) was purchased from Sigma-Aldrich 
and made up in DMSO. NF449, a suramin analogue, was purchased from 
Abcam (Cambridge, UK) and used to pretreat cells at 10 µM for 30 minutes 
prior to ligand stimulation as previously reported (Halls and Cooper, 2010). 
The availability of YM-254890, a specific Gq/11 inhibitor (Takasaki et al., 2004), 
has been described as restricted by the scientific community (Xiong et al., 
2016). However, this compound was readily available and purchased from 
Wako Pure Chemical Industries Ltd (Osaka, Japan) and used at 100 nM for 
30 minutes prior to ligand stimulation. The specific Gβγ small molecule 
inhibitor gallein  (Santa Cruz Biotechnology, Inc, Texas, USA) (Lehmann et 
al., 2008) was used to pretreat cells at 0.1 µM, 1 µM and 10 µM for 30 
minutes (Dubin et al., 2012) prior to ligand stimulation. The cAMP analogue 
and PKA inhibitor Rp-8-bromo-cAMP (Rp-8-Br-cAMP) (Sigma-Aldrich) 
(Schwede et al., 2000) was used to pre-treat cells at 10 µM for 15 minutes 
(Gjertsen et al., 1995) prior to ligand stimulation. The inhibitory were all made 
up in DMSO and in experiemnts ‘untreated’ cells were treated with the 
equivalent amount of DMSO as a control.  
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2.6.  Constructs and molecular biology 	
2.6.1.  RAMP constructs 	
cDNA constructs of pcDNA3.1 expressing N-terminally FLAG-tagged RAMPs 
were kindly donated by Prof. Patrick Sexton (Monash University, Australia). 
The dual expression pVITRO1-neo-MCS vector (pVITRO) (Figure 2.2) was 
purchased from InvitroGen (Paisley, UK). Various pVITRO constructs were 
made using standard molecular cloning techniques including RAMP1 (as a 
none interacting control) or FLAG-tagged RAMP2 at multiple cloning site 1 
(MCS1) with or without N-terminally myc-tagged GCGRmCherry at multiple 
cloning site 2 (MCS2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. pVITRO1-neo-mcs vector map. The pVITRO1-neo-mcs 
plasmid, containing two multiple cloning sites (MCS), is selected with 
kanamycin in E.coli and G418 in mammalian cells. Taken from 
InvitroGen document containing information about the vector.  
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2.6.2.  GCGR constructs 
 
GCGR ICL1 alanine mutants (G165A, L166A, S167A, K168A, L169A, H170A, 
C171A and T172A) were kindly donated by Dr. Ali Jazayeri (Heptares 
Therapeutics). Dr Cathryn Weston, a past member of the Dr Ladds 
Laboratory group, previously cloned myc-GCGR into the vector pmCherry-N1 
vector and pcDNA3.1  (Clontech Laboratories, 632523). The GCGR mutants 
(Table 2.2) were made using this pmCherry-N1 vector expressing myc-tagged 
GCGR.  
All oligonucleotides used for mutagenesis were designed using the 
online Agilent Genomics  ‘QuikChange Primer Design’ tool (Table 2.2). For 
multiple and single mutations, the QuikChange Lightening Multi Site-Directed 
Mutagenesis Kit (Agilent Technologies) or QuikChange Lightening Site-
Directed Mutagenesis Kit (Agilent Technologies) was used in accordance with 
the manufacturers instructions, respectively. The reaction components and 
cycle parameters for each of the QuikChange Lightening kits are detailed in 
Table 2.3 and Table 2.4, respectively. The elongation cycle parameter of 186 
seconds is based on 30 seconds/kb for the template size of 6203 bp 
(pmCherry-N1 vector (4722 bp) with the inserted GCGR (1431 bp)). All 
mutants in the pmCherry-N1 vector were sequenced using the CMV forward 
oligonucleotide (CGCAAATGGGCGGTAGGCGTG) and mCherry reverse 
oligonucleotide (CATGAACTCCTTGATGATGGC).  
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Table 2.2. Oligonucleotides used to create GCGR mutants in ICL1, TM2, TM4 and 
helix 8. WT GCGR was initially cloned into pmCherry-N1 vector and all 
oligonucleotides designed using the online Agilent Genomics ‘QuikChange Primer 
Design’ tool. 
 
Target 
 
Product 
 
Oligonucleotide targeting 
sense strand of template 
 
 
Oligonucleotide targeting 
antisense strand of template 
 
ICL1  S167A, 
K168A 
489GGTGCAGTGCAGCgcGC
TGAGGCCCCCC517 
517GGGGGGCCTCAGCgcGCT
GCACTGCACC489 
ICL1 S167R, 
K168R 
488GGTGCAGTGCAGCcTtCT
GAGGCCCCCCA517 
517TGGGGGGCCTCAGaAgGCT
GCACTGCACC488 
TM2 R173A 503CGTGGATGGCATTGgcG
GTGCAGTGCAGCT534 
534AGCTGCACTGCACCgcCAA
TGCCATCCACG503 
TM2 R173A, 
N174A 
500GATTCGCGTGGATGGCA
gcGgcGGTGCAGTGCAGCTT
GC540 
540GCAAGCTGCACTGCACCgc
CgcTGCCATCCACGCGAATC50
0 
TM4 V280A 820CTGCCCAGGGGcCGACG
AACAGCATGGGGGCAC852 
852GTGCCCCCATGCTGTTCGT
CGcCCCCTGGGCAG820 
TM4 L277A, 
V280A 
820CTGCCCAGGGGcCGACG
AACgcCATGGGGGCAC852 
852GTGCCCCCATGgcGTTCGT
CGcCCCCTGGGCAG820 
TM41 G271A, 
L277A, 
V280A 
825GGGCACCCCAGgCGATG
CCCAGG803 
 
803CCTGGGCATCGcCTGGGG
TGCCC825 
 
Helix 8 E406A 1205GCTCCGACTGCACCgCC
TTGTTGAGGAAG1233 
1233CTTCCTCAACAAGGcGGT
GCAGTCGGAGC1205 
Helix 8 E410A 1220GCCGCCGCAGCgCCGA
CTGCACC1242 
1242GGTGCAGTCGGcGCTGCG
GCGGC1220 
Helix 82 E406A, 
E410A 
1220GCCGCCGCAGCgCCGA
CTGCACC1242 
1242GGTGCAGTCGGcGCTGCG
GCGGC1220 
1Triple mutant made using double mutant as template 
2Double helix 8 mutant made using E406A as template, therefore oligonucleotides used 
to make double mutant are the same as creating single E410A mutant 
The start and end nucleotide position within the GCGR sequence bound by the 
oligonucleotide are indicated by superscript and point mutations are indicated by lower 
case. 
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2.6.3.  GLP-1R construct 
 
The GLP-1R in pGFP-N1 vector was generously donated to us by Dr. 
Alessandro Bisello (Univeristy of Pittsburgh). 
 
 
 
 
	
Table 2.3. Reaction components for QuikChange (site or multi site-
directed) mutagenesis kit. 
 
Site-Directed Mutagenesis Kit 
 
 
Multi Site-Directed Mutagenesis Kit 
10x reaction buffer 5µl 10x reaction buffer 2.5µl 
dsDNA template 100 ng dsDNA template 100 ng 
Sense primer 125 ng Sense primer 100 ng 
Antisense primer 125 ng Antisense primer 100 ng 
dNTP mix 1µl dNTP mix 1µl 
QuikSolution 
reagent 
1.5µl QuikSolution reagent 0.75µl 
ddH2O To a final volume 
of 50µl 
ddH2O To a final 
volume of 25µl 
QuikChange 
Lightening enzyme 
blend 
1µl QuikChange 
Lightening Multi 
enzyme blend 
1µl 
			
Table 2.4. Cycle parameters for QuikChange (site or multi site-directed) 
mutagenesis kit. 
 
Site-Directed Mutagenesis Kit 
 
 
Multi Site-Directed Mutagenesis Kit 
Step Cycles Temp Time (s) Step Cycles Temp Time (s) 
1 1 95°C  120  1 1 95°C  120  
2 18 95°C 20  2 30 95°C 20  
60°C 10 55°C 30 
68°C 186 65°C 186 
3 1 68°C 300 3 1 65°C 300 
4 1 4°C Paused  4 1 4°C Paused  		
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2.6.4.  A2AR constructs  
 
The A2AR receptor was first cloned into the pmCherry-N1 vector and the 
mutants subsequently made using the QuikChange Lightening Site-Directed 
Mutagenesis Kit (Agilent Technologies) in accordance with the manufacturers 
instructions and as detailed previously (Tables 2.3 and 2.4). The elongation 
cycle parameter of 179 seconds is based on 30 seconds/kb for the template 
size of 5952 bp (pmCherry-N1 vector (4722 bp) with the inserted A2AR (1230 
bp)). The oligonucleotides used for site-directed mutagenesis were designed 
using the online Agilent Genomics ‘QuikChange Primer Design’ tool (Table 
2.6.8).  
  
Table 2.5. Oligonucleotides used to create A2AR mutants in ICL1 region, TM1, 
ICL1 and TM2. WT A2AR was initially cloned into pmCherry-N1 vector and all 
oligonucleotides designed using the online ‘QuikChange Primer Design’ tool. 
 
Product 
 
 
Oligonucleotide targeting sense 
strand of template 
 
 
Oligonucleotide targeting 
antisense strand of template 
L33A 74GCAGGTTGCTGTTGgcCCACA
CGGCCCAGC103 
103GCTGGGCCGTGTGGgcCAACA
GCAACCTGC74 
N34A 77TCTGCAGGTTGCTGgcGAGCC
ACACGGCCC106 
106GGGCCGTGTGGCTCgcCAGCA
ACCTGCAGA77 
S35A 79ACGTTCTGCAGGTTGgcGTTG
AGCCACACGGC110 
110GCCGTGTGGCTCAACgcCAAC
CTGCAGAACGT79 
N36A 81GGTGACGTTCTGCAGGgcGCT
GTTGAGCCACACG114 
114CGTGTGGCTCAACAGCgcCCT
GCAGAACGTCACC81 
L37A 84GTTGGTGACGTTCTGCgcGTT
GCTGTTGAGCCAC117 
117GTGGCTCAACAGCAACgcGCA
GAACGTCACCAAC84 
Q38A 86AGTAGTTGGTGACGTTCgcCA
GGTTGCTGTTGAGCC121 
121GGCTCAACAGCAACCTGgcGA
ACGTCACCAACTACT86 
N39A 87CACAAAGTAGTTGGTGACGgc
CTGCAGGTTGCTGTTGAGC126 
126GCTCAACAGCAACCTGCAGgc
CGTCACCAACTACTTTGTG87 
V40A 93CCACAAAGTAGTTGGTGgCGT
TCTGCAGGTTGCTG127 
127CAGCAACCTGCAGAACGcCAC
CAACTACTTTGTGG93 
T41A 95CACCACAAAGTAGTTGGcGAC
GTTCTGCAGGTTGC129 
129GCAACCTGCAGAACGTCgCCA
ACTACTTTGTGGTG95 
N42A 96CAGTGACACCACAAAGTAGG
CGGTGACGTTCTGCAGGTTG135 
135CAACCTGCAGAACGTCACCgcC
TACTTTGTGGTGTCACTG96 
The start and end nucleotide position within the GCGR sequence bound by the 
oligonucleotide are indicated by superscript and point mutations are indicated by lower 
case 
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2.7.  RNA extraction, quality determination and cDNA synthesis 	
2.7.1.  RNA extraction 
 
Where possible, all solutions and glassware were treated with 0.1 percent 
(v/v) diethyl pyrocarbonate (DEPC) for the inactivation of RNase prior to 
autoclaving. Gel electrophoresis tank for RNA integrity analysis was treated 
for 10 minutes with 3 percent hydrogen peroxide.  
RNA was extracted from HEK 293T or Hep 3B cells cultured to ~80 
percent confluence in a 6-well plate using an RNeasy Plus Mini Kit purchased 
from QIAGEN (Manchester, UK) in accordance with the manufacturers 
instructions. The principle of this kit involves homogenisation of cells in a 
buffer containing the strong protein denaturant guanidine-isothiocyanate, 
immediately inactivating RNase. The lysate was then passed through a spin 
column to eliminate genomic DNA (gDNA). Here, guanidine-isothiocyanate 
(being a strong chaotropic agent) also disrupting the structure of the nucleic 
acid and helps to drive gDNA binding to the column. Ethanol was then added 
to the flow through, providing binding conditions for RNA, and subsequently 
passed through a RNeasy spin column where the RNA binds to the 
membrane prior to elution in RNase free water.  
Briefly, HEK 293T or Hep 3B cells in a 6-well plate was washed in 
PBS, trypsinated and FBS supplemented medium added. The suspended 
cells were then transfer to an RNase free polypropylene tube and centrifuged 
for 5 minutes at 300 x g in a microcentrifuge (RPM ~2000). The supernatant 
was aspirated and the pellet loosened by flicking the base of the tube prior to 
addition of 600 µl of Buffer RLT Plus containing β-mercaptoethanol (β-ME) 
(10 µl per 1 ml Buffer RLT Plus) to initiate cell lysis. β-ME addition to the 
buffer is essential and irreversibly denatures RNases released following the 
cell lysis through reducing disulphide bonds. The tube was then vortexed 
briefly and the homogenised lysate transferred to the gDNA elimination 
column placed in a 2 ml collection tube. Following ha centrifugation step at > 
8000 x g (>10,000 RPM) for 30 seconds, 1 volume of 70 percent ethanol was 
	 56 
added to the flow through and transferred to an RNeasy spin column placed 
in a 2 ml collection tube. All the following centrifugation steps were performed 
at > 8000 x g (>10,000 RPM). This column was then centrifuged for 15 
seconds, the flow through discarded prior a wash with 700 µl of Buffer RW1 
and additional 15 seconds centrifugation. The spin column then received two 
washes with 500 µl of Buffer RPE twice and centrifuged for 15 seconds 
followed by 2 minutes. In the final step, the RNeasy spin column was 
transferred to a 1.5 ml collection tube and 50 µl of RNase free water added 
prior to centrifugation for 1 minute. 
 
2.7.2.  RNA quality determination  
 
RNA quality was determined using Nanodrop technology (NanoDrop Lite, 
Thermo Scientific, Wilmington, USA). Pure RNA was indicated with an 
A260/A280 ratio of 1.9–2.1. This ratio is influenced by the solution the RNA is 
eluted in (i.e. water or Tris-HCl) (Okamoto and Okabe, 2000). As such, all 
samples including those with low ratios were further analysed by denaturing 
agarose gel electrophoresis with a ratio of 28s rRNA to 18s rRNA at 
approximately 2:1 indicative of good quality RNA. To make 1 L of running 
buffer, in a fume hood, 20 ml of 37 percent formaldehyde (Sigma-Aldrich) and 
100 ml of 10X MOPS (3-(N-morpholino)propanesulfonic acid) buffer (0.4 M 
MOPS (pH 7.0), 0.1 M sodium acetate, 0.01 M EDTA) was added to 880 ml of 
water. For the gel, 1g of agarose in 72 ml of water was heated until dissolved 
and then cooled to 60°C prior to addition of 10 ml 10X MOPS buffer and 18 
ml 37 percent formaldehyde (12.3 M). Prior to RNA loading, the samples were 
added to equal volumes of the ethidium bromide and formamide containing 
RNA loading dye (Thermo Fisher Scientific, R0641) and heated to 70°C for 10 
minutes to denature. 
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2.7.3.  cDNA synthesis 	
Following RNA extraction and quality determination, complementary DNA 
(cDNA) synthesis was carried out using a QuantiTect Reverse Transcription 
Kit (QIAGEN) according to the manufacturers instructions. Here, 1 µg of RNA 
was used for cDNA synthesis as the protocol was optimised for 10 pg to 1 µg 
of RNA.  Following cDNA synthesis, the samples were placed on ice prior to 
amplification using PCR and Taq DNA polymerase (Thermo Fisher Scientific), 
in accordance with the manufacturers instructions (cycle parameters detailed 
in Tables 2.6 and 2.7) 
 All oligonucleotides for reverse transcription-PCR (RT-PCR) (Table 
2.6) were ordered from Sigma-Aldrich and checked for off-targets using NCBI 
Primer-BLAST. All oligonucleotides were initially tested using vectors 
containing the receptor of interest as template DNA at both 50°C and 60°C. In 
order to determine the size of the PCR products, a 100 bp DNA ladder (New 
England BioLabs, N3231, Massachusetts, USA) was used. 
Table 2.6. Oligonucleotides used in RT-PCR of cDNA synthesised from RNA 
extracted from Hep 3B cells. Reference for each oligonucleotide pair is indicated. 
Gene GenBank 
accession 
number 
Sense 
oligonucleotide 
Antisense 
oligonucleotide 
Siz
e 
Anne
-aling 
temp 
(°C) 
GAPDH1 NM_002046   
 
642TGCACCACCA
ACTGCTTAGC661 
728GGCATGGACTG
TGGTCATGAG708 
87 60 
GCGR2 NM_000160 
 
418CCAGTGTCAC
CACAACCTGA437 
494AGGAATACTTGT
CGAAGGTTCTGT47
1 
77 60 
GLP-1R3 NM_002062 864CTACGTGAGC
ATAGGCTGGG883 
998ATGGGCAGCCG
GATAATGAG 
979 
135 60 
GIPR2 NM_000164 
 
1232CCAAGCTCGG
CTTTGAGAT1214 
1275GTAGAGGACG
CTGACCAGGA1256 
62 60 
CLR4 NM_005795 
 
1150ACCAGGCCTT
AGTAGCCACA1169 
1445ACAAATTGGGC
CATGGATAA1426 
296 60 
RAMP14 NM_005855 
 
210CTGCCAGGAG
GCTAACTACG229 
507GACCACGATGA
AGGGGTAGA488 
298 60 
RAMP24 NM_005854 
 
232GGGGGACGGT
GAAGAACTAT251 
458GTTGGCAAAGT
GGATCTGGT439  
227 60 
RAMP34 NM_005856 
 
90AACTTCTCCCG
TTGCTGCT108 
442GACGGGTATAA
CGATCAGCG423  
353 60 
1 Stockinger et al., 2004.2 Zwermann et al., 2009. 3 Ge et al., 2014. 4 Linscheid et al., 
2005. The start and end nucleotide position within the sequence bound by the 
oligonucleotide are indicated by superscript 
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Table 2.7. Gene specific oligonucleotides to human Gα-subunits used in RT-
PCR of cDNA synthesised from RNA extracted from Hep 3B cells. PrimerBank 
IDs (Spandidose et al., 2010) are also provided. (See Table 1.1 for more 
information on Gα-subunits). 
Gene GenBank 
accession 
number/Prim
er Bank ID 
Sense 
oligonucleotide 
Antisense 
oligonucleotide 
Size Annea
l-ing 
temp 
(°C) 
GNAS AJ224868/ 
3297877a1 
51CGACGACACT
CCCGTCAAC69 
227CCCGGAGA
GGGTACTTTTC
CT207 
177 60 
GNAI1 NM_002069/ 
156071490c1 
254TTAGGGCTAT
GGGGAGGTTGA2
74 
439GGTACTCTC
GGGATCTGTT
GAAA417 
186 60 
GNAI2 NM_0011664
25/261878574
c1 
94TACCGGGCGG
TTGTCTACA112 
182GGGTCGGC
AAAGTCGATCT
G163 
89 60 
GNAI3 NM_006496/ 
169646784c1 
55ATCGACCGCA
ACTTACGGG73 
283AGTCAATCT
TTAGCCGTCC
CA263 
229 60 
GNAZ NM_002073/ 
45580725c1 
44GGTCCCGGAG
AATTGACCG62 
218ATGAGGGG
CTTGTACTCCT
TG198 
175 60 
GNAO NM_138736/ 
162461737c1 
44GGAGCAAGGC
GATTGAGAAAA64 
212GGCTTGTAC
TGTTTCACGTC
T192 
169 60 
GNAQ NM_002072/ 
312176363c1 
189TGGGTCAGGA
TACTCTGATGAA
G211 
332TGTGCATGA
GCCTTATTGTG
C312 
144 60 
GNA11 NM_002067/ 
115511048c1 
220GGCTTCACCA
AGCTCGTCTAC24
0 
391CACTGACGT
ACTGATGCTC
G372 
172 60 
GNA12 NM_007353/ 
42476110c1 
246CCGCGAGTTC
GACCAGAAG264 
490TGATGCCAG
AATCCCTCCA
GA470 
245 60 
GNA13 NM_006572/ 
215820623c1 
79CAGCAACGCA
AGTCCAAGGA98 
298CCAGCACCC
TCATACCTTTG
A278 
220 60 
GNA14 NM_004297/ 
222418795c1 
263GAGCGATGGA
CACGCTAAGG282 
430TCCTGTCGT
AACACTCCTG
GA410 
168 60 
GNA15 NM_002068/ 
156104882c1 
354CCAGGACCCC
TATAAAGTGACC
375 
479GCTGAATCG
AGCAGGTGGA
AT459 
126 60 
The start and end nucleotide position within the sequence bound by the 
oligonucleotide are indicated by superscript 
	 59 
										
 2.8.  Pharmacological characterisation techniques 
 
2.8.1. cAMP accumulation assay  	
1,000 HEK 293T or CHO-K1 cells/well were assayed 24 hours post-
transfection and stimulated with appropriate ligand for 8 minutes prior to 
cAMP accumulation measured using LANCE® cAMP Detection Kit 
(PerkinElmer) (Figure 2.3) in accordance with the manufacturers instructions. 
In order to achieve a bigger signalling window for cAMP assays using CHO-
K1 cells transfected with A2AR, cells were assayed 48 hours post-transfection 
rather than 24 hours.  
For hepatocytes from isolated C57BL/6 mice and Hep 3B cells, 5000 
cells/well were stimulated for 30 minutes and cAMP accumulation measured 
using LANCE® Ultra cAMP Detection Kit (PerkinElmer) (Figure 2.4) in 
accordance with the manufacturers instructions.  
Ligands were diluted in stimulation buffer (PBS supplemented with 0.1 
percent BSA and 0.5mM of the non-specific inhibitor of cAMP and cGMP 
phosphodiesterases (PDEs) 3-Isobutyl-1-methylxanthine (IBMX) (Sigma-
Aldrich) (Schmidt et al., 2000)) to the appropriate concentration range to be 
assayed. Cells were harvested, counted using a heamocytometer, re-
suspended in stimulation buffer and seeded at the appropriate concentration 
in a white 384-well Optiplates (PerkinElmer). The plate was sealed with a 
ThermalSeal® film (EXCEL Scientific, California, US) during incubation 
periods before detecting the time-resolved fluorescence resonance energy 
transfer (TR-FRET) signal using a Mithras LB 940 Ex. λ 340 nm and Em. λ 
Table 2.8.  Cycling parameters for Taq DNA 
polymerase for 200 bp product 
Step Cycles Temperature Time (s) 
1 1 94°C  180  
2 30 94°C 45 
60°C 30 
72°C 18 
3 1 72°C 600 
4 1 4°C Paused  
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665 nm (Berthold technology). TR-FRET combines standard FRET 
technology with time-resolved measurement of fluorescence, allows the 
elimination of short-lived background fluorescence. Here, with the acceptor 
emitting long-lived fluorescence when engaged in FRET, a delay of around 
50-150 µ seconds between excitation and measurement allows any non-
specific short-lived emission to be eliminated. All results were normalised to 
responses seen to endogenous ligand or forskolin maximum (100 µM) 
(Sigma-Aldrich).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Principles of the LANCE® cAMP assay kit. The assay is based 
on competition for binding sites on the cAMP specific antibody between the 
europium labelled cAMP tracer (Streptavidin labelled with europium tightly 
bound to biotin labelled cAMP) and free cAMP produced by the stimulated 
cells (sample cAMP). Light pulse at 340 nm excited the europium of the cAMP 
tracer and the energy emitted is transferred to the Alexa Fluor® 647 labelled 
anti-cAMP antibodies, if bound to the tracer, generating a TR-l signal at 665 
nm. The fluorescence intensity measured at 665 nm will decrease in the 
presence of excess cAMP giving a signal which is inversely proportional to the 
concentration of cAMP. 
Excitation at 340 nm Energy transfer 
Streptavidin 
Eu 
Emission at 615 nm 
Alexa 
TR-FRET Emission at 665 nm 
cAMP 
Alexa-cAMP specific  
antibody 
Biotin-cAMP 
No TR-FRET 
Excess cAMP 
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2.8.2.  Phospho-ERK assay  	
ERK1/2 phosphorylation was measured using the homogeneous time 
resolved fluorescence (HTRF)® Phospho-ERK (T202/Y204) Cellular Assay 
Kit (Cisbio Bioassays, Codolet, France) two-plate format in according with the 
manufacturers instructions. This kit is based on similar principles to the TR-
FRET technology used in the LANCE® cAMP Detection Kit (PerkinElmer), 
combining standard FRET technology with time-resolved measurement of 
fluorescence. HEK 293T cells, 48 hours post-transfection and 24 hours serum 
starved, and Hep 3B cells, serum starved for 4 hours, were harvested using 
0.05 percent Trypsin-EDTA and washed before plating in HBS (50,000 
cells/well) on a white 384-well Optiplates (PerkinElmer). Following 5 minutes 
ligand stimulation at 37oC the cells were incubated at room temperature, on 
an orbital shaker, for 30 minutes with the provided total protein lysis buffer 
(Triton X100) and blocking reagent (sodium orthovanadate). Cells were then 
incubated for 2 hours at room temperature with premixed phospho-ERK1/2 
Cryptate (donor)/d2 antibody (acceptor) (v/v) prepared in detection buffer. At 
Figure 2.4. Principles of the LANCE® Ultra cAMP assay kit. The assay 
principle is similar to that of the LANCE® cAMP assay kit, where there is 
again competition between the europium labeled cAMP tracer and the sample 
cAMP for binding to the cAMP-specific monoclonal antibody. Here however, 
rather than labeled with Alexa Fluor® 647, the antibody is labeled with 
ULightTM dye. 
Excitation at 340 nm 
Energy transfer 
Eu 
Emission at 615 nm 
TR-FRET Emission at 665 nm 
cAMP 
ULight-cAMP specific  
antibody 
cAMP 
No TR-FRET 
Excess cAMP 
ULightTM 
ULightTM 
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all incubation stages, the plate was sealed with a ThermalSeal® film (EXCEL 
Scientific). Plate reading was conducted using a Mithras LB 940 (Berthold 
technology). All results were normalised to 5 minutes stimulation with 1 µM 
Phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich), a direct protein 
kinase C (PKC) activator (Jiang and Fleet, 2012) 
 
2.8.3.  Intracellular Ca2+ mobilisation assay 
 
HEK 293T or CHO-K1 cells were transfected 24 hours following plating at 
50,000 cells per well of a Poly-L-lysine (PLL) (Sigma-Aldrich) coated 96 well 
F-bottom µCLEAR® black CELLSTAR® microplates (Greiner Bio-One). 48 
hours post-transfection, cell media was removed, washed once in HBS and 
incubated with 100 µl per well of Fluo-8, AM (21092-AT) (Stratech Scientific, 
Newmarket, UK) or CalciFluor™ Rhod-4, AM (Santa Cruz Biotechnology, Inc) 
dye solution (Ca2+ containing HBS with Pluronic® F-127 (Thermo Fisher 
Scientific), at a 1:1000 dilution) for 1 hour in the dark at room temperature. 
Such dyes allow the measurement of Ca2i mobilisation from the endoplasmic 
reticulum (ER), downstream from Gq–mediated signalling (Figure 2.5). Fluo-8, 
AM was used for all assays with the exception of those investigating 
receptors containing a GFP-tag. For GFP-tagged constructs, Rhod-4, AM was 
the dye of choice.   
In order to achieve the optimal Ca2+i mobilisation signal in assays 
using CHO-K1 cells, HBS was supplemented with probenecid (soluble at 1 M 
NaOH) (Alfa Aesar, Massachusetts, USA) to inhibit organic-anion transporters 
and thereby block efflux of intracellular dyes (Di Virgillo F et al., 1990). In 
such experiments, probenecid (working concentration of 2.5 mM and the 
supplemented HBS subsequently buffered to pH 7.4) was used in all wash 
stages and dye loading, excluding the final step before ligand addition.  
Following dye removal, cells were washed and treated with 100 µl of 
Ca2+ containing HBS for 30 minutes at room temperature in the dark to allow 
for de-esterification. In experiments using the specific Gq/11 inhibitor YM-
254890 (Takasaki et al., 2004), the Ca2+ containing HBS was supplemented 
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with 100 nM YM-254890. The HBS was then replaced with nominally Ca2+ 
free HBS prior to ligand stimulation with 20 µl of each ligand at appropriate 
concentrations. Detection of Fluo-8, AM or CalciFluor Rhod-4, AM was then 
conducted on a FlexStation® Multi-Mode Microplate Reader (Molecular 
Devices, Sunnyvale, California US), using Ex. λ 490 nm and Em. λ 520 nn or 
Ex. 530 nm and Em. 555 nm, respectively. For each individual experiment, 
the minimum and maximum fluorescence values (F) of the indicator (Fmin and 
Fmax) when Ca2+-free (addition of 20 µl nominally Ca2+ free HBS containing 
0.1 percent triton and 10 mM BAPTA (selective chelator of Ca2+)) and Ca2+-
saturated (addition of 20 µl HBS containing 0.1 percent triton, 10 mM CaCl2), 
together with the background fluorescence were determined. Once 
background fluorescence was subtracted from each reading, the cytosolic 
free Ca2+ concentration ([Ca2+]i) was calculated using the equation:  
 
 
 
 
where Kd for Fluo-8 AM is 390 nM and the Kd for Rhod-4 AM 525 nM. For data 
analysis, the original Ca2+i responses are plotted as change in intracellular 
Ca2+ (Δ[Ca2+]i nM) over time and the maximum response at each ligand 
concentration plotted against log concentration to generate concentration 
dose-response curves.   Data were analysed using a three-parameter logistic 
equation to acquire pEC50, Emax, Basal and Span (refers to the range (Emax – 
Basal)) values.  
 
 
2.8.4.  IP1 accumulation assay 
 
The accumulation of inositol monophosphate (IP1), the downstream 
metabolite of inositol 1, 4, 5-triphosphate (IP3) induced by the activation of 
phospholipase C (PLC), was measured using the IP-One HTRF® assay kit 
(Cisbio Bioassays) (Figure 2.5) in accordance with the manufacturers 
[!"!!]! = !!  ! (! − !!"#)(!!"# − !) 	
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instructions. This assay utilises lithium chloride (LiCl) which inhibits the 
activity of inositol monophosphatase preventing the breakdown of IP1, thus 
resulting in accumulation of IP1 which can be measurement as a substitute for 
IP3 (Garbison et al., 2004). Based on a competition or native IP1 and IP1 
coupled to the dye d2 by the monoclonal antibody, the signal is inversely 
proportional to the concentration of IP1 in the cell lysate.   
HEK 293T cells were harvested, re-suspended in stimulation buffer 
and counted 48 hours post-transfection.  Cells were plated at various 
densities in a 7 µl volume of stimulation buffer were plated on white 384-well 
Optiplates (PerkinElmer). Ligands were diluted in stimulation buffer containing 
LiCl (50 mM) to the appropriate concentration range to be assayed. Cells 
were subsequently stimulated with 7 µl of ligand, the plate sealed with a 
ThermalSeal® film (EXCEL Scientific) and then incubated for 2 hours at 
37oC. Following the addition of the HTRF® reagents, IP1 coupled to the dye 
d2 followed by the monoclonal antibody labeled with Lumi4TM-Tb cryptate 
specific for IP1 (3 µl of each), the plate was incubation for 2 hour at room 
temperature prior to HTRF® signal detection using a Mithras LB 940 
(Berthold technology) Ex. λ 620 nm and Em. λ 665 nm. All results were 
calculated from the 665nm / 620nm ratio and expressed as a percentage of 
the response seen to carbacol.  
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2.9. Receptor cell-surface expression analysis 
 
2.9.1. Enzyme-linked Immunosorbent Assay (ELISA)  
  
HEK 293T cells were seeded onto PLL-coated 24-well plates and assayed 48 
hours post-transfection. All incubation steps were conducted at room 
temperature on a orbital shaker unless stated otherwise. Cells were fixed with 
250 µl of formaldehyde (3.7 percent) for 15 minutes without shaking, washed 
three times with PBS and treated with 500 µl of PBS supplemented with 1 
percent BSA (Sigma-Aldrich, A2153) for 45 minutes. Cells were then 
Figure 2.5 Schematic of Gq–mediated signalling following GPCR activation 
and tools to measure the downstream signalling components. Activation of 
phospholipase C (PLC) by Gq leads to increased intracellular diacylglycerol 
(DAG) and inositol 1,3-5,triphosphate (IP3). Elevated intracellular levels of IP3 in 
turn act on IP3R on endoplasmic reticulum (ER), leading to mobilisation of Ca2+ 
from the ER (Mikoshiba, 2007) which can be measured using fluorescent Ca2+ 
binding dyes such as Fluo-8, AM (Startech Scientific) (image shows Ca2+ 
signalling HEK 293 cells) IP1 can be measured using the IPOne assay (Cisbio 
Bioassays) to infer intracellular levels of IP3. This assay utilises lithium chloride 
(LiCl), which inhibits the breakdown of IP1 resulting in accumulation in the cells 
(Garbison et al., 2004). 
 
Ligand	bound	GPCR	
αq	
Ca2+	
	
IP3	
IP2	IP1	
LiCl	
Myo-inositol	
PLCβ	
	
	
IPOne	assay	-	Cisbio	
PIP2	 DAG	
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incubated for 1 hour with 250 µl of primary antibody (mouse anti-myc, (Fisher 
Scientific, Loughborough, UK) or mouse anti-FLAG M2 (Sigma-Aldrich) 
diluted 1:2000 in PBS with 1 percent BSA. Following a second wash stage 
and a second blocking stage for 15 minutes, cells were incubated for 1 hour 
with 250 µl of secondary antibody (anti-mouse horseradish peroxidase (HRP)-
linked antibody (GE-Healthcare, Pittsburg, PA) in PBS) diluted 1:4000. 
Following a final wash stage, cells were treated with 250 µl of SigmaFast O-
phenylenediamine dihydrochloride (OPD) (Sigma-Aldrich) in accordance with 
manufacturers instructions. The reaction was stopped with 1M sulphuric acid 
(H2SO4) and absorbance measured using a Mithras LB 940 microplate reader 
(Berthold technology) at 492 nm. Ideally, readings were normalised to co-
transfected RAMP2/CLR as 100 percent and untagged RAMP1 as a none-
interacting control as 0 percent, where appropriate.  
 
 
2.9.2. Fluorescence-activated cell sorting (FACS) analysis of GCGR cell-
surface expression 
 
HEK 293T cells were harvested 48 hours post-transfection with GCGR 
constructs using a non-enzymatic cell dissociation solution (Sigma-Aldrich) 
and washed with PBS prior to counting. 1 x 106 cells were washed three times 
in FACS buffer (PBS supplemented with 1 percent BSA and 0.03 percent 
sodium azide) before re-suspending in 50 µl FACS buffer containing anti-
GCGR (AGR-024 (Alomone Labs, Jerusalem, Israel)) at 1:50 dilution and 
incubated at room temperature for 1 hour. All samples were washed three 
times with FACS buffer and re-suspended in 50 µl FACS buffer containing 
Allophycocyanin (APC)-conjugated anti-Rabbit IgG (Thermo Fisher Scientific, 
31984) at 1:150 dilution and incubated for 1 hour at room temperature in the 
dark. The cells received a final three washes and were re-suspended in 300 
µl FACS buffer. Due to propidum iodide (PI) (Thermo Fisher Scientific) 
staining (10 µl per sample for 10 minutes) only showing less than 5 percent of 
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the population as dead and showing considerable spectral overlap with APC it 
was not used to eliminate dead cell from data analysis.  
FACS analysis was conducted using a BD Accuri™ C6 Plus Flow 
Cytometer which is equipped with a blue (488 nm) and red (640 nm) laser, 
two light scatter detectors (FSC and SCC) and four fluorescence detectors 
(FL1 Em. λ 530/30 nm, FL2 Em. λ 585/40 nm, FL3 Em. λ 570 and FL4 Em. λ 
675/25 nm). FL2 and FL4 optical filters were chosen for PI (Ex. λ 535 nm and 
Em. λ 617 nn) and APC (Ex. λ 633 nm and Em. λ 660 nn), respectively. 
Unstained cells and cells transfected with vector alone were used as controls 
for autofluorescence and unspecific antibody binding, respectively. All data is 
collected by the flow cytometer and analysis can be conducted at anytime 
using the BD Accuri™ C6 software (Section 3.9). As such, experimental set 
up and data collection was equivalent regardless of the fluorescent protein 
tagged to the GCGR (GFP- or mCherry-tagged). The images for figures were 
made in FlowJo® (V7.6.5), an analysis platform for single-cell flow cytometry 
analysis.  
 
 
2.10.  Molecular biology techniques 
 
2.10.1.  Molecular cloning reagents  	
All restriction endonucleases, T4 DNA ligase and Taq DNA polymerase were 
purchased from Life Technologies Ltd and used in accordance with the 
manufacturers instructions. Taq DNA polymerase was used for amplification 
of DNA products for the purpose of analysis.  The high fidelity DNA 
polymerase Phusion® (New England BioLabs) was used for amplification of 
products to be used in cloning. Sigma-Aldrich synthesised all 
oligonucleotides. Standard methods of DNA preparation were utilised as 
previously described (Sambrook et al, 1989). Plasmid DNA was isolated and 
purified using a QIAprep Miniprep Kit (Qiagen) and recovered from agarose 
gels using QIAquick Gel Extraction Kit (Qiagen). 
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2.10.2.  Bacterial transformation 	
Escherichia coli (E. coli) DH5α competent cells (Stratagene, San Diego, 
California, US) were used for amplification of plasmids. An aliquot of DH5α 
cells, stored at -80°C, was thawed on ice for 30 minutes prior to addition of 
100 ng of high quality DNA, gentle mixing and a further 30 minutes incubation 
on ice. The competent cell and DNA mixture was then subject to heat shock 
at 42°C for 30 seconds and returned to ice for 2 minutes. 500 µl of pre-
warmed Lysogeny broth (LB) broth was added to the cells and incubated 
shaking (220 RPM) at 37°C for one hour. Following this step, an appropriate 
volume was plated on prewarmed agar plates containing the selective 
antibiotic, the plate inverted and incubated at 37°C for 16 hours overnight.  
 
2.10.3.  PCR amplification of DNA for cloning 	
The DNA polymerase Phusion® High-Fidelity DNA polymerase (New England 
BioLabs) was used in accordance with the manufacturers instructions for a 
total reaction volume of 50 µl. This reaction contained Phusion HF buffer, 10 
ng of template DNA, 200 µlM deoxyribonucleoside triphosphates (dNTPs) 
consisting of dATP, dCTP, dGTP and dTTP (purchased from Fermentas) and 
0.5 µM of both forward and reverse oligonucleotides (Synthesised by Sigma-
Alrich Co Ltd). Post addition of 0.5 µl of the polymerase enzyme itself 
thermocycling was conducted in a T3 Thermocycler (Biometra, Göttingen 
Germany).  
 
2.10.4.  PCR screening of plasmid DNA from bacterial colonies 	
Single bacterial colony was suspended in 100 µl of sterile distilled H2O and 1 
µl of this suspension used as a template in a 10 µl PCR reaction. The PCR 
products and 1 kb DNA ladder (New England BioLabs, N3232) were ran on a 
1-2 percent agarose gel stained with 0.5 µg/ml ethidium bromide to 
determining the presence or absence of DNA insert.   
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2.10.5.  Quality control and sequencing of DNA 	
Quality of DNA was checked through gel electrophoresis on 1-2 percent 
agarose gel stained with 0.5 µg/ml ethidium bromide and the 260/280 nm 
ratio (~1.8 accepted as pure) determined through measurement of nucleic 
acid concentration using a Nanodrop Lite (Thermo Fisher Scientific). 
Sequencing of constructs prior to use was completed by GATC (GATC 
Biotech, London, UK). 
 
2.11. Common media 
 
2.11.1. Hanks balanced salt solution (HBS)  	
HBS was made both Ca2+ containing and Ca2+-free (Table 2.9) and adjusted 
to pH 7.3 using NaOH. All protocols using HBS contain Ca2+ unless stated 
otherwise.  
 
Table 2.9. Components Ca2+ containing and Ca2+-free of HBS 
Component Final Concentration Amount per 1 L 
NaCl 135mM 7.89g 
KCl 5.9mM 0.44g 
MgCl2.6H2O 1.2mM 0.245g 
CaCl2 * 1.5mM 1.5ml of 1M stock 
HEPES 11.6mM 2.75g 
Glucose 11.5mM 2.05g 
* Not added for Ca2+-free HBS 
 
2.11.2. Phosphate buffer saline (PBS) 	
PBS was made using tablets (Sigma-Aldrich, P4417) dissolved in deionised 
water and autoclaved. Here a single tablet in 200 ml water gives a solution 
composed of 0.1 M phosphate buffer, 0.0027 M potassium chloride and 0.137 
M sodium chloride solution at a pH of 7.4.  
 
2.11.3. Bacterial growth medium  	
Lysogeny broth (LB broth) was made using LB broth powder (Sigma-Aldrich, 
L3022) and used for growth of E. coli bacteria. Here, 10 g of powder was 
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dissolved in 500 ml of deionised water prior to autoclaving for sterilisation. 
Addition of antibiotic (Ampicillin or kanamycin at a working concentration of 
100 µg/mL or 50 µg/mL, respectively (both purchased from Sigma-Aldrich)), 
where appropriate, was performed after cooling. Similarly, LB broth agar 
plates were made using LB broth powder with the addition of agar  (Sigma-
Aldrich, 05040). Again, autoclaving was performed and antibiotic added as 
appropriate following cooling to 60°C in a water bath. Pouring of plates was 
performed next to a flame. Plates were allowed to solidify and dry at room 
temperature overnight before sealing in a bag and storing at 4°C. 
 
2.12.  Data analysis 	
All concentration response data were analysed using Prism 6 version 6.0h 
(GraphPad Software Inc., San Diego, California, US). –logEC50 (pEC50) and 
Emax values were determined using the following three-parameter logistic 
equation as described previously (May et al., 2007): 
 
 
 
where Basal represents the y value in the absence of ligand(s); Emax is the 
maximal system stimulation in the presence of ligand(s) (in other words the 
lower and upper plateaus of the concentration response curve); [A] is the 
ligand concentration, and logEC50 is the concentration of ligand which 
generates a half maximal response (Emax). 
 
To determine efficacy in the system, data was fitted to the operational model 
of agonism (Black and Leff, 1983) using the following equation, which was 
manually inputted into Prism 6 by Dr Graham Ladds: 
 
 
 
! = !"#"$ + (!!!" − !!"#"$)1+ 10(!"#!"!"!!"# ! )!!
! = !"#"$ + !! − !!"#"$1+ ( 10!"#!! + (10!"#![!]))/(10(!"#!!!"#![!]))!
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where Basal represents the y value in the absence of ligand; Em is the 
maximal system stimulation; KA is the dissociation constant of agonist-
receptor in molar concentration; [A] is the ligand concentration, and τ is the 
operational measure of efficacy which as previously mentioned incorporates 
both signalling efficacy and receptor density. 
This model explicitly describes agonist function in terms of the ligand-
receptor interaction and the subsequent receptor signal transduction cascade 
(Kenakin et al., 2012). This allows the estimation of log KA, the agonist-
receptor functional dissociation constant, and log τ, the operational measure 
of efficacy which incorporates signalling efficacy (the efficacy of the agonist to 
activate a particular pathway and the ability and the system to convert the 
receptor stimulus into a response) and receptor density (Kenakin et al., 2003, 
Wootten et al., 2016). The operational model of agonism is widely used but a 
number of limitations, which include the fact that the model does not consider 
dynamics and does not account for ligand-independent signaling (Stott et al., 
2016). In addition, the model cannot correct for examples in which other co-
factors that affect signaling are differentially expressed, such as GRKs 
(Gundry et al., 2017). 
Where appropriate, the obtained values of efficacy, τ, and dissociation 
constant, KA, were then used to quantify signalling bias as change in log 
(τ/KA) (∆log(τ/KA)) relative to the reference ligand or wild-type receptor, as 
described previously (Kenakin et al., 2012): 
 ∆!"# !!! = !"# !!! !"#$ − !"# !!! !"#"$"%&" !"#$%& 
 ∆!"# !!! = !"# !!! !"#$%# − !"# !!! !"#$ !"#$ 
 
To determine the actual ligand bias (∆∆log(τ/KA)) of an agonist for one 
pathway over another it is necessary to evaluate the differences between 
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∆log(τ/KA) values for a given agonist between pathways and  is given by the 
equation: ∆∆!"# !!! = ∆!"# !!! !"#!!"# ! − ∆!"# !!! !"#!!"# ! 
 
pEC50, basal, maximal responses, pKA and log τ obtained from fitting 
concentration response curves were compared by paired Student’s t-test or 
one-way ANOVA followed by Dunnett’s test for multiple comparisons. Cell-
surface analysis data from ELISA or FACS analysis was compared by one-
way ANOVA followed by Dunnett’s test for multiple comparisons. 
 
 
2.13.  Modeling mutant GPCR structure  	
Modeller (version 9.18) can be used for homology and comparative modeling 
of protein 3D-structure (Eswar et al., 2007) and allows us to mutate specific 
residues within a pre-existing protein structure where Protein Data Bank 
(PDB) files exist. The PDB format provides a standard representation for 
protein structures derived from X-ray and NMR studies. Here, Modeller was 
used for rapid comparative modeling for each substitution mutation made in 
both the GCGR and A2AR to provide predictions to help explain experimental 
data. The current available GCGR PDB files used in this work included 5XEZ 
(Zhang et al., 2017), 5ee7 (Jazayeri et al., 2016) and 4l6r (Siu et al., 2013) 
and for A2AR includes 3EML (Jaakola et al., 2008). 
The Modeller command (mod9.18 mutate_model.py seq1 165 ALA A > 
seq1A.log) was run from the Mac OS X ‘Terminal’ application using Python 
2.3. This command reads the PDB file (in the example this is seq1), changes 
the sequence as determined by the residue number and defined amino acid 
on the specified chain (in this example; 165, alanine (ALA) and A (only one 
chain in the chosen PDB files), respectively), build new coordinates for the 
other atoms and write the mutated file (seq1A.log). All PDB files were viewed 
in MacPyMol (version 1.7.4.5) and the WT (original PDB file) and mutated 
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receptor (PDB file created by running the command) compared visually to 
assess any predicted changes in amino acid interactions and structure.  
 
 
2.14.  Live cell imaging in HEK 293 cells  	
Transfected cells were seeded into an 8-well microscope slide (Thistle 
Scientific, Glasgow, UK) and placed in a humidified 5 percent CO2 incubator 
at 37°C for 25 hours. Growth medium was replaced with HEPES buffer 
(Thermo Fisher Scientific) prewarmed to 37°C, as detailed previously (Weston 
et al., 2015). Cells were viewed on a True Confocal Scanner Leica TCS SP5 
microscope (Leica Microsysems Ltd, Milton Keynes, UK).  
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Chapter 3.  Establishing a robust assay system 
	
3.1. Introduction  
In the work presented in this thesis, investigation of receptor pharmacology 
required utilisation of a number of assays for the measurement of 
downstream signalling components, receptor cell-surface expression 
analysis, pharmacological tools and cell lines. Having recently started to 
utilise cell lines for the investigation into receptor cell signalling, these 
methods were new to the Ladds’ research group and required optimisation in 
order to establish robust assay systems.  In this chapter, steps taken to 
achieve such optimisation for a number of variables for the measurement of 
cAMP and IP1 accumulation are detailed. These variables included; cell 
number, ligand stimulation time, DNA concentration at transfection, time post-
transfection and DNA transfection reagent. We also investigated the activity 
of two G protein inhibitors for the purpose of exploring G protein-coupling of 
GPCR.  
We conducted characterisation of a number cell lines, utilised in 
chapters 4 and 5 to answer key research questions. These included the 
generated stably GCGR expressing HEK 293 cell line, various CRISPR G 
protein and β-arrestin1/2 knockout HEK 293 cell lines (gifted from Dr Asuka 
Ioune) and the immortalised human hepatocellular carcinoma cell line, Hep 
3B.  
Finally, we detailed steps in the analysis of data acquired from FACS, 
conducted using the BD Accuri™ C6 Plus Flow Cytometer, to quantify GCGR 
cell-surface expression. Using this method of receptor cell-surface analysis, 
we also investigated the possibility of manipulating cell-surface expression by 
altering DNA concentration. This was conducted with the aim of achieving 
equal WT and mutant receptor cell-surface expression in order to investigate 
the influence of such mutation on GCGR signalling, independent of cell-
surface expression variability. 
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3.2.  Optimisation of the cAMP assay  
3.2.1.  Cell number 
 
In order to establish a robust assay system, optimisation of cell number for 
the cAMP accumulation assay (LANCE® cAMP Detection Kit or LANCE® 
Ultra cAMP Detection Kit) are essential. Flp-In HEK 293T cells stably 
expressing the GLP-1R (hereafter referred to as Flp-In GLP-1R HEK cells) 
and Flp-In CHO-K1 cells stably expressing the GLP-1R (hereafter referred to 
as Flp-In GLP-1R CHO-K1 cells) were acquired at the beginning of this work 
and, despite expressing GLP-1R rather than the predominant receptor of 
interest (GCGR), provide an initial starting point for establishing a robust 
assay system. 
Flp-In GLP-1R HEK cells were plated at a range of cell numbers in a 
384-well plate and stimulated for 30 minutes with forskolin prior to measuring 
cAMP accumulation. The cAMP standard curve (SC) was used to assess the 
dynamic range of the assay and to estimate the quantity of cAMP produced 
by a cell (Figure 3.1). The concentration dose-responses seen to forskolin at 
the various cell numbers were shown to reside within the cAMP SC (Figure 
3.2). Unsurprisingly, the basal cAMP accumulation and forskolin maximum 
response were shown to be cell number dependent with both showing 
elevations on increasing cell number (Table 3.1). The signalling window at 
4,000 and 5,000 cells per well was reduced (as indicated by the span) with an 
apparent increased forskolin potency (Table 3.1), indicating that we are at the 
upper end of the dynamic range of the LANCE® cAMP assay. These findings 
suggest that the optimal cell number was 1,000 or 2,000 where the forskolin 
concentration dose-response curve covers most of the linear region of the 
cAMP SC (marked by the dashed grey line in Figures 3.1 and 3.2) and show 
the largest signalling window (span). With these findings in mind, 1,000 cells 
per well was chosen as the optimal number for the experiments utilising the 
LANCE® cAMP assays described in chapters 4 and 5, unless otherwise 
stated. 
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Figure 3.1. Typical LANCE cAMP standard curve. The representative curve 
contains 4 repeats conducted in duplicate. The grey dashed line marks the 
linear region of the cAMP standard curve. All values are mean ± SEM 
expressed LANCE Signal at 665 nm detected using a Mithras LB 940 
(Berthold technology) Ex. λ 340 nm and Em. λ 665 nm. 
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Figure 3.2. Forskolin stimulated cAMP response in Flp-In HEK 293T cells 
plated at various densities. Flp-In HEK 293T cells expressing GLP-1R were 
plated at various cell numbers on a 384-well plate, exposed to forskolin for 30 
minutes and cAMP accumulation detected. The grey dashed line marks the 
linear region of the cAMP standard curve as shown in Figure 3.1. All values 
are mean ± SEM expressed as percentage cAMP standard curve (SC) 
response where n = 3 independent experimental repeats, conducted in 
duplicate.  
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3.2.2.  Ligand stimulation time  
3.2.2.1. To include or exclude the ‘true basal’ stimulation point? 
 
Flp-In HEK 293T stably expressing GLP-1R showed a concentration-
dependent increases in cAMP accumulation following forksolin stimulation for 
30 minutes and the fitted concentration dose-response curve was found to 
reside within the dynamic range of the cAMP assay (Figure 3.1). However, 
the ideal stimulation time appeared to depend on the potency of the ligand 
investigated and the cellular model chosen. The fitted concentration dose-
response curve to cAMP accumulation data acquired in Flp-In GLP-1R CHO-
K1 cells or Flp-In CHO-K1 cells stably expressing GCGR (hereafter referred 
to as Flp-In GCGR CHO-K1 cells) were found to depend on the inclusion or 
Table 3.1.  Forskolin stimulated cAMP response in Flp-In HEK 293T 
cells plated at various densities. Potency (pEC50), maximal response 
(Emax), basal and span for forskolin response measured in Flp-In HEK 293T 
cells stably expressing GLP-1R using a cAMP accumulation assay 
 
 cAMP 
Cell number pEC50 a Emax b Basal c Span d 
1,000 6.12 ±0.1 64.5 ±1.7 29.9 ±1.0 34.5 ±1.9 
2,000 6.38 ±0.1 71.2 ±1.3* 41.8 ±0.9*** 29.5 ±1.5 
4,000 6.95 ±0.2** 72.1 ±1.2** 50.7 ±1.0*** 21.4 ±1.5*** 
5,000 6.92 ±0.1** 81.6 ±0.9*** 57.3 ±0.8*** 24.4 ±1.2** 
 
Flp-In HEK 293T cells stably expressing GLP-1R were stimulated with 
forskolin prior to measurement of cAMP accumulation to generate 
concentration response curves. To calculate pEC50, Emax, Basal and Span 
values, data were analysed using a three-parameter logistic equation. 
.a Negative logarithm of forskolin concentration required to produce a half-
maximal response 
b Maximal response to  forskolin as percentage cAMP standard curve (SC) 
c The low plateau of the fitted sigmoidal concentration dose-response curve 
d The difference between Emax and basal signalling 
All values are mean ± SEM expressed percentage cAMP SC response 
where n = 3 independent experimental repeats, conducted in duplicate. 
Statistical significance (*, p<0.05;**, p<0.01;***, p<0.001) comparing 
forskolin response in 1,000 cells/well was determined by one-way ANOVA 
with Dunnett’s post test. 
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exclusion of the ‘true basal’ (stimulation with buffer only) data point (Figure 
3.3).  
In Flp-In GCGR CHO-K1 cells, a 30 minute stimulation with 
oxyntomodulin produced a concentration dose-response where the fitted 
curve at low concentrations of oxyntomodulin (0.01 pM to 10 pM) was in line 
with the ‘true basal’, irrespective of inclusion or exclusion of the ‘true basal’ 
stimulation data point (Figure 3.3 A). Here, the fitted oxyntomodulin 
concentration dose-response curves were identical, irrespective of the ‘true 
basal’ point. However, stimulation with GCG, known to be a more potent 
agonist at the GCGR when compared to oxyntomodulin (Weston et al., 2015, 
Section 4.2.1), showed a significantly elevated cAMP accumulation (72.6 ±1.9 
percentage forskolin response) at only 0.1 pM of GCG (Figure 3.3 A).  
A similar scenario was found in Flp-In GLP-1R CHO-K1 cells (Figure 
3.3 B). A 30 minute stimulation of Flp-In GLP-1R CHO-K1 cells with the small 
molecule agonist of GLP-1R, BETP (Willard et al., 2012), produces a 
concentration dose-response where the cAMP accumulation points at low 
concentrations of the compound (10 pM - 0.1 µM) were in line with the ‘true 
basal’ stimulation point (shown as 10 pM on Figure 3.3 B). However, 
stimulation with 0.1 pM of GLP-1(7-36)amide showed a large cAMP 
accumulation (78.3 ±1.1 percentage forskolin response).  
The LANCE® cAMP assay utilises IBMX, a non-specific inhibitor of 
cAMP and cGMP PDEs (Schmidt et al., 2000), therefore any cAMP produced 
in the cell will accumulate over the stimulation time period. As a result of this 
large cAMP accumulation between the ‘true basal’ stimulation point and the 
lowest ligand concentration of GCG or GLP-1(7-36)amide, a sigmoidal 
concentration dose-response curve for either ligand could not be determined 
(Table 3.2).  These results are likely to be due to high receptor expression 
where potent agonists, even at very low concentrations, over the 30-minute 
stimulation period is sufficient to induce a large cAMP accumulation and a 
resulting decreased signalling window. Given this finding, further optimisation 
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into the stimulation time was required to circumvent this issue (Section 
3.2.2.2). 
 
Figure 3.3. cAMP response in Flp-In HEK 293T cells stably expressing 
the GLP-1R or GCGR, with or without the true basal stimulation point. A) 
Flp-In HEK 293T cells stably expressing GCGR were stimulated with GCG or 
oxyntomodulin for 30 minutes and cAMP accumulation detected. B) Flp-In 
HEK 293T cells stably expressing A) GLP-1R were stimulated with GLP-1(7-
36)amide or BETP for 30 minutes and cAMP accumulation detected. Cells 
were plated at 1,000 cells per well of a 384-well plate. The ‘true basal’ cAMP 
response is the point at which cells were ‘stimulation’ with buffer only in the 
absence of ligand.  All values are mean ± SEM expressed as percentage 
forskolin response where n = 2 independent experimental repeats, conducted 
in triplicate.  
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 3.2.2.2.  Optimising stimulation time  
 
In order to address the issue surrounding elevated cAMP accumulation at 
very low ligand concentrations, a time course of GLP-1(7-36)amide 
stimulation at various concentrations was performed using Flp-In GLP-1R 
CHO-K1 cells. Here, Flp-In GLP-1R CHO-K1 cells were stimulated with 
forskolin (100 nM), GLP-1(7-36)amide (0.1 nM, 10 nM or 100 nM) or 
Table 3.2.  cAMP response in Flp-In HEK 293T cells stably expressing the 
GLP-1R or GCGR,  with or without the true basal stimulation point. Potency 
(pEC50), maximal response (Emax), basal and span for forskolin response measured 
in Flp-In CHO-K1 cells stably expressing GLP-1R or GCGR using a cAMP 
accumulation assay 
 
Flp-In GCGR CHO-K1 cells 
Ligand +/- True basal  pEC50 a Emax b Basal c Span d 
GCG + N.D    
GCG -  11.09 ±0.2 72.6 ±1.9 72.6 ±3.2 21.3 ±3.6 
Oxyntomodulin + 9.54 ±0.1 91.6 ±3.1 8.9 ±2.2 82.7 ±3.7 
Oxyntomodulin - 9.46 ±0.1 92.3 ±2.2 12.6 ±1.7 79.7 ±2.7 
Flp-In GLP-1R CHO-K1 cells 
Ligand +/- True basal  pEC50 a Emax b Basal c Span d 
GLP-1 + N.D    
GLP-1  - 11.4 ±0.2 95.7 ±1.1 78.4 ±2.1 17.3 ±2.3 
BETP + 5.68 ±0.1 39.1 ±1.9 8.5 ±1.9 30.6 ±2.0 
BETP - 5.68 ±0.1 39.1 ±1.9 8.5 ±1.9 30.6 ±2.0 
 
Flp-In CHO-K1 cells stably expressing GCGR or GLP-1R were stimulated with 
forskolin prior to measurement of cAMP accumulation to generate concentration 
response curves. To calculate pEC50, Emax, Basal and Span values, data were 
analysed using a three-parameter logistic equation. +/- Indicates the inclusion (+) or 
exclusion (-) of the ‘true basal’ stimulation point where cells received stimulation with 
buffer only. 
.a Negative logarithm of forskolin concentration required to produce a half-maximal 
response 
b Maximal response to  forskolin as percentage forskolin response 
c The low plateau of the fitted sigmoidal concentration dose-response curve 
d The difference between Emax and basal signalling 
All values are mean ± SEM expressed percentage forskolin response where n = 2 
independent experimental repeats, conducted in duplicate. Statistical significance (*, 
p<0.05;**, p<0.01;***, p<0.001) comparing ligand responses with or without the ‘true 
basal’ stimulation point was determined by unpaired Student’s t-test (two-tailed). 
N.D denotes not determined, here a true concentration dose-response curve could 
not be fitted to the stimulation data 
 
 
	 81 
stimulation buffer only for 2, 4, 8, 16 or 32 minutes prior to measurement of 
cAMP accumulation.  
Importantly, there was no cAMP accumulation detected following 
stimulation with buffer only at any time point (Figure 3.4). As would be 
expected, the mean cAMP accumulation measured following forskolin or 
GLP-1(7-36)amide stimulation was shown to increase with increasing 
stimulation time (Table 3.2). No significant difference was found between the 
responses measured at 2 and 4-minute stimulation with GLP-1(7-36)amide or 
forskolin. Fitting a three-parameter logistics equation to the cAMP 
accumulation data acquired for each time point following GLP-1(7-36)amide 
stimulation at 0.1 nM, 10 nM and 100 nM produced clear concentration dose-
response curves (Figure 3.5). These data show an enhanced signalling 
window with stimulation time greater than 4 minutes. It is assumed that a 
sigmoidal concentration dose-response curve for 32-minute stimulation would 
not be fitted if a cAMP accumulation point acquired from 0.1 pM GLP-1(7-
36)amide stimulation was included, as previously indicated (Figure 3.3 B).   
The ideal stimulation time would give a large signalling window and 
allow any potential differences in maximum response between ligands to be 
detected. When analysing the responses across GLP-1(7-36)amide 
concentrations and forskolin for each time point, with the exception of 
stimulation buffer only, there was found to be no significant difference in 
mean responses for 2 or 4 minutes stimulation when compared to 0.1 nM 
GLP-1(7-36)amide stimulation (Table 3.2). 
At 32, 16 and 8 minute stimulation, there was a significantly different 
response detected between GLP-1(7-36)amide (0.1 nM) and forskolin 
stimulation. The stimulation time of 8 minutes was the only time which 
showed a significantly different cAMP accumulation between GLP-1(7-
36)amide concentrations (0.1 nM versus 100 nM) (41.52 ±0.96 and 52.39 
±3.06 percentage forskolin response, respectively). 
To asses if the stimulation time of 8 minutes is also appropriate for an 
alternative cell line, Flp-In GLP-1R HEK cells (1,000 and 2,000 cells per well) 
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were stimulated with GLP-1(7-36)amide for 8 minutes and cAMP 
accumulation detected (Figure 3.6). There was shown to be a robust cAMP 
response without an elevated basal for 1,000 cells per well whereas 2,000 
cells still showed a slight elevated basal cAMP level (22.0 ±2.9 percent 
forskolin response). The findings presented here suggest that 8 minutes 
stimulation time and the cell density of 1,000 cells appears to be ideal to 
avoid experimentally induced elevations in basal responses and to enable the 
detection of any potential differences in maximal reposes between ligands. 
With these findings in mind, 8 minutes stimulation time and 1,000 cells per 
well were used in experiments utilising the cAMP assays described in 
chapters 4 and 5, unless otherwise stated.  
 
 
 
 
 
 
 
Figure 3.4. cAMP response in Flp-In CHO-K1 cells stably expressing the 
GLP-1R at various time points. Flp-In GLP-1R CHO-K1 cells (1000 cells per 
well of a 384-well plate) were stimulated with forskolin, GLP-1(7-36)amide or 
stimulation buffer only (no ligand) for various times and cAMP accumulation 
detected. All values are mean ± SEM expressed as percentage forskolin 
response where n = 3 independent experimental repeats, conducted in 
duplicate.  
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Figure 3.5. cAMP concentration dose-response in Flp-In CHO-K1 cells 
stably expressing the GLP-1R at various time points. Three-parameter 
logistics equation fitted to the time point data presented in figure 3.4. Flp-In 
GLP-1R CHO-K1 cells were stimulated with GLP-1(7-36)amide (GLP-1) for 
various times and cAMP accumulation detected. Arrow indicates the optimal 
stimulation time. All values are mean ± SEM expressed as percentage 
forskolin response at 32 minutes where n = 3 independent experimental 
repeats, conducted in duplicate.  
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Figure 3.6. 8 minutes stimulation time at 1,000 and 2,000 cells/well is 
optimal in Flp-In HEK 293T cells stably expressing the GLP-1R. Flp-In 
HEK 293T cells expressing GLP-1R were plated at 1,000 or 2,000 cells/well of 
a 384-well plate, stimulated with GLP-1(7-36)amide for 8 minutes and cAMP 
accumulation detected. Arrow indicates the optimal cell density. All values are 
mean ± SEM expressed as percentage forskolin response where n = 3 
independent experimental repeats, conducted in duplicate.  
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3.2.3.  DNA concentration and time post-transfection  
 
Reducing the ligand stimulation time to 8 minutes was shown to be optimal for 
the measurement of cAMP accumulation in stably expressing Flp-In HEK 
293T and CHO-K1 cells (Section 3.2.2.2). In cells transfected with high copy 
number constructs, such as the vectors pmCherry-N1 expressing GCGR and 
pcDNA3.1 expressing GFP-tagged GCGR, and stimulated for 8 minutes 48 
hours post-transfection, these was found to be a high cAMP accumulation at 
very low concentrations of GCG (0.1 pM – 10 pM) resulting in an elevated 
‘basal’ cAMP response (Figure 3.7). A sigmoidal concentration dose-
response could not be determined with the inclusion of the ‘true basal’ 
stimulation point (Figure 3.7), as was previously described (Section 3.2.2.1, 
Figure 3.3). With the aim of reducing this elevated basal, an optimisation into 
DNA concentration and incubation time post-transfection (prior to 
experimental assay) was conducted. 
 
 
 
 
 
 
 
 
Here, HEK 293T cells in a 24-well plate were transfected with various 
concentrations of pcmCherry-N1 expressing GCGR and assayed for ligand 
Figure 3.7. cAMP response in HEK 293T cells transfected with pcDNA3.1 
containing GCGR: HEK 293T cells 48 hours post transfection with pcDNA3.1 
containing GFP-tagged GCGR were stimulated with GCG for 8 minutes and 
cAMP accumulation detected. Cells were plated at 1000 cells per well of a 
384-well plate. The ‘true basal’ cAMP response is the point at which cells were 
‘stimulation’ with buffer only in the absence of ligand.  All values are mean ± 
SEM expressed as percentage forskolin response where n = 2 independent 
experimental repeats, conducted in duplicate.  
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stimulated cAMP accumulation 24 or 48 hours post-transfection (Figure 3.8). 
The responses seen to stimulation of cells transfected with 50 ng per well of 
GCGR containing vector or vector alone showed significantly reduced 
maximal response, basal and span at both 24 and 48 hours post-transfection 
when compared to 250 ng per well (Figure 3.8 and Table 3.3). In addition, 
these responses were not significantly different from each other, possibly 
indicating unsuccessful transfection at 50 ng per well. Although the measured 
response to GCG in vector only transfected cells could indicate a low level of 
endogenous GCGR expression, the determined potency showed large 
variability in the data (pEC50 8.95 ±0.9 and 9.75 ±0.5 for 24 and 48 hours 
post-transfection, respectively) and consequently, low confidence in the 
determined response.  
The cAMP response to GCG stimulation 24 and 48-hours post-
transfection with GCGR concentrations of 150 and 200 ng per well showed no 
significant differences for potency, maximal response, basal or span values 
(Table 3.3) when compared to 250 ng per well. This indicates that, at least for 
this vector within HEK 293T cells, an increase in DNA concentrations above 
150 ng per well does not translate into an enhanced cAMP response. A direct 
comparison between 24 and 48 hours post-transfection indicate a clear 
discrepancy between basal cAMP levels and the measured range of the 
response (Table 3.3). At 48 hours, there is an elevated basal cAMP 
accumulation and reduction in the signalling window as a consequence. This 
is likely to be an artefact of high receptor expression and as such, where 
transfection of receptor is required, cAMP assays were conducted 24 hours 
post-transfection with 250 ng of DNA (Figure 3.8). For experiments 
investigating weak responses, such as the in CHO-K1 cells transfected with 
A2AR, 48 hours post-transfection was conducted.  
To further investigate the influence of DNA concentration at 24 hours 
post-transfection on the measured cAMP accumulation, HEK 293 cells (gifted 
from Dr Asuka Ioune) were transfected with pmCherry-N1 containing GCGR 
at either 500 ng or 250 ng per well (24-well plate) and stimulated with GCG or 
	 87 
oxyntomodulin (Figure 3.9). Despite a small reduction in oxyntomodulin 
stimulated maximum response at 250 ng per well when compared to 500 ng 
per well (Emax 60.1 ±4.0 and 72.9 ±4.3 percentage forskolin response, 
respectively), there was shown to be no significance difference between each 
responses measured at the two DNA concentrations (Table 3.4). This finding 
confirmed that doubling the DNA concentration at transfection did not 
translate to a proportional increased in maximum cAMP accumulation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. cAMP response in HEK 293T cells 24 or 48 hours post-
transfection with pcDNA3.1 containing GCGR. HEK 293T cells A) 24 or B) 
48 hours post-transfection with pcDNA3.1 containing GFP-tagged GCGR 
were stimulated with GCG for 8 minutes and cAMP accumulation detected. 
Cells were plated at 1,000 cells per well of a 384-well plate. The ‘true basal’ 
point (‘stimulation’ with buffer only) for data acquired from 48 hours post-
transfected cells was excluded to allow fitting of the three-parameter 
concentration dose-response curve. Arrow indicates 250 ng at 24-hours post 
transfection as the chosen optimal conditions. All values are mean ± SEM 
expressed as percentage forskolin response where n = 2 independent 
experimental repeats, conducted in duplicate.  
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Table 3.3. cAMP response in HEK 293T cells 24 or 48 hours post-transfection 
with pcDNA3.1 containing GCGR. Potency (pEC50), maximal response (Emax), 
basal and span for GCG stimulated cAMP response measured in GCGR 
transfected HEK 293T cells 24 and 48 hours post-transfection, measured using 
cAMP assay 
 
 24 hours post-transfection 
DNA (ng/well) pEC50 a Emax b Basal c Span d 
Vector only 8.95 ±0.9 11.0 ±2.5*** 3.0 ±1.3 7.9 ±2.7*** 
50 8.87 ±1.2 1.9 ±3.9*** -5.4 ±2.1** 7.3 ±4.2*** 
100 10.18 ±0.2 42.1 ±2.3* 2.5 ±2.0 39.6 ±3.0* 
150 10.36 ±0.1 55.8 ±2.4 2.6 ±2.2 53.2 ±3.1 
200 10.12 ±0.2 58.3 ±4.0 8.6 ±3.2 57.3 ±5.0 
250 10.19 ±0.2 58.3 ±3.8 8.1 ±3.2 58.3 ±4.9 
 48 hours post-transfection (-True basal) 
DNA (ng/well) pEC50 a Emax b Basal c Span d 
Vector only 9.75 ±0.5 16.0 ±1.8*** 5.7 ±1.6*** 10.3 ±2.3** 
50 9.32 ±0.3 15.8 ±1.2*** 4.5 ±1.3*** 11.2 ±1.7** 
100 9.86 ±0.2 33.5 ±2.1*** 33.5 ±1.9* 24.8 ±2.0 
150 10.14 ±0.2 68.8 ±1.8 48.2 ±2.1 20.6 ±2.7 
200 9.87 ±0.2 67.6 ±1.8 42.9 ±2.4 24.7 ±3.2 
250 9.74 ±0.2 68.1 ±2.3 42.3 ±2.1 25.9 ±3.0 
 
HEK 293T cells 24 or 48 hours post-transfection with pcDNA 3.1 containing GCGR 
were stimulated with GCG prior to measurement of cAMP accumulation.  
.a Negative logarithm of GCG concentration required to produce a half-maximal 
response 
b Maximal response to  GCG as percentage forskolin response 
c The low plateau of the fitted sigmoidal concentration dose-response curve 
d The difference between Emax and basal signalling 
All values are mean ± SEM expressed percentage forskolin response in mock 
transfected (Vector only) where n = 3 independent experimental repeats, conducted 
in duplicate. Statistical significance (*, p<0.05;**, p<0.01;***, p<0.001) between 
responses when compared to 250 ng/well of vector containing GCGR was 
determined  by one-way ANOVA with Dunnett’s post test.  
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Table 3.4. Influence of DNA concentration at transfection on 
measured cAMP response in HEK 293 cells. Potency (pEC50), maximal 
response (Emax), basal and span for GCG/oxyntomodulin stimulated cAMP 
response measured in GCGR transfected HEK 293 cells using cAMP 
assay 
 GCG 
DNA (ng/well) pEC50 a Emax b Basal c Span d 
250 8.7 ±0.1 64.4 ±1.9 5.2 ±1.4 59.2 ±2.3 
500 8.9 ±0.1 69.9 ±2.0 5.3 ±1.8 64.4 ±3.6 
 Oxyntomodulin 
DNA (ng/well) pEC50 a Emax b Basal c Span d 
250 7.0 ±0.1 60.1 ±4.0 6.6 ±1.4 53.5 ±4.2 
500 7.3 ±0.1 72.9 ±4.3 8.8 ±1.3 63.5 ±3.0 
 
HEK 293 cells were transfected with pmCherry-N1 containing GCGR and 
stimulated 24 hours post-transfection with GCG/oxyntomodulin prior to 
cAMP accumulation measurement.  
To calculate pEC50, Emax, basal and span values, data were analysed using 
a three-parameter logistic equation. 
a Negative logarithm of GCG/Oxyntomodulin concentration required to 
produce a half-maximal response 
b Maximal response to GCG/Oxyntomodulin as percentage forskolin 
response (Mock transfected with Vector) 
c The low plateau of the fitted sigmoidal concentration dose-response curve 
d The difference between Emax and basal signalling 
Statistical significance (*, p<0.05;**, p<0.01;***, p<0.001) comparing 
GCG/Oxyntomodulin response at the two DNA  concentration was 
determined using unpaired t test.  
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Figure 3.9. Influence of DNA concentration at transfection on measured 
cAMP response in HEK 293 cells. HEK 293 cells were transfected with 500 
ng/well or 250 ng/well of pmCherry-N1 vector containing GCGR. HEK 293 cells 
(1,000 cells/well), 24 hours post-transfection, were exposed to GCG or 
oxyntomodulin for 8 minutes and cAMP accumulation detected. All values are 
mean ± SEM expressed as percentage forskolin response (100 µM) (mock 
transfected with vector only) were n = 2 independent experimental repeats, 
conducted in duplicate.  	
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3.3.  Transfection reagent  
There are many transfection reagents available to laboratories for the 
introduction of DNA or RNA into cell lines. In our laboratory, Fugene® HD 
transfection reagent was predominantly used for DNA transfection due to its 
apparent low toxicity to cells and ease of transfection of difficult-to-transfect 
cell lines, such as primary cell lines (Gresch and Altrogge et al., 2012). Here, 
polyethylenimine (PEI), a high-charge cationic polymer that readily binds to 
negatively charged DNA, was investigated as an alternative due to its low 
cost (0.0095 pence per transfection with 500 ng of DNA versus 56 pence i.e. 
5936 times cheaper).  
Quantification of ATP as a measure of cell viability was performed in 
PEI or Fugene® HD transfected and untransfected cells using the CellTiter-
Glo® Luminescent Cell Viability Assay (Figure 3.10) (See section 3.8.1 for 
optimisation of ATP assay). There was a significant lower ATP amount for 
both PEI and Fugene® HD transfected HEK 293 cells when compared to 
untransfected cells indicating reduced viability as a consequence of 
transfection. Importantly, there was no statistically significant difference 
between cells transfected with PEI or Fugene® HD suggesting these two 
reagents have equal effects on HEK 293 cell viability.  
In order to measure any differences between transfections reagents at 
the secondary messenger level, the cAMP response to GCG and 
oxyntomodulin was measured in both PEI or Fugene® HD transfected HEK 
293 cells (Figure 3.11 and Table 3.5). Importantly, the potency measured for 
either GCG or oxyntomodulin showed no significant difference between 
transfection reagents. There was however a significantly bigger maximum 
response for GCG and oxyntomodulin (Emax 69.8 ±2.0 and 72.9 ±4.3 
percentage forskolin response, respectively) and signalling window, as 
determined by the span (63.9 ±2.5 and 63.5 ±3.0 percentage forskolin 
response, respectively), for Fugene® HD transfected cells when compared to 
PEI transfected cells (Emax 97.4 ±1.3 and 95.5 ±3.6, Span 86.9 ±1.7 and 83.9 
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±3.7 percentage forskolin response). This is likely to indicate a slightly 
superior transfection efficiency with Fugene® HD when compared to PEI.  
Due to the levels of HEK 293 cell viability being equivalent irrespective 
of the transfection reagent used and PEI being significantly cheaper when 
compared to Fugene® HD, PEI was utilised for transfection of HEK 293 cells 
in routine experiments. For experiments where the maximal response is 
required or in the case where a small measured response needs to be 
maximised, Fugene® HD should be considered.  
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Figure 3.10. Influence of transfection reagent on cell viability in HEK 293. 
Quantification of ATP as a measure of cell viability was conducted using the 
CellTiter-Glo® Luminescent Cell Viability Assay (Promega) in a 384-well 
format with 5,000 cells/well. Comparison of ATP produced from untransfected 
WT HEK 293 cells and GCGR transfected WT HEK 293 cells with either PEI 
or Fugene HD (24 hours post transfection with 500 ng of DNA). Values are 
mean ± SEM expressed in Moles were n ≥ 4 independent experimental 
repeats, conducted in quadruplicate. Statistical significance in comparison to 
WT and between transfection reagents was determined using one-way 
analysis of variance and Dunnett’s post-test.  	
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Figure 3.11. Comparison of transfection reagents on measured cAMP 
response. HEK 293 cells transfected with 500 ng/well of pmCherry-N1 vector 
containing GCGR were stimulated with GCG or oxyntomodulin for 8 minutes 
and cAMP accumulation detected. All values are mean ± SEM expressed as 
percentage forskolin response (100 µM) (mock transfected with vector only) 
were n = 2 independent experimental repeats, conducted in duplicate.). 
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Table 3.5. Comparison of transfection reagents on measured cAMP 
response. Potency (pEC50), maximal response (Emax), basal and span for 
GCG/oxyntomodulin stimulated cAMP response measured in Fugene® HD 
or PEI GCGR transfected HEK 293 cells as measured using a cAMP assay 
 GCG 
Reagent pEC50 a Emax b Basal c Span d 
PEI 8.9 ±0.1 69.8 ±2.0 5.3 ±1.8 63.9 ±2.5 
Fugene  8.9 ±0.1 97.4 ±1.3*** 10.5 ±1.1 86.9 ±1.7** 
 Oxyntomodulin 
Reagent pEC50 a Emax b Basal c Span d 
PEI 7.3 ±0.1 72.9 ±4.3 8.8 ±1.3 63.5 ±3.0 
Fugene 7.4 ±0.1 95.5 ±3.6*** 11.7 ±1.6 83.9 ±3.7* 
 
HEK 293 cells were transfected with pmCherry-N1 containing GCGR using 
Fugene® HD or PEI and stimulated 24 hours-post transfection with 
GCG/oxyntomodulin for 8 minutes prior to cAMP accumulation 
measurement.  
a Negative logarithm of GCG/oxyntomodulin concentration required to 
produce a half-maximal response 
b Maximal response to GCG/oxyntomodulin as percentage forskolin 
response (Mock transfected with Vector) 
c The low plateau of the fitted sigmoidal concentration dose-response curve 
d The difference between Emax and basal signalling 
Statistical significance (*, p<0.05;**, p<0.01;***, p<0.001) comparing 
GCG/Oxyntomodulin response between the two transfection reagents was 
determined using  unpaired t-test (two-tailed) 
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3.4.  Tools to investigate G protein bias  
3.4.1.  NF449; an antagonist of Gs 
 
Many GPCRs have been reported to couple and initiate pathways through 
multiple G proteins (Woehler and Ponimaskin, 2009). Some class B GPCRs 
have been suggested to couple to Gs as well as Gi, including GCGR (Xu and 
Xie, 2009). To determine if we could block Gs in order to study Gi-coupling 
(Figure 3.12), we investigated the activity of NF449, a selective inhibitor of the 
P2X1 receptor with reported inhibitory activity for Gs (Hohenegger et al., 
1998). Flp-In GCGR CHO-K1 cells received a 30-minute pre-treatment with 
NF449 or DMSO control prior to stimulated with forskolin, GCG, 
oxyntomodulin or CT (the cognate ligand to CTR, known to couple to Gs). 
Importantly, NF449 treatment had no influence on the forskolin 
mediated cAMP response (Figure 3.13 A and Table 3.6) indicating that this 
compound has no influence on AC mediated cAMP accumulation. There was 
no difference in the measured cAMP responses to GCG or oxyntomodulin 
stimulated with or without NF449 treatment (Figure 3.13 B and Table 3.6) 
indicating the absence of detectable Gi-coupling at the GCGR. This is distinct 
from a report suggesting Gi/o-coupling of the GCGR (Xu and Xie, 2009). 
However, GCGR could be very efficiently coupled to Gs or there may be a 
high receptor reserve in this cell line making inhibition difficult to detect. With 
this in mind, we next sought to investigate the ability of NF449 to inhibit the 
Gs-stimulated cAMP response following stimulation of an endogenously 
expressing Gs-coupled receptor.  
The concentration-dependent cAMP accumulation to CT indicated the 
endogenous expression of CTR in Flp-In GCGR CHO-K1 cells (Figure 3.13 C 
and Table 3.6). When comparing NF449 pre-treated cells stimulated with CT 
when to untreated cells, there was a significant rightward shift in potency 
(pEC50 9.01 ±0.2 and 10.18 ±0.2, respectively) as predicted (Figure 3.12), but 
no significant change in maximal response in. This finding suggests that CT is 
potentially Gi-coupled and NF449 is indeed capable of inhibiting Gs activity 
	 94 
but this inhibition is not complete, even for an endogenously expressed 
receptor such as CTR. Within this in mind, it is likely that in cell lines where 
receptor expression is high, the incomplete inhibition of Gs activity by NF449 
allows the remaining Gs protein to efficiently activate AC leading to a full 
cAMP response. In order to assess Gi-coupling of GCGR, and indeed other 
receptors, it may be necessary to conduct Gs inhibition experiments in cell 
lines that endogenously express the receptor of interest. Alternatively, a Gs 
knockout cell line in combination with initial forskolin stimulation could be 
used whereby we look for an inhibition of the cAMP response with increasing 
ligand concentration.  
 
Figure 3.12. Schematic of NF449 activity at GS and predicted 
concentration dose-response data. ACs receives stimulatory signals from 
Gs and inhibitory signals from Gi (Tang and Gilman, 1991). GPCRs known to 
couple to Gs-stimulate intracellular cAMP formation though AC whereas 
receptors which couple to Gi result in inhibition of cAMP formation by AC. 
NF449 is a selective inhibitor of the P2X1 receptor with reported inhibitory 
activity for Gs (Hohenegger et al., 1998). If a GPCR is coupled to both Gs and 
Gi-mediated pathways, treatment with NF449 could be predicted to reduce the 
maximum cAMP response when compared to untreated (shown here) or 
reduce the potency of the ligand tested.  
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Figure 3.13. Assessing NF449 as an inhibitor of GS activity. Flp-In GCGR 
CHO-K1 cells (1,000 cells/well) were pre-treated with NF449 10 µM or DMSO 
control for 30 minutes prior to stimulated with A) forskolin, B) the GCGR 
agonists, GCG or oxyntomdulin or C) CT for 8 minutes and cAMP 
accumulation detection. All values are mean ± SEM expressed as percentage 
forskolin response where n = 3 independent experimental repeats, conducted 
in duplicate.  
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3.4.4.  YM-254890; an inhibitor of Gq  
 
A number of GPCRs are reported to couple to the Gq family of G proteins 
including the oxytocin receptor (OTR) (Gimpl and Fahrenholz, 2001), leading 
to Ca2+i mobilisation and elevation in cellular IP3 (Figure 2.5). The cyclic 
depsipeptide YM-254890 is described as a specific Gq/11 inhibitor (Takasaki et 
al., 2004) through blocking of GDP exchange for GTP (Nishimura et al., 
2010). In order to investigate Gq/11-coupling at a receptor of interest, cells 
were pre-treated with YM-254890 for 30 minutes prior to ligand stimulation 
Table 3.6. Assessing NF449 as an inhibitor of GS activity. Potency (pEC50), 
maximal response (Emax), affinity (pKA) and coupling efficacy (logτ) for GCGR and CT 
agonists +/- NF449 measured Flp-In GCGR CHO-K1 cells using a cAMP accumulation 
assay 
cAMP 
Ligand pEC50 a Emax b pKAc log τd 
Forskolin 6.32 ±0.2 90.2 ±4.6 5.68 ±0.2 0.57 ±0.12 
Forskolin (+NF449) 6.35 ±0.2 90.0 ±4.6 5.64 ±0.2 0.58 ±0.13 
GCG 10.91 ±0.1 105.5 ±3.0 10.08 ±0.2 0.77 ±0.12 
GCG (+NF449) 10.92 ±0.1 108.3 ±2.5 9.97 ±0.2 0.88 ±0.21 
Oxyntomodulin  9.48 ±0.1 110.5 ±4.0 8.89 ±0.2 0.46 ±0.07 
Oxyntomodulin (+NF449) 9.51 ±0.1 91.8 ±2.4 8.92 ±0.1 0.46 ±0.04 
CT 10.18 ±0.2 35.2 ±2.0 9.98 ±0.2 -0.23 ±0.05 
CT (+NF449)  9.01 ±0.2** 28.1 ±2.6 8.95 ±0.2* -0.32 ±0.04 
 
Flp-In GCGR CHO-K1 cells (1,000 cells/well) were pre-treated with NF449 10µM or 
DMSO control for 30 minutes prior to stimulated with froskolin, GCG, oxyntomodulin or 
CT for 8 minutes and cAMP accumulation detected to generate concentration response 
curves. To calculate pEC50 and Emax, data were analysed using a three-parameter 
logistic equation.  Data was also analysed by an operational model of agonism  (Black 
and Leff, 1983) to determine affinity (pKA) and coupling efficacy (log τ). 
a Negative logarithm of ligand concentration required to produce a half-maximal 
response 
b Maximal response to ligand as percentage forskolin (-NF449)  
c The negative logarithm of the relative equilibrium disassociation constant for each 
ligand generated through use of the operational model for partial agonism relative to 
NF449 untreated ligand stimulation. 
d τ is the coupling efficiency parameter, generated by comparison to the NF449 
untreated ligand using the operational model for partial agonism  
Statistical significance (*, p<0.05;**, p<0.01;***, p<0.001) comparing NF449 treated to 
untreated  for each of the ligands was determined unpaired Student’s t-test (two-tailed). 
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and measurement Ca2+i mobilisation using fluorescent Ca2+ binding dyes 
such as Fluo-8, AM as detailed in section 2.8.3. To assess potential off-target 
activity of YM-254890, specifically on G protein-dependent and G protein-
independent (forskolin) mediated changes in cAMP levels, cAMP 
accumulation was measured in transfected HEK 293T cells stimulated with 
the appropriate ligand in the presence or absence of YM-254890 30 minute 
pre-treatment. 
There was found to be no significant difference in cAMP accumulation 
in forskolin stimulated untransfected HEK 293T cells (Figure 3.14 A and Table 
3.7) or to GCG and GLP-1(7-36)amide stimulated GCGR and GLP-1R 
transfected HEK 293T cells, respectively (Figure. 3.14 B/C and Table 3.7), 
with or without YM-254890 treatment. This finding suggests YM-254890 
treatment has no influence on the ability of HEK 293T cells to produce a 
cAMP response through either Gs-dependent (GCGR and GLP-1R) or Gs-
independent  (forskolin) mechanism. In addition, given the similar response in 
YM-254890 treated and untreated HEK 293T cells, YM-254890 has no 
apparent toxicity to HEK 293T cells. 
The Ca2+i response in HEK 293T cells stimulated with ionomycin, a 
Ca2+ ionophore, was unaffected by YM-254890 pretreatment (Figure 3.15 A 
and Table 3.8). This finding confirms that ionomycin causes a Ca2+i response 
independent of Gq/11 and YM-254890 has no apparently off-target activity. On 
the other hand, YM-254890 pre-treatment was shown to completely abolish 
the Ca2+i mobilisation in GCGR and GLP-1R transfected HEK 293T cells 
stimulated with GCG or GLP-1(7-36)amide, respectively (Figures 3.15 B/C 
and Table 3.8). The ability of YM-254890 to inhibit Ca2+i responses from 
GCGR (See Section 4.3.1 for further analysis of the Ca2+i response at the 
GCGR) and GLP-1R transfected cells stimulated with ligand, confirms these 
pathways are Gq/11-mediated and not through downstream signalling via Gs-
coupling or alternative G proteins.  
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Figure 3.14. YM-254890 treatment has no effect on measured cAMP 
response in HEK 293T cells. HEK 293T cells received 30 minutes treatment 
with YM-254890 (100 nM) or DMSO control immediately prior to plating on a 
384-well Optiplate. The cAMP response was detected following 8 minutes 
stimulation with A) forskolin in untransfected HEK 293T cells B) GCG in HEK 
293T cells transfected with pcDNA3.1 expressing GCGR or C) GLP-1(7-
36)amide in HEK 293T cells transfected with pcDNA3 expressing GLP-1R. All 
values are mean ± SEM expressed as percentage forskolin response where n 
≥ 3 independent experimental repeats, conducted in duplicate.  
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Figure 3.15. Effect of YM-254890 treatment on Ca2+i response in HEK 
293T cells: HEK 293T cells received 30 minutes treatment with YM-254890 
(100 nM) or DMSO control immediately prior ligand stimulation and Ca2+i 
mobilisation measured. A) Untransfected HEK 293T cells were stimulated with 
ionomycin B) HEK 293T cells transiently expressing pVITRO1 vector 
containing mCherry-tagged GCGR (48 hours post transfection) stimulated with 
GCG or C) HEK 293T cells transiently expressing pcDNA3.0 vector containing 
mCherry-tagged GLP-1R (48 hours post transfection) stimulated with GLP-
1(7-36)amide. All values are mean ± SEM expressed as percentage GCG 
response where n ≥ 3 independent experimental repeats, conducted in 
duplicate.  
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3.5.  Optimisation of the IPOne assay 
Ca2+i mobilisation is downstream of Gq-mediated activation of PLC-β (Figure 
2.5). An alternative readout of the Gq-mediated signalling cascade is IP1, the 
downstream metabolite of IP3, which can be measured using the IP-One 
HTRF® assay kit (Cisbio Bioassays) (Section 2.8.4). This assay utilises LiCl, 
which inhibits the breakdown of IP1 resulting in accumulation in the cells 
(Garbison et al., 2004). In order to achieve the optimal signalling window for 
measuring IP1 accumulation using this kit, both cell number and ligand 
stimulation time must be optimised.  
For GCGR and GLP-1R described as predominantly Gs-coupled, the 
measured ligand potency for Ca2+i mobilisation was weaker when compared 
to cAMP accumulation (Tables 3.8 and 3.7, respectively). In order to 
investigate the maximum measurable signal and optimisation for this assay, 
the predominantly Gq-coupled oxytocin receptor (OTR) (Gimpl and 
Fahrenholz, 2001) was chosen. HEK 293 cells transfected with the OTR (48 
hours post-transfection) were plated at a range of cell densities in a 384-well 
plate and stimulated for either 1 or 2 hours with oxytocin (OT) prior to 
measuring IP1 accumulation.  
The concentration responses seen to both 1 and 2-hour stimulation 
with OT at the various cell numbers were shown to reside within the SC 
(Figure 3.16 and Table 3.9). The measured potency for OT showed some 
variation between cell numbers, although this was not significant. Both the 
basal IP1 level and the maximum response to OT stimulation was found to 
depend on the number of cells per well and showed an increase with 
increasing cell number. The difference between the maximum response and 
the basal response (span) was found to be largest for 20,000 cells per well at 
both stimulation times, but slightly bigger following 2 hours stimulation when 
compared to 1 hour (35.2 ±1.8 and 32.9 ±1.7 percentage SC, respectively).  
This finding indicated that 20,000 cells per well with a 2-hour stimulation time 
	 103 
were the optimal conditions to achieve the largest signalling window for the 
measurement of IP1 accumulation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16. Cell number and stimulation time optimisation for IP1 
accumulation assay. HEK 293 cells transiently expressing the Oxytocin 
receptor (48 hours post transfection) were seeded at various densities (5,000, 
10,000, 20,000 or 30,000 cells/well) exposed to Oxytocin for A) 1 hour or B) 2 
hours and IP1 accumulation detected using the IP-One HTRF® assay kit (Cisbio 
Bioassays). All values are mean ± SEM expressed as percentage IP1 standard 
curve (SC) were n = 1, conducted in duplicate.  
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Table 3.9.  Cell number and stimulation time optimisation for IP1 
accumulation assay Potency (pEC50), maximal response (Emax), basal and span 
HEK 293 cells transfected with OTR measured using IP1 accumulation assay 
 
 1 hour stimulation 
Cell number pEC50 a Emax b Basal c Span d 
5,000 8.49 ±0.6 21.5 ±3.8 6.8 ±1.7 14.6 ±3.9 
10,000 9.34 ±0.3 30.3 ±2.1 8.3 ±1.2 21.9 ±2.4 
20,000 9.31 ±0.1 54.8 ±1.4 21.9 ±1.0 32.9 ±1.7 
30,000 9.46 ±0.3 67.2 ±3.1 38.6 ±2.1 28.6 ±2.1 
 2 hour stimulation 
Cell number pEC50 a Emax b Basal c Span d 
5,000 9.67 ±0.2 24.0 ±1.3 5.1 ±1.0 18.9 ±1.5 
10,000 9.21 ±0.1 45.4 ±1.1 13.0 ±0.7 32.5 ±1.3 
20,000 9.72 ±0.1 64.5 ±1.5 29.3 ±1.1 35.2 ±1.8 
30,000 9.91 ±0.1 73.8 ±1.4 41.8 ±1.1 32.0 ±1.8 
 
HEK 293 cells transiently expressing the OTR (48 hours post transfection) were 
seeded at various densities (5,000, 10,000, 20,000 or 30,000 cells/well) exposed to 
oxytocin for 1 hour or 2 hours  and IP1 accumulation detected.  To calculate pEC50 
and Emax, data were analysed using a three-parameter logistic equation.   
a Negative logarithm of OT concentration required to produce a half-maximal 
response 
b Maximal response to OT given as the percentage standard IP1 curve (SC) 
c The low plateau of the fitted sigmoidal concentration dose-response curve 
d The difference between Emax and basal signalling 
Statistical significance (*, p< 0.05;**, p<0.01;***, p<0.001) of the difference between 
responses when compared to that in 5,000 cells for each stimulation time was 
determined by one-way ANOVA with Dunnett’s post test. 
Bold text highlights the cell number that produced the largest signalling window  
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3.6.  Generation of a HEK 293 cell line stably expressing GCGR 
Transfection, the introduction of foreign nucleic acid into cells, can either be 
transient or stable (Kim and Eberwine, 2010).  Here, we generate a HEK 293 
cell line stably expressing GCGR to overcome issues associated with 
transfection variability across experiments and across the cell population, in 
addition to speeding up experiments once the cell line has been generated. 
HEK 293 cells were transfected with pmCherry-N1 vector expressing GCGR 
(generating a C-terminally mCherry-tagged GCGR) and selection of stable 
cells performed using the appropriate concentration of Geneticin® (G418) 
(800 µg/ml), as indicated by performing a kill curve of HEK 293 cells (Section 
2.1.3).   
Confocal fluorescence microscopic images of HEK 293 cells selected 
for using G418 showed the presence of mCherry-tagged GCGR localised 
both on the membrane surface and within what appear to be vesicles within 
the cytoplasm of the cell (Figure 3.17). These vesicles may contain mCherry 
only, or the fluorescently tagged receptor being trafficked to or away from the 
cell-surface. In order to check if this GCGR expression was functional, these 
HEK 293 cells and HEK 293 cells transiently transfected with the same vector 
(pmCherry-N1 expressing GCGR) were stimulated with GCG or 
oxynotmodulin and the cAMP response measured (Figure 3.18 and Table 
3.10).  Both the GCG and oxyntomodulin concentration-dependent cAMP 
responses showed no significant differences between the transient or stable 
cell lines for any of the measured parameters. This finding suggests similar 
GCGR signalling regardless of transient or stable transfection. These cells, 
presumably with a greater proportion expressing the receptor of interest, were 
used to investigate the GCGR-mediated ERK1/2 activation in an attempt to 
maximise the signalling window (Section 4.4.2.2). 
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Figure 3.17. Cell-surface expression of mCherry-tagged GCGR in G418 
selected HEK 293 cells. HEK 293 cells were transfected with pmCherry-N1 
containing GCGR and stably transfected cells selected for using Geneticin® 
(G418) at a concentration of 800 µg/ml. The stable cell line was confirmed 
using confocal fluorescence microscopy. Yellow arrow indicates cell-surface 
localised receptor whereas possible vesicles containing the receptor are 
indicated by the white arrow.  
Figure 3.18. Comparison of cAMP response in transient and stable 
GCGR expressing HEK 293 cells. HEK 293 cells transiently (24 hours post 
transfection) or stably expressing mCherry-tagged GCGR were exposed to 
GCG or oxyntomodulin for 8 minutes and cAMP accumulation detected. All 
values are mean ± SEM expressed as percentage forskolin response where n 
≥ 5 independent experimental repeats, conducted in duplicate. 
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3.7.  Receptors expression in a hepatic cell line: Hep 3B 
3.7.1.   Investigating GPCR mRNA expression in Hep 3B cells 
 
In the work presented in this thesis, both stable and transient transfected cell 
lines were used for the investigation of GCGR signalling. We sought to 
characterise the immortalised human hepatocellular carcinoma cell line, Hep 
3B, with the aim of moving into a move physiologically relevant system and so 
removing the complication associated with overexpression of receptors. 
Despite the use of Hep 3B and similar cell lines in research, little is currently 
known about the GPCR expression and associated pharmacology. Through 
the use of RT-PCR we investigated the GPCR expression profile of the Hep 
3B cell line with a particular focus on GCGR, known to be expressed in 
hepatocytes, RAMPs and G proteins.  
The resulting RT-PCR products from samples extracted from Hep 3B 
cells were analysed by gel electrophoresis and densitometry. mRNA 
expression was detected for the housekeeping gene GAPDH, GCGR and 
RAMP2 and small levels detected for GIPR, CLR, RAMP1 and RAMP3 
(Figure 3.19). Analysis of G protein mRNA expression revealed Hep 3B cells 
express Gαs, Gαi1-3, Gαq, Gα11 and Gα12/13 -subunits (Figure 3.20).  
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Figure 3.19. Expression profile of receptors in Hep 3B cells. RNA was 
extracted from Hep 3B, genomic DNA eliminated and then cDNA synthesised 
for the analysis of GCG, GLP-1R, GIPR, CLR and RAMP1-3 expression by 
RT-PCR using specific oligonucleotides (Table 2.6) (60°C). Representative 
image of products from PCR analysed by gel electrophoresis  (2 percent 
agarose gel) with 100 bp ladder for size comparison. Vector DNA containing 
the receptor target was used as a positive control at (10 ng per reaction).  A 
reaction containing GAPDH primers with water added rather than cDNA was 
used as a negative control. Hep 3B cells were at passage number 4 (1 
passage after extraction from N2 (stocks at P3)). 	
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3.7.2.  Optimisation of the cAMP assay in Hep 3B cells 
 
We next sought to determine the capacity of Hep 3B cells to signal via cAMP 
for the purpose of further pharmacological characterisation of endogenous 
receptor expression. As was conducted for cell lines transiently or stably 
expressing a receptor of interest (Section 3.2), it was necessary to determine 
the optimum cell density giving the highest signalling window, while staying 
within the assays dynamic range.  
Here, the cAMP accumulation following forskolin or GCG stimulation 
was determined for Hep 3B cells at various cell densities using the LANCE® 
cAMP assay kit. Forskolin showed a concentration-dependent increase in 
cAMP accumulation in Hep 3B cells, with no significant difference between 
the four cell densities tested (Figure 3.21 and Table 3.11). The average basal 
Figure 3.20. Expression profile of G proteins in Hep 3B cells. RNA was 
extracted from Hep 3B, genomic DNA eliminated and then cDNA synthesised 
for the analysis of G protein expression by RT-PCR using specific primers 
(Table 2.7) (60°C). Representative image of products from PCR analysed by 
gel electrophoresis  (2 percent agarose gel with 100 bp ladder for size 
comparison). Bars represent combined results from PCR samples analysed 
using densitometry, where n = 4 independent experimental repeats. Note that 
Hep 3B cells used for this RT-PCR analysis were passage number 5, 6, 7 and 
8 (N2 stocks at P3).   
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responses were approximately 63.0 percent of the cAMP SC. The maximum 
forskolin responses (100 µM) approached 100 percent of the SC as the 
number of cells increased from 2,000 to 20,000 cells per well, with the largest 
span determined at 10,000 cells per well (41.2 ±1.5 percentage SC) (Table 
3.11). These findings suggested that we were at the upper end of the cAMP 
assay kits dynamic range and increasing cell number further would reduce 
the forskolin signalling window. A concentration-dependent cAMP 
accumulation was also detected for GCG at 10,000 and 20,000 cells per well 
with a significantly reduced span (5.5 ±0.7 and 6.8 ±1.1 percentage SC, 
respectively) when compared to forskolin (41.2 ±1.5 and 33.3 ±2.0 
percentage SC, respectively), whereas no response could be determined for 
2,000 or 4,000 cells per well (Figure 3.22 and Table 3.11).  
These initial tests indicated a small signalling window for GCG and the 
difficulty in acquiring a high cell count for Hep 3B cells indicated a need for a 
more sensitive cAMP assay. The more sensitive LANCE® Ultra cAMP assay 
kit gave a larger signalling window for 5,000 cells per well (Figure 3.23) when 
compared to 20,000 cells per well (18.6 ±1.2 and 6.8 ±1.1 percent SC, 
respectively) (Table 3.11).   
Despite an improvement in the signalling window using the more 
sensitive assay (LANCE® Ultra cAMP assay kit), a direct comparison 
between the GCG response detected in Hep 3B cells when compared to HEK 
293 cells transiently transfected with GCGR (5,000 rather than 1,000 cells per 
well, respectively), show a significant reduced amplitude and potency (Figure 
3.24 and Table 3.12). This may reflect a relatively low level of GCGR 
expression when compared to that seen in a GCGR transfected cell line 
and/or reduced coupling to the cAMP signalling pathway. The signalling 
components and associated expression levels are likely to be different within 
Hep 3B and HEK 293 cells. It should also be noted that the reproducibility of 
these results using Hep 3B cells decrease as the age increases above 
passage 8 and as such, only young cells (passage < 8) should be used for 
experiments. To achieve the maximum signalling window in experiments 
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utilising Hep 3B cells to investigate ligand stimulated cAMP accumulation, the 
LANCE® Ultra cAMP assay kit was used with a 30 minute ligand stimulation 
of 5,000 cells per well. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21. cAMP response to forskolin in Hep 3B at various cell 
densities. Hep 3B cells at various cell densities (2,000, 4,000, 10,000 or 
20,000 cells/well) were exposed to forskolin for 30 minutes and cAMP 
accumulation detected using the LANCE cAMP kit. All values are mean ± 
SEM expressed as percentage cAMP standard curve (SC) where n = 2 
independent experimental repeats, conducted in duplicate. 
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Figure 3.22. cAMP response to GCG in Hep 3B at 10,000 and 20,000 
cells/well: Hep 3B cells at 10,000 or 20,000 cells/well were exposed to GCG 
for 30 minutes and cAMP accumulation detected using the LANCE cAMP kit. 
All values are mean ± SEM expressed as percentage cAMP standard curve 
(SC) where n = 2 independent experimental repeats, conducted in duplicate. 
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Figure 3.23. cAMP response to GCG in Hep 3B at 5,000 cells/well as 
measured using the LANCE® Ultra cAMP assay kit. Hep 3B cells at 5,000 
cells/well were exposed to GCG for 30 minutes and cAMP accumulation 
detected using the more sensitive LANCE Ultra cAMP kit. All values are mean 
± SEM expressed as percentage forsolin response (100 µM) where n ≥ 5 
independent experimental repeats, conducted in duplicate. 
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Figure 3.24. Comparison of cAMP response to GCG in Hep 3B and GCGR 
transfected HEK 293 cells. Hep 3B cells (5,000 cells/well) or GCGR 
transfected HEK 293 cells (1,000 cells/well)  (Gifted from Dr Asuka Ioune) 
were stimulated with GCG for 30 or 8 minutes prior cAMP accumulation 
detection using the normal cAMP kit or a more sensitive cAMP kit, 
respectively. All values are mean ± SEM expressed as percentage of 
individual forskolin response (100 µM) (100%) and individual basal response 
(0%) where n ≥ 5 independent experimental repeats, conducted in duplicate. 
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Table 3.11. 	 Optimisation of the cAMP assay in Hep 3B cells. Potency 
(pEC50), maximal response (Emax), basal and span for forskolin/GCG 
stimulated cAMP response measured Hep 3B cells using the LANCE/LANCE 
Ultra cAMP assay kit  
 Forskolin 
Cells/well pEC50 a Emax b Basal c Span d 
2,000  7.15 ±0.1 90.2 ±0.7 57.1 ±0.7 33.1 ±1.0 
4,000 7.52 ±0.1 96.0 ±0.6 69.5 ±0.6 26.4 ±0.8 
10,000 7.51 ±0.1 99.5 ±1.1 58.3 ±1.1 41.2 ±1.5 
20,000 7.71 ±0.2 100.6 ±1.4 67.3 ±1.5 33.3 ±2.0 
5,000* 7.25 ±0.1 94.6 ±2.0 66.2 ±1.7 28.4 ±1.5 
 GCG 
Cells/well pEC50 a Emax b Basal c Span d 
2,000 N.R 52.5 ±1.7 N.R 
4,000 N.R 54.5 ±1.8 N.R 
10,000  9.27 ±0.3 62.1 ±0.6 56.6 ±0.5 5.5 ±0.7 
20,000  8.93 ±0.4 72.7 ±0.9 66.1 ±0.8 6.8 ±1.1 
5,000* 8.28 ±0.2 62.6 ±0.9 81.2 ±0.9 18.6 ±1.2 
Hep 3B cells were stimulated with forskolin or GCG prior to measurement of 
cAMP accumulation to generate concentration response curves. To calculate 
pEC50, Emax, Basal and Span values, data were analysed using a three-
parameter logistic equation. 
.a Negative logarithm of forskolin/GCG concentration required to produce a 
half-maximal response 
b Maximal response to forskolin/GCG as percentage cAMP standard curve 
c The low plateau of the fitted sigmoidal concentration dose-response curve 
d The difference between Emax and basal signalling 
All values are mean ± SEM expressed percentage cAMP standard curve 
where n = 2 independent experimental repeats, conducted in duplicate. 
N.R denotes no response. In this case, a concentration dose-response could 
not be fitted with considerable accuracy due to variation between repeats.  
* and Italic text represents result acquired using the more sensitive LANCE 
Ultra cAMP kit 
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3.8.  Characterisation of CRISPR knockout HEK 293 cell lines  
3.8.1. Growth rate and viability  
 
The parental HEK 293 cell line and various CRISPR G protein and β-
arrestin1/2 knockout HEK 293 cell lines (gifted to us by Dr Asuka Inoue) 
provide a potentially invaluable tool for the investigation of various GPCR 
signalling pathways. We first sought to conduct some basic characterisation 
experiments to assay any variation between the parental and knockout cell 
lines in terms of growth rate, viability and signalling capacity. Here we 
investigate if the knockout of each G protein or β-arrestin1/2 had an influence 
on growth rate and viability.  
The quantification of ATP as a measure of cell viability was conducted 
using the CellTiter-Glo® Luminescent Cell Viability Assay (Recino et al., 
Table 3.12.  Comparison of cAMP response to GCG in Hep 3B and GCGR 
transfected HEK 293 cells. Potency (pEC50), maximal response (Emax), basal 
and span for forskolin/GCG stimulated cAMP response measured Hep 3B or 
GCGR transfected HEK 293 cells using the LANCE/LANCE Ultra cAMP assay 
kit 
 
 GCG 
Cell type pEC50 a Emax b Basal c Span d 
HEK 293 9.09 ±0.1 80.5 ±1.6 6.4 ±1.1 74.2 ±1.8 
Hep 3B* 8.28 ±0.2*** 2.3 ±1.0*** 2.3 ±0.7 15.7 ±1.2*** 
 
Hep 3B cells or HEK 293 cells transfected with pmCherry-N1 containing 
GCGR were stimulated with GCG prior to measurement of cAMP accumulation 
to generate concentration response curves. To calculate pEC50, Emax, Basal 
and Span values, data were analysed using a three-parameter logistic 
equation. 
a Negative logarithm of GCG concentration required to produce a half-maximal 
response 
b Maximal response to GCG as percentage forskolin response 
c The low plateau of the fitted sigmoidal concentration dose-response curve 
d The difference between Emax and basal signalling 
All values are mean ± SEM expressed percentage forskolin response where n 
≥ 5 independent experimental repeats, conducted in duplicate.  
* and Italic text represents result acquired using the more sensitive LANCE 
Ultra cAMP kit 
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2017). As would be expected, cell number directly correlates with luminescent 
output (R2 = 0.98) (Figure 3.25) and as such, cell number must be accounted 
for when investigating variability between cell lines. To further investigate any 
differences in viability across cell lines, repeats were conducted using 5,000 
cells per well and luminescence (RLU) values were normalised to an ATP 
standard (Figure 3.8.1.2). There was found to be a significantly increase 
amount of ATP in ΔGαs, ΔGαq and ΔGαs/q/12 when compared to parental (WT) 
HEK 293 cells whereas the Δβ-arrestin1/2 cell line showed similar ATP levels. 
Although ATP amount is a measure of viability, and these findings may 
indicate an increased viability with Gαs, Gαq and Gαs/q/12 knockout, cells can 
also release ATP in response to mechanical stress or biological activation 
(Ostrom et al., 2000). It could be possible that ΔGαs, ΔGαq and ΔGαs/q/12 cell 
lines are more susceptible to such mechanical stress or biological activation 
(as might be imposed by trypsinisation, for example) in comparison to WT 
and Δβ-arrestin1/2 cells. 
The growth profiles of WT and G proteins or β-arrestin1/2 knockout 
HEK 293 cell lines were tested over various time points within a 72-hour 
period following plating at 100,000 cells per well of a 24-well tissue culture 
plate. There was found to be considerable variation in growth rate across the 
72-hour period with the difference becoming more evident as the time post 
seeding increases  (Figure 3.27). On day 3 (72 hours post seeding), WT and 
ΔGαq cells reached confluence and showed a faster growth when compared 
to the other cell lines. 
Interestingly, cell viability does not appear to correlate with growth rate. 
For example, Δβ-arrestin1/2 cell line despite showing reduced growth when 
compared to WT at 48 and 72 hours had similar ATP levels (Figure 3.8.1.2). 
On the other hand the ΔGαq cell line, which showed a more similar growth 
rate to WT, had increased ATP levels. ΔGαs and ΔGαs/q/12, which showed a 
reduced growth when compared to WT at 48 and 72 hours, again show an 
increase in ATP levels. It appears that an increase in ATP levels i.e. viability 
cannot account for a faster growth rate and other factors are in play. This 
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variability should be considered when interpreting experimental data acquired 
using these knockout cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25. Cell number directly correlates with luminescent output for 
CellTiter-Glo® Luminescent Cell Viability Assay. Quantification of ATP, as 
a measure of cell viability, for 1,000, 5,000 and 10,000 cells shows a strong 
correlation between cell number luminescent output (R2 = 0.98). 
Figure 3.26. Measurement of cell viability in HEK 293 knockout cell lines. 
Quantification of ATP as a measure of cell viability was conducted using the 
CellTiter-Glo® Luminescent Cell Viability Assay (Promega) in a 384-well 
format. Comparison of ATP produced from WT HEK 293 cells and knockout 
cell lines at 5,000 cells/well. All values from individual experiments are 
interpolated to an ATP standard. Values are mean ± SEM expressed in Moles 
were n ≥ 4 independent experimental repeats, conducted in quadruplicate. 
Statistical significance in comparison to WT was determined using one-way 
analysis of variance and Dunnett’s post-test.  	
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3.8.2.  Maximum cAMP response in CRISPR knockout HEK 293 cell lines  
 
In order to investigate GPCR signalling in the CRISPR knockout cell lines, it is 
necessary to initially compare the maximal signalling capacity of the 
downstream signalling component of interest. In the case of a cAMP 
accumulation assay, this would be the maximum cAMP response of the 
system. Here, each cell line was stimulated for 8 minutes with 100 µM of the 
potent AC activator, forskolin, and the cAMP accumulation measured.  
The maximum forskolin response determined in Δβ-arrestin1/2 or ΔGαq 
was not significantly different to WT (Figure 3.28). There was however a 
significantly reduced cAMP accumulation in both ΔGαs and ΔGαs/q/12 when 
compared to WT (Figure 3.28) indicating a reduced capacity for cAMP 
production in these cell lines. Interestingly, there was found to be no 
significant difference between the cAMP responses determined in ΔGαs and 
ΔGαs/q/12 suggesting the reduction capacity for cAMP signalling is attributable 
to the absence of the Gαs-subunit. ACs receives stimulatory signals from Gs 
and inhibitory signals from Gi (Tang and Gilman, 1991). It could be 
Figure 3.27. Comparison of cell growth profiles of WT and knockout HEK 
293 cell lines. All lines were seeded at 100,000 cells per well of a 24-well 
tissue culture plate (200 cells/µl in a 500 µl volume of media) at time-point 
zero and density at various time points (21, 24, 27, 45, 48, 51, 69, 72 and 75 
hours) determined using manual counting with a haemocytometer. On the 
third day following seeding (72 hours) WT and ΔGαq had reached confluence. 
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speculated that in the ΔGαs HEK 293 cell line, where basal stimulatory signals 
from Gs are presumably absent, Gi is able to bind and inhibit AC to a greater 
extent thereby leading to a reduced cellular cAMP level. 
The interpretation of these data presumes the only difference between 
parental HEK 293 cells and the knockout cell lines is the absence of the G 
protein or β-arrestin1/2. However, it is possible that the reduction in cAMP 
capacity is independent of the targeted knockout. Indeed, the process of 
genome editing and subsequent growth in vitro imposes selective conditions 
on the cells that often adapt through mutation (Lin et al., 2014). As such, the 
cell lines may have cellular variations in addition to the targeted deletion. The 
findings presented here suggest that cAMP data acquired from these cells 
should be normalised to the maximum forskolin response measured in each 
individual cell line thereby attempting to account for the variability in cAMP 
signalling capacity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.28. Maximal forskolin responses in HEK 293 knockout cell lines. 
WT and knockout HEK 293 cell lines transiently expressing pmCherry-N1 
vector containing GCGR (24 hours post transfection) were exposed to 100 µM 
forskolin for 8 minutes and cAMP accumulation detected. All values are mean 
± SEM expressed as percentage WT forskolin response were n ≥ 5 
independent experimental repeats, conducted in duplicate. Statistical 
significance in comparison to WT was determined using one-way analysis of 
variance and Dunnett’s post-test.   
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3.8.3.  cAMP response in ΔGαs HEK 293 cells changes over time 
 
The ΔGαs HEK 293 cell line could be used for the investigation of Gi-coupling 
at a particular GPCR of interest. In theory, this was similar to using NF449 to 
inhibit Gs and looking for a reduction in cAMP accumulation (Figure 3.12). 
Here, ΔGαs HEK 293 cells transfected with a vector expressing the GPCR 
would need to receive an initial forskolin stimulation to cause an elevation in 
intracellular cAMP levels. We would then look for a reduction in the cAMP 
levels following stimulation with a ligand active at this GPCR as an indicator 
of Gi-coupling. We first sought to confirm an absence of Gs-mediated 
signalling through performing a cAMP accumulation assay in ΔGαs HEK 293 
cells transfected with pmCherry-N1 expressing GCGR.  
The cAMP accumulation following GCG stimulation of ΔGαs HEK 293 
cells transfected with GCGR was shown to change over passage number 
(Figure 3.29 and Table 3.13). There was no detectable cAMP response from 
cells early from nitrogen storage (passage < 5). However, as passage number 
increased, there appeared to be a gain in cAMP response to GCG 
stimulation. This gained GCG response had a significantly reduced potency 
and maximal response when compared to WT HEK 293 cells (pEC50 8.32 
±0.3 and 9.13 ±0.1, Emax 57.3 ±6.5 and 90.9 ±2.2, respectively). This finding 
may indicate the presence of a mixed population of cells, with Gαs–subunit 
expression presence or absent. A number of the CRISPR-Cas9-mediated 
biallelic knockout cell lines, including ΔGαs and ΔGαs/q/12 HEK 293 cells, have 
been shown to have a slower growth rate when compared to the WT HEK 
293 parental cell line (Figure 3.27). As a result of this growth disadvantage, if 
there were a small subclonal (contaminating) population within the culture 
with a faster growth rate, they would in time outgrow the mutant population. 
With this in mind, experiments should be conducted on cells with a low 
passage number (<5). However, without conducting western blot analysis and 
confirming the lack of each particular G protein and β-arrestin1/2 over time, 
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the data acquired from these gifted cell lines need to be interpreted with 
caution. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Table 3.13. cAMP response in ΔGαs HEK 293 cells changes over passage. 
Potency (pEC50), maximal response (Emax), basal and span for GCG stimulated cAMP 
response in WT and ΔGαs HEK 293 cells transiently transfected with pmCherry-N1 
expressing GCGR 
 cAMP 
 pEC50 a Emax b Basal c Span d 
WT 9.13 ±0.1 90.9 ±2.2 5.1 ±1.7 85.8 ±2.7 
ΔGαs low passage N.R 0.2 ±1.2 N.R 
ΔGαs high passage 8.32 ±0.3*** 57.3 ±6.5*** 0.5 ±3.6 56.8 ±7.1*** 
Parental WT HEK 293 cells or ΔGαs HEK 293 cells (either low passage (< 5 out of 
nitrogen storage) or high passage (>5 out of nitrogen storage)) were transiently 
transfected with GCGR and stimulated with GCG prior to measurement of cAMP 
accumulation to generate concentration response curves for each construct. To 
calculate pEC50, Emax, Basal and Span values, data were analysed using a three-
parameter logistic equation 
a Negative logarithm of GCG concentration required to produce a half-maximal 
response 
b Maximal response to GCG as percentage forskolin response (for each individual cell 
line) 
c The low plateau of the fitted sigmoidal concentration dose-response curve 
d The difference between Emax and basal signalling.  
Statistical significance (*, p<0.05;**, p<0.01;***, p<0.001) comparing GCG response 
between the WT and high passage ΔGαs HEK 293 cells was determined using 
unpaired Student’s t-test (two-tailed). N.R denotes no response 
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Figure 3.29. cAMP response in ΔGαs HEK 293 cells changes over passage. 
WT and ΔGαs HEK 293 cells transiently expressing pmCherry-N1 vector 
expressing GCGR (24 hours post transfection) were exposed to GCG for 8 
minutes and cAMP accumulation detected. The ΔGαs HEK 293 cells were either 
low passage (< 5 out of nitrogen storage) or high passage (>5 out of nitrogen 
storage). All values are mean ± SEM expressed percentage maximum forskolin 
response for each individual cell line were n ≥ 5 independent experimental 
repeats, conducted in duplicate. 
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3.8.4.  Maximum PMA response in CRISPR knockout HEK 293 cell lines  
 
These CRISPR knockout cell lines may provide a useful tool in investigating 
the upstream components important in GCGR-mediated ERK signalling. 
Having shown a reduced capacity for forskolin mediated cAMP accumulation 
in ΔGαs and ΔGαs/q/12, we next sought to investigate the maximum activation 
of ERK1/2 between the various cell lines. Here, each cell line was stimulated 
for 5 minutes with 1 µM PMA, a direct protein kinase C (PKC) activator 
(Robinson et al., 1992), and pERK1/2 measured using the homogeneous time 
resolved fluorescence (HTRF)® Phospho-ERK (Thr202/Tyr204) Cellular 
Assay Kit (Cisbio Bioassays). 
There was found to be a significant elevation in PMA stimulated 
ERK1/2 phosphorylation, as indicated by the increased HTRF ratio, for all 
knockout cell lines when compared to WT HEK 293 cells (Figure 3.30). This 
finding indicates enhanced ERK1/2 signalling capacity within the knockout 
cell lines and may indicate higher PKC expression levels when compared to 
WT. In order to account for this variability in further analysis of ERK1/2 
activation described in chapter 4, the ligand stimulated pERK1/2 responses 
were normalised to the response measured to PMA response each individual 
cell line.   
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3.8.5.  Summary  
Initial characterisation of the gifted parental and various CRISPR G protein 
and β-arrestin1/2 knockout HEK 293 cell lines indicated significant variability 
in terms of viability, growth rate and maximum cAMP accumulation/pERK 
activation.  There were significantly increased ATP levels in ΔGαs, ΔGαq and 
ΔGαs/q/12 when compared to WT, suggesting an increased viability. Another 
possible explanation may have been an increased susceptibility to 
mechanical stress or biological activation (as might be imposed by 
trypsinisation, for example) thereby resulting in increased ATP release. 
Interestingly, cell viability did not appear to correlate with growth rate and 
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Figure 3.30. Comparison of PMA responses in HEK 293 knockout cell 
lines. WT and knockout HEK 293 cell lines transiently expressing pmCherry-
N1 vector containing GCGR (48 hours post transfection) were exposed to 1 
µM PMA for 5 minutes and pERK1/2 detected. All values are mean ± SEM 
expressed as the HTRF ratio were n ≥ 5 independent experimental repeats, 
conducted in duplicate. Statistical significance in comparison to WT was 
determined using one-way analysis of variance and Dunnett’s post-test.   
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whereas WT and ΔGαq cells reached confluence and showed a faster growth 
when compared to the other cell lines, they had similar ATP levels. 
The maximum cAMP accumulation, as determined by forskolin 
stimulation at 100 µM, was significantly reduced in both ΔGαs and ΔGαs/q/12. 
This finding indicates a reduced capacity for cAMP production independent of 
G proteins. As may be expected ΔGαs transfected with pmCherry-N1 
expressing GCGR showed no cAMP response following GCG stimulated. 
However, there was found to be a gain in cAMP response with increasing 
passage number. This latter finding indicated a mixed population of cells, 
presence or absence of Gαs-subunit expression and outgrowth of the mutant 
population.  
There was found to be a significant elevation in PMA stimulated 
ERK1/2 phosphorylation, for all knockout cell lines when compared to WT. 
Despite showing a reduced capacity for cAMP signalling, ΔGαs and ΔGαs/q/12 
appear to show an enhanced ability for ERK1/2 activation thereby suggesting 
both enhanced and reduced expression/regulation of various signalling 
pathway components. This finding provides additional evidence to suggest 
these knockout cell lines have cellular differences other than the individual G 
protein or β-arrestin1/2 knockout, which may be due as a consequence of the 
knockout (compensatory) or independent. Indeed, the process of genome 
editing and passage may have induced selective conditions resulting in 
additional cellular variations other than the targeted deletion. Given the 
variability in viability, growth rate, cAMP and pERK1/2 maximum responses, 
data acquired using these knockout cell lines should be interpreted with 
caution. In addition, when analysing both cAMP and pERK1/2 response data 
acquired using these cells, the ligand stimulated responses should be initially 
normalised to the maximum response (forskolin or PMA) determined for each 
individual cell lines prior to further normalisation and comparison.  
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3.9. Analysis of GCGR cell-surface expression using fluorescence-
activated cell sorting (FACS) 
3.9.1.  FACS: Data collection and analysis  
 
Flow cytometery assesses the fluorescence of thousands of individual cells in 
seconds and allows a larger scale investigation of cells at a population level 
when compared to traditional fluorescence microscopy. In the work presented 
in this thesis, FACS was conducted using the BD Accuri™ C6 Plus Flow 
Cytometer to quantify receptor cell-surface expression in collaboration with Dr 
Matthew Harper (Department of Pharmacology, University of Cambridge). 
Specifically, this technique was used for the cell-surface expression analysis 
of WT and mutant GCGR. 
The following figures show analysis of data acquired from 
untransfected and mCherry-tagged GCGR (WT and mutant) transfected HEK 
293 cells as examples of data collection and analysis, which was performed 
on data presented in chapter 5. Here in order to quantify WT and mutant 
GCGR cell-surface expression in HEK 293 cells, transfected cells were 
incubated with anti-GCGR antibody followed by APC-conjugated anti-rabbit 
IgG secondary antibody. The fluorescence detector FL4 (Em. λ 675/25 n) was 
used to detect APC fluorescence and data subsequently analysed as 
described here.  
Manual gating of untransfected HEK 293 cells was conducted in order 
to exclude debris and dead cells from analysis with 82.8 percent of events 
included (Figure 3.31). Gating for single cells was then conducted to exclude 
clumps of cells and accounted for 81.2 percent of the population (Figure 
3.32). For non-transfected cells, stained with both primary and secondary 
antibodies, the histogram generated from debris removal and single cell 
gating reveals a single peak, as would be expected (Figure 3.33). To assess 
unspecific binding of APC-conjugated secondary antibody, HEK 293 cells 
were transfected with vector only (pmCherry-N1) and stained with both 
primary and secondary antibodies. A visible shift in FL4 fluorescence was 
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seen with the emergence of two peaks, indicating the occurrence of 
unspecific binding and two distinct populations of HEK 293 cells, respectively 
(Figure 3.33). 
FACS sorted HEK 293 cells transfected with vector expressing 
mCherry-tagged WT GCGR showed a visible shift in FL4 fluorescence 
intensity which was greater than that observed for both untransfected and 
vector only transfected (Figure 3.33). This finding suggested that WT GCGR 
were indeed detected on the cell-surface of HEK 293 cells. The histograms 
generated from HEK 293 cells transfected with vector expressing TM4 mutant 
GCGR (L277A, V280A) showed a reduced shift in FL4 when compared to the 
histogram generated from HEK 293 cells transfected with vector expressing 
WT GCGR, suggesting a reduced cell-surface expression (Figure 3.34). 
Again, there is an emergence of two peaks for both WT and all mutant GCGR 
transfected HEK 293 cells indicating two distinct populations. 
It should be noted that a test with propidium iodide (PI) to assess the 
proportion of dead cells accounted for less than 5 percent of the collected 
events and could not account for the additional peak. It appears transfections, 
regardless of receptor expression, was causing the emergence of two distinct 
populations. This finding is unexpected and cannot be explained with any 
certainty. However, transfection could be inducing a change in the regulation 
of HEK 293 cell size giving rise to two distinctly different sized populations.  
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Cell debris 
Figure 3.31. FACS data analysis: example manual gating of 
untransfected HEK 293 cells. HEK 293 cells were incubated with anti-GCGR 
antibody followed by APC-conjugated anti-rabbit IgG secondary antibody. 
Data was acquired on a BD Accuri C6 and analysed with BD Accuri
TM
 C6 
software with a total of 20,000 gated events captured. Here, cells are 
analysed using side scatter area (SSC-A) by forward scatter area (FSC-A). 
The drawn gate excludes events with low FSC and high SSC thereby 
excluding debris and dead cells from analysis.  
Figure 3.32. FACS data analysis: example gating of single untransfected 
HEK 293 cells. HEK 293 cells were incubated with anti-GCGR antibody 
followed by APC-conjugated anti-rabbit IgG secondary antibody. Data was 
acquired on a BD Accuri C6 and analysed with BD Accuri
TM
 C6 software with 
a total of 20,000 gated events captured. Here, FSC-Height (FSC-H) by FSC-
Area (FSC-A) is plotted. Cells along the diagonal are the single cells and are 
gated, as shown by the black box. The single cells account for 81.2% of the 
population. The cells off this diagonal are clumps of cells and are excluded 
from the data.  
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Figure 3.33. Example histograms generated from flow cytometry of 
untransfected and vector only/GCGR transfected HEK 293 cells. HEK 293 
cells untransfected (blue), transfected with mCherry-N1 vector only (grey) and 
WT mCherry-tagged GCGR (red) were incubated with anti-GCGR antibody 
followed by APC-conjugated anti-rabbit IgG secondary antibody. Data were 
acquired on a BD Accuri C6 and analysed with BD Accuri
TM
 C6 software. A 
total of 20,000 gated events captured. y-axis, cell count; x-axis, log scale of 
fluorescence intensity (FL4-A). The data is represented in two different ways; 
A) Stacked histograms and B) overlaid histograms. Right-shifted plot indicates 
more cell-surface expression. 
A                                                     B 
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3.9.2. DNA concentration at transfection and detectable cell-surface 
expression 
 
As has been indicated by cAMP accumulation assays, receptor DNA 
concentration at transfection can influence the maximum cAMP response 
following ligand stimulation when below a given concentration (possibly 150 
ng per well, as previously indicate (Section 3.2.3)). This finding could be 
interpreted in two ways. Firstly, DNA amount above a certain concentration 
does not increase the level of receptor cell-surface expression 
proportionately. Alternatively, despite a change in receptor cell-surface 
expression, the cAMP accumulation assay is able to detect similar maximal 
levels following ligand stimulation, presumably because there is more 
receptor than effectors in the system. 
Achieving similar levels of cell-surface expression for WT and mutant 
GPCRs could be a valuable tool allowing the investigation into how the 
receptor mutation influences downstream signalling component levels 
Figure 3.34. Example histograms generated from flow cytometry of WT 
or mutant GCGR transfected HEK 293 cells. HEK 293 cells transfected with 
WT mCherry-tagged GCGR (red) or the double GCGR TM4 mutant (L277A 
V280A) (orange) were incubated with anti-GCGR antibody followed by APC-
conjugated anti-rabbit IgG secondary antibody.  
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independent of receptor cell-surface expression. In order to investigate if DNA 
concentration at transfection influences receptor cell-surface expression, 
FACS was performed on HEK 293 cells transfected with varying amounts of 
WT and mutant GCGR DNA, and analysed as previously described (Section 
3.9.1).  
There was shown to be a reduction in cell-surface expression with 
decreasing concentration of DNA for WT and a number of GCGR mutants 
(Figure 3.35). However, this reduction in cell-surface expression was not 
proportional to the changes in DNA concentration. For example, when 
transfected with half the amount of DNA (125 ng of rather than 250 ng), the 
decrease in cell-surface expression was shown to be only 20.9 percent for 
WT GCGR and 17.6 percent for the helix 8 E406A GCGR mutant. This 
evidence suggests that although DNA amount at transfection can influence 
receptor cell-surface expression, controlling expression through altering DNA 
concentration is not a trivial task. It seems that an alternative system other 
than transient transfection where expression levels are suggested to not be 
as high, such as the Flp-In expression system (Wootten et al., 2016), may be 
preferable to overcome issues associated with high expression.  
 
  
 
 
 
 
 
 
 
 
 
 
 
	 131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	
 
Figure 3.35. DNA concentration at transfection and 
detectable cell-surface expression of WT and mutant 
GCGR, as determined by FACS analysis. FACS analysis was 
conducted 48 hours post transfection of HEK 293 with 0.5 µg, 
0.25 µg or 0.125 µg (indicated by 0.5, 0.25 or 0.125 on the 
graph) WT or mutant GCGR containing pmCherry-N1 DNA per 
well of a 24-well plate. Cells were incubated with anti-GCGR 
antibody (1:50 dilution) followed by APC-conjugated anti-rabbit 
IgG secondary antibody (1:150 dilution). The values represent 
median FL4 with the data normalised to vector transfected (0%) 
and WT GCGR (100%), n = 1. 
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Chapter 4.  Investigating GCGR pharmacology 
 
4.1.  Introduction 
Having performed a number of assay optimisations and cell line 
characterisations (Chapter 3), I next sought to utilise these established assay 
systems to investigate the hypothesis that GCGR signals through multiple 
pathways. Studies have highlighted the possibility that GCGR couples to 
alternative G proteins other than the classical Gs-coupled GCGR pathway 
such Gq/11 (Xu and Xie, 2009 and Wakelam et al., 1986). In this chapter, 
GCGR signalling and G protein-coupling at the GCGR using assays 
measuring cAMP accumulation, pERK1/2 response or Ca2+i mobilization is 
investigated. We also look to investigate the influence of RAMP2, known to 
interact with GCGR (Christopoulos et al., 2003), on the classic Gs-coupled 
GCGR pathway. 
In addition to characterising the activity of two known GCGR agonists 
(GCG and oxyntomodulin) and two potential GCGR antagonist (des-
His1,[Glu9]-glucagon amide (des-His1,[Glu9]-GCG) and L-168,049), the activity 
of the GCG analogue, TH-GCG, was also investigated. TH-GCG was 
previously reported to stimulated production of inositol phosphates but not 
cAMP and this finding was proposed to indicate the existence of two distinct 
receptors for GCG (Wakelam et al., 1986). We investigated the hypothesis 
that TH-GCG is acting at the classical GCGR and that these previous findings 
could be explaining by signalling bias, where the downstream signalling 
cascade initiated by TH-GCG is predominantly through Gq-coupling. 
GCG is known to cause a rapid, concentration-dependent 
phosphorylation and activation of MEK1/2 and ERK1/2 (Jiang et al., 2001). 
However, extensive detail into the signalling pathways leading to this 
activation is lacking. It was reported that both a PKA (H-89) and MEK 
(PD98059) inhibitor completely abolished GCG induced ERK1/2 activation in 
β cells and HEK 293 cells (Dalle et al., 2004 and Jiang et al., 2001, 
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respectively), indicating that both cAMP-dependent PKA and MEK (upstream 
from ERK1/2) activity is necessary for ERK1/2 activation. Other research has 
also implicated the importance of the PLC/Ca2+i cascade for ERK1/2 
phosphorylatiom (Li et al., 2006). ERK activation is described to be 
downstream of both G protein (Gs, Gi, Gq and the Gβγ subunit) and β-arrestin 
mediated pathways (DeWire et al., 2007). Although implicated in GCGR 
desensitisation and down regulation (Krilov et al., 2011), relatively little 
research has been conducted on the role of β-arrestins in GCGR signalling. 
To expand on these findings, we conducted an investigation into the potential 
G protein and β-arrestins mediated pathways leading to ERK1/2 activation. 
This work utilising multiple cell lines including HEK 293T, HEK 293, 
CHO-K1 and Hep 3B cells, in addition to hepatocytes extracted from C57BL/6 
mice. Despite the use of Hep 3B cells and similar cell lines in research, little is 
currently known about the receptor expression and associated pharmacology. 
Having investigated the GPCR and RAMPs mRNA expression in Hep 3B cells 
and identified the likely expression of GCGR (Section 3.7), I next sought to 
investigate functional protein expression through the cAMP accumulation and 
a pERK1/2 response assay kits.  
 
4.2.  Investigating the cAMP response at the GCGR  
4.2.1.  GCG and oxyntomodulin stimulates a robust cAMP response 
 
Although the role of glucagon (GCG) in blood glucose regulation is well 
studied, a far more complex picture emerged with this pancreatic hormone 
shown to also regulate lipid metabolism, stimulate energy expenditure and 
induce satiety, to name a few (Habegger et al., 2010).  In order to explore the 
full pharmacological potential of GCG, we sought to investigate the 
mechanism of action at the GCGR. 
Using HEK 293 cells transfected with pmCherry-N1 expressing GCGR 
containing the C-terminal mCherry-tag, we first wanted to confirm previous 
reports that GCGR mediates its effects through Gs-coupling. The following 
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experiments were performed in line with optimisations presented in chapter 3 
(Section 3.2). GCGR transfected HEK 293 cells, challenged with GCG or 
oxyntomodulin, induced a concentration-dependent increase in cAMP 
concentration (Figure 4.1 A and Table 4.1). There was also found to be a 
concentration-dependent increase in cAMP accumulation to GLP-1(7-
36)amide (Figure 4.1 and Table 4.1). These responses were found to be 
GCGR specific with no cAMP accumulation detected in vector only 
transfected HEK 293 cells (Figure 4.1 C). Oxyntomodulin displayed 
significantly reduced in both potency and affinity when compared to GCG 
(Table 4.1) and confirms previous findings of reduced potency (Weston et al., 
2015). Similarly, GLP-1(7-36)amide also showed a significantly reduced 
potency and affinity when compared to GCG and also showed a reduced 
efficacy, as determined by fitting the operational model of agonism (Table 
4.1).  
The basal response to both oxynotomodulin and GLP-1(7-36)amide 
was also significantly lower than GCG. This elevated basal response for GCG 
is likely a reflection of the cAMP assay sensitivity rather than a true elevation. 
As was shown elsewhere (Section 3.2.2.1), very low concentrations of GCG 
ligand was shown to activate GCGR leading to perceived elevated basal 
cAMP level. Oxyntomodulin on the other hand, with reduced potency, did not 
show this elevation in basal cAMP (Section 3.2.2.1, Figure 3.3 A). 
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Figure 4.1. cAMP response in GCGR transfected HEK 293 cells: HEK 
293 cells transiently expressing A/B) pmCherry-N1 vector containing 
GCGR or C) vector only were stimulated with GCG, oxyntomodulin or 
GLP-1(7-36)amide for 8 minutes and cAMP accumulation detected. All 
values are mean ± SEM expressed as percentage forskolin response 
where n ≥ 5 independent experimental repeats, conducted in duplicate. 
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4.2.2.  Variation in absolute potencies of GCG and oxyntomodulin at 
GCGR 
 
When investigating the GCG and oxyntomodulin induced cAMP response, 
there were found to be clear differences between the responses measured in 
two cell lines; HEK 293T (gifted from Professor Colin Taylor in the 
Department of Pharmacology) and HEK 293 cells transiently transfected with 
pmCherry-N1 expressing GCGR (Figure 4.2).  Here, when all variables were 
accounted for such as DNA concentration, DNA quality and cell confluency at 
transfection, the measured potencies (pEC50) and maximum response (Emax) 
for each agonist were significantly different between cell lines (Table 4.2.2).  
HEK 293T cells showed a reduced potency and maximal response 
when compared to HEK 293 cells, despite presumably expressing the 
temperature-sensitive allele of the SV40 T antigen. This T antigen enables 
the amplification of vectors containing the SV40 origin of replication and 
increases the expression level obtained by transfection (Lin et al., 2014).  
The differences between these two cell lines tested, and indeed other 
cell lines, is likely due to a number of cellular variables. One big variable is 
likely to be the cytosolic signalling molecules that interact with the agonist 
bound receptor either directly or indirectly ultimately leading to the cellular 
response. In other words, some cell lines will have the ability to amplify the 
response to a greater extent than another. It appears that these two cell lines 
differ in sensitivity to the agonist stimulation i.e. the ability to transduce the 
signal. HEK 293 may have an increased receptor density and stimulus-
response efficiency when compared to HEK 293T leading to the increased 
maximal response and potency of the agonist. This is reflected by the smaller 
log τ values in HEK 293T compared to HEK 293 cells (Table 4.2). These 
findings highlight what is often seen in science, where the reported potency 
for a ligand can be very different between laboratory groups and is likely to 
depend on the assay system and cell lines used. This particular HEK 293T 
cell lines were not used in further experiments, and others were acquired 
	 138 
which showed a greater GCGR stimulated cAMP response for experiments 
detailed later (Section 4.3 and 4.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. cAMP responses in GCGR transfected HEK 293T and HEK 
293 cells. HEK 293T and HEK 293 (cells transiently expressing 
pmCherry-N1 vector containing GCGR (24 hours post transfection) were 
exposed to GCG or oxyntomodulin for 8 minutes and cAMP accumulation 
detected. All values are mean ± SEM expressed as percentage forskolin 
response (for each individual cell line) where n ≥ 5 independent 
experimental repeats, conducted in duplicate.  
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4.2.3.  Mammalian expression vectors: A comparison of cAMP signalling 
in GCGR transfected HEK 293  
4.2.3.1.  Measured potency varies between vectors 
 
Transfection, the introduction of foreign nucleic acid into cells, was used 
extensively in this work for the characterisation of GCGR pharmacology. The 
gene of interest was cloned into an expression vector (plasmid), which 
directed the host cellular machinery to express the protein of interest. Here, 
we investigate the cAMP response in HEK 293 cells transfected with one of 
three different vectors expressing GCGR  
HEK 293 cells were transfected with pmCherry-N1, pcDNA3.1 or 
pVITRO1 (Table 4.3) expressing GCGR and stimulated for 8 minutes with 
GCG or oxyntomodulin (24-hours post transfection) prior to measurement of 
cAMP accumulation. The GCG and oxyntomodulin responses measured in 
HEK 293 cells transfected with GCGR containing pmCherry-N1 vector 
showed significantly lower potency when compared to the potency 
determined in cells transfected with pcDNA3.1 or pVITRO1 expressing GCGR 
(Figure 4.3 and Table 4.4). This finding could indicate a receptor with reduced 
signalling capability, possibly as a consequence of the mCherry-tag. The 
maximal response for both GCG and oxyntomodulin were not significantly 
different between vectors. However, the measured affinity and coupling 
efficacy of both ligands were determined to be greater in pcDNA3.1 and 
pVITRO1 transfected cells when compared to pmCherry-N1.  
 
 
 
 
 
 
 
Table 4.3.  Size, promoter and enhancers present in three 
mammalian expression vectors.  
Vector Size (bp) Promoter Enhancer 
pmCherry-N1  4722  CMV  CAG 
pcDNA3.1 5428 CMV CAG  
pVITRO1  6295 rEF-1α/mEF-1α CMV/SV40 
Cytomegalovirus immediate-early promoter (CMV) 
rat/mouse elongation factor 1α promoter (rEF-1α/ mEF-1α).  
Simian virus 40 (SV40) enhancer 
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4.2.3.2.  Significantly elevated basal for pcDNA3.1 and pVITRO1 when 
compared to pmCherry-N1 expressing GCGR 
 
Despite cAMP assay optimisations including time-post transfection the assay 
was conducted, cell density and ligand stimulation time (Section 3.2), the 
basal response in HEK 293 cells transfected with either GCGR containing 
pcDNA3.1 or pVITRO1 was elevated at low concentration of GCG stimulation 
(0.01 pM to 1 pM), whereas at the ‘true basal’ stimulation point (no ligand), 
the response aligned with zero percentage forskolin response (Figure 4.3).  
There was a significantly elevated basal response to GCG and 
reduced span, in pcDNA3.1 and pVITRO1 when compared to pmCherry-N1 
(Table 4.4). This finding could indicate that GCGR expression is higher from 
pcDNA3.1 and pVITRO1 vectors leading to greater GCGR cell-surface 
expression and activation over the 8-minute stimulation period at very low 
ligand concentrations. The reduced span in the GCG stimulated cAMP 
response in pcDNA3.1 and pVITRO1 is most probably a consequence of this 
elevated basal response, leading to a smaller signalling window.  
An elevated basal cAMP response was only seen for oxyntomodulin 
stimulation in HEK 293 cells transfected with pVITRO1 expressing GCGR; 
possibly suggesting that expression from pVITRO1 is superior to pcDNA3.1. 
In a mammalian expression vector, the promoter is used to drive the gene 
expression and vary in strength depending on the cellular context. 
Interestingly, pVITRO1 has a different promoter when compared to the other 
two vectors tested and may offer an explanation to a superior expression 
level. Indeed, a systematic comparison between various promoters in a 
number of cell types revealed elongation factor 1α promoter (EF-1α) (present 
in pVITRO1, Table 4.4) to show consistently strong expression in all cell types 
tested, including HEK 293T cells  (Qin et al., 2010). On the other hand, the 
CMV promoter showed variability in expression across cell types with very 
strong promotion shown in HEK 293T cells (Qin et al., 2010). 
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Figure 4.3. cAMP response in HEK 293 cells transfected with pcDNA3.1 
or pVITRO1 expressing GCGR. HEK 293 cells transiently (24 hours post 
transfection) expressing GCGR containing pcDNA3.1 or pVITRO1 were 
exposed to GCG for 8 minutes and cAMP accumulation detected. All values 
are mean ± SEM expressed as percentage forskolin response where n ≥ 5 
independent experimental repeats, conducted in duplicate.  
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4.2.4.  Summary 
 
The results presented here confirm the concentration-dependent increase in 
cAMP concentration following both GCG or oxyntomodulin stimulation at the 
GCGR. As previously reported (Weston et al., 2015), oxyntomodulin was 
confirmed to be significantly reduced in potency and affinity (as measured 
using the operational model of agonism (i.e. indirect)) when compared to 
GCG. There was also found to be a concentration-dependent increase in 
cAMP accumulation following GLP-1(7-36)amid stimulation but with a 
significantly reduced potency, affinity and efficacy. This latter finding confirms 
previous findings reporting the activity of GLP-1(7-36)amide at the GCGR 
(Weston et al., 2015).  
Interestingly, depending on the chosen cellular model, there was found 
to be variation in measured potency and maximal response with a lower 
potency response measured to both GCG and oxytnomodulin stimulation in 
HEK 293T cells when compared to HEK 293 cells. These measured 
differences between HEK 293 and HEK 293T cells, and indeed other cell 
lines, is likely due to a number of cellular variables. One big variable is likely 
to be the cytosolic signalling molecules that interact with the agonist bound 
receptor either directly or indirectly ultimately leading to the cellular response. 
In other words, some cell lines will have the ability to amplify the response to 
a greater extent than another. Indeed, the absolute potency of an agonist at 
GPCRs is not only dependent on the affinity and intrinsic efficacy operating at 
the level of that particular receptor, but also on the properties of the assay 
system (Kenakin et al., 2012). The assay system is a complex combination of 
receptor density and factors that translate the receptor stimulus into cellular 
response (stimulus-response mechanisms) (Kenakin, 2003). These findings 
presented here highlight that the potency measured for a particular ligand is 
variable and is likely to depend on a number of factors including the cell line, 
receptor expression systems and chosen assay.  
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Similarly, the measured parameters were also dependent on the 
chosen vector with reduced potency, affinity and efficacy measured in cells 
transfected with GCGR containing pmCherry-N1 when compared to 
pcDNA3.1 or pVITRO1. The similar 260/280 nm ratio of all three DNA 
constructs indicating similar DNA quality, determined using a Nanodrop Lite 
(Thermo Fisher Scientific), and similar size of the plasmids (Table 4.3) 
suggests these variable cannot account for the differences in potency for 
GGC or oxyntomodulin measured between vectors. Similarly, differences in 
vector promoters cannot explain these findings given that both pcDNA3.1 and 
pmCherry-N1 have the same CMV promoter. Given the vectors are not 
identical, they are likely to be transcribed differently regardless of the type of 
promoter. The reduced potency, affinity and efficacy of GCG and 
oxyntomodulin at the mCherry-tagged GCGR suggest this C-terminal addition 
may be interfering with the signalling at the GCGR. However, the ability to 
visualise the receptor makes it an invaluable tool for the investigation of 
GCGR signalling.  
 
 
4.3.  Investigating the intracellular Ca2+ response at the GCGR  
4.3.1 GCG and oxyntomodulin stimulates intracellular Ca2+ response at 
GCGR 
 
In addition to the classical Gs-coupled GCGR pathway, studies have 
highlighted the possibility that GCGR couples to alternative G proteins such 
as Gq/11 (Xu and Xie, 2009, Wakelam et al., 1986). Having demonstrated that 
GCG and oxyntomodulin stimulation at the GCGR induces a concentration-
dependent increase in cAMP, we next sought to investigate if a number of 
peptide ligands acting at the GCGR (Section 4.2.1) result in intracellular Ca2+  
(Ca2+i) release from the endoplasmic reticulum (ER) and if this response was 
Gq/11 mediated.  
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HEK 293T cells transfected with pmCherry-N1 expressing GCGR and 
GCGR stably expressing CHO-K1 cells were stimulated with increasing 
concentrations of GCG, oxyntomodulin or GLP-1(7-36)amide and the Ca2+i 
mobilisation measured using a FlexStation® Multi-Mode Microplate Reader. 
The results are presented as changes in Ca2+i concentration over time to 
each ligand concentration in transfected HEK 293 and stable CHO-K1 cells 
(Figure 4.4 and 4.6, respectively) and as dose-response curves through fitting 
the highest response at each ligand concentration to a three-parameter 
logstics equation (Figure 4.5 and 4.7, respectively). A robust concentration-
dependent increase in Ca2+i response was detected following stimulation with 
GCG or oxyntomodulin in both cell lines (Table 4.5). Importantly, these Ca2+i 
responses measured at the highest ligand concentration were abolished 
through a 30-minute pre-treatment with the specific Gq/11 inhibitor, YM-254890 
(Takasaki et al., 2004 and Section 3.4.4), thereby confirming the Ca2+i 
response is Gq/11 mediated.   
In both cell lines, oxyntomodulin was shown to have significantly 
reduced potency when compared to GCG. In HEK 293T cells, oxyntomodulin 
showed a similar maximum response when compared to GCG identifying it as 
a lower potency full agonist of the GCGR mediated Ca2+i response. However, 
in CHO-K1 cells stably expressing GCGR, oxyntomodulin showed a reduced 
maximal response suggesting it is partial agonist of the Ca2+i response rather 
than a full agonist. 
Despite similar potencies for the measured Ca2+i in each cell line for 
each ligand, in HEK 293T cells oxyntomodulin was demonstrated to have 
reduced affinity when compared to GCG whereas in CHO-K1 cells 
oxyntomodulin showed similar affinity yet reduced efficacy when compared to 
GCG. These findings reflect those previously reported for the cAMP response 
findings (Figure 4.2) suggesting differences in measured responses between 
cell lines. These differences are likely due to a number of cellular variables 
such as differences in cytosolic signalling molecules that interact with the 
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agonist bound receptor either directly or indirectly ultimately leading to 
variable cellular responses. 
A Ca2+i response to GLP-1(7-36)amide was only determined at the 
highest tested concentration (100 µM) in HEK 293T cells and as such, a true 
dose-response curve could not be fitted due to insufficient data points. The 
response at 100 µM was abolished with a 30 minute pre-treatment with YM-
254890 thereby indicating that this response was Gαq/11 mediated. These data 
suggest the activity of GLP-1(7-36)amide is very weak at inducing an Ca2+i 
response through GCGR. Alternatively such high concentration of ligand may 
force the receptor into an interaction/active state, which would otherwise not 
occur. When tested in GCGR stably expressing CHO-K1 cells, although a 
response at 100 µM GLP-1(7-36)amide was not tested, no response was 
detected at a concentration of 10 µM (Figure 4.6 C).  
The findings presented here highlight that ligand activated GCGR is 
not only able to couple to Gs leading to concentration-dependent increases in 
cAMP, but can also induce a Gq/11 mediated Ca2+i response. 
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Figure 4.4 Ca2+i mobilisation in HEK 293T cells expressing GCGR +/- YM-
254890 treatment. HEK 293T cells transiently expressing pVITRO1 vector 
containing mCherry-tagged GCGR (48 hours post transfection) received 30 
minutes treatment with YM-254890 (100 nM) or DMSO control immediately 
prior to ligand stimulation with A) GCG, B) oxyntomodulin or C) GLP-1(7-
36)amide and Ca2+i mobilisation measured. All values are mean ± SEM 
expressed change in Ca2+I where n ≥ 3 independent experimental repeats, 
conducted in duplicate. 
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Figure 4.5. Ca2+i mobilisation dose-response in HEK 293T cells 
expressing GCGR +/- YM-254890 treatment. HEK 293T cells transiently 
expressing pVITRO1 vector containing mCherry-tagged GCGR (48 hours post 
transfection) received 30 minutes treatment with YM-254890 (100 nM) or 
DMSO control immediately prior to ligand stimulation with A) GCG, B) 
oxyntomodulin or C) GLP-1(7-36)amide and Ca2+i mobilisation measured. All 
values are mean ± SEM expressed as percentage GCG response where n ≥ 3 
independent experimental repeats, conducted in duplicate.  
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Figure 4.6. Ca2+i mobilisation in GCGR stably expressing CHO-K1 cells 
+/- YM-254890 treatment. CHO-K1 cells stably expressing GCGR stimulation 
with A) GCG, B) oxyntomodulin or C) GLP-1(7-36)amide at various 
concentrations and Ca2+i mobilisation measured. All values are mean ± SEM 
expressed as change in intracellualar Ca2+ (Ca2+i) where n ≥ 3 independent 
experimental repeats, conducted in duplicate. 
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Figure 4.7. Ca2+i mobilisation dose-response in GCGR stably expressing 
CHO-K1 cells +/- YM-254890 treatment. CHO-K1 cells stably expressing 
GCGR received 30 minutes treatment with YM-254890 (100 nM) or DMSO 
control immediately prior to ligand stimulation with A) GCG, B) oxyntomodulin 
or C) GLP-1(7-36)amide and Ca2+i mobilisation measured. All values are 
mean ± SEM expressed as percentage GCG response where n ≥ 3 
independent experimental repeats, conducted in duplicate. 
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4.4.  Investigating the ERK1/2 response at the GCGR  
4.4.1.  GCG stimulates a ERK1/2 response in three GCGR expressing 
cell lines 
 
ERK activation is described to be downstream of both G protein (Gs, Gi, Gq 
and the Gβγ subunit) and β-arrestin mediated pathways, which are 
independent of each other (DeWire et al., 2007). Here, I sought to investigate 
the signalling components important in the GCGR-mediated ERK1/2 
activation.  
Using three alternative GCGR expressing cell lines, either stable CHO-
K1 (10,000 cells/well) or transfected HEK 293T or HEK 293 cells (50,000 
cells/well) and the (HTRF)® Phospho-ERK (Thr202/Tyr204) Cellular Assay 
Kit, we initially tested the pERK1/2 response following a 5 minute stimulation 
with GCG. A pERK1/2 response was measured following GCG stimulation in 
all three cell lines tested, with no significant difference in potency. CHO-K1 
cells stably expressing GCGR following stimulation with GCG showed a 
pERK1/2 response that was larger than the measured PMA response (Emax 
191.9 ±11.3 percentage PMA response (1 µM)). A pERK1/2 response was 
also measured following GCG stimulation in HEK 293T and HEK 293 cells 
transfected with pmCherry-N1 expressing GCGR, although the maximal 
response was reduced in comparison to that seen in CHO-K1 cells (Figure 
4.8 and Table 4.6). This discrepancy in maximal response between HEK 
293T/HEK 293 cells and CHO-K1 cells was despite the facts 1/5 of the 
number of cells were used (10,000 cells per well when compared to 50,000 
cells per well). There are two potential interpretations as to why a significant 
difference in the maximum pERK1/2 response occured, which may or may 
not be independent. Firstly, CHO-K1 cells may contain a greater level of the 
signalling components involved in the ERK1/2 response downstream of the 
receptor itself or there may be greater level of coupling to pathways leading to 
pERK1/2. Interestingly, Cisbio Bioassays provide a kit to measure total 
ERK1/2 (Total ERK1/2 Cellular Assay Kit) and validation experiments 
	 155 
performed by the company measuring the total ERK1/2 in various cell lines 
showed a similar but slightly greater level of total ERK1/2 in HEK 293 cells 
when compared to CHO-K1 cells. This suggests that difference in total 
ERK1/2 was unlikely to account for this increased pERK1/2 response seen in 
CHO-K1 cells, although differences in other signalling components may 
indeed provide an explanation.  
Alternatively, the difference in response may be a consequence of 
receptor expression levels. In the stable CHO-K1 cells, where GCGR 
expression is expressed across the population this response is likely to be 
amplified providing a bigger signalling window. In GCGR transfected cells the 
levels of receptor expression may be lower in comparison to these CHO-K1 
cells and as a result, we may be at the lower end of the assays dynamic 
range.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. GCG stimulated pERK1/2 response in three alternative cell 
lines. HEK 293T or HEK 293 cells transiently expressing pmCherry-N1 vector 
containing GCGR (48 hours post transfection) or CHO-K1 cells stably 
expressing GCGR were serum starved for 24 hours and exposed to GCG for 
5 minutes before measuring pERK1/2. CHO-K1 cells were plated at 10,000 
cells per well in a 384-well plate whereas for HEK 293T and HEK 293 cells 
50,000 cells per well were plated. All values are mean ± SEM expressed as 
percentage PMA response (1 µM) where n ≥ 5 independent experimental 
repeats, conducted in duplicate.  
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4.4.2.  Measured potency of GCG and oxyntomodulin stimulated 
pERK1/2 response is cell line dependent   
4.4.2.1. pERK1/2 response in GCGR transfected HEK 293T cells and 
GCGR stable CHO-K1 cells 
  
Having established GCG induces a pERK1/2 response in various GCGR 
expressing cell lines, we next wanted to investigate if the GCG related 
peptide, oxyntomodulin, is also able to induce a pERK1/2 response in HEK 
293T cells transfected with pmCherry-N1 expressing GCGR and CHO-K1 
cells stably expressing GCGR.  
Similar to GCG, oxyntomodulin induced a concentration-dependent 
increase in pERK1/2 in both GCGR expressing CHO-K1 and HEK 293T cells 
(Figure 4.9). The pERK1/2 response to GCG and oxyntomodulin in 
transfected HEK 293T cells showed no significant difference between 
measured potency, maximal response, affinity and efficacy (Figure 4.9 A and 
Table 4.7). In CHO-K1 cells stably expressing GCGR, again a similar 
maximum response was measured for GCG and oxyntomodulin, but 
oxyntomodulin showed a significant reduced potency (pEC50 6.89 ±0.2 and 
5.85 ±0.1, respectively) and affinity (Figure 4.9 B and Table 4.7). A reduced 
potency was also found for the oxyntomodulin stimulated cAMP response 
measured in GCGR expressing cell lines (Section 4.2.1). This finding 
suggests oxyntomodulin has a reduced potency when compared to GCG at 
inducing pathways leading to both cAMP and pERK1/2 elevation.  
It may be that the indistinguishable responses for GCG and 
oxyntomodulin in transfected HEK 293T cells is due to an experimental 
limitations rather than true cellular differences between HEK 293T and CHO-
K1 cells. If this is the case, caution is required when interpreting such data 
particularly in the case where cell lines are used with particularly small 
pERK1/2 responses (Emax) such as that seen in transfected HEK 293 (Figure 
4.8). Increasing the cell number above 50,000 per well is not recommended 
by the pERK1/2 assay kit supplier (Cisbio Bioassays), therefore in order to 
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maximise the signalling window for the measurable pERK1/2 response within 
HEK 293 cells it may be necessary to create stable cell lines to ensure a 
greater proportion of cells express the receptor of interest.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. GCG and oxyntomodulin stimulated pERK1/2 response in 
GCGR transfected HEK 293T cells and CHO-K1 cells stably expressing 
GCGR. A) HEK 293T transiently expressing pmCherry-N1 vector containing 
GCGR (48 hours post transfection) or B) CHO-K1 cells stably expressing 
GCGR were serum starved for 24 hours and exposed to GCG or oxyntomodulin 
for 5 minutes before measuring pERK1/2. CHO-K1 cells were plated at 10,000 
cells per well and HEK 293T cells at 50,000 cells per well in a 384-well plate. All 
values are mean ± SEM expressed as percentage PMA (1 µM) response where 
n ≥ 5 independent experimental repeats, conducted in duplicate.  
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4.4.2.2. pERK1/2 response in a generated GCGR stable HEK 293 cell line  
 
In an attempt to maximise the signalling window for the measurable pERK1/2 
response within HEK 293 cells, a stable cell line was made to ensure a 
greater proportion of cells express the receptor of interest (Section 3.6.).  
GCG stimulation in GCGR stably expressing HEK 293 cells induced a 
pERK1/2 response (Figure 4.10 and Table 4.8), which was comparable in 
potency (pEC50 6.04 ±0.20) to the response in GCGR transfected HEK 293 
cells and HEK 293T cells (pEC50 6.23 ±0.35 and 6.12 ±0.19, respectively) 
(Figure 4.8 and Table 4.6). There was found to be an elevation in maximal 
response for this stable cell line in comparison to GCGR transient transfected 
HEK 293 cells (14.0 ±2.6 and 30.7 ±3.5 percentage PMA response, 
respectively). This finding suggests that stable expression of GCGR does 
indeed increase the signalling window for pERK1/2 response analysis at the 
GCGR. It may be interesting to expand on these findings further by 
investigating the difference in GCGR cell-surface expression between stable 
and transiently transfected cells. 
The measured potency of oxyntomodulin was not significantly different 
when compared to GCG (pEC50 5.38 ±0.34 and 6.04 ±0.20, respectively). 
This finding is likely an experimental limitation where we are at the lower end 
of the assay dynamic range, as was suggested to be the case in transfected 
HEK 293T cells. Despite an increased in the signalling window with this 
GCGR stable HEK 293 cell line and a small difference in potency between 
GCG and oxyntomodulin, it could be suggested that GCGR stable CHO-K1 
cells appear to be a more valuable cellular model for further investigation into 
pERK1/2 responses. In addition, the enhanced pERK1/2 signalling window for 
this stable GCGR expressing HEK 293 cell line was not considered great 
enough to justify repeating GCGR signalling analysis which was already done 
in HEK 293 cells transfected with GCGR (Section 4.2.1 and 4.3.1). 
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Figure 4.10. GCG and Oxyntomodulin stimulated pERK1/2 response in 
HEK 239 cells stably expressing GCGR.  HEK 293 cells stably expressing 
GCGR were stimulated with GCG or oxyntomodulin for 5 minutes before 
measuring pERK1/2. Cells were plated at 50,000 cells per well in a 384-well 
plate. All values are mean ± SEM expressed as percentage PMA response (1 
µM) where n ≥ 5 independent experimental repeats, conducted in duplicate.  
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4.4.3.  PKA and cAMP play no role in the GCGR stimulated ERK1/2 
response 
 
Protein kinase A (PKA) is known to be an important component of ERK1/2 
activation (Dumaz and Marais, 2003) (Figure 4.11) and a number of studies 
have utilised PKA inhibitors to indicate the importance of this signalling 
component in GPCR stimulated ERK1/2 activation (Gesty-Palmer et al., 
2006). In this work, one such inhibitor, the cAMP analogue Rp-8-bromo-cAMP 
(Rp-8-Br-cAMP) was used to determine the role of PKA in GCGR mediated 
ERK1/2 activation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. G protein mediated activation of extracellular signal-regulated 
kinase 1 and 2 (ERK1/2) through both α and βγ subunits.  Chen et al., 2014 
demonstrated that the Gβγ subunit, phosphoinositide 3-kinase (PI3K), and protein 
kinase C (PKC) were involved in the gland hormone melatonin 1 (MT1)-mediated 
activation of ERK1/2 through the GPCR, MT1 receptor. Gallein, a specific Gβγ 
small molecule inhibitor (Lehmann et al., 2008), can be used to investigate the 
role of Gβγ subunit in GCGR stimulated ERK1/2 phosphorylation. GPCRs known 
to couple to Gs stimulate intracellular cAMP formation through adenylyl cyclase 
(AC) which acts on protein kinase A (PKA). PKA is known to be an important 
component of ERK1/2 activation (Dumaz and Marais, 2003). The cAMP analogue 
Rp-8-bromo-cAMP (Rp-8-Br-cAMP) is a known antagonist of PKA (Schwede et 
al., 2000) and can be used as a tool to investigate the role of PKA and upstream 
signalling components in GCGR mediated ERK activation.  
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Here, CHO-K1 cells stably expressing GCGR were pre-incubated with 
Rp-8-Br-cAMP (10 µM) for 15 minutes prior to ligand stimulation and pERK1/2 
measurement. CHO-K1 cells stably expressing GCGR showed a 
concentration-dependent pERK1/2 response to both GCG and oxyntomodulin 
(Figure 4.12). The potency of oxytnomodulin is lower than that detected for 
GCG (pEC50 6.89 ±0.20 and 5.85 ±0.13, respectively), as previously indicated 
(Figure 4.5). This is also the case for the cAMP response measured in these 
CHO-K1 cells stably expressing GCGR and suggests that oxyntomodulin has 
a reduced potency at the GCGR to elicit a cAMP and a pERK1/2 response 
when compared to GCG. Importantly, there was no induced pERK1/2 
response detected following stimulation with forksolin (Figure 4.12), indicating 
that cAMP elevation alone could not induce a pERK1/2 response  
Pre-incubation of CHO-K1 cells with the PKA inhibitor, Rp-8-bromo-
cAMP, had no effect on the measured pERK1/2 response to either GCG or 
oxyntomodulin stimulation (Figure 4.13 and Table 4.9). The lack of significant 
difference between the two responses suggests that both GCG and 
oxyntomodulin stimulated pERK1/2 response is independent of PKA. These 
data, in combination with the lack of pERK1/2 response following forskolin 
stimulation suggests that elevated levels of cAMP cannot account for the 
measured pERK1/2 response in these cells.  
 
 
 
 
 
 
 
 
Figure 4.12. pERK1/2 response in CHO-K1 cells stably expressing 
GCGR: CHO-K1 cells stably expressing GCGR were serum starved for 24 
hours and exposed to GCG, oxyntomodulin or forskolin for 5 minutes before 
measuring pERK1/2. CHO-K1 cells were plated at 10,000 cells per well in a 
384-well plate. All values are mean ± SEM expressed as percentage GCG 
response where n ≥ 5 independent experimental repeats, conducted in 
duplicate.  
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Figure 4.13. pERK1/2 response in CHO-K1 cells stably expressing GCGR 
+/- PKA inhibitor: CHO-K1 cells stably expressing GCGR were serum 
starved for 24 hours and pretreated for 15 minutes with the cAMP analogue 
Rp-8-bromo-cAMP (Rp-8-Br-cAMP) or DMSO control prior to stimulation with 
A) GCG or B) oxyntomodulin for 5 minutes before measuring pERK1/2. CHO-
K1 cells were plated at 10,000 cells per well in a 384-well plate. All values are 
mean ± SEM expressed as percentage GCG response in Rp-8-Br-cAMP 
untreated cells where n ≥ 5 independent experimental repeats, conducted in 
duplicate.  
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4.4.4.  The specific Gβγ subunits inhibitor, gallein, had no effect on the 
measured pERK1/2 response  
 
In the case of G protein mediated ERK1/2 activation, both α and βγ subunits 
are able to activate the ERK cascades (Eishingdrelo and Kongsamut, 2013) 
(Figure 4.11). To define the role of Gβγ subunit in GCGR stimulation ERK1/2 
phosphorylation, CHO-K1 cells stably expressing GCGR were pre-incubated 
for 30 minutes with gallein (10, 1 or 0.1 µM), a specific Gβγ small molecule 
inhibitor (Lehmann et al., 2008), or DMSO control prior to GCG or 
oxynotmodulin stimulation and subsequent pERK1/2 measurement.  
As previously shown (Figure 4.12), CHO-K1 cells stably expressing 
GCGR showed a concentration-dependent pERK1/2 response to both GCG 
or oxyntomodulin stimulation (Figure 4.14). Pretreatment with gallien, had no 
effect on the measured pERK1/2 response to either GCG or oxyntomodulin at 
any of the tested inhibitor concentration in terms of potency or maximal 
response (Figure 4.14 and Table 4.10). This finding suggests that signalling 
via the Gβγ-subunit cannot account for the GCGR-mediated pERK1/2 
response. 
The basal level of pERK1/2 showed an elevation with 10 µM gallein 
pretreatment. Whereas the true basal (stimulation with HBS only) response 
aligned at zero (percentage GCG), there appears to be an elevation in the 
basal pERK1/2 level at very low concentrations of GCG or oxytnotmodulin. 
This finding suggests that Gβγ inhibition alone, in absence of any ligand, has 
no effect on the basal pERK1/2 response. However, at low concentrations of 
ligand (0.1 nM – 10 nM), it appears Gβγ inhibition causes an elevation in 
pERK1/2. One speculation into the cause of this elevation could be the 
inability of the Gα-subunit to re-bind the Gβγ and complete the G protein 
cycle, thereby remaining active and stimulating a single or multiple pathways 
leading to elevated basal pERK1/2.  
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Figure 4.14. pERK1/2 response in CHO-K1 cells stably expressing GCGR 
+/- Gβγ inhibitor. CHO-K1 cells stably expressing GCGR were serum stared 
for 24 hours and pretreated for 30 minutes with the specific Gβγ small 
molecule inhibitor, gallein, at various concentrations (10, 1 or 0.1 µM) or 
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minutes and measuring pERK1/2. CHO-K1 cells were plated at 10,000 cells 
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4.4.5.  The specific Gq/11 inhibitor, YM-254890, reduced the potency of the 
pERK1/2 response following GCG stimulation  
 
All the Gq family members (Gq, G11, G14 and G15/16) have been shown to 
activate ERK1/2 via the stimulation of PLCβ (Goldsmith and Dhanasekaran, 
2007). Here, an investigation was made into the role of the Gq-mediated 
pathway in the GCGR mediated pERK1/2 response using the specific Gq/11 
inhibitor, YM-254890.  
Having initially used YM-254890 to confirm the Ca2+i response to GCG 
stimulation in GCGR transfected HEK 293 cells and CHO-K1 cells stably 
expressing GCGR was Gq/11 mediated (Section 4.3), we sought to investigate 
if Gq/11 was also important in the GCG stimulated pERK1/2 response. Here, 
CHO-K1 cells stably expressing GCGR received a 30-minute pre-incubation 
with YM-254890 prior to stimulation with GCG and measurement of pERK1/2 
(Figure 4.15 and Table 4.1). The potency and affinity of the GCG stimulated 
pERK1/2 response was significantly reduced in YM-254890 treated cells 
when compared to untreated DMSO control (pEC50 6.09 ±0.17 and 6.80 
±0.11, pKA 5.44 ±0.3 and 6.36 ±0.1, respectively) (Table 4.1).  This finding 
suggests that Gq/11 plays a role in the GCG stimulated pERK1/2 response in 
CHO-K1 cells stably expressing GCGR. However, given the maximal 
response to GCG was not significantly different in treated and untreated cells, 
it appears other cellular components and pathways, such as the β-arrestin 
mediated pathway, are also responsible for the measured pERK1/2 response. 
Of note, the Gβγ subunit released from Gq-coupled GPCRs has also 
been shown to activate PLCβ and therefore can also lead to activation of 
ERK1/2 via PLC-DAG-PKC as well as PLC-IP3-Ca2+ pathways (Goldsmith 
and Dhanasekaran, 2007). Given that there was no difference in pERK1/2 
response in Gβγ inhibitor treated and untreated GCGR expressing CHO-K1 
cells, this result may infer that only the Gα-subunit of Gq/11 and not the Gβγ is 
responsible for this reduced potency.  
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Figure 4.15. pERK1/2 response in CHO-K1 cells stably expressing GCGR 
+/- Gq/11 inhibitor. CHO-K1 cells stably expressing GCGR were serum stared 
for 24 hours and pretreated for 30 minutes with the specific Gq/11 inhibitor, 
YM-254890, at various concentrations (100 nM) or DMSO control prior to 
stimulation with GCG for 5 minutes and measuring pERK1/2. CHO-K1 cells 
were plated at 10,000 cells per well in a 384-well plate. All values are mean ± 
SEM expressed as percentage GCG response in DMSO control treated cells 
where n ≥ 5 independent experimental repeats, conducted in duplicate.  
 
 
 
	 172 
 
	T
ab
le
 4
.1
1.
  
pE
R
K
1/
2 
re
sp
on
se
 in
 C
H
O
-K
1 
ce
lls
 s
ta
bl
y 
ex
pr
es
si
ng
 G
C
G
R
 +
/- 
G
q/
11
 in
hi
bi
to
r. 
P
ot
en
cy
 
(p
E
C
50
), 
m
ax
im
al
 re
sp
on
se
 (E
m
ax
), 
ba
sa
l, 
sp
an
, a
ffi
ni
ty
 (p
K
A
) a
nd
 c
ou
pl
in
g 
ef
fic
ac
y 
(lo
gτ
) f
or
 G
C
G
 in
 C
H
O
-K
1 
ce
lls
 s
ta
bl
y 
ex
pr
es
si
ng
 G
C
G
R
  -
/+
 Y
M
-2
54
89
0 
m
ea
su
re
d 
us
in
g 
a 
pE
R
K
1/
2 
as
sa
y 
  
pE
R
K
1/
2 
 
pE
C
50
 a
 
E m
ax
 b
 
B
as
al
 c 
Sp
an
 d 
pK
A
 e
 
lo
g 
τ 
f  
G
C
G
 o
nl
y 
6.
80
 ±
0.
11
 
95
.9
 ±
4.
0 
2.
8 
±3
.2
 
93
.0
 ±
4.
8 
6.
36
 ±
0.
1 
0.
24
 ±
0.
05
 
+ 
Y
M
-2
54
89
0 
6.
09
 ±
0.
17
**
 
11
4.
5 
±1
3.
6 
-7
.6
 ±
5.
0 
12
2.
1 
±1
3.
7 
5.
44
 ±
0.
3*
 
0.
54
 ±
0.
21
 
 C
H
O
-K
1 
ce
lls
 s
ta
bl
y 
ex
pr
es
si
ng
 G
C
G
R
  
-/+
 p
re
tre
at
m
en
t w
ith
 th
e 
sp
ec
ifi
c 
G
αq
/1
1 
in
hi
bi
to
r, 
Y
M
-2
54
89
0,
 w
er
e 
st
im
ul
at
ed
 w
ith
 G
C
G
 a
nd
 t
he
 p
E
R
K
1/
2 
re
sp
on
se
 t
o 
G
C
G
 m
ea
su
re
d 
in
 o
rd
er
 t
o 
ge
ne
ra
te
 c
on
ce
nt
ra
tio
n 
re
sp
on
se
 c
ur
ve
s.
 T
o 
ca
lc
ul
at
e 
pE
C
50
, 
E
m
ax
, 
B
as
al
 a
nd
 S
pa
n 
va
lu
es
, 
da
ta
 w
er
e 
an
al
ys
ed
 u
si
ng
 a
 t
hr
ee
-
pa
ra
m
et
er
 lo
gi
st
ic
 e
qu
at
io
n.
 D
at
a 
w
as
 a
ls
o 
an
al
ys
ed
 b
y 
an
 o
pe
ra
tio
na
l m
od
el
 o
f a
go
ni
sm
  
(B
la
ck
 a
nd
 L
ef
f, 
19
83
) t
o 
de
te
rm
in
e 
af
fin
ity
 (p
K
A
) a
nd
 c
ou
pl
in
g 
ef
fic
ac
y 
(lo
g 
τ)
. 
a  N
eg
at
iv
e 
lo
ga
rit
hm
 o
f l
ig
an
d 
co
nc
en
tra
tio
n 
re
qu
ire
d 
to
 p
ro
du
ce
 a
 h
al
f-m
ax
im
al
 re
sp
on
se
 
b 
M
ax
im
al
 re
sp
on
se
 to
 li
ga
nd
 a
s 
pe
rc
en
ta
ge
 G
C
G
 re
sp
on
se
  
c 
Th
e 
lo
w
 p
la
te
au
 o
f t
he
 fi
tte
d 
si
gm
oi
da
l d
os
e-
re
sp
on
se
 c
ur
ve
 
d 
Th
e 
di
ffe
re
nc
e 
be
tw
ee
n 
E
m
ax
 a
nd
 b
as
al
 s
ig
na
lli
ng
 
e 
Th
e 
ne
ga
tiv
e 
lo
ga
rit
hm
 o
f f
un
ct
io
na
l a
ffi
ni
tie
s 
th
at
 d
es
cr
ib
es
 th
e 
af
fin
ity
 o
f t
he
 r
ec
ep
to
r 
w
he
n 
co
up
le
d 
to
 a
 
gi
ve
n 
si
gn
al
lin
g 
pa
th
w
ay
 g
en
er
at
ed
 th
ou
gh
 u
se
 o
f t
he
 o
pe
ra
tio
na
l m
od
el
 fo
r p
ar
tia
l a
go
ni
sm
 
f τ
 is
 th
e 
co
up
lin
g 
ef
fic
ie
nc
y 
pa
ra
m
et
er
 g
en
er
at
ed
 th
ou
gh
 u
se
 o
f t
he
 o
pe
ra
tio
na
l m
od
el
 fo
r p
ar
tia
l a
go
ni
sm
 
S
ta
tis
tic
al
 s
ig
ni
fic
an
ce
 (
*,
 p
<0
.0
5;
**
, p
<0
.0
1;
**
*,
 p
<0
.0
01
) 
co
m
pa
re
d 
to
 G
C
G
 r
es
po
ns
e 
in
 u
nt
re
at
ed
 C
H
O
-K
1 
ce
lls
 w
as
 d
et
er
m
in
ed
 b
y 
un
pa
ire
d 
S
tu
de
nt
’s
 t-
te
st
 (t
w
o-
ta
ile
d)
 
 
	 173 
4.4.6.  Investigating the importance of G proteins and β-arrestin1/2 in 
GCGR stimulated pERK1/2 response  
 
To further investigate the potentially important upstream signalling component 
in the pERK1/2 response following GCGR stimulation, the parental (WT) and 
various CRISPR G protein and β-arrestin1/2 knockout HEK 293 cell lines 
(gifted to us by Dr Asuka Inoue), previously characterised in Section 3.8, were 
utilised. 
A concentration-dependent increase in pERK1/2 was measured 
following GCG stimulation in WT and CRISPR G protein and β-arrestin1/2 
knockout HEK 293 transfected with pmCherry-N1 expressing GCGR (Figure 
4.16). This pERK1/2 response measured to GCG stimulation in the knockout 
cell was not significantly different in any of the measured parameters (pEC50, 
Emax, Basal, Span values, affinity (pKA) and coupling efficacy (log τ)) when 
compared to WT. Of note, the signalling window was small in this HEK 293 
cell line (15.0 ±2.8% PMA response (1 µM)) as was shown earlier (Figure 
4.16 and Table 4.12). As such, there was high variability in the data resulting 
in uncertainty in the fitted dose-response curves. With this in mind, drawing 
conclusions from these data is difficult. Despite this uncertainty, the pERK1/2 
response in Gαq (ΔGαq and ΔGαs/q/12) and β-arrestin1/2 knockout cell lines 
showed a reduction in maximum pERK response to GCG (Emax 79.1 ±13.7, 
62.9 ±13.0 and 61.0 ±14.8, respectively, expressed as a percentage of WT 
response) when compared to WT (Emax 103.6 ±19.4). This finding could 
indicate the GCGR-mediated ERK1/2 activation is through a combination of 
Gαq and β-arrestin1/2 mediated pathways. 
It appears in order to draw useful conclusions from these cell lines, an 
enhancement in the GCG signalling window would be required. However, the 
maximum cell number of 50,000 per well (as recommended by the pERK1/2 
assay kit supplier (Cisbio Bioassays)) was used, and the only other 
alternative to enhance the possible window would be to increase GCGR 
expression via stable cell line generation. However, the generation of GCGR 
	 174 
stable WT HEK 293 cells was shown to only enhance the GCG stimulated 
pERK1/2 response by approximately 2-fold when compared to transfected 
WT HEK 293 cells (30.7 ±3.5 and 14.0 ±2.6 expressed as a percentage PMA 
response (1 µM), respectively). This small enhancement and additional cell 
line manipulation is likely to not be sufficient to justify the generation of the 
additional GCGR stable cell lines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16. GCG stimulated pERK1/2 response in WT and various 
knockout HEK 239 cells lines.  WT and various G protein or β-arrestin1/2 
knockout HEK 293 cell lines were transfected with GCGR and stimulated with 
GCG for 5 minutes before measuring pERK1/2. Cells were plated at 50,000 
cells per well in a 384-well plate. All values are mean ± SEM expressed as 
percentage GCG response in WT cells where n ≥ 5 independent experimental 
repeats, conducted in duplicate.  
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4.4.7.  Summary  
 
ERK1/2 activation is described to be downstream of both the Gα and Gβγ 
subunits of G protein including Gs, Gi, and Gq (DeWire et al., 2007). The 
results presented here have utilised a number of inhibitors including Rp-8-
bromo-cAMP, gallein and YM-254890 targeted at inhibiting PKA, Gβγ and 
Gq/11, respectively. Whereas treatment with PKA and Gβγ specific inhibitors 
showed no effect on the measured pERK1/2 response to GCG or 
oxyntomodulin, inhibition of Gq/11 showed a reduction in potency of GCG.  
The inability of PKA inhibition by Rp-8-bromo-cAMP or the genetic 
knockout of Gαs to influence the pERK1/2 response measured to GCG 
stimulation suggested that GCGR mediated pERK1/2 activation is 
independent of Gs stimulated pathway. Interestingly, the GCG and 
oxyntomodulin response following Gβγ inhibition through gallien treatment at 
10 µM showed an elevated basal pERK1/2 response at very low 
concentrations of ligand. One may speculate that the initial activation of 
GCGR at these very low ligand concentrations initiates the pERK1/2 cascade 
at a low level and that Gβγ is prevented from re-grouping with the Gα-subunit 
which in turn can continuously activate the pathway leading to ERK1/2 
activation.   
The potency of the GCG stimulated pERK1/2 response was reduced 
following Gq/11 inhibition using YM-254890, suggesting that Gq/11 plays a role 
in the GCG stimulated pERK1/2 response at the GCGR. Consistent with 
these findings, chelation of Ca2+i was found to reduce GCG-mediated ERK1/2 
activation, suggesting an increase in Ca2+i is required for maximal ERK 
activation (Jiang et al., 2001). 
The pERK1/2 data acquired in the knockout cell lines should be 
interpreted with caution due to the lack of statistical significance between 
responses and small signalling window. With this in mind, the pERK1/2 
response in Gαq (ΔGαq and ΔGαs/q/12) and β-arrestin1/2 knockout cell lines 
showed a reduction in maximum response. This finding may suggest that the 
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pERK1/2 response is produced by a combination of Gq/11 and β-arrestin1/2 
mediated pathways.  
Given the inability to fully inhibit the pERK1/2 response to ligand 
stimulation of GCGR with any of the tested inhibitors or knockout cell lines, it 
appears that the pERK1/2 response is a combination of a number of cellular 
components/pathways. It should also be noted that the knockout cell lines 
might display functional compensation, providing an explanation as to why we 
may not have seen full knockdown of GCGR-mediated ERK1/2 activation. An 
important follow up experiment would be to investigate the pERK1/2 response 
in Δβ-arrestin1/2 knockout HEK 293 cells transfected with GCGR, in the 
presence and absence of YM-254890 treatment. These data would provide 
additional evidence to support the hypothesis ERK1/2 phosphorylation in 
response to GCG stimulation at the GCGR is through a combination of both 
Gq and β-arrestin1/2 mediated pathways. 
 
 
4.5.  Pharmacological characterisation of two potential GCGR 
antagonists  
4.5.1. des-His1,[Glu9]-glucagon amide is a partial agonist at the GCGR in 
transfected HEK 293T cells  
 
Receptor antagonists are useful tools for investigating the mechanism of 
action for cognate ligands.  The GCG peptide analogue, des-His1,[Glu9]-
glucagon amide (des-His1,[Glu9]-GCG), has been reported to act as an 
antagonist of GCG in several systems (Unson et al., 1989) although the exact 
mechanisms of action in terms of binding and affect on downstream signaling 
at GCGR is not known. Here, we investigate the activity of des-His1,[Glu9]-
GCG in HEK 293T cells transfected with pcDNA3.1 expressing GCGR using 
the cAMP accumulation assay.  
As previously shown, GCG stimulation of HEK 293T cells transfected 
with GCGR induced a concentration-dependent increase in cAMP (pEC50 of 
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10.03 ±0.1 and Emax of 98.4 ±3.6 (percentage GCG response)) (Figure 4.17). 
It should be noted that the HEK 293T cells used for GCGR transfection in this 
assay were different to those previously used which showed reduced cAMP 
signalling to both GCG and oxyntomodulin (Figure 4.2). Importantly, the 
maximal response measured for GCG was reduced when compared to the 
maximum forskolin response (Emax of 147.8 ±4.8) (Figure 4.17) and as such, 
the GCG response is within this maximum range allowing any enhancement 
in cAMP signal to be measureable (i.e. within the dynamic range of the 
assay). 
Co-stimulation of HEK 293T cells with GCG and des-His1,[Glu9]-GCG 
at a concentration of 1 µM and 10 µM, respectively, showed a rightward shift 
in measured GCG potency whereas there was no significant change in 
maximal response (Figure 4.18 A). Although this reduction in GCG potency 
only reached statistical significance at 10 µM of des-His1,[Glu9]-GCG  (Table 
4.13), this result suggests antagonism at the GCGR. In comparison to GCG 
stimulation only, the basal cAMP level is significantly elevated following co-
stimulation with 1 or 10 µM des-His1[Glu9]-GCG and very low GCG 
concentrations (≤ 10 pM). In addition, there was a significantly reduces span 
at 10 µM des-His1[Glu9]-GCG co-stimulation. This finding suggests that des-
His1[Glu9]-GCG has some agonistic activity at the GCGR. 
Indeed, simulation with only des-His1,[Glu9]-GCG produced a robust 
cAMP response and when compared to GCG showed a reduced potency 
(pEC50 10.03 ±0.1 and 7.64 ±0.2, respectively) and maximal response (Emax 
98.4 ±3.6 and 63.6 ±2.9, respectively) (Figure 4.18 B). The response to des-
His1,[Glu9]-GCG stimulation in vector only transfected HEK 293T cells 
showed a significantly reduced maximal response and basal response when 
compared to that seen in GCGR transfected HEK 293T cells (Figure 4.19 and 
Table 4.13). These findings suggests that the cAMP response following des-
His1,[Glu9]-GCG stimulation is indeed through the GCGR and it appears to be 
acting as a partial agonist. The small dose-response curve fitted to data from 
des-His1,[Glu9]-GCG stimulation in vector only transfection HEK 293T cells 
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showed variability in potency (pEC50 8.08 ±0.5) and may indicate noise in the 
cAMP assay or a low level of GCGR expression.  
Cells stimulated with 1 nM of GCG with increasing concentrations of 
des-His1,[Glu9]-GCG remained at a plateau between des-His1,[Glu9]-GCG 
concentrations of 0.01 nM – 10 nM, and although not significant,  showed a 
small inhibition of the measured cAMP response at concentrations of 0.1 µM 
– 10 µM with a measured half maximal inhibitory concentration (pIC50) of 6.01 
±1.3 (Figure 4.18 B).  
The findings presented here suggests des-His1,[Glu9]-GCG to be a 
partial agonist at the GCGR in transfected HEK 293T cells. It should be noted 
that any partial agonist also acts as a competitive antagonist and provides an 
explanation for the reduced cAMP response following 1 nM GCG treatment at 
high concentrations of des-His1[Glu9]-GCG (1 and 10 µM). 
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Figure 4.17. GCG dose-response is within the dynamic range of the 
cAMP assay in HEK 293T cells. HEK 293T cells transiently transfected 
with GCGR (1,000 cells/well) were exposed to GCG or forskolin for 8 
minutes and cAMP accumulation detected using the LANCE cAMP kit. All 
values are mean ± SEM expressed as percentage GCG response where n 
≥ 5 independent experimental repeats, conducted in duplicate. Here, the 
true basal for GCG (stimulation buffer without ligand) aligned with zero 
percentage GCG response but was excluded to allow better fit of the 
three-parameter logistic equation. 
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Figure 4.18. Activity of des-His1,Glu9-GCG in GCGR transfected HEK 
293T cells. HEK 293T cells transiently transfected with GCGR (1,000 
cells/well) were exposed to A) GCG with or without various concentration 
of des-His1,Glu9-GCG, or B) des-His1,Glu9-GCG alone or in combination 
with 1nM GCG for 8 minutes and cAMP accumulation detected using the 
LANCE cAMP kit. All values are mean ± SEM expressed as percentage 
GCG response where n ≥ 5 independent experimental repeats, conducted 
in duplicate. Here, the true basal (stimulation buffer without ligand) aligned 
with zero percentage GCG response but was excluded to allow better fit of 
the three-parameter logistic equation. 
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Figure 4.19. cAMP response to des-His1,Glu9-GCG in GCGR/vector 
only transfected HEK 293T cells. HEK 293T cells transiently transfected 
with GCGR or vector alone (1,000 cells/well) were exposed to des-
His1,Glu9-GCG for 8 minutes and cAMP accumulation detected using the 
LANCE cAMP kit. All values are mean ± SEM expressed as percentage 
GCG response where n ≥ 5 independent experimental repeats, conducted 
in duplicate. 
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4.5.2.  L-168,049 is a competitive antagonist at the GCGR in HEK 293T 
cells  
 
L-168,049, a small molecule non-peptide, has previously been reported to be 
a non-competitive antagonist of GCGR in several systems (Cascieri et al., 
1999). Given des-His1,[Glu9]-GCG was found to be a partial agonist in GCGR 
transfected HEK 293T cells, we looked to investigate the activity of L-168,049 
as a potential GCGR antagonist.  
Here, HEK 293T cells transfected with pcDNA3.1 expressing GCGR, 
were stimulated with GCG only or in combination with varying concentration 
of L-168,049 (Figure 4.20 A). Co-stimulation with GCG and increasing 
concentrations of L-168,049 showed a progressive parallel rightward shift of 
the dose-response for GCG towards higher concentrations (Table 4.14). This 
shift in potency, although evident from as little as 0.01 µM L-168,049, only 
reached statistical significance at 1 µM and 10 µM with a two-log shift (Figure 
4.20 A). There was found to be no significant changes in maximal (Emax) or 
basal response with L-168,049 co-stimulation at any of the tested 
concentration. Given that co-stimulation of GCGR transfected HEK 293T cells 
with GCG and increasing concentrations of L-168,049 produced a 
progressive rightward shift in the GCG dose-response and the maximal 
response remained unchanged, L-168,049 could be classified as a 
competitive antagonist at the GCGR. However, it is likely that there is a high 
receptor reserve in the transfected cells where stimulation of only a fraction of 
this GCGR population produces a maximal response. As such, inhibition of 
the GCG response by L-168,049 could not occur unless this reserve was 
depleted or higher concentrations of antagonists were tested. With this in 
mind, in our hands and under these test conditions L-168,049 could be 
classified as a competitive antagonist at the GCGR, rather than a non-
competitive antagonist, as was previously described (Cascieri et al., 1999).  
Cells co-stimulated with GCG at a concentration of 1 nM and 
increasing concentration of L-168,049 showed a half maximal inhibitory 
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concentration (pIC50) of 7.08 ±0.3 (Figure 4.20). Simulation with L-168,049 
alone produced a cAMP response but showed reduced potency and maximal 
response when compared to GCG (pEC50 10.03 ±0.1 and 8.76 ±0.2, Emax 
98.4 ±3.6 and 46.6 ±1.2, respectively) (Figure 4.20 B). This finding is similar 
to that seen for des-His1,[Glu9]-GCG, although L-168,049 shows increased 
potency in comparison (pEC50 7.64 ±0.2 and 8.76 ±0.2, respectively). This 
finding suggests that L-168,049 may have agonistic activity at the GCGR. 
However, control experiments in HEK 293T cells expressing vector alone 
showed no significant difference between the L-168,049 induced cAMP 
response in GCGR or vector only expressing HEK 293T cells (Figure 4.21 
and Table 4.14). This finding suggests the apparent agonistic response is not 
GCGR specific and L-168,049, being yellow in colour, may have fluorescent 
properties causing an apparent dose-response curve with increasing 
concentrations. Further experiments may need to include a “no cells” control 
in order to subtract the baseline signal and categorically identify that L-
168,049 is not acting at another receptor other than GCGR to cause an 
apparent dose-response.  
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Figure 4.20. Activity of L-168,049 in GCGR transfected HEK 293T 
cells. HEK 293T cells transiently transfected with GCGR (1,000 cells/well) 
were exposed to A) GCG with or without various concentration L-168,049 
or B) L-168,049 alone or in combination with 1nM GCG for 8 minutes and 
cAMP accumulation detected using the LANCE cAMP kit. The dashed 
grey arrow represents the expected reduction in maximal response on 
stimulation with higher L-168,049 concentrations if receptor reserve was 
depletion. All values are mean ± SEM expressed as percentage GCG 
response where n ≥ 5 independent experimental repeats, conducted in 
duplicate. Here, the true basal (stimulation buffer without ligand) aligned 
with 0 percentage GCG response but was excluded to allow better fit of 
the three-parameter logistic equation. 
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Figure 4.21. cAMP response to L-168,049 in GCGR/vector only 
transfected HEK 293T cells: HEK 293T cells transiently transfected with 
GCGR or vector alone (1,000 cells/well) were exposed to L-168,049  for 8 
minutes and cAMP accumulation detected using the LANCE cAMP kit. All 
values are mean ± SEM expressed as percentage GCG response where n 
≥ 5 independent experimental repeats, conducted in duplicate. 
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4.5.3.  Summary  
 
The findings presented here in HEK 293T cells transfected with pcDNA3.1 
expressing GCGR characterise the GCG peptide analogue des-His1,[Glu9]-
GCG, previously reported to act as an antagonist of GCG in several systems 
(Unson et al., 1989), as a partial agonist at the GCGR. On the other hand, L-
168,049 was characterised as a competitive antagonist at the GCGR. 
Stimulation of GCGR transfected HEK 293T cells with des-His1,[Glu9]-
GCG or L-168,049 was shown to stimulate cAMP accumulation. It could be 
argued that receptor expression may be higher in this transfected system 
when compared to an endogenously expressing cell lines and therefore we 
may be amplifying a small agonistic response. Whereas the des-His1,[Glu9]-
GCG stimulated cAMP response was shown to be GCGR specific, the L-
168,049 induced cAMP response was not. With these findings in mind, it 
appears that neither des-His1,[Glu9]-GCG or L-168,049 can be used as 
antagonists to investigate specific GCGR signalling. If L-168,049 is used, 
controls for autofluorescence need to be considered.  
 
 
 
4.6.  Investigating the action of a potential GCGR biased agonist; TH-
GCG 
4.6.1.  TH-GCG induces a robust cAMP response in GCGR transfected 
HEK 293T cells  
 
The GCG analogue TH-GCG was previously reported in hepatocytes to 
neither activate AC nor cause cAMP response, but was shown to fully 
stimulate glycogenolysis, gluconeogenesis and stimulates the production of 
inositol phosphates (Wakelam et al., 1986). This was described as an 
alternative mechanism by which GCG activation may exert its effects 
independent of cAMP and that this may indicate the existence of two distinct 
receptors for GCG, one coupled to inositol phospholipid breakdown and 
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another coupled to stimulate AC activity. Here, we investigate the hypothesis 
that TH-GCG is acting at the classical GCGR and that these early findings 
can be explaining by signalling bias where the downstream signalling 
cascade initiated by TH-GCG is predominantly through Gq-coupling. 
We first sought to confirm that TH-GCG was unable to stimulate cAMP 
production using our assay system of HEK 293T cells transfected with GCGR 
expressed from the CMV promoter using pmCherry-N1. A robust cAMP 
response was determined in these HEK 293T cells following GCG or TH-
GCG stimulation (Figure 4.22). TH-GCG showed a significantly reduced 
potency when compared to GCG (pEC50 7.05 ±0.14 and 9.52 ±0.12, 
respectively), with non-significant reduced maximal response (Emax 87.8 ±4.8 
and 101.5 ±4.6, respectively) (Table 4.15). These data suggest TH-GCG to 
be a lower potency agonist at the GCGR in HEK 293T cells transfected 
GCGR. Notably, HEK 293T cells transfected with vector alone showed a very 
weak response to TH-GCG, with large error for all the output parameters 
acquired from fitted data with a three-parameter logistic equation (Figure 
4.23, Table 4.15). This result suggests the cAMP response seen to TH-GCG 
stimulation is GCGR specific. 
Given the similar maximal response but reduced potency of TH-GCG 
at the GCGR, it appears TH-GCG is a lower potency full agonist at the GCGR 
in HEK 293T cells, most probably through the classical Gs-coupled pathway. 
This finding is distinct from previous reports in hepatocytes indicating TH-
GCG does not cause an increase in cAMP (Wakelam et al., 1986, Lenzen et 
al., 1990). This unexpected finding may be as a result of receptor expression 
in the transfected HEK 293T cells when compared to primary hepatocytes. 
Alternatively, or in combination with receptor expression, the GCGR may be 
strongly coupled to the cAMP signalling components within HEK 293T cells, 
which may not be the case in hepatocytes. In order to test this theory, cells 
endogenously expressing GCGR, such as the hepatocyte cell line, Hep 3B, 
were tested for a TH-GCG stimulated cAMP response (Section 4.6.4).   
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Figure 4.22. TH-GCG induces a concentration-dependent increase in 
cAMP accumulation in HEK 293T cells expressing GCGR. HEK 293T cells 
transiently (24 hours post transfection) expressing mCherry-tagged GCGR 
were exposed to GCG or TH-GCG for 8 minutes and cAMP accumulation 
detected. All values are mean ± SEM expressed as percentage GCG 
response where n ≥ 5 independent experimental repeats, conducted in 
duplicate.  
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Table 4.15.  TH-GCG induces a concentration-dependent increase in cAMP 
accumulation in HEK 293T cells expressing GCGR. Potency (pEC50), maximal 
response (Emax), basal and span for GCG and TH-GCG stimulated cAMP response 
measured in GCGR/vector only transfected HEK 293T cells 
HEK 293T 
cAMP 
Ligand pEC50 a Emax b Basal c Span d 
GCG 9.52 ±0.12 101.5 ±4.6 9.1 ±2.7 92.4 ±5.1 
TH-GCG  7.05 ±0.14*** 87.8 ±4.8 4.7 ±3.6 83.0 ±5.7 
TH-GCG (Vector control) N.R 6.7 ±3.6 N.R 
 
GCGR transfected (or vector only transfected) HEK 293T cells were stimulated with 
GCG or TH-GCG prior to measurement of cAMP accumulation to generate concentration 
response curves. To calculate pEC50, Emax, Basal and Span values, data were analysed 
using a three-parameter logistic equation. 
a Negative logarithm of GCG/TH-GCG concentration required to produce a half-maximal 
response 
b Maximal response to  GCG/TH-GCG as percentage GCG response 
c The low plateau of the fitted sigmoidal dose-response curve 
d The difference between Emax and basal signalling 
All values are mean ± SEM expressed percentage GCG response where n ≥ 5 
independent experimental repeats, conducted in duplicate. Statistical significance (*, 
p<0.05;**, p<0.01;***, p<0.001) in the difference between the cAMP responses to TH-
GCG and GCG was determined by unpaired Student’s t-test (two-tailed). 
N.R denotes no response or where a true dose-response curve could not be generated 
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Figure 4.23. TH-GCG stimulated cAMP response is GCGR-dependent in 
HEK 293T cells. HEK 293T cells transiently (24 hours post transfection) 
expressing mCherry-tagged GCGR or vector only were exposed to GCG or 
TH-GCG for 8 minutes and cAMP accumulation detected. All values are mean 
± SEM expressed as percentage forskolin response where n ≥ 5 independent 
experimental repeats, conducted in duplicate.  
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4.6.2.  TH-GCG fails to induce an Ca2+i in GCGR transfected HEK 293T 
cells  
 
Having demonstrated a clear ability of TH-GCG to stimulate cAMP production 
in HEK 293T cells transfected with pmCherry-N1 expressing GCGR, we next 
wanted to determine if TH-GCG displayed a more potent activation of Ca2+i 
release from the endoplasmic reticulum (ER).  
HEK 293T cells were seeded in a 96-well plate, transfected with 
GCGR and stimulated with increasing concentrations of GCG or TH-GCG 
with the Ca2+i mobilisation measured using a FlexStation® Multi-Mode 
Microplate Reader. In line with previous findings (Section 4.3.1), a robust 
GCG stimulated Ca2+i response was detected in GCGR transfected HEK 
293T cells, which was abolished by a 30 minute pre-treatment with the 
specific Gq/11 inhibitor, YM-254890 (Figure 4.24 A and Table 4.16), thereby 
confirming the Ca2+i mobilisation was Gq/11-mediated.  
TH-GCG showed no detectable Ca2+i response with or without YM-
254890 pre-treatment (Figure 4.24 B and Table 4.16). This finding was 
unexpected given that previous findings have suggested TH-GCG stimulation 
in hepatocytes induces an inositol phosphate response (Wakelam et al., 
1986, Lenzen et al., 1990) and inositol phosphate production is downstream 
of the Gq/11-mediated Ca2+i response (Goldsmith and Dhanasekaran, 2007). 
This lack of detectably Ca2+i mobilisation may simply reflect the differences in 
cellular components between HEK 293T cells and hepatocytes. Alternatively, 
this hepatocyte cell line may not have been capable of inducing a measurable 
Ca2+i mobilisation due to a reduced amplification when compared to HEK 
293T cells transiently transfected with GCGR. 
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Figure 4.24. TH-GCG fails to induce a Ca2+i response in HEK 293T cells 
expressing GCGR. HEK 293T cells transiently expressing GCGR (48 hours post 
transfection) were exposed to A) GCG, B) TH-GCG and Ca2+i mobilisation 
measured +/- 30 minutes treatment with YM-254890 (100 nM) or DMSO control. All 
values are mean ± SEM expressed as percentage GCG response where n ≥ 3 
independent experimental repeats, conducted in duplicate.  
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4.6.3.  TH-GCG fails to induce a detectable IP1 response in GCGR 
transfected HEK 293T cells 
 
The mobilisation of Ca2+i can occur through a number of different signal 
transduction cascades. One such mechanism is the production of inositol 
triphosphate (IP3) through classical Gq-coupling to PLCβ leading to activation 
of IP3 receptors expressed on the ER and subsequent release of Ca2+ 
(Goldsmith and Dhanasekaran, 2007). TH-GCG has been reported to 
stimulate the production of inositol phosphates (Wakelam et al., 1986). IP3 is 
rapidly broken down to inositol monophosphate (IP1), which is then further 
degraded to myo-inositol. With the addition of LiCl, IP1 degradation is 
Table 4.16.  TH-GCG fails to induce a Ca2+i response in HEK 293T cells 
expressing GCGR Potency (pEC50), maximal response (Emax), basal and span for 
GCG and TH-GCG stimulated  Ca2+i mobilisation measured in GCGR transfected HEK 
293T cells  
 
HEK 293T 
Ca2+i 
Ligand pEC50 a Emax b Basal c Span d 
GCG 7.01 ±0.13 103.6 ±5.7 -0.1 ±4.4 103.7 ±6.8 
GCG (+ YM-254890) N.R    
TH-GCG  N.R    
TH-GCG (+ YM-254890) N.R    
 
GCGR transfected (or vector only transfected) HEK 293T cells were stimulated with 
GCG or TH-GCG prior to measurement of Ca2+i response or IP1 response to generate 
concentration response curves. CHO-K1 cells stably expressing GCGR were 
stimulated with GCG or TH-GCG and the IP1 response measured. To calculate pEC50, 
Emax, Basal and Span values, data were analysed using a three-parameter logistic 
equation. 
.a Negative logarithm of GCG/TH-GCG concentration required to produce a half-
maximal response 
b Maximal response to  GCG/TH-GCG as percentage GCG response 
c The low plateau of the fitted sigmoidal dose-response curve 
d The difference between Emax and basal signalling 
All values are mean ± SEM expressed percentage GCG response where n ≥ 5 
independent experimental repeats, conducted in duplicate.  
N.R denotes no response or where a true dose-response curve could not be 
generated.  
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inhibited and accumulates, thereby allowing measurement (as a substitute for 
IP3) using the IP-One HTRF® assay kit (Cisbio Bioassays) previously 
optimised for OTR (Section 3.5).  
Here, we sought to quantify IP1 accumulation in HEK 293T cells 
expressing GCGR. Unfortunately, and despite optimisation of the IPOne 
assay used to measure IP1 accumulation (Section 3.5), the measurement of 
IP1 accumulation in GCGR transfected HEK 293T cells showed no response 
to GCG or TH-GCG (Figure 4.25 A). In order to increase any potential IP1 
signal, CHO-K1 cells stably expressing GCGR were also tested which 
showed uniform GCGR expression. Only a very weak response to GCG was 
measured at the highest GCG concentration (10 µM) in these CHO-K1 cells 
and a full dose-response curve could not be fitted due to insufficient data 
points (Figure 4.25 B). Again, TH-GCG showed no detectable IP1 response. 
Given this finding and the small signalling window for the IP1 response 
detected in oxytocin receptor transfected HEK 293T cells following oxytocin 
stimulation (Figure 3.5 and Table 3.5), a predominantly Gq-coupled receptor 
(Gimpl and Fahrenholz, 2001), this assay appears to lack sufficient sensitivity. 
Given the TH-GCG stimulated cAMP response was reduced in potency when 
compared to GCG, and GCG gave a very weak IP1 response, the lack of IP1 
response following TH-GCG was expected. Although this finding reflects the 
lack of Ca2+i mobilisation and is likely to hold true, we cannot exclude the 
possibility that a more sensitive assay may detect an IP1 response to TH-
GCG and indeed, a more robust IP1 response following GCG stimulation.  
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Figure 4.25. TH-GCG fails to induce a measurable IP1 response in HEK 
293T cells or CHO-K1 cells expressing GCGR. HEK 293T cells transfected 
with GCGR or CHO-K1 cells stably expressing GCGR (20,000 cells/well) were 
stimulated with GCG or TH-GCG for 2 hours and IP1 accumulation detected 
using the IP-One HTRF® assay kit (Cisbio Bioassays). All values are mean 
± SEM expressed as percentage GCG response n = 2, conducted in duplicate.  
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4.6.4.  TH-GCG shows a distinctly different cAMP response in the 
hepatocyte cell line; Hep 3B 
 
Previous studies indicating TH-GCG stimulates an inositol phosphates 
response in the absence of a cAMP response was conducted in hepatocytes 
extracted from male Sprague-Dawley rats (Wakelam et al., 1986) or guinea 
pigs (Lenzen et al., 1990). In order to further investigate the activity of TH-
GCG in a cellular context more closely matches that of these early 
experiments (Wakelam et al., 1986, Lenzen et al., 1990), the cAMP response 
was measured in the hepatocellular cell line, Hep 3B, endogenously 
expressing GCGR (Section 3.7). 
Using the more sensitive LANCE® Ultra cAMP detection kit (Section 
2.8.1, Figure 2.4), we sought to measure any potential cAMP response 
following GCG or TH-GCG stimulation in Hep 3B cells. This cAMP 
accumulation assay required a 30 minute ligand stimulation of 5,000 cells/well 
in line with optimisation experiments in chapter 3 (Section 3.7.2). As 
expected, Hep 3B cells showed a robust cAMP response following GCG 
stimulation (pEC50 9.08 ±0.16) (Figure 4.26 and Table 4.17). This finding and 
further characterisation of Hep 3B cells, which is presented later (Section 
4.8), strongly suggests the endogenous expression of GCGR. The dose-
response curve acquired from fitting a three-parameter logistics equation to 
the TH-GCG stimulated cAMP data was less robust with apparent fluctuating 
levels of cAMP at the basal response. There was a small reduction in the 
cAMP levels below the fitted basal response at high concentrations of TH-
GCG (0.1 µM, 1 µM and 10 µM) with a measured pIC50 of 6.96 ±0.72. Despite 
large variability in this TH-GCG stimulated cAMP response data, the results 
are distinctly different to those measured in transfected HEK 293T cells that 
characterised TH-GCG as a partial agonist at the GCGR. Although the cAMP 
response in Hep 3B cells more closely reflects the previously reported 
findings for this GCG analogue in hepatocytes (Wakelam et al., 1986, Lenzen 
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et al., 1990), caution needs to be taken when interpreting these data due to 
the high variability in the TH-GCG stimulated cAMP data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.17.  TH-GCG fails to induce a concentration-dependent increase 
in cAMP accumulation in Hep 3B cells Potency (pEC50), maximal response 
(Emax), basal and span for GCG and TH-GCG stimulated cAMP response in 
Hep 3B cells 
 
cAMP 
Ligand pEC50 a Emax b Basal c Span d 
GCG 9.08 ±0.16 101.2 ±5.0 -8.6 ±5.8 109.8 ±7.4 
TH-GCG N.R    
 
Hep 3B cells were stimulated with GCG or TH-GCG prior to measurement of 
cAMP accumulation to generate concentration response curves. To calculate 
pEC50, Emax, Basal and Span values, data were analysed using a three-
parameter logistic equation. 
.a  pEC50: Negative logarithm of GCG concentration required to produce a half-
maximal response 
b Maximal response to  GCG/TH-GCG as percentage GCG response 
c The low plateau of the fitted sigmoidal dose-response curve 
d The difference between Emax and basal signalling 
All values are mean ± SEM expressed percentage GCG response where n ≥ 5 
independent experimental repeats, conducted in duplicate.  Statistical 
significance (*, p<0.05;**, p<0.01;***, p<0.001) in response between GCG and 
TH-GCG was determined by one-way unpaired Student’s t-test (two-tailed) 
Figure 4.26. TH-GCG fails to induce a concentration-dependent increase 
in cAMP accumulation in Hep 3B cells. Hep 3B cells (5,000 cells/well) were 
exposed to GCG or TH-GCG for 30 minutes and cAMP accumulation detected 
using a LANCE Ultra cAMP kit. All values are mean ± SEM expressed as 
percentage GCG response where n ≥ 3 independent experimental repeats, 
conducted in duplicate.  
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4.6.5.  Investigation the cAMP response to TH-GCG in hepatocytes 
extracted from C57BL/6 mice  
4.6.5.1.  TH-GCG induces a robust cAMP response in C57BL/6 
hepatocytes  
 
The experiments utilising Hep 3B to investigate cAMP accumulation in 
response to TH-GCG provided a more physiologically relevant cell line, closer 
to the cellular model used in early experiments (Wakelam et al., 1986 and 
Lenzen et al., 1990), when compared to HEK 293T cells to investigate the 
activity of TH-GCG. The opportunity arose to allow acquisition of freshly 
isolated hepatocytes from C57BL/6 mice culled for the purpose of pancreatic 
islet isolation for a separate collaborative project with Dr Maja Wallberg in the 
Department of Pathology (University of Cambridge). These mouse 
hepatocytes were stimulated with GCG or TH-GCG for 30-minutes prior to 
cAMP accumulation detected using the LANCE® Ultra cAMP Detection Kit. 
Initially, the capacity for these cells to signal was tested through 
forksolin stimulation at two cell densities. Stimulation of C57BL/6 hepatocytes 
plated at both 5,000 and 10,000 cells/well induced a dose dependent cAMP 
response to forskolin, indicated the capability to produce a cAMP signal via 
AC (Figure 4.27 and Table 4.18). There was no significant difference between 
potency and maximal response between the two cell numbers. However, the 
basal response in 10,000 cells/well was elevated relative to 5,000 cells/well 
producing a smaller span (Table 4.18) and as such, 5,000 cells per well was 
chosen to conduct further experiments.  
Stimulation of C57BL/6 hepatocytes induced a robust cAMP response 
in a dose-dependent manner to both GCG and TH-GCG (Figure 4.28). The 
response to TH-GCG was significantly reduced in potency and affinity when 
compared to GCG (Table 4.19). Given the known expression of GCGR in the 
liver, the cAMP response measured following GCG stimulation was expected. 
The cAMP response to TH-GCG however, was an unexpected result due to 
findings reported here in Hep 3B cells and earlier studies in hepatocytes 
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suggesting a lack of cAMP response (Wakelam et al., 1986, Lenzen et al., 
1990). Given the lack of cAMP response to TH-GCG in vector only 
transfected HEK 293T cells, the activity of TH-GCG in these hepatocytes is 
also likely through GCGR stimulation rather than an alternative receptor. If 
TH-GCG is indeed acting through GCGR as expected, it appears to be a 
lower potency agonist when compared to GCG.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27. Forskolin induces a concentration-dependent increase in 
cAMP accumulation in C57BL/6 hepatocytes. Hepatocytes were  isolated 
from the liver of C57BL/6 mice and plated at either 5,000 or 10,000 cells per 
well in a 384-well plate prior to stimulated with forskolin for 30 minutes and 
detections of cAMP accumulation. All values are mean ± SEM expressed as 
percentage forskolin response in 5,000 cells/well where n = 2 independent 
experimental repeats, conducted in duplicate.  
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Table 4.18. Forskolin induces a concentration-dependent increase in 
cAMP accumulation in C57BL/6 hepatocytes. Potency (pEC50), 
maximal response (Emax), basal and span for forskolin response 
measured in C57BL/6 hepatocytes using a cAMP accumulation assay 
 
cAMP 
Cells/well pEC50 a Emax b Basal c Span d 
5,000 7.24 ±0.09 97.6 ±2.6 0.3 ±2.4 97.3 ±3.4 
10,000  7.14 ±0.07 99.6 ±1.7 26.0 ±1.5*** 73.6 ±2.2* 
 
C57BL/6 hepatocytes (5,000 or 10,000 cells/well) were stimulated with 
forskolin prior to measurement of cAMP accumulation to generate 
concentration response curves. To calculate pEC50, Emax, Basal and Span 
values, data were analysed using a three-parameter logistic equation. 
.a Negative logarithm of GCG/TH-GCG concentration required to produce 
a half-maximal response 
b Maximal response to  GCG/TH-GCG as percentage GCG response 
c The low plateau of the fitted sigmoidal dose-response curve 
d The difference between Emax and basal signalling 
All values are mean ± SEM expressed percentage GCG response where 
n = 3 independent experimental repeats, conducted in duplicate. 
Statistical significance (*, p<0.05;**, p<0.01;***, p<0.001) in the difference 
in response between 5,000 and 10,000 cells was determined by unpaired 
Student’s t-test (two-tailed).  
 
Figure 4.28. TH-GCG and GCG induce a concentration-dependent 
increase cAMP accumulation in C57BL/6 hepatocytes. Hepatocytes 
were isolated from the liver of C57BL/6 mice and stimulated with varying 
concentrations of glucagon (GCG) or TH-GCG for 30 minutes prior to cAMP 
accumulation detection. All values are mean ± SEM expressed as percentage 
GCG where n = 3 independent experimental repeats, conducted in duplicate.  
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4.6.6.  TH-GCG stimulated a pERK1/2 response in GCGR transfected 
HEK 293 cells but fails to stimulate a response in stable CHO-K1 cells  
 
The ability of TH-GCG to induce a pERK1/2 response has not been 
previously investigated. Here, we investigate the pERK1/2 response following 
TH-GCG stimulation in two GCGR expressing cell lines; transfected HEK 
293T cells and stable CHO-K1 cells.  
The pERK1/2 response to GCG and TH-GCG in transfected HEK 293T 
cells showed no significant difference between measured potency, maximal 
response, affinity and efficacy (Figure 4.29 A and Table 4.20). These data 
suggests TH-GCG acts as a full agonist of the pERK1/2 response following 
GCGR activation. In CHO-K1 cells stably expressing GCGR, whereas GCG 
induced a concentration-dependent increase in pERK1/2, TH-GCG failed to 
induce a response (Figure 4.29 B and Table 4.20).  
These findings suggest the pERK1/2 response to TH-GCG is cell line 
dependent and may reflect differences in cellular components of the pERK1/2 
pathway between the cell lines.  However, caution should be exercised when 
interpreting the data in GCGR transfected HEK 293T cells due to the 
relatively low signalling window when compared to CHO-K1 cells. Similarly to 
what was previously suggested for the similar pERK1/2 responses following 
GCG and oxyntomodulin stimulation in GCGR transfected HEK 293T cells 
(Section 4.4.2), it may be that the indistinguishable responses between GCG 
and TH-GCG is due to an experimental limitation where we at the lower end 
of the dynamic range of the assay. Given the GCGR stable CHO-K1 cells 
appear to be a more robust system for the analysis of pERK1/2 responses 
(Section 4.4.2.1), it seems reasonable to conclude that, at least in this cell 
line, TH-GCG fails to induce a pERK1/2 response. 
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Figure 4.29. Investigating the TH-GCG stimulated pERK1/2 response in 
GCGR transfected HEK 293T cells and CHO-K1 cells stably expressing 
GCGR. A) HEK 293T transiently expressing pmCherry-N1 vector containing 
GCGR (48 hours post transfection) or B) CHO-K1 cells stably expressing 
GCGR were serum stared for 24 hours and exposed to GCG or TH-GCG for 5 
minutes before measuring pERK1/2. CHO-K1 cells were plated at 10,000 cells 
per well and HEK 293T cells at 50,000 cells per well in a 384-well plate. All 
values are mean ± SEM expressed as percentage PMA response (1 µM) 
where n ≥ 5 independent experimental repeats, conducted in duplicate.  
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4.6.7.  Summary  
 
The findings in GCGR transfected HEK 293T cells are distinct from those 
previously reporting the activity of TH-GCG  (Wakelam et al., 1986, Lenzen et 
al., 1990) and suggest TH-GCG acts as a partial agonist at the GCGR leading 
to activation of cAMP accumulation, most probably through the classical Gs-
dependent pathway. The lack of a detectable Ca2+i and IP1 response to TH-
GCG stimulation in GCGR transfected HEK 293T cells appears to contradict 
the suggestion that this agonist acts through an alternative coupled pathway 
leading to inositol phospholipid breakdown. In comparison to the findings in 
GCGR transfected HEK 293T cells, the lack of detectable cAMP response in 
Hep 3B cells more closely reflects the previously reported findings for this 
GCG analogue in hepatocytes (Wakelam et al., 1986, Lenzen et al., 1990). 
However, caution needs to be taken when interpreting these data due to the 
high variability in the TH-GCG stimulated cAMP data in Hep 3B cells. 
TH-GCG stimulation of C57BL/6 hepatocytes induced a robust cAMP 
response in a dose-dependent manner and was identified as a partial agonist 
when compared to GCG. Previous studies looking at cAMP production in 
response to TH-GCG were measured in hepatocytes extracted from male 
Sprague-Dawley rats (Wakelam et al., 1986) or guinea pigs (Lenzen et al., 
1990). Although it could be argued that the hepatocytes from C57BL/6 mice 
may respond differently to TH-GCG stimulation when compared to those from 
rats or guinea pig, a more rational explanation is the differences between the 
methods used for cAMP measurement and the relative sensitivities. Indeed, a 
direct comparison between the methods used here and in previous research 
(Wakelam et al., 1986) highlighted two completely different methods. Here, 
the cAMP response was measured after a 30 minute challenge with GCG or 
TH-GCG at a range of concentrations (10 µM – 0.01 nM) in the presence of 
IBMX (0.5 mM) using the highly sensitive LANCE® Ultra cAMP Detection Kit 
(PerkinElmer). On the other hand, despite using IBMX (1 mM), Wakelam et 
al., 1986 measured intracellular cAMP after a 5 minute challenge of 
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hepatocytes at a single concentration (10 nM) using a binding assay utilising 
a protein from bovine muscle with high specificity for cAMP as described 
previously (Brown et al., 1971). Aside from the fact a cAMP response may 
have been detected in rat hepatocytes if a higher concentration of TH-GCG 
was used, it is likely that the LANCE® Ultra cAMP detection kit has superior 
sensitivity. We can only assume the TH-GCG which was synthesised by Alta 
Biosciences (University of Birmingham, UK) was correct, but the possibility 
remains that we have an analogue which is variable to the TH-GCG used in 
these early studies. 
In conclusion, using a sensitive cAMP accumulation assay, this work 
characterises TH-GCG as a partial agonist in both GCGR transfected HEK 
293T cells and in C57BL/6 mice hepatocytes. Although GCG was shown to 
also stimulate a Ca2+i response in GCGR transfected HEK 293T cell in a 
Gq/11-dependent manner, this was not the case for TH-GCG. With this in mind 
and contradictory to early findings, it appears TH-GCG is not a biased agonist 
at the GCGR and is acting through the classical Gs-coupled pathway leading 
to cAMP production.  
Finally, this work also reports for the first time an investigation into the 
TH-GCG stimulated pERK1/2 response. The findings suggest a cell line 
dependent TH-GCG stimulated pERK1/2 response at the GCGR where a 
concentration-dependent increase in pERK1/2 was only reported in GCGR 
transfected HEK 293T cells and not stable CHO-K1 cells. On the other hand, 
with the conclusion that GCGR stable CHO-K1 cells appear to be a more 
robust system for the analysis of pERK1/2 responses (Section 4.4.2.1), it may 
be argued that TH-GCG stimulation at the GCGR does not induce a pERK1/2 
response. As a side note, given the GCG stimulated pERK1/2 response was 
shown to be partially Gq/11 -dependent (Section 4.4.5), future experiments 
could include an investigation into the measured pERK1/2 response to TH-
GCG stimulation in HEK 293T cells transfected with GCGR with and without 
the Gq/11 inhibitor, YM-254890. Such findings would indicate if the potential 
pERK1/2 response to TH-GCG stimulation at the GCGR is Gq/11-mediated.  
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4.7.  Investigation the pharmacological consequences of RAMP2-GCGR 
interaction 
4.7.1.  Cell-surface expression of GCGR is not influenced by RAMP2 co-
expression 
 
GCGR is known to interact with RAMP2 (Christopoulos et al., 2003), although 
the pharmacological role of this RAMP2-GCGR interaction remains unknown. 
We first looked to investigate if the cell-surface expression of GCGR is 
influenced by co-expression of RAMP2 using ELISA. Here, HEK 293T cells 
were transfected with pcDNA3.1 vector expressing myc-tagged GCGR only 
(0.25 µg per well in a 24-well plate) or in combination with varying 
concentrations of pcDNA3.1 expressing FLAG-tagged RAMP2 (FLAG-
RAMP2). pcDNA3.1 expressing RAMP1, was used to maintain the total DNA 
concentration at transfection to 0.50 µg per well in a 24-well plate. The choice 
to use RAMP1 rather than vector only was based on the attempt to put the 
same pressure on the cell in terms of transcription and translation.  
Consistent with previous finding (Weston et al., 2015), the cell-surface 
expression of GCGR was not influenced by co-expression with FLAG-RAMP2 
at any of the tested FLAG-RAMP2 DNA concentrations (Figure 4.30). 
However, increasing the amount of RAMP2 relative to GCGR resulted in 
elevated levels of FLAG-tagged RAMP2 at the plasma membrane (Figure 
4.31). Here, the cell-surface expression of FLAG-RAMP2 is concentration-
dependent with increasing amount of FLAG-RAMP2 DNA at transfection 
correlating with increased cell-surface expression up until a GCGR:RAMP2 
ratio of 0.8:1. At this point, the RAMP2 expression appears to have reached a 
plateau where increasing the RAMP2 concentration further does not translate 
to increased cell-surface expression. As would be expected, this finding 
confirms that increasing the level of DNA at transfection translates to 
increased protein expression to a certain point, after which saturation is 
effectively reached. Notably, there was no significant difference in cell-surface 
expression of FLAG-RAMP2 with or without co-expression of GCGR (Figure 
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4.31 ratio 1:1 vs 1:0). This confirms that cell-surface expression of RAMP2 is 
not influenced by GCGR.  
RAMPs transport poorly to the cell-surface when expressed alone 
(Wootten et al., 2013). Interestingly, FLAG-RAMP2 was detected on the cell-
surface in the absence of GPCR co-transfection. This finding suggests the 
endogenous expression of another RAMP interacting receptor by HEK 293T 
cells such as CLR, which requires RAMP expression to reach the cell-
surface, or CT receptor. 
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Figure 4.30. RAMP2 does not influence the cell-surface expression of 
myc-tagged GCGR in transfected HEK 293T cells. HEK 293T cells were 
transfected with myc-tagged GCGR (0.25 µg/well of a 24-well plate) and 
varying amounts of FLAG-tagged RAMP2. In order to keep the total amount 
of DNA at transfection constant (0.50 µg/well of a 24-well plate), RAMP1 
DNA was used as a non-interacting control. ELISA was conducted 48-hours 
post transfection using primary antibody mouse anti-myc at a 1:2000 dilution 
followed by anti-mouse HRP-linked secondary antibody at a 1:4000 
dilution.Values are mean ± SEM expressed as percentage 1:1 FLAG-
RAMP2:myc-GCGR ratio response where n ≥ 5 independent experimental 
repeats, conducted in duplicate. Statistical significance (*, p<0.05;**, 
p<0.01;***, p<0.001) in the difference in cell-surface expression when 
compared to myc-GCGR only (0:1) was determined by one-way ANOVA 
with Dunnett’s post test. 
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Figure 4.31. GCGR does not influence the cell-surface expression of 
FLAG-tagged RAMP2 in transfected HEK 293T cells. HEK 293T cells 
were transfected with myc-tagged GCGR (0.25 µg/well of a 24-well plate) 
and varying amounts of FLAG-tagged RAMP2. In order to keep the total 
amount of DNA at transfection constant (0.50 µg/well of a 24-well plate), 
RAMP1 DNA was used as a non-interacting control. ELISA was conducted 
48-hours post transfection using primary antibody mouse anti-FLAG at a 
1:2000 dilution followed by anti-mouse HRP-linked secondary antibody at a 
1:4000 dilution. Values are mean ± SEM expressed as percentage 1:0 
FLAG-RAMP2:myc-GCGR ratio response (100%) and GCGR only 
transfected control (0%) where n ≥ 5 independent experimental repeats, 
conducted in duplicate. Statistical significance (*, p<0.05;**, p<0.01;***, 
p<0.001) in the difference in cell-surface expression when compared to 
RAMP2:GCGR ratio of 1:1 was determined by one-way ANOVA with 
Dunnett’s post test. 
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4.7.2.  RAMP2 potentiated the response of GCG at the GCGR  
 
Having shown the cell-surface expression of GCGR was not influenced by co-
expression of RAMP2 in transfected HEK 293T cells, we next sought to 
investigate any pharmacological consequence of this potential RAMP2-
GCGR interaction. 
As previously conducted for cell-surface expression analysis, HEK 
293T cells were transfected with GCGR and varying concentrations of 
RAMP2 and the none-interacting control RAMP1 to maintain the DNA 
concentration at transfection to 0.50 µg/well of a 24-well plate. These cells 
were stimulated with GCG and the cAMP accumulation detected. As 
expected, GCG stimulated a robust cAMP response in HEK 293T cells 
transfected with pcDNA3.1 expressing GCGR  (pEC50 10.75 ±0.18, Emax 
101.3 ±5.6 GCGR only response) (Figure 4.31 and Table 4.21). There was 
found to be no significant difference in the measured potency with RAMP2 co-
transfection. On the other hand, there was a RAMP2-dependent increase in 
maximal response and span (Table 4.21). Here, increasing the RAMP2 level 
relative to GCGR resulted in a concentration-dependent increase in maximal 
cAMP response, which reached nearly a 5-fold increase in at a 1:1 ratio (Emax 
463.5 ±47.5 percentage GCGR only response). The significant increase in 
relative efficacy (logτ) suggests that RAMP2 increases the ability of GCGR to 
transduce the signal following GCG stimulation (Figure 4.31). At a 
RAMP2:GCGR ratio of 0.8:1 and 1:1, there was also found to be a significant 
increase in affinity suggesting that RAMP2 expression increases the affinity of 
GCG for the GCGR. This is distinct from previous findings used ligand binding 
which reported no change in receptor affinity for GCG with RAMP2 co-
expression (Weston et al., 2015). 
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Figure 4.32. RAMP2 potentiates the GCG response at the GCGR in 
transfected HEK 293T cells. HEK 293T cells were transfected with GCGR 
(0.25 µg/well of a 24-well plate) and increasing amounts of RAMP2. RAMP1 
was used to maintain the total DNA concentration at transfection to 0.50 
µg/well as a non-interacting control (Christopoulos et al., 2003). A) cAMP 
response was detected in HEK 293T cells (1,000 cells/well) following a 8 
minutes stimulation with GCG. B) Coupling efficacy (log τ) for GCG at each of 
the GCGR:RAMP2 ratios, determined using the operational model of agonism  
(Black and Leff, 1983). All cAMP accumulation values are mean ± SEM 
expressed as percentage 0:1 RAMP2:GCGR ratio response where n ≥ 5 
independent experimental repeats, conducted in duplicate.  
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4.7.3.  No RAMP2-dependent potentiation of GCG response in HEK 293T 
cells transfected with GCGR and RAMP2 dual expression vector  
 
When co-transfecting cells with two or more different DNA constructs, the 
question of transfection efficiency, in terms of equal cellular uptake and 
expression arises. Such differences in the population of assayed cells would 
make the dissection of a signalling pathway difficult.  With this in mind, a dual 
expression vector (pVITRO1) containing both constructs of interest was 
made; myc-GCGR at multiple cloning site 1 (MCS1) and FLAG-RAMP2 at 
multiple cloning site 2 (MCS2)  (henceforward known as R2-GCGR). Control 
vectors containing myc-GCGR only at MCS1 and one also containing FLAG-
RAMP3 (as a none interacting RAMP control) at multiple cloning site 2 
(MCS2)  (henceforward known as GCGR and R3-GCGR, respectively) was 
also made.  
HEK 293T cells transfected with these pVITRO1 constructs were 
stimulated with GCG and cAMP accumulation detected. GCG stimulated a 
robust cAMP response in HEK 293T cells transfected with GCGR only 
expressing pVITRO1 (pEC50 11.3 ±0.1, Emax 105.5 ±3.4 expressed as 
percentage GCGR only expressing vector) (Figure 4.33 and Table 4.22). 
Transfection of HEK 293T with the R2-GCGR dual expression vector showed 
no significant potentiation in GCG stimulated cAMP response when compared 
to either GCGR only expressing vector or R3-GCGR. This was unexpected; 
given the previous findings showing a RAMP2-dependent increase in 
maximal response to GCG (Figure 4.31 A). The two experiments used 
different vectors (pcDNA3.1 and pVITRO1) and may provide an explanation if 
transfection efficiency and expression is variable. Another concern is the 
possibility that despite the presence of a single copy of RAMP2 and GCGR 
on the dual expression vector, this does not necessarily translate to 1:1 
protein expression. 
ELISA was used to investigate if the cell-surface expression of FLAG-
tagged RAMP2 was similar in HEK 293T cells transfected with pVITRO1 
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expressing FLAG-RAMP2 only or FLAG-RAMP2 and GCGR (R2-GCGR).  
FLAG-RAMP2 and CLR co-transfection was used as a positive control for a 
known RAMP2 interaction that has been reported to increase cell-surface 
expression of RAMP2 (Weston et al., 2015). As expected, co-expression of 
FLAG-RAMP2 only expressing pVITRO1 with CLR resulted in a significant 
increase in cell-surface expression of FLAG-RAMP2 (Figure 4.34) confirming 
that RAMP2:CLR interaction increases trafficking to the cell-surface. 
Interestingly, FLAG-RAMP2 cell-surface expression was found to be 
significantly higher when expressed from multiple cloning site 2 (MCS2) in the 
absence of GCGR at multiple cloning site 1 (MCS1) (Figure 4.34). In other 
words, it was noted that FLAG-RAMP2 cell-surface expression when cells 
were transfected with FLAG-RAMP2 only (ratio 1:0) was significantly more 
when compared to cells transfected with equal amounts of R2-GCGR (ratio 
0:1) (Figure 4.34). This finding was unexpected given the only difference 
between these vectors is the presence or absence of GCGR at MCS1 and 
previous findings confirmed that neither the cell-surface expression of GCGR 
nor RAMP2 was influenced by co-expression (Figure 4.30 and 4.31, 
respectively). This may suggest that the transcription of RAMP2 is limited by 
the transcription of GCGR at MCS2 or that RAMP2 is being sequestered by 
GCGR somewhere in the receptor life-cycle. These data highlight that 
although in theory a 1:1 DNA ratio of GCGR to RAMP2 exists in dual 
expression vectors, this may not necessarily to translate to a 1:1 protein 
expression ratio. An alternative explanation may be that RAMP1 actually 
influenced the previous reported results (section 4.7.2). However, given that 
previous findings have reported that GCGR does not interact with RAMP1 
(Christopoulos et al., 2003, Weston et al., 2015), this is unlikely to be the 
case.  
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Figure 4.33. RAMP2 fails to potentiate the cAMP response in HEK 293T 
cells transfected with the pVITRO vector expressing GCGR and RAMP2. 
HEK 293T cells were transfected with the pVITRO1 dual expression vector 
containing myc-GCGR at multiple cloning site 1 (MCS1), with either no 
additional receptor in MCS2, FLAG-RAMP2 (MCS2) (R2-GCGR) or RAMP3 
(R3-GCGR) (as a non-interacting RAMP control). 48-hours post transfection, 
HEK 293T cells (1,000 cells/well) were stimulated for with GCG for 8 minutes 
and cAMP accumulation measured. All values are mean ± SEM expressed as 
percentage GCGR only expressing pVITRO1 response where n ≥ 5 
independent experimental repeats, conducted in duplicate.  
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Figure 4.34. FLAG-RAMP2 cell-surface expression was elevated in HEK 
293T cells transfected with pVITRO1 expressing RAMP2 only when 
compared to pVITRO1 expressing RAMP2 and GCGR. Cell-surface 
expression of RAMP2-FLAG, in HEK 293T cells transfected  (0.25 µg/well of 
a 24-well plate) with the dual expression vector (pVITRO1) containing 
FLAG-RAMP2 at multiple cloning site 2 (MCS2) only (R2) or FLAG-RAMP2 
with GCGR at multiple cloning site 1 (MCS1) (R2-GCGR). ELISA was 
conducted 48-hours post transfection using primary mouse anti-FLAG at a 
1:2000 dilution followed by anti-mouse HRP-linked secondary antibody at a 
1:4000 dilution. Values are mean ± SEM expressed as % R2 + CLR (100%) 
and vector only transfected control (0%) where n ≥ 5 independent 
experimental repeats, conducted in duplicate. Statistical significance (*, 
p<0.05;**, p<0.01;***, p<0.001) in the differences in cell-surface expression 
between R2 only and R2-GCGR expressing vector was determined by 
unpaired Student’s t-test (two-tailed). 	
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4.7.4.  Summary 
 
RAMPs are known to interact with a number of GPCR leading to changes in 
cell-surface expression and ligand preferences (Christopoulos et al., 2003). 
Although an interaction between GCGR and RAMP2 has previously been 
reported (Christopoulos et al., 2003), the pharmacological consequence of 
this was not investigated. The results presented here identify a 
pharmacological consequence of RAMP2 and GCGR interaction, which is 
independent of cell-surface expression. There was found to be a RAMP2-
dependent change in cAMP response to GCG with a RAMP2 concentration-
dependent increase in maximal response. Interestingly, this finding could not 
be reproduced using a dual expression vector expressing both GCGR and 
RAMP2. Although this was unexpected, investigation into the RAMP2 cell-
surface expression suggested that RAMP2 expression from MCS2 of the 
vector was reduced when GCGR was at MCS1. A change in RAMP2 
expression relative to GCGR from the pVITRO1 vector may provide an 
explanation as to why a potentiation in GCG stimulated cAMP response was 
not seen. Speculation as to the cause of this reduced RAMP2 cell-surface 
expression includes the possibility that RAMP2 transcription is limited by the 
transcription of GCGR or that GCGR is somehow sequestering RAMP2.  
These data highlight that although in theory a 1:1 DNA ratio of GCGR 
to RAMP2 exists in the dual expression vector, this does not appear to 
translate to a 1:1 protein expression ratio. This not only makes the 
investigation of RAMP2-GCGR interaction and pharmacology difficult, but 
also suggests the need for vector optimisation and investigation of expression 
levels in transfection experiments. Indeed, this raises further challenging 
questions such as the required number of RAMP2 to a single GCGR in order 
to lead to a potentiated cAMP response, as has been reported here.  
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4.8.  Pharmacology in a hepatic cell line: Hep 3B 
4.8.1.  GCG and oxyntomodulin stimulates a robust cAMP response in 
Hep 3B cells  
 
We previously investigated the GPCR and RAMPs mRNA expression in Hep 
3B cells and, in combination with initial cAMP assays, suggested the likely 
expression of GCGR (Section 3.7). We wanted to expand on these initial 
experiments and give an indication of mRNA translation and functional protein 
expression in Hep 3B cells.  
Hep 3B cells (5,000 cells/well) were stimulated with various ligands 
and cAMP accumulation detected using the LANCE cAMP Ultra detection kit 
(Section 2.8.1, Figure 2.8.1.2). A robust cAMP response was detected for 
GCG and oxyntomodulin in Hep 3B cells with similar passage number (Figure 
4.35). No response was detected for GLP-1(7-36)amide, GIP(1-42) or (GIP). 
In addition, stimulation with the breakdown products of GLP-1(7-36)amide 
and GIP (GLP-1(9-36)amide and GIP(3-42), respectively) showed no 
detectable cAMP accumulation.  
Oxyntomodulin is reported to be both an agonist of the GLP-1R and 
GCGR, despite showing a 10-fold or 100-fold reduction in potency when 
compared to the endogenous ligands GLP-1(7-36)amide or GCG, 
respectively (Pocai et al., 2009). In accordance with this, and what was 
previously shown in transfected HEK 293 (Section 4.2.1), the potency of 
oxyntomodulin is approximately 100-fold lower than that seen to GCG (Table 
4.23) suggesting that oxyntomodulin is acting at the GCGR. Studies have 
highlighted that GCGR ligands including GCG and oxyntomodiulin can 
activate the GLP-1R, whereas GLP-1(7-36)amide has been suggested not to 
act at the GCGR (Runge et al., 2003). In accordance with this, the lack of 
GLP-1(7-36)amide response suggests both the absence of GLP-1R 
expression itself and confirms the lack of GLP-1(7-36)amide activity at the 
GCGR in Hep 3B cells.  
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When looking at individual dose-responses to GCG and oxyntomodulin 
acquired from experiments using both early (<8) and late (>8) passage, there 
is considerable variation in pEC50 values (mean pEC50 8.82 ± 0.74 and 7.15 ± 
0.84, respectively) (Figure 4.36). This variability may be explained by a lack of 
stability in terms of receptor expression and the apparent loss of GCGR 
expression from as early as passage 8 supports this argument.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.35. cAMP signalling profile in Hep 3B cells. Hep 3B cells 
(5,000 cells/well) with similar passage number (> 4 from N2 but less than 
8), were exposed to various ligands for 30 minutes and cAMP 
accumulation detected using a LANCE cAMP Ultra kit. All values are 
mean ± SEM expressed as percentage forskolin response (100 µM) where 
n ≥ 5 independent experimental repeats, conducted in duplicate.  
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4.8.2.  Adrenomedullin stimulates a cAMP response in Hep 3B cells  
 
In order to give a pharmacological indication of RAMP1-3 protein expressed, 
peptides known to be active at the CLR only when in combination with 
RAMPs (CGRP, AM and adrenomdeullin 2 (AM2)) were utilised. A 
concentration-dependent cAMP response was detected for AM in Hep 3B 
cells with similar passage number, whereas there was no response detected 
to AM2 or CGRP stimulation (Figure 4.37 and Table 4.24). Similarly to the 
GCG and oxyntomodulin response data, when looking at individual dose-
responses to AM acquired from experiments using various Hep 3B passages, 
there was considerable variation in potency values (mean pEC50 8.00 ± 1.32) 
(Figure 4.38). Again, this variability may be explained by a lack of stability in 
terms of receptor expression. 
Figure 4.36. The measured potency for GCG and oxyntomodulin 
varies across experimental repeats in Hep 3B cells. Hep 3B cells 
(5,000 cells/well) were exposed to GGC or oxyntomodulin for 30 minutes 
and cAMP accumulation detected using a LANCE cAMP Ultra kit. The 
scatter plot shows single pEC50 value acquired through fitting each repeat 
data to a three-parameter logistic equation. All values are mean ± SD 
where n ≥ 9 independent experimental repeats. 
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The specificity of CGRP, AM and AM2 for CLR is conferred by RAMPs 
where expression of both is essential for the formation of functional receptors 
(Choksi et al., 2002). RT-PCR results indicated significant mRNA expression 
of RAMP2 with a small level of CLR, RAMP1 and RAMP3 (Section 3.7.1). It 
has been suggested in a number of transfection studies that CLR functions as 
a CGRP preferring receptor when co-expressed with RAMP1 whereas it 
forms an AM and AM2 preferring receptor when co-expressed with RAMP2 or 
RAMP3, respectively (Choksi et al., 2002). According to the rank order of 
potency at the various CLR and RAMP combinations (Table 4.25), the 
response to AM stimulation in Hep 3B cells, in addition to the RT-PCR results 
(Figure 3.7.1), suggests the endogenouse expression of a functional AM 
receptor  (CLR and RAMP2).  
To add an additional layer of complexity, AM is also known to act at the 
CTR and the amylin receptor (CTR expressed in combination with RAMPs) 
(Christopoulos et al., 1999). An alternative explanation to the AM induced 
cAMP response aside from the stimulation of a functional AM receptor may 
be the expression and stimulation of the CTR or amylin receptor. In order to 
exclude this possibility and identify the receptor responsible for the measured 
AM response, Hep 3B cells need to be stimulated with CT and amylin. 
However, if Hep 3B cells do indeed express CTR or amylin receptor, and the 
various agonists exhibit the rank order of potency as previously indicated 
(Table 4.26), CGRP stimulation should give a greater response than AM at 
the CTR, AMY1 and AMY3 receptor. With this in mind, the lack of detectable 
CGRP response could indicate that AM is likely to be acting at the AM 
receptor.  
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Table 4.24. cAMP signalling profile in Hep 3B cells. Potency (pEC50), maximal 
response (Emax), basal, span, affinity (pKA) and coupling efficacy (logτ) for various 
ligand measured in Hep 3B cells using a cAMP accumulation assay 
cAMP  
Ligand pEC50 a Emax b Basal c Span d pKA e log τ f 
AM 7.91 ±0.27 8.32 ±1.03 -1.65 ±0.8 9.97 ±1.2 7.86 ±0.3 -0.96 
±0.06 
AM2 N.R -2.21 ±0.8 N.R 
CGRP N.R -0.01 ±0.9 N.R 
 
Hep 3B cells were stimulated with adrenomedullin (AM), adrenomedullin 2 (AM2) or 
calcitonin gene related peptide (CGRP) prior to measurement of cAMP accumulation to 
generate concentration response curves for each construct. To calculate pEC50, Emax, 
Basal and Span values, data were analysed using a three-parameter logistic equation. 
Data was also analysed by an operational model of agonism  (Black and Leff, 1983) to 
determine affinity (pKA) and coupling efficacy (log τ). 
a Negative logarithm of ligand concentration required to produce a half-maximal 
response 
b Maximal response to ligand as percentage forskolin response  
c The low plateau of the fitted sigmoidal dose-response curve 
d The difference between Emax and basal signalling 
e The negative logarithm of functional affinities that describes the affinity of the receptor 
when coupled to a given signalling pathway generated through use of the operational 
model for partial agonism 
f τ is the coupling efficiency parameter generated through use of the operational model 
for partial agonism 
All values are mean ± SEM expressed as percentage forskolin response where n ≥ 5 
independent experimental repeats, conducted in duplicate. 
N.R. denotes no response 
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Figure 4.37. cAMP signalling profile in Hep 3B cells. Hep 3B cells 
(5,000 cells/well) with similar passage number (> 4 from N2 but less than 
8), were exposed to various ligands for 30 minutes and cAMP 
accumulation detected using a LANCE cAMP Ultra kit. All values are 
mean ± SEM expressed as percentage forskolin response (100 µM) where 
n ≥ 5 independent experimental repeats, conducted in duplicate.  
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Figure 4.38. The measured potency for AM varies across 
experimental repeats in Hep 3B cells. Hep 3B cells (5,000 cells/well) 
were exposed to AM for 30 minutes and cAMP accumulation detected 
using a LANCE cAMP Ultra kit. The scatter plot shows single pEC50 value 
acquired though fitting each repeat data to a three-parameter logistic 
equation. All values are mean ± SD where n ≥ 9 independent experimental 
repeats. 
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Table 4.25. Rank order of potency at the CLR with RAMP1-3. Adapted from Moore 
and Salvatore et al., 2012  
 CT AMY1 AMY2 AMY3 
Composition CT CT + RAMP1 CT  + RAMP2 CT  + RAMP3 
Rank order of 
potency 
CT≥AMY,CGRP
>AM,AM2 
AMY≥CGRP≥
AM2>CT>AM 
Poorly 
defined 
AMY>CGRP>
AM2>CT>AM 	
Table 4.24. Rank order of potency at the CALCR receptor with and 
without RAMP1-3. Adapted from Moore and Salvatore et al., 2012 
 CGRP AM AM2 
Composition CLR + RAMP1 CLR + RAMP2 CLR + RAMP3 
Rank order of 
potency 
CGRP≥AM>AM2>
AMY 
AM>>CGRP,AM2 
>AMY 
AM≥CGRP, 
AM2>AMY 
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4.8.3.  GCG, oxyntomodulin and GLP-1(7-36)amide induce a pERK1/2 
response in Hep 3B cells 
 
Given the probable expression of GCGR in Hep 3B cells (Section 3.7) and 
having demonstrated that GCG or oxynotmodulin stimulation of HEK 293T 
cells transfected with GCGR and CHO-K1 cells stably expressing GCGR 
induces a concentration-dependent increase in pERK1/2 (Section 4.4.2.1), we 
looked to investigate if a pERK1/2 response could also be measured in Hep 
3B cells. In addition to investigation the pERK1/2 response to GCG and 
oxyntomodulin stimulation, we also test the response to GLP-1(7-36)amide.  
The latter was included due to the previous finding showing a lack of cAMP 
induced response to GLP-1(7-36)amide in Hep 3B cells.  
A pERK1/2 response was detected following GCG, oxyntomodulin and 
GLP-1(7-36)amide stimulation in Hep 3B cells (Figure 4.39 A). The potency of 
the measured response to both oxyntomodulin and GLP-1(7-36)amide was 
lower when compared to GCG, although this was only significant for GLP-1(7-
36)amide (Table 4.27). Notably, oxyntomodulin had a higher maximum 
response and basal level of pERK1/2 when compared to GCG. If this 
pERK1/2 response is through stimulation of GCGR, this would indicate that 
although showing reduced potency similar to what is seen for oxyntomodulin 
stimulated cAMP accumulation in Hep 3B cells, oxyntomodulin is able to 
induce a greater level of pERK1/2 when compared to GCG. Although a three-
parameter does-response was fitted to these data, the points acquired for 
GCG and oxyntomodulin stimulation could also be fitted with linear regression 
suggesting more repeats may be needed for a better fit.  
Surprisingly, the potency of the pERK1/2 response to GCG or 
oxyntomodulin stimulation was lower in GCGR transfected HEK 293T cells 
(pEC50 6.12 ±0.19 and 6.25 ±0.22, respectively) and CHO-K1 cells (pEC50 
6.89 ±0.20 and 5.85 ±0.13, respectively) expressing stably GCGR (Section 
4.4.2.1) when compared to that measured in Hep 3B cells (pEC50 9.13 ±0.32 
and 8.20 ±0.37). This finding may indicate a greater coupling of GCGR to the 
 228 
pERK1/2 pathway within Hep 3B cells (at early passage) when compared to 
these alternative cell lines.  
The GLP-1(7-36)amide concentration-dependent increase in pERK1/2 
response was unexpected given the previous finding indicating a lack of 
cAMP response to GLP-1(7-36)amide stimulation in Hep 3B cells. Given the 
cAMP response indicated the absence of GLP-1R expression, It may be 
speculated that this pERK1/2 response detected here is GCGR-mediated. 
However, a more likely explanation for this finding is the variable loss of 
receptor expression in Hep 3B cells over passage number. Speculatively, it 
may be that Hep 3B cells used in the experiments characterising the cAMP 
responses to GLP-1(7-37)amide had lost the GLP-1R, whereas the Hep 3B 
cells used in the analysis of ERK1/2 activation expressed GLP-1R. If this was 
indeed the case, the elevated oxyntomodulin pERK1/2 response when 
compared to GCG and GLP-1(7-36)amide could be as a consequence of 
stimulation of both GCGR and GLP-1R. 
The ability to measure a pERK1/2 response was shown to depend on 
the cell passage number, with experiments using as early as passage 8 
failing to induce a response (Figure 4.39 B). Similarly to what was seen for 
ligand stimulated cAMP responses in Hep 3B cells, there was high variability 
in the measured potency for the ligand stimulated pERK1/2 responses (Table 
4.27).  Again, this variability may be explained by a lack of stability in terms of 
receptor expression and the apparent loss of a measurable pERK1/2 
response at early passage supports this argument. 
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Figure 4.39. GCG, oxyntomodulin and GLP-1(7-36)amide stimulates a 
pERK1/2 response in ‘young’ Hep 3B cells. Hep 3B cells were serum stared 
for 4 hours and stimulated with GCG, oxyntomodulin or GLP-1(7-36)amide for 5 
minutes before measuring pERK1/2. Cells were plated at 50,000 cells per well 
(maximum cell number suggested by kit supplier) of a 384-well plate. All values 
are mean ± SEM expressed as percentage PMA response (1 µM) where n = 3 
independent experimental repeats including cells from passage 3, 4 and 5 (A) 
and n = 2 at 8 (B), conducted in duplicate.  
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4.8.4.  Pharmacological characterisation of two potential GCGR 
antagonists in Hep 3B cells 
4.8.4.1.  des-His1,[Glu9]-GCG appears to acts as non-competitive 
antagonist of the GCG stimulated cAMP response in Hep 3B cells  
 
We previously characterised des-His1,[Glu9]-GCG as a partial agonist at the 
GCGR in HEK 293T cells transfected with pcDNA3.1 expressing GCGR. 
Here, we investigated its activity in Hep 3B cells endogenously express 
GCGR.   
Using the more sensitive cAMP assay (LANCE cAMP Ultra detection 
kit), the cAMP response in Hep 3B cells was measured following stimulation 
with GCG alone or in combination with varying concentration of des-
His1,[Glu9]-GCG (Figure 4.40 and Table 4.28). Co-stimulation of Hep 3B cells 
with GCG and 1 µM or 0.1 µM of des-His1,[Glu9]-GCG showed a reduction in 
maximum cAMP response which only reached statistical significance at 1 µM. 
There was found to be no significant rightward shift in potency when co-
stimulated with 1 µM of des-His1,[Glu9]-GCG. Although this data may suggest 
des-His1,[Glu9]-GCG acts as a non-competitive antagonist in Hep 3B cells, 
caution should be exercised when interpreting these data given the  large 
variability in response. 
A dose-response curve was fitted to data acquired from stimulation 
with des-His1,[Glu9]-GCG alone with an apparent reduced basal cAMP 
response at 10 µM of des-His1,[Glu9]-GCG. However, this stimulation data 
was variable resulting in large error and is unlike to be a true response. This 
is distinct from the agonistic activity of des-His1,[Glu9]-GCG characterised in 
GCGR transfected HEK 293T cells. 
When comparing the cAMP response to GCG stimulation in Hep 3B 
cells between experiments looking at either L-168,049 or des-His1,[Glu9]-
GCG, there is significantly different potencies (pEC50 8.14 ±0.2 and 9.43 ±0.2, 
respectively). Whereas experiments investigating des-His1,[Glu9]-GCG 
conducted using very early passage (<4) Hep 3B cells gave a higher pEC50 
 232 
(9.43 ±0.2), GCG responses determined from later passage (>4 but <8) 
looking at the activity of L-168,049 and ligand screening showed lower 
potency (pEC50 8.14 ±0.2 and 8.28 ±0.16, respectively). As previously 
indicated, there was considerable variability in measured potency values 
acquired from fitting a three-parameter logistics equation to individual repeats 
of GCG, oxyntomodulin or AM stimulated cAMP data from various 
experimental repeats (Figure 4.36 and 4.38). Again, these data indicates poor 
reproducibility when using Hep 3B cells and is most likely due to loss of 
receptor with increasing passage.  
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Figure 4.40. Activity of des-His1,Glu9-glucagon amide in Hep 3B. 
Hep 3B cells (5,000 cells/well) were exposed to GCG with or without 
various concentration of des-His1,Glu9-glucagon amide (des-His1,Glu9-
GCG), or des-His1,Glu9-GCG alone for 30 minutes and cAMP 
accumulation detected using the LANCE Ultra cAMP kit. All values are 
mean ± SEM expressed as percentage GCG response where n = 3 
independent experimental repeats, conducted in duplicate. 
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4.8.4.2.  L-168,049 acts as a competitive antagonist of the GCG 
stimulated cAMP response 
 
We previously characterised L-168,049 as a non-competitive antagonist at 
the GCGR in HEK 293T cells transfected with pcDNA3.1 expressing GCGR. 
Here, an investigation was made into the activity of this compound in Hep 3B 
cells endogenously express GCGR. Using the more sensitive cAMP assay 
(LANCE cAMP Ultra detection kit), the cAMP response in Hep 3B cells was 
measured following stimulated with GCG alone or in combination with varying 
concentration of L-168,049 (Figure 4.41 and Table 4.29).  
 Stimulated with GCG in combination with increasing concentrations of 
L-168,049, showed a rightward shift in GCG potency with statistical 
significance reached at the antagonist concentration of 1 µM and above 
(Figure 4.41 and Table 4.29). L-168,049 stimulation alone showed no cAMP 
response in Hep 3B cells and suggests this compound has no agonistic 
activity. Interestingly however, there was a significant increase in basal 
response and a small but non significant increase in maximal response to 
GCG with increasing concentrations of L-168,049. This finding may indicate 
some agonistic activity of the compound or, more likely, fluorescent property 
leading to an apparent elevation with increasing concentrations (as was 
previously indicated in HEK 293T cells transfected with GCGR (Section 
4.5.2)).  
Ligand stimulation in combination with a non-competitive antagonist is 
expected to reduce the maximal response when compared to ligand 
stimulation alone. With this in mind, the results suggested L-168,049 to be a  
competitive antagonist and were unexpected given that this compound was 
found to be a non-competitive antagonist elsewhere (Section 4.5.2 and 
Cascieri et al., 1999). However, an attempt to conduct Schild analysis of the 
data gave a slope of 0.2 rather than 1 and does not support the conclusion 
that this is a competitive antagonist. Again, due to variability of data acquired 
using Hep 3B cells, caution needs to be taken when interpreting the data.  
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Figure 4.41. Activity of L-168,049 in Hep 3B. Hep 3B cells (5,000 
cells/well) were exposed to GCG with or without various concentration of 
L-168,049, or L-168,049 alone for 30 minutes and cAMP accumulation 
detected using the LANCE Ultra cAMP kit. All values are mean ± SEM 
expressed as percentage GCG response where n = 3 independent 
experimental repeats, conducted in duplicate. 
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4.8.5.  Summary  
 
Primary human hepatocytes are considered to be the gold standard for the 
study of metabolism in the liver but their phenotypic instability and restricted 
accessibility has made way for alternative such as the immortalised human 
hepatocellular carcinoma cell line, Hep 3B. Despite the use of this and similar 
cell lines in research, little is currently known about the receptor expression 
and associated pharmacology. Here, Hep 3B cells were found to express 
mRNA for various G proteins (Gs, Gi1-3, Gq, G11 and G12/13), GCGR, RAMP2, 
small levels of GIPR, CLR, RAMP1 and RAMP3.  
The combined GCGR mRNA detection and robust response to GCG 
and oxytnomodulin strongly suggests the endogenous expression of GCGR, 
as would be expected for a hepatocyte cell line (Taborsky, 2010). Studies 
have highlighted that GCGR ligands including GCG and oxyntomodiulin can 
activate the GLP-1R, whereas GLP-1(7-36)amide has been suggested not to 
act at the GCGR (Runge et al., 2003). In accordance with this, the lack of 
GLP-1(7-36)amide response suggests both the absence of GLP-1R 
expression itself and confirms the lack of cAMP response to GLP-1(7-
36)amide stimulation at the GCGR in Hep 3B cells. However, this finding is 
contradictory to the concentration-dependent increase in cAMP accumulation 
found in GLP-1(7-36)amide stimulated HEK 293 cells transfected with GCGR 
(Section 4.2.1) and may be due to a lack of RAMP2 expression (Weston et 
al., 2015) 
Previous work has identified cross-reactivity of GLP-1R ligands, 
including GLP-1(7-36)amide and liraglutide at the GCGR, which was 
abolished by a RAMP2 interaction (Weston et al., 2014, Weston et al., 2015). 
Such a previously unidentified role for GLP-1(7-36)amide ligands could be 
explained by the wide tissue expression of RAMPs. The background of a cell 
type, including the RAMP expression profile, and variation between cell 
batches can contribute greatly to the experimental observations (Tilakaratne 
et al., 2000). Indeed, the observation that GLP-1(7-36)amide can act on 
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GCGR (Section 4.2.1, Weston et al., 2014, Weston et al., 2015) may depend 
on the absence of expression of RAMP2 in the particular tissue or cell type 
investigated. Alternatively, this apparent activity of GLP-1(7-36)amide ligands 
at the GCGR in transfected cell lines may be as a consequence of high 
receptor expression when compared to an endogenously expressing cell line.  
Here, in the case of Hep 3B cells, the lack of GLP-1(7-36)amide stimulated 
cAMP response may be a consequence of RAMP2 expression and interaction 
thereby abolishing the response.  
Given the lack of cAMP response to GLP-1(7-36)amide, the GLP-1(7-
36)amide concentration-dependent pERK1/2 response  measured in Hep 3B  
is surprising and complicates the interpretation of the data.  These findings 
may be explained by a variability in the loss of receptor expression over 
passage number. Speculatively, it may be that the experiments investigating 
the cAMP responses to GLP-1(7-36)amide stimulation had lost expression of 
GLP-1R and therefore failed to induce a detectable level of cAMP, whereas 
experiments looking at pERK1/2 response had a given level of GLP-1R 
expression in the Hep 3B cells used.  
Given the rank order of potency at the various CLR/CT and RAMP 
combinations (Tables 4.25 and 4.26), the cAMP response detected following 
stimulation with AM but not AM2 or CGRP was interpreted as the expression 
of a functional AM receptor through the expression of CLR in combination 
with RAMP2. This robust response may not have been expected given the 
low level of detectably CLR expression when compared to GAPDH. However, 
the correlation between mRNA and protein expression is notoriously poor with 
most reports finding only a weak correlation between the two (Maier et al., 
2009). Even if the RT-PCR results do indeed reflect protein expression levels 
within Hep 3B, GPCR expression levels may not need to be high in order to 
produce a response as a result of signal amplification 
In this work, the activity of two potential GCGR antagonists, des-
His1,[Glu9]-GCG and L-168,049, were investigated in Hep 3B cells and the 
findings were distinct from those determined in HEK 293T cells. L-168,049 
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was characterised as a competitive antagonist in HEK 293T cells and Hep 3B 
cells rather than a non-competitive antagonist as previously reported 
(Cascieri et al., 1999). des-His1,[Glu9]-GCG was characterised as a partial 
agonist in GCGR transfected HEK 293T cells but a non-competitive 
antagonist in Hep 3B cells.  
There was considerable variability in data acquired using Hep 3B cells 
for both cAMP and pERK1/2 assays with an apparent loss in response using 
cells at passage 8 or higher. This indicates poor reproducibility when using 
Hep 3B cells and is most likely due to loss of receptor with increasing 
passage. In light of these data variability and time constraint on ligand 
stimulated responsiveness in Hep 3B cells, it appears that these cells are 
somewhat less valuable as a hepatocyte cell model to investigate GCGR 
signalling. 
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Chapter 5.  Investigating pharmacological role of GCGR 
regions 
5.1.  Introduction  
 
A number of studies looking at class B GPCRs have proposed critical roles 
for residues within ICL1-3 including maintaining GPCR in an inactive state 
(Martínez-Archundia and Correa-Basurto, 2014), coupling to G proteins 
(Mathi et al., 1997, Conner et al., 2006 and Kleinau et al., 2010), protein 
folding and correct transport (Thomas et al., 2007). In the work presented in 
this thesis, an investigation into the importance of GCGR regions and 
conserved residues for cell-surface expression and downstream signaling 
components (cAMP, pERK1/2 and Ca2+i mobilisation) was performed in line 
with optimisations presented in chapter 3. These included the GCGR ICL1 
region (G1651.63-T1722.45), TM2 residue R1732.46, helix 8 residues E4068.49 
and E4108.53 and three TM4 residues (G2714.49, L2774.55, V2804.58). 
Despite significant differences between class A and B GPCRs, all 
share a common molecular architecture and bind the same G proteins 
suggesting a similar mechanism of receptor activation and G protein binding 
(Cordomí et al., 2015). Until relatively recently, the available crystal structures 
were limited to class A GPCRs. Multiple crystal structures (both active and 
inactive) exist for the class A A2AR including the A2AR bound to the agonists 
NECA and adenosine (Lebon et al., 2011), CGS 21689 (Lebon et al., 2015), 
UK-432097 (Xu et al., 2011) and the antagonist ZM241385 (Liu et al., 2012, 
Doré et al., 2013, Jaakola et al., 2008,). In this thesis, due to the availability of 
these multiple crystal structures, the A2AR was chosen as a class A Gs-
coupled receptor to investigate the importance of ICL1. 
To aid in interpretation of the experimental results, Modeller (version 
9.18) was used to mutate specific residues within the currently available 
GCGR/A2AR structures. All structures were viewed in MacPyMol (version 
1.7.4.5) and the WT (original PDB file) and mutated receptor (PDB file 
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created by running the command) compared visually to assess any predicted 
changes in amino acid interactions and structure.  
5.2.  Investigating pharmacological role of GCGR intracellular loop 1  
 
5.2.1.  Cell-surface expression of GCGR intracellular loop 1 mutants 
 
Mutations in the ICL1 region (Figure 5.1 A and Table 5.1) of a number of 
GPCRs, including the GLP-1R, have been implicated to result in both reduced 
cell-surface expression and secondary messenger responses (Mathi et al., 
1997 and Underwood et al., 2013). In this work, using ICL1 region GCGR 
mutants (G165A-T172A), kindly donated by Dr. Ali Jazayeri (Heptares 
Therapeutics), and a number of assays measuring downstream responses we 
investigated the importance of this region (residues G165-T172) for receptor 
cell-surface expressing and signalling. 
We first sought to investigate the cell-surface expression of both WT 
and mutant GCGR. Here, HEK 293 cells were transiently transfected with 
pcDNA3.1 containing the GFP-tagged GCGR and cell-surface expression 
determined using FACS analysis as previously described (Section 3.10.1). 
Confocal fluorescence microscopy images of HEK 293 cells expressing GFP-
tagged WT GCGR showed localisation on the membrane surface (Figure 5.2 
A). Seven of the eight ICL1 mutants tested showed similar cell-surface 
fluorescent levels and only C171A failed to show any cell-surface expression 
(Figure 5.2 A). The images for C171A showed complete absence of protein 
expression with no detectable GFP, suggesting a complete lack of expression 
and/or premature degradation. Through FACS analysis, the cell-surface 
expression of all but three mutants, L166A, H170A and T172A, were 
significantly reduced when compared to WT GCGR (70.2 ±12.2, 59.4 ±18.2, 
75.3 ±9.8 percentage WT, respectively) (Figure 5.2 B).  These findings 
suggest that a number of amino acids within the ICL1 region of GCGR, 
appear to be important in trafficking to the cell-surface.  
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Figure 5.1. GCGR family structure-based alignment. A) GPCRdb.org 
structure-based alignment of part of TM1, ICL1 and part of TM2 within the GCGR 
family receptors; growth-hormone-releasing hormone (GHRH) receptor, GIPR, 
GLP-1R, GLP-2R, GCGR and the secretin receptor. B) Alignment of the class B 
GPCR ICL1 region, described as the K/RKLH motif (Vohra et al., 2013) C) The 
residue position within TM1, ICL1 and TM2 of GCGR are given in both absolute 
and Class B (Wootten et al., 2013c) numbers. Here, only the specific targeted 
regions for alanine substitution mutation within GCGR are shown. Amino acid 
residues are given as the single amino acid code and colours illustrate residue 
physico-chemical properties (Table 5.1). 
A 
B 
C 
 TM1  ICL1  TM2  
GHRHR L V A L  R R L H  C P R N 
GIPR L S L F  R R L H  C T R N 
GLP-1R L L G F  R H L H  C T R N 
GLP-2R L L F L  R K L H  C T R N 
GCGR L G G L  S K L H  C T R N 
Secretin R L C A F  R R L H  C T R N 
Consensus L L + +  R R L H  C T R N 	 	
  ICL1  
CTR  R S L G  
CLR  K S L S  
CRF1R  R S I R  
CRF2R  R S I R  
GHRHR  R R L H  
GIPR  R R L H  
GLP-1R  R H L H  
GLP-2R  R K L H  
GCGR  S K L H  
Secretin R  R R L H  
PTH1R  R R L H  
PTH2R  R R L H  
PAC1R  R R L H  
VPAC1R  R R L H  
VPAC2R  R R L H  
Consensus  R + L H  
	
  ICL1  TM2 
GCGR G L  S K L H  C T R N 
Absolute Position 165 166  167 168 169 170  171 172 173 174 
Class B number 1.63 1.64  12.48 12.49 12.50 12.51  2.44 2.45 2.46 2.47 
	
  TM1  ICL1  TM2 
 
GCGR 
Amino acid   L  S        N 
Absolute position 165 166  167 168 169 170  171 172 173 174 
Class B n r .  1.6   12.  12.  .  . 1  . 4 . 5 .46 2.47 
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A  
 Alanine (Ala, A) Valine (Val, V), Leucine (Leu, L), Isoleucine (Ile, I), 
Methionine (Met, M) 
 Glycine (Gly, G) 
 Proline (Pro, P) 
 Cysteine (Cys, C) 
 Tyrosine (Tyr, Y), Phenylalanine (Phe, F), Trytophan (Trp, W) 
 Threonine (Thr, T), Serine (Ser, S), Asparagine (Asn, N), Glutamine 
(Gln, Q) 
 Lysine (Lys, K), Arginine (Arg, R) 
 Histidine (His, H) 
 Glutamate (Glu, E), Aspartate (Asp D) 
  
B  
 17% consensus 
 33% consensus 
 50% consensus 
 67% consensus 
 100% consensus 
Table 5.1. Colour code key for structural-alignment. A) amino acid colour 
code and B) percentage consensus (approximate) colour code acquired from 
GPCRdb.org 
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Figure 5.2. Cell-surface expression of WT and GCGR ICL1 
mutants. HEK 293 cells were transfected with WT or mutant GCGR 
and cell-surface expression determined by A) confocal fluorescence 
microscopy (24 hours post transfection) representative image for 
each mutant and B) FACS analysis (48 hours post transfection); anti-
GCGR primary antibody at a 1:50 dilution, APC-conjugated IgG 
secondary antibody at a 1:150 dilution. All values are mean ± SEM 
expressed as percentage WT GCGR (100%) and vector only 
transfected control (0%) where n = 3 independent experimental 
repeats, conducted in duplicate. Arrow indicates cell-surface localised 
receptor.  Statistical significance (*, p<0.05; **, p<0.01; ***, p<0.001) 
compared to WT was determined by one-way ANOVA with Dunnett’s 
post test. 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
10 m WT G165A L166A 
S167A K168A L169A 
H170A T172A C171A 
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5.2.2.  cAMP response in GCGR ICL1 transfected HEK 293 cells 
  
Having showed various ICL1 GCGR mutants had reduced cell-surface 
expression, we next sought to investigate the pharmacological consequences 
of these mutants. Here, HEK 293 cells transiently transfected with pcDNA3.1 
expressing WT or the mutant GCGR were stimulated with GCG and the 
cAMP accumulation detected using the LANCE® cAMP detection kit.  
With the exception of C171A, which showed no detectable cAMP 
response, there was found to be no significant difference in potency, basal 
response, span, affinity or efficacy for the measured cAMP response to GCG 
stimulation of WT and mutant GCGR (Figure 5.3 and Table 5.2). This lack of 
cAMP response in C171A transfected HEK 293 cells reflects the lack of 
detectable cell-surface expression, as was previously shown (Figure 5.3).   
There was found to be a significantly reduced maximal response in 
G165A when compared to WT GCGR (Emax 73.4 ±3.7 and 102.9 ±4.2, 
respectively) that suggests that glycine at position 165 is important in the 
GCGR mediated cAMP response to GCG. Although there was found to be a 
reduced cell-surface expression for G165A (Figure 5.3), given the similar or 
lower cell-surface expression detected for other ICL1 mutants with similar 
cAMP responses to WT GCGR, this is unlikely to account for the reduced 
cAMP response. It may be speculated that this amino acid is important in the 
coupling to Gs. 
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Figure 5.3. Effect of GCGR ICL1 mutants on cAMP response. HEK 293 
cells transiently expressing pcDNA3.1 vector containing WT or alanine 
GCGR ICL1 mutants (24 hours post transfection) were exposed to GCG 
for 8 minutes and cAMP accumulation detected. All values are mean ± 
SEM expressed as percentage WT forskolin response where n ≥ 5 
independent experimental repeats, conducted in duplicate. Arrow 
indicated significant change (Table 5.2) between WT and mutant 
response.  
 
0 -13 -12 -11 -10 -9 -8 -7 -6
0
50
100
150
Log[GCG]M
c
A
M
P 
Re
sp
o
ns
e
 
(%
 W
T)
WT
G165A
0 -13 -12 -11 -10 -9 -8 -7 -6
0
50
100
150
Log[GCG]M
c
A
M
P 
Re
sp
o
ns
e
 
(%
 W
T)
WT
S167A
0 -13 -12 -11 -10 -9 -8 -7 -6
0
50
100
150
Log[GCG]M
c
A
M
P 
Re
sp
o
ns
e
 
(%
 W
T)
WT
L169A
0 -13 -12 -11 -10 -9 -8 -7 -6
0
50
100
150
Log[GCG]M
c
A
M
P 
Re
sp
o
ns
e
 
(%
 W
T)
WT
C171A
0 -13 -12 -11 -10 -9 -8 -7 -6
0
50
100
150
Log[GCG]M
c
A
M
P 
Re
sp
o
ns
e
 
(%
 W
T)
WT
L166A
0 -13 -12 -11 -10 -9 -8 -7 -6
0
50
100
150
Log[GCG]M
c
A
M
P 
Re
sp
o
ns
e
 
(%
 W
T)
WT
K168A
0 -13 -12 -11 -10 -9 -8 -7 -6
0
50
100
150
Log[GCG]M
c
A
M
P 
Re
sp
o
ns
e
 
(%
 W
T)
WT
H170A
0 -13 -12 -11 -10 -9 -8 -7 -6
0
50
100
150
Log[GCG]M
c
A
M
P 
Re
sp
o
ns
e
 
(%
 W
T)
WT
T172A
 247 
	Table
 5
.2
.  
Ef
fe
ct
 o
f 
G
C
G
R
 IC
L1
 m
ut
an
ts
 o
n 
cA
M
P 
re
sp
on
se
. P
ot
en
cy
 (p
E
C
50
), 
m
ax
im
al
 re
sp
on
se
 (E
m
ax
), 
ba
sa
l, 
sp
an
, 
af
fin
ity
 (
pK
A
) 
an
d 
co
up
lin
g 
ef
fic
ac
y 
(lo
gτ
) 
va
lu
es
 fo
r 
cA
M
P
 r
es
po
ns
e 
to
 G
C
G
 s
tim
ul
at
io
n 
in
 W
T/
m
ut
an
t G
C
G
R
 tr
an
sf
ec
te
d 
H
E
K
 2
93
 c
el
ls
 
 
cA
M
P 
C
on
st
ru
ct
 
pE
C
50
 a
 
E m
ax
 b
 
B
as
al
 c 
Sp
an
 d 
pK
A
 e
 
lo
g 
τ 
f 
W
T 
9.
98
±0
.1
 
10
2.
9 
±4
.2
 
13
.6
 ±
3.
5 
89
.3
 ±
5.
3 
9.
72
±0
.2
 
-0
.1
7 
±0
.0
5 
G
16
5A
 
10
.0
0 
±0
.2
 
73
.4
 ±
3.
7*
* 
3.
3 
±3
.0
 
70
.1
 ±
4.
7 
9.
93
±0
.2
 
-0
.3
4 
±0
.0
5 
L1
66
A
 
10
.2
7 
±0
.2
 
99
.4
 ±
4.
0 
7.
9 
±3
.7
 
91
.5
 ±
5.
3 
10
.0
6 
±0
.2
 
-0
.2
0 
±0
.0
4 
S
16
7A
 
9.
78
 ±
0.
1 
97
.1
±3
.9
 
17
.3
 ±
3.
0 
79
.8
 ±
4.
8 
9.
57
 ±
0.
2 
-0
.2
3 
±0
.0
4 
K
16
8A
 
9.
95
 ±
0.
1 
10
3.
2 
±4
.1
 
8.
0 
±3
.6
 
95
.3
 ±
5.
3 
9.
68
 ±
0.
2 
-0
.1
2 
±0
.0
5 
L1
69
A
 
9.
98
 ±
0.
2 
94
.4
 ±
5.
5 
4.
3 
±4
.7
 
90
.1
 ±
7.
0 
9.
74
 ±
0.
3 
-0
.1
3 
±0
.0
9 
H
17
0A
 
9.
73
 ±
0.
3 
10
4.
0 
±8
.0
 
17
.5
 ±
6.
1 
86
.6
 ±
9.
7 
9.
59
 ±
0.
2 
-0
.1
5 
±0
.0
5 
C
17
1A
 
N
.R
 
-5
.9
 ±
2.
0 
N
.R
 
T1
72
A
 
9.
83
 ±
0.
2 
94
.8
 ±
0.
2 
14
.3
 ±
4.
3 
80
.5
 ±
6.
8 
9.
57
 ±
0.
2 
-0
.2
0 
±0
.0
5 
 W
T 
or
 m
ut
an
t G
C
G
R
 w
er
e 
tra
ns
ie
nt
ly
 e
xp
re
ss
ed
 in
 H
E
K
 2
93
 c
el
ls
 a
nd
 s
tim
ul
at
ed
 w
ith
 G
C
G
 p
rio
r t
o 
m
ea
su
re
m
en
t o
f c
A
M
P
 
ac
cu
m
ul
at
io
n 
to
 g
en
er
at
e 
co
nc
en
tra
tio
n 
re
sp
on
se
 c
ur
ve
s 
fo
r 
ea
ch
 c
on
st
ru
ct
.T
o 
ca
lc
ul
at
e 
pE
C
50
, 
E
m
ax
, 
B
as
al
 a
nd
 S
pa
n 
va
lu
es
, d
at
a 
w
er
e 
an
al
ys
ed
 u
si
ng
 a
 th
re
e-
pa
ra
m
et
er
 lo
gi
st
ic
 e
qu
at
io
n.
 D
at
a 
w
as
 a
ls
o 
an
al
ys
ed
 b
y 
an
 o
pe
ra
tio
na
l m
od
el
 o
f 
ag
on
is
m
  (
B
la
ck
 a
nd
 L
ef
f, 
19
83
) t
o 
de
te
rm
in
e 
af
fin
ity
 (p
K
A
) a
nd
 c
ou
pl
in
g 
ef
fic
ac
y 
(lo
g 
τ)
. 
a  N
eg
at
iv
e 
lo
ga
rit
hm
 o
f G
C
G
 c
on
ce
nt
ra
tio
n 
re
qu
ire
d 
to
 p
ro
du
ce
 a
 h
al
f-m
ax
im
al
 re
sp
on
se
 
b 
M
ax
im
al
 r
es
po
ns
e 
to
 G
C
G
 a
s 
pe
rc
en
ta
ge
 fo
rs
ko
lin
 r
es
po
ns
e 
(M
oc
k 
tra
ns
fe
ct
ed
 w
ith
 V
ec
to
r)
, t
he
n 
no
rm
al
iz
ed
 to
 th
e 
W
T 
re
sp
on
se
 
c 
Th
e 
lo
w
 p
la
te
au
 o
f t
he
 fi
tte
d 
si
gm
oi
da
l d
os
e-
re
sp
on
se
 c
ur
ve
 
d 
Th
e 
di
ffe
re
nc
e 
be
tw
ee
n 
E
m
ax
 a
nd
 b
as
al
 s
ig
na
lli
ng
 
e 
Th
e 
ne
ga
tiv
e 
lo
ga
rit
hm
 o
f f
un
ct
io
na
l a
ffi
ni
tie
s 
th
at
 d
es
cr
ib
es
 th
e 
af
fin
ity
 o
f t
he
 re
ce
pt
or
 w
he
n 
co
up
le
d 
to
 a
 g
iv
en
 s
ig
na
llin
g 
pa
th
w
ay
 g
en
er
at
ed
 th
ou
gh
 u
se
 o
f t
he
 o
pe
ra
tio
na
l m
od
el
 fo
r p
ar
tia
l a
go
ni
sm
 
f τ
 is
 th
e 
co
up
lin
g 
ef
fic
ie
nc
y 
pa
ra
m
et
er
 g
en
er
at
ed
 th
ou
gh
 u
se
 o
f t
he
 o
pe
ra
tio
na
l m
od
el
 fo
r p
ar
tia
l a
go
ni
sm
 
A
ll 
va
lu
es
 a
re
 m
ea
n 
± 
S
E
M
 e
xp
re
ss
ed
 a
s 
pe
rc
en
ta
ge
 W
T 
fo
rs
ko
lin
 r
es
po
ns
e 
w
he
re
 n
 ≥
 5
 i
nd
ep
en
de
nt
 e
xp
er
im
en
ta
l 
re
pe
at
s,
 c
on
du
ct
ed
 i
n 
du
pl
ic
at
e.
S
ta
tis
tic
al
 s
ig
ni
fic
an
ce
 (
*,
 p
<0
.0
5;
**
, 
p<
0.
01
;*
**
, 
p<
0.
00
1)
 c
om
pa
re
d 
to
 W
T 
G
C
G
R
 w
as
 
de
te
rm
in
ed
 b
y 
on
e-
w
ay
 A
N
O
V
A
 w
ith
 D
un
ne
tt’
s 
po
st
 te
st
 
 248 
5.2.3. pERK1/2 response in GCGR ICL1 mutants transfected HEK 293 
cells 
 
We next looked to investigate if the amino acids in ICL1 were important in the 
pERK1/2 response. Here, HEK 293 cells transiently transfected with 
pcDNA3.1 expressing WT or the mutant GCGR were stimulated with GCG 
and the pERK1/2 response determined.  
As previously reported  (Section 4.4), GCG stimulated a concentration-
dependent increase in pERK1/2 in HEK 293 cells transfected with WT GCGR 
(Figure 5.4) 
Similarly to what was reported for the cAMP response in GCGR ICL1 
mutants, with the exception of C171A, there was found to be negligible 
differences in ERK1/2 phosphorylation following GCG stimulation in ICL1 
GCGR mutants when compared to WT GCGR (Figure 5.4 and Table 5.3). It 
should be noted that the measured pERK1/2 responses showed variability 
between repeats and resulted in large error for the measured parameters. 
Nevertheless, these results suggest that the ICL1 plays a minimal, if any, role 
in the pERK1/2 signalling.   
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Figure 5.4. Effect of GCGR ICL1 mutants on pERK1/2 response. HEK 
293 cells transiently expressing pcDNA3.1 vector containing WT or 
alanine GCGR ICL1 mutants (48 hours post transfection and 24 hours 
serum starved) were exposed to GCG for 5 minutes and pERK1/2 
measured. All values are mean ± SEM expressed as percentage WT 
GCGR response where n ≥ 5 independent experimental repeats, 
conducted in duplicate. Arrow indicated significant change (Table 5.3) 
between WT and mutant response. 
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5.2.4.  Intracellular Ca2+ response in GCGR ICL1 mutants transfected 
HEK 293 cells 
 
The findings presented elsewhere highlight that ligand activated GCGR is not 
only able to couple to Gs leading to concentration-dependent increases in 
cAMP accumulation, but can also induce a Gq/11-mediated Ca2+i response 
(Section 4.3). Here we investigated if mutation of the ICL1 region of GCGR 
influences the GCG stimulated Ca2+i mobilisation.  
HEK 293 cells (transfected with GFP-tagged WT or mutant GCGR post 
plating) were loaded with CalciFluor™ Rhod-4, AM dye, stimulated with 
increasing concentrations of GCG and the Ca2+i mobilisation measured using 
a FlexStation® Multi-Mode Microplate Reader. A 30-minute pre-treatment 
with the specific Gq/11 inhibitor YM-254890 (Takasaki et al., 2004) was used to 
confirm if the measured Ca2+i responses were Gq/11-mediated. GCG 
stimulation of HEK 293 cells transfected with WT GCGR and ICL1 mutant 
GCGRs, with the exception of C171A which showed no detectable Ca2+i 
response, showed a concentration-dependent increase in Ca2+i mobilisation 
with no significant difference in potency (Figure 5.5 and Table 5.4). These 
responses were abolished with YM-254890 treatment confirming the 
responses were indeed Gq/11-mediated.  
K168A, L169A, H170A and T172A showed a reduction in Ca2+i when 
compared to WT GCGR (Emax 65.2 ±5.5, 54.4 ±4.8, 50.9 ±4.9, 70.0 ±5.3 and 
111.5 ±4.5 respectively). In addition, K168A, L169A, H170A and T172A also 
showed a significant reduction in efficacy when compared to WT GCGR (log τ 
0.10 ±0.07, -0.08 ±0.06, -0.12 ±0.06, 0.28 ±0.08 and 1.12 ±0.20, 
respectively). The reduced cell-surface expression (Figure 5.2) does not 
seem to correlate with reductions in maximal Ca2+i response for all mutants, 
and therefore is unlikely to account for these results. It should be noted that 
logτ values were not correction for cell-surface expression as with transient 
transfection where expression levels are high we can lose some receptor 
expression without losing efficacy, presumably because there is more 
 252 
receptor than effector. As such, correction for cell-surface expression is only 
suitable for systems where receptor expression is not as high compared to 
transient transfection. For example, whereas we see a significantly reduced 
cell-surface expression of G165A, the maximal Ca2+i response is not 
significantly different to WT GCGR. The findings suggest that the amino acids 
K168, L169, H170 and T172 of ICL1 may play a role in Gq/11-mediated 
signalling, possibly through interactions with Gq/11 itself, whereas they 
appears to play less of a role in Gs-mediated signalling. It could be suggested 
that these residues play a role in signalling bias at the GCGR.  
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Figure 5.5. Effect of GCGR ICL1 mutants on Ca2+i response. HEK 293 
cells transiently transfected with pcDNA3.1 vector expressing WT or 
alanine GCGR ICL1 mutants (48 hours post transfection) were exposed to 
GCG and Ca2+i mobilisation measured. All values are mean ± SEM 
expressed as percentage WT GCGR response where n ≥ 5 independent 
experimental repeats, conducted in duplicate. Arrow indicates significant 
change (Table 5.4) between WT and mutant response. 
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5.2.5.  Assessing the bias for each pathway at ICL1 mutants 
 
The values of efficacy, τ, and dissociation constant, KA, obtained from fitting 
the operational model of agonism  (Black and Leff, 1983) for the cAMP, 
pERK1/2 and Ca2+i responses were used to quantify signalling bias as 
change in log (τ/KA) (∆log(τ/KA)) relative to the WT receptor, as described 
previously (Section 2.10.7). The difference between these ∆log(τ/KA) values 
was then calculated for Ca2+i mobilisation and cAMP response for the ICL1 
mutant GCGRs, with the pERK1/2 response set as the reference pathway. 
Here, the antilog values are graphically represented in a radar plot (Figure 
5.6).  
The radar plot shows the mutants K168A, L169A and H170A (relative 
to WT and when pERK1/2 is set as the reference pathway) is biased away 
from Ca2+i. This was also found to be the case for L166A.  Interestingly, 
L169A and K168A appear to have biased towards cAMP accumulation 
relative to pERK1/2 whereas most of the other mutants with the exception of 
T172A are biased away from cAMP accumulation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6. Radar plot of antilog ΔΔ(Tau/K
A
). The plot shows 
antilog ΔΔ(Tau/K
A
) values for Ca2+i mobilisation and cAMP 
accumulation for the ICL1 mutant GCGR relative to WT GCGR 
with the pERK1/2 response set as the reference pathway.  
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5.2.6.  Molecular modelling of ICL1 mutants in three GCGR structures 
 
Modeller (version 9.18) was used to mutate the various ICL1 residues 
(residues G165-T172) to alanine within the three available protein structures 
of inactive GCGR for which PDB files exist; 5XEZ (Zhang et al., 2017), 4L6R 
(Siu et al., 2013) and 5EE7 (Jazayeri et al., 2016). The resulting PDB files 
were viewed in MacPyMol (version 1.7.4.5) and the WT and mutated receptor 
compared visually to assess any predicted changes in amino acid interactions 
and structure (Table 5.5). For illustrative purposes, the ICL1 region targeted 
for alanine substitution (G165-T172), in addition to R173 and N174 that are 
investigated later (Section 5.4.2) are shown within the NNC0640 bound full 
length GCGR structure (Zhang et al., 2017)  (Figure 5.7). Images acquired in 
MacPyMol comparing WT and modelled ICL1 alanine mutants, as can be 
seen later for the A2AR (Figure 5.14), are not shown for these GCGR ICL1 
mutants (G165A-T172A) as polar interactions are largely identical between 
the ICL1 residues regardless of alanine mutation. 
There was found to be considerable variability in the interactions 
between the three different structures for the ICL1 region. For example, T172 
of the NNC0640 bound full length GCGR (Zhang et al., 2017) showed no 
polar interactions whereas T172 in the NNC0640 bound 7TM domain of 
GCGR (Siu et al., 2013) showed a polar interaction with I176.  Mutation to 
alanine had no effect on the interactions within the receptor structures for 
most residues. In addition, the lack of consistency between lost or gained 
interactions between structures on mutation make predictions as to the cause 
of changes in measured responses difficult.  
There were no obvious and consistent changes in interactions for 
G165, K168A, L169A, H170A and T172A.  This finding may lend further 
evidence to indicate that the reduced cAMP response measured for G165 
and reduced Ca2+i response measured for K168A, L169A, H170A and T17 
was as a consequence of reduced coupling to Gs or Gq/11, respectively.  
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Table 5.5. Comparison of GCGR residue polar contacts within WT and 
modelled ICL1 mutant structures 
 
NNC0640 bound full length GCGR 3 Å (5XEZ) 
G165 None  G165A None 
L166 None L166A None 
S167 None S167A None 
K168 Cys171 K168A Cys171 
L169 None L169A Leu166 
H170 Arg261 H170A Arg261 
C171 Lys168 Ala175 C171A Lys168 
T172 None  T172A Ala175 
NNC0640 bound GCGR 3.4 Å (4L6R) 
G165 None G165A None 
L166 None L166A None 
S167 None S167A His170 
K168 Cys171 Asn174  K168A Cys171 
L169 None  L169A None  
H170 None  H170A None  
C171 Lys168 C171A Lys168 
T172 Ile176 T172A None 
MK-0893 bound GCGR 2.5 Å (5EE7) 
G165 Ala161 G165A Ala161 Ser167 
L166 Ile162 Leu169 L166A Ile162 Leu169 
S167 His170 S167A His170 
K168 None K168A None  
L169 Leu166 Cys171 Asn174 L169A Leu166 Cys171 Asn174 
H170 Leu163 Gly164 Ser167 H170A Ser167 
C171 Leu169 Asn174 Ala175 C171A Leu169 Asn174 Ala175 
T172 Ala175 Ile176 Asp1157 T172A Ile176 Asp1157 
 
Mutant models of the GCGR were made using Modeller and the resulting PDB 
structures compared with WT in PyMOL for any loss/gain of polar interactions. 
Alanine mutants were modelled for NNC0640 bound full length GCGR solved to a 
resolution of 3 Å ((PDB ID: 5XEZ) (Zhang et al., 2017), NNC0640 bound GCGR 
solved to a resolution of 3.4 Å ((PDB ID: 4I6R) (Siu et al., 2013) and MK-0893 
bound GCGR solved to a resolution of 2.5 Å. 
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5.2.7.  Summary 
 
Using FACS for cell-surface expression analysis and assays for the 
measurement of downstream signaling components, we investigate the 
importance of the ICL1 region (residues G165-T172) in the GCGR expression 
and signalling. Cell-surface expression analysis of the ICL1 GCGR mutants 
revealed complete absence of C171A expression and a significant reduced 
expression of G165A, S167A, K168A and L169A GCGR mutants. These data 
indicates an importance of these amino acids for successful translation and/or 
trafficking to the cell-surface.  
In particular, the complete lack of GFP in the confocal image of C171A 
indicated absence of receptor expression or premature degradation. Similarly, 
C217 in the ICL1 of human PTHR1 was implicated as a critical determinant of 
cell-surface translocation and function with the mutant receptor found to 
localise to the interior of the cell (Thomas et al., 2007). It may be that a 
mutation in C171 leads to receptor misfolding and recognition by the cellular 
machinery for degradation. As might be expected given the lack of C171A 
cell-surface expression, there was no cAMP, pERK1/2 or Ca2+i response 
following GCG stimulation.  
There was negligible difference in cAMP production between any of 
the ICL1 GCGR mutants that demonstrated cell-surface expression with the 
exception of G165A, which showed a reduced maximal response when 
compared to WT GCGR (Emax 73.4 ±3.7 and 102.9 ±4.2 percentage WT 
response, respectively). This finding suggests that G165 is important in the 
GCGR mediated cAMP response to GCG, possibly through interaction with 
Gs. Similarly, there was no significant difference between the pERK1/2 
responses between mutants and WT GCGR. Interestingly however, K168A, 
L169A, H170A and T172A showed a reduction in maximal Ca2+i response to 
GCG (Emax expressed as percentage WT GCGR: 65.2 ±5.5, 54.4 ±4.8, 50.9 
±4.9 and 70.0 ±5.3, respectively) which through the use of a specific inhibitor, 
YM-254890, was confirmed to be Gq/11-mediated. This finding suggests that 
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the amino acids K168, L169, H170 and T172 of GCGR ICL1 (i.e. the residues 
towards TM2) may play a role in Gq/11-mediated signalling, possibly through 
interactions with Gq/11. It could be suggested that these residues play a role in 
signalling bias at the GCGR, although the mechanism remains unclear. 
These findings are in line with work conducted by Ian Winfield (Dr Ladds 
Group) investigating the importance of ICL1 in G protein-coupling at the CLR.  
Due to the highly conserved nature of ICL1 within GPCRs both in terms of 
length and amino acid sequence, these results might also be important for 
other GPCRs. We aimed to further expand on this work by investigating 
potential interaction sites between ICL1 region and helix 8 (Section 5.4.3).  
 
5.3. Investigating the role of A2AR ICL1 in cAMP signalling 
 
5.3.1. NECA stimulated CHO-K1 cells fail to show a cAMP response  
 
We have demonstrated the importance of a number of amino acids within the 
ICL1 region of the GCGR (residues G165-T172) for cAMP and Ca2+i 
signalling. Given the highly conserved nature of ICL1 within GPCRs both in 
terms of length and amino acid sequence, we sought to investigate if this 
region was also important in a class A Gs-coupled GPCR, the A2AR. An 
alignment for this ICL1 region within GCGR and A2AR is shown in Figure 5.8. 
Initial cAMP accumulation assays to NECA stimulation in untransfected 
HEK 293 and CHO-K1 cells demonstrated a robust response to NECA in 
HEK 293 cells but not CHO-K1 cells (Figure 5.9). This finding suggests the 
endogenous expression of one or a number of the adenosine receptors (A1R, 
A2AR, A2BR or A3R) in HEK 293 cells. Given the absence of a cAMP response 
in CHO-K1 cells, these were chosen as the cellular model to test the various 
ICL1 A2AR mutants. 
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5.3.2.  NECA stimulated cAMP response in WT and mutant A2AR 
 
Stimulation of CHO-K1 cells transfected with A2AR failed to induce a Ca2+i 
response (Figure 5.10), as has been previously reported (Orr et al., 2015). 
With this in mind, we looked to solely investigate the importance of ICL1 on 
cAMP responses following stimulation with the adenosine receptor agonist, 
NECA. 
The A2AR receptor was first cloned into the pmCherry-N1 vector, the 
ICL1 region (L33-N42) alanine mutants made using site-directed mutagenesis 
and confirmed by sequencing. CHO-K1 cells transfected with pmCherry-N1 
expressing WT or mutants A2AR demonstrated a concentration-dependent 
cAMP accumulation to NECA stimulation (Figure 5.11 and 5.6 respectively). 
Here, all responses are normalised to maximum forskolin response in mock-
transfected CHO-K1 cells (vector only) to allow comparison between 
maximum responses to NECA.  
Of the ten ICL1 A2AR mutants tested, the potency of NECA was 
significantly reduced for N34A and L37A (pEC50 5.77 ±0.1 and 5.16 ±0.2) 
when compared to WT A2AR (pEC50 6.23 ±0.1). These two mutants also 
showed reduced affinity, although this was only significant for L37A when 
compared to WT (pKA 4.77 ±0.2 and 5.77 ±0.1 respectively) (Table 5.6). 
Given the reduced potency of NECA in N34A and L37A, these amino acids 
appear to be important in the receptors signalling capabilities.  The reduced 
affinity suggests these amino acids may be important in binding of NECA. 
However, without performing a ligand-binding assay, the mechanism 
underlying the decrease in NECA potency for the mutant N34A and L37A 
cannot be determined.   
The maximum response was reduced for N34A, Q38A and N42A (Emax 
61.3 ±2.0, 60.6 ±2.7 and 56.3 ±3.1 percentage mock forskolin response, 
respectively) when compared to WT A2AR (Emax 69.5 ±1.7). There was a 
significantly reduced basal cAMP response in N34A, L37A, Q38A and N42A 
(4.3 ±1.0, 0.3 ±1.8, 0.2 ±1.5 and 3.7 ±1.9 percentage mock forskolin) when 
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compared to WT A2AR  (11.5 ±1.0 percentage mock forskolin).  These data 
suggest that the A2AR has a low level of basal activity in the absence of 
ligand, and these amino acids may play a role in maintaining this basal 
activity. On the other hand, T41A showed a significantly elevated basal cAMP 
response (26.5 ±1.1). The elevated basal of T41A translated to a significantly 
reduced signalling window, as indicated by the reduced span (44.3 ±1.8 
percentage mock forskolin). This finding suggest T41A, independent of 
ligand, is in an active conformation resulting in an elevated basal cAMP level, 
possibly via Gs-coupling.  
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Figure 5.10. NECA failed to stimulate Ca2+i mobilisation in CHO-K1 cells 
expressing A2AR. CHO-K1 cells transiently transfected with pmCherry-N1 
vector expressing A2AR (48 hours post transfection) were exposed to 
ionomycin (control) and NECA and Ca2+I mobilisation measured. All values 
are mean ± SEM expressed as percentage Ionomycin response where n = 2 
independent experimental repeats, conducted in duplicate.  
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Figure 5.11. Effect of A2AR ICL1 mutants on NECA stimulated cAMP 
response. CHO-K1 cells transiently expressing WT or alanine containing A2AR 
ICL1 mutants (48 hours post transfection, 1000 cells/well) were exposed to NECA 
for 8 minutes and cAMP accumulation detected. All values are mean ± SEM 
expressed as percentage forskolin mock response (mock transfected with vector 
only) where n ≥ 5 independent experimental repeats, conducted in duplicate. 
Arrow indicates significant change in pEC50 or elevated basal cAMP levels (Table 
5.6) between WT and mutant.  
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5.3.3. CGS 21680 stimulated cAMP response in WT and mutant A2AR 
 
With a number of mutants showing distantly different NECA stimulated cAMP 
response when compared to WT A2AR, we next wanted to identify if these 
amino acids were also important for the cAMP response following stimulation 
with another A2AR active compound, the A2AR selective CGS 21680 (Jarvis et 
al., 1989), or if the mutants showed ligand specific differences. 
CHO-K1 cells transfected with A2AR showed a concentration-
dependent increase in cAMP accumulation when stimulated with CGS 21680 
(Figure 5.12 and Table 5.7). Of the ten ICL1 A2AR mutants tested, the 
potency and maximum response was significantly reduced for N34A (pEC50 
5.50 ±0.1, Emax 48.9 ±3.4) when compared to WT (pEC50 6.00 ±0.2, Emax 61.5 
±4.0). The other nine mutants showed no significant difference in measured 
potency or maximum response to CGS 21680. However, L37A and N42A 
also showed a reduced maximum response but we only see a significantly 
reduced span when compared to WT for L37A (59.6 ±4.5 and 43.7 ±3.7, 
respectively). There was also a reduced maximal response in N39A, which 
translated to a significant reduced span when compared to WT (44.2 ±2.7 and 
59.6 ±4.5, respectively). N39A also showed a significantly reduced coupling 
efficacy (log τ  -0.51 ±0.05). 
As was previously shown (Figure 5.11 and Table 5.6), there was found 
to be a ligand-independent elevation in basal cAMP accumulation in CHO-K1 
cells transfected with T41A when compared to WT A2AR (19.8 ±2.2 and 1.9 
±2.4, respectively). Again, this elevated basal cAMP accumulation translated 
to a significantly reduced signalling window when compared to WT, as 
indicated by the reduced span (38.7 ±4.3 and 59.6 ±4.5, respectively). This 
finding suggest mutation of T41 to alanine, increases the level of 
constitutively active at the A2AR. 
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Figure 5.12. Effect of A2AR ICL1 mutants on CGS21680 stimulated cAMP 
response. CHO-K1 cells transiently expressing WT or alanine containing A2AR 
ICL1 mutants (48 hours post transfection, 1000 cells/well) were exposed to NECA 
for 8 minutes and cAMP accumulation detected. All values are mean ± SEM 
expressed as percentage forskolin mock response (mock transfected with vector 
only) where n ≥ 5 independent experimental repeats, conducted in duplicate. 
Arrow indicates significant change in pEC50 or elevated basal cAMP levels (Table 
5.7) between WT and mutant. 
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5.3.4.  Molecular modelling of ICL1 mutants in A2AR structures 
 
Modeller (version 9.18) was used to mutate a number of ICL1 residues to 
alanine within four available protein structures of A2AR for which PDB files 
exist; 4EIY (Liu et al., 2012), 2YDV (Lebon et al., 2011), 4UHR (Lebon et al., 
2015) and 5G53 (Carpenter et al., 2016). These included N34, L37, Q38, T41 
and N42, which showed a NECA or CGS 21680 stimulated cAMP 
accumulation significantly different to WT (Table 5.6 and 5.7, respectively). 
The resulting PDB files were viewed in MacPyMol (version 1.7.4.5) and the 
WT and mutated receptor compared visually to assess any predicted changes 
in amino acid interactions and structure (Table 5.8). As an example and to aid 
in illustration of polar interactions within WT and modelled mutated structure 
of A2AR, images generated in MacPyMol for antagonist (ZM241385) bound 
A2AR (Liu et al., 2012) are shown (Figure 5.13 and 5.14).  
Although the polar interactions for each residue showed variability 
between the four structures, there were a number of conserved interactions 
and lost interactions within the modelled mutated A2AR structures irrespective 
of agonist/antagonist/G protein bound.  
The modelled A2AR containing alanine at position 34 showed a number 
of lost interactions and may account for the significantly reduced potency and 
maximum response to both NECA and CGS 21680. The lost interactions 
included helix 8 residues T2988.53 and E2948.49, which were found to make a 
polar interaction with N34 in the majority of the A2AR structures investigated 
(Table 5.8). Another potentially important interaction lost on mutation to 
alanine included N36.  
Within all four A2AR structures, L37 was shown to form polar 
interactions with N39 and N42 and were maintained within the modelled L37A 
structures. Interestingly, within the NECA-bound and G protein-bound A2AR 
structures, mutation of L37 to alanine resulted in a gained interaction with 
N34. However, this gained polar contact had no effect on the interactions of 
N34 (with T2988.53 and E2948.49) and the modelled structure does not appear 
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to offer an explanation for the reduced potency and maximum response to 
both NECA and CGS 21680. 
Depending on the structure analysed, Q38 was shown to interact with 
V31, W32, N34 and S35. Whereas the interaction with V31 was found in all 
four of the A2AR structures, the interaction with N34, W32 or S35 was found in 
three of the four investigated. On mutation to alanine, all of these interactions, 
with the exception of S35, were lost and may provide an indication as to the 
significantly reduced maximum response to NECA.  
Viewing the crystal structure of the active-like conformation bound 
CGS 21680 A2AR revealed that T41 interacts with D101 and R102 of the 
E/DRY motif and Y112 in ICL2. Although these interactions were only found in 
one of the three structures analysed here, T41 was shown to interact with 
D101 within two other A2AR structures (Xu et al., 2011 and Dore et al., 2011). 
The E/DRY motif in TM3, is one of the mostly highly conserved sequences 
motifs in GPCRs (Rovati et al., 2007) and is proposed to form part of the 
“ionic lock” stabilise the inactive receptor conformation (Vogel et al., 2008). 
These interactions were lost in the modelled CGS 21680 bound T41A mutant 
A2AR (4UHR) structure and may provide an explanation for the constitutive 
activity found for this mutated A2AR. In other words, on mutation the “ionic 
lock” is broken resulting in a constitutively active A2AR. Interestingly, the 
equivalent position for T412.39 within GCGR is R1732.46 and was investigated 
further (Section 5.4.2). 
N42 was found to interact with L37, N39 and V46 in all four A2AR 
structures. Whereas the interactions between N42 with N39 and V46 were 
maintained on mutation to alanine, the interaction with L37 was lost. There 
was also found to be a gained interaction for this position with V45 in three of 
the four structures used to modelled mutant A2AR. These interaction changes 
may provide an explanation for the reduced maximum response.  
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Table 5.8. Comparison of A2AR residue polar contacts within WT and 
modelled A2AR mutant crystal structures 
ZM241385 bound (4EIY) 
N34 
 
Leu37 Glu294 Thr298* N34A 
 
Leu37  
L37 
 
Asn34 Asn39* Asn42* L37A 
 
Asn34 Asn39* Asn42* 
Q38 
 
H bond Val31* Trp32 Q38A 
 
None 
T41 
 
H2O H bond(x2) Phe44 Val45 T41A 
 
Phe44 Val45 
N42 H2O H bond(x2) Leu37* 
Asn39*(x2) Val46* 
N42A Asn39* Val46* 
NECA bound (2YDV) 
N34 
 
Ala30 Asn36 Glu294 Thr298* N34A 
 
Ala30  
L37 
 
Asn39* Asn42* L37A 
 
Asn34 Asn39* Asn42*  
Q38 
 
Val31* Trp32 Ser35 Q38A 
 
Ser35 
T41 
 
None T41A 
 
Phe44 
N42 Leu37* Asn39*(x2) Val46* N42A Asn39*(x1) Val45 Val46* 
CGS21680 bound (4UHR)  
N34 
 
Ala30 Asn36 Leu37 Gln38 
Glu294 Thr298* 
N34A 
 
Ala30 Gln38  
L37 
 
Asn34 Asn39* Asn42* L37A 
 
Asn39* Asn42* 
Q38 
 
Val31* Asn34 Ser35 Q38A 
 
Ser35 
T41 
 
Phe44 Asn39 Val45 Asp101 
Arg102 Tyr112 
T41A 
 
Phe44  
N42 Leu37* Asn39* Val46* N42A Asn39* Val45 Val46* 
Engineered G protein bound (5G53) 
N34 
 
Ala30 Asn36 Gln38 Thr298* N34A 
 
Ala30 Gln38  
L37 
 
Asn39* Asn42* L37A 
 
Asn34 Asn39* Asn42* 
Q38 
 
Val31* Trp32 Asn34 Ser35 Q38A 
 
Ser35 
T41 
 
None T41A 
 
Phe44 Val45 
N42 Leu37* Asn39*(x3) Val46* N42A Asn39*(x2) Val46* 
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Mutant models of the A2AR were made using Modeller and the resulting PDB 
structures compared with WT in PyMOL for any loss/gain of polar interactions. 
Alanine mutants (with a cAMP accumulation significantly different to WT (Table 
5.6)) were modelled for A) antagonist (ZM241385) bound A2AR solved by Liu et al., 
2012 at a resolution of 1.8 Å (PDB ID: 4EIY), B) agonist (NECA) bound A2AR 
solved by Lebon et al., 2011 at a resolution of 2.6 Å (PDB ID: 2YDV), C) agonist 
(CGS21680) bound A2AR solved by Lebon et al., 2015 at a resolution of 2.6 Å 
(PDB ID: 4UHR) and D) engineered Gs-protein bound at a resolution of 3.5 Å by 
Carpenter et al., 2016 (PDB ID: 5G53). 
Conserved interactions irrespective of agonist/antagonist/G protein bound are 
indicated by * 
Underlined residues (e.g. Val45) indicate gain of polar interaction.  
A residue with more than one polar interaction with another residue is indicated by 
(xn), where n gives the number of interactions.  
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5.3.5.  Summary 
 
In this work, the A2AR was chosen as a class A Gs-coupled receptor to 
investigate the importance of the ICL1 region in receptor signalling as was 
conducted for the class B GPCR, GCGR. The potency (pEC50), maximal 
response (Emax), basal, span, affinity (pKA) and coupling efficacy (logτ) values 
for the cAMP response to NECA or CGS 21680 stimulation showed no 
significant differences between that measured in WT A2AR and the A2AR 
mutants L33A, S35A, N36A, V40A. These data suggest that these amino 
acids are unlikely to play an important role in the A2AR mediated cAMP 
response to either agonist.  
Mutation of asparagine at position 34 of A2AR to alanine resulted in a 
significantly reduced potency and maximum response to both NECA and 
CGS 21680. This finding suggests that N34 is important in the activity of A2AR 
to both agonists which may or may not be dependent on cell-surface 
expression. Interestingly, N34 was found to interact with the conserved helix 8 
residue T2988.53 and E2948.49 within all four and three of the A2AR structures 
investigated, respectively (Table 5.4). These interactions were lost within the 
modelled N34A structures and may indicate the importance of ICL1 and helix 
8 interactions within A2AR for activation and/or signal transduction following 
ligand stimulation (NECA and CGS 21680). Interestingly, the equivalent 
positions for E2948.49 and T2988.53 within GCGR are E4068.49 and E4108.53, 
respectively, and were investigated further (Section 5.4.3).  
Alanine substitution of L37 in A2AR resulted in a reduced potency and 
maximum response to both NECA and CGS 21680 suggesting L37 is 
important in the A2AR mediated cAMP response. However, there was only 
found to be a significantly reduced potency and affinity of NECA. Given that 
L37 appears to play a more significant role in the NECA stimulated cAMP 
response when compared to the CGS 21680, this finding may indicate a role 
for L37 in signalling bias at the A2AR. 
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Given the basal cAMP level is independent of ligand stimulation, the 
finding that a number of A2AR mutants showed significantly reduced basal 
cAMP levels in NECA stimulated cells but not for CGS 21680 suggests some 
variation that is independent of receptor mutation and ligand stimulation. With 
the exception of the measured elevated basal cAMP level in T41A, it appears 
that any significant differences in basal response may be due to experimental 
variable rather than a true biological effect. 
Mutation of threonine at position 41 within the TM2 region (T412.39) of 
A2AR to alanine resulted in agonist independent increase in basal activity 
within CHO-K1 cells. T41 was found to interact with D101 and R102 of the 
E/DRY motif and Y112 in the ICL2 in three A2AR structures (Xu et al., 2011, 
Dore et al., 2011 Lebon et al., 2015). These residues are implicated to be 
involved in the ionic lock of the A2AR and proposed to stabilise the inactive 
receptor conformation (Martínez-Archundia and Correa-Basurto, 2014). 
Interestingly, mutations within the E/DRY motif have been shown to induce 
constitutive activity for a number of GPCRs including the β2AR, rhodopsin 
receptor and oxytocin receptor (OTR) (Rovati et al., 2007). Similarly, it 
appears that mutation of T41 of the A2AR increases the level of constitutive 
activity at the A2AR, possibly due to the loss of hydrogen bonds with residues 
involved in the ionic lock. 
N42A showed reduced maximum response to both NECA and CGS 
21680, although this was only significantly reduced for NECA. When 
comparing the cAMP responses between NECA and CGS 21680 in the Q38A 
and N39A A2AR mutants, there were some clear differences. Whereas Q38A 
showed a significantly reduced maximum response to NECA when compared 
to WT, there was no such reduced maximal response to CGS 21680. On the 
other hand, whereas N39A showed a reduced CGS 21680 maximal response 
and efficacy, there was no such reduction following NECA stimulation. These 
findings may indicate the importance of ICL1 residues in signalling bias at the 
A2AR and warrants further investigation.   
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 The findings presented here suggest the ICL1 region of A2AR plays a 
bigger role in the cAMP response when compared to the ICL1 region of the 
GCGR, where there was significantly reduced signalling for only one mutant 
(G165A). In order to further expand on these findings, analysis of the cell-
surface expression of each A2AR mutant needs to be conducted. This will give 
an indication as to whether the reduced signalling of some mutants could be 
explained by changes in receptor cell-surface expression. In addition, it may 
be interesting to investigate the effect of these mutants on the pERK1/2 
response given that A2AR has been reported to activate ERK1/2 signalling 
(Schulte and Fredholm, 2000, Orr et al., 2015). 
 
5.4.  An investigation into conserved GPCR residues within GCGR 
 
5.4.1.  An investigation into the ‘[K/R]KLH’ motif in GCGR 
 
The [K/R]KLH motif occurs in the ICL1 of both class A and B GPCR families 
(Vohra et al., 2013). Within the class B GPCR family, the consensus 
sequence is R12.48[+]LH with 9 of the 15 members having the sequence RRLH 
or RKLH (Figure 5.1). Rather than K/R, GCGR has a serine at this position 
(S16712.48) giving the sequence SKLH (Figure 5.15). In a model of the CLR in 
complex with G protein, K16712.48 within the sequence K16712.48SLS was 
suggested to interact with the Gβ and possibly with the helix 8 residue (E8.49) 
(Vohra et al., 2013). However, within the cryo-EM structures of GLP-1R and 
CTR in complex with heterotrimeric Gs (Liang et al., 2017 and Zhang et al., 
2017b, respectively), R12.48 was shown not to interact with Gβ or helix 8 
residue (E8.49).  
We previously investigated the cAMP accumulation in HEK 293 cells 
transfected with a number of alanine substitution mutations within ICL1 of 
GCGR including S167A and K168A, which showed no significant effects on 
cAMP accumulation (Figure 5.4). Here, we investigate the consequences of 
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converting the serine to a positive charged arginine, effectively making the 
ICL1 sequence within GCGR closer to the consensus ‘[K/R]KLH’ motif and 
possibly creating an interaction between S167R12.48 and a glutamate residue 
within helix 8 such as E4068.49 or E4108.53. Molecular modelling of the 
S167R12.48 mutant within the full-length structure of GCGR suggests the gain 
of a polar interaction with E4108.53 rather than E4068.49 (Figure 5.16). S16712.48 
was shown to interact with E4108.53 in the NNC0640 bound GCGR structure 
(Siu et al., 2013) but not the full-length structure (Zhang et al., 2017) (Table 
3.3.3), possibly indicating differing interactions between the inactive 
conformational state. 
Using FACS analysis, similar levels of cell-surface expression were 
found for WT and S167R (100.9 ±6.3 percentage WT response) (Figure 
5.17). The effect of this mutation on the GCG and oxyntomodulin stimulated 
cAMP response was investigated. The responses between WT and S167R 
appeared similar for both GCG or oxyntomodulin stimulation (Figure 5.18 and 
Table 5.9) suggesting this this residue is not critical for cAMP response.  
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Figure 5.18. cAMP response in WT and S167R GCGR mutants. HEK 293 
cells transiently expressing pmCherry-N1 vector containing WT or S167R 
GCGR (24 hours post transfection) were exposed to A) GCG or B) 
oxyntomodulin for 8 minutes and cAMP accumulation detected. All values are 
mean ± SEM expressed as percentage forskolin response (mock transfected 
with vector only) where n ≥ 5 independent experimental repeats, conducted in 
duplicate. Arrow indicated change between WT and mutant response. 
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Figure 5.17. WT and S167R GCGR show similar cell-surface expression in 
HEK 293 cells as determined by FACS analysis. FACS analysis was 
conducted 48 hours post transfection of HEK 293 with WT or mutant GCGR 
containing pmCherry-N1. Anti-GCGR primary antibody at a 1:50 dilution, APC-
conjugated IgG secondary antibody at a 1:150 dilution. Normalised to vector 
transfected (0%) and WT (100%), n = 3 independent experimental repeats. 
Statistical significance compared to WT was determined by unpaired Student’s 
t-test (two-tailed). 
 
 283 
	
Ta
bl
e 
5.
9.
  c
A
M
P 
re
sp
on
se
 in
 W
T 
an
d 
S1
67
R
 G
C
G
R
 m
ut
an
ts
. P
ot
en
cy
 (p
EC
50
), 
m
ax
im
al
 re
sp
on
se
 (E
m
ax
), 
ba
sa
l, 
sp
an
, 
af
fin
ity
 (
pK
A
) 
an
d 
co
up
lin
g 
ef
fic
ac
y 
(lo
gτ
) 
va
lu
es
 f
or
 c
A
M
P
 r
es
po
ns
e 
to
 G
C
G
/o
xy
nt
om
od
ul
in
 
st
im
ul
at
io
n 
in
 W
T/
m
ut
an
t G
C
G
R
 tr
an
sf
ec
te
d 
H
E
K
 2
93
 c
el
ls
 
G
C
G
 
C
on
st
ru
ct
 
pE
C
50
 a
 
E m
ax
 b
 
B
as
al
 c 
Sp
an
 d 
pK
A
 e
 
lo
g 
τ 
f  
W
T 
9.
09
 ±
0.
1 
81
.5
 ±
1.
5 
7.
6 
±1
.1
 
74
.0
 ±
1.
8 
8.
38
 ±
0.
1 
0.
60
 ±
0.
04
 
S
16
7R
 
9.
26
 ±
0.
1 
83
.1
 ±
2.
8 
7.
0 
±2
.5
 
76
.1
 ±
3.
6 
8.
52
 ±
0.
2 
0.
65
 ±
0.
09
 
O
xy
nt
om
od
ul
in
 
C
on
st
ru
ct
 
pE
C
50
 a
 
E m
ax
 b
 
B
as
al
 c  
Sp
an
 d  
pK
A
 e
 
lo
g 
τ 
f  
W
T 
7.
27
 ±
0.
1 
81
.5
 ±
2.
2 
0.
9 
±1
.0
 
80
.7
 ±
2.
3 
6.
54
 ±
0.
1 
0.
64
 ±
0.
06
 
S
16
7R
 
7.
59
 ±
0.
1 
84
.7
 ±
2.
1 
4.
1 
±1
.1
 
80
.6
 ±
2.
3 
6.
79
 ±
0.
1 
0.
72
 ±
0.
07
 
 W
T 
or
 
m
ut
an
t 
G
C
G
R
 
w
er
e 
tra
ns
ie
nt
ly
 
ex
pr
es
se
d 
in
 
H
E
K
 
29
3 
ce
lls
 
an
d 
st
im
ul
at
ed
 
w
ith
 
G
C
G
 
or
 
ox
yn
to
m
od
ul
in
 p
rio
r 
to
 m
ea
su
re
m
en
t o
f c
A
M
P
 a
cc
um
ul
at
io
n 
to
 g
en
er
at
e 
co
nc
en
tra
tio
n 
re
sp
on
se
 c
ur
ve
s 
fo
r 
ea
ch
 c
on
st
ru
ct
. 
To
 c
al
cu
la
te
 p
E
C
50
, 
E
m
ax
, 
B
as
al
 a
nd
 S
pa
n 
va
lu
es
, 
da
ta
 w
er
e 
an
al
ys
ed
 u
si
ng
 a
 t
hr
ee
-
pa
ra
m
et
er
 lo
gi
st
ic
 e
qu
at
io
n.
 D
at
a 
w
as
 a
ls
o 
an
al
ys
ed
 b
y 
an
 o
pe
ra
tio
na
l m
od
el
 o
f a
go
ni
sm
  
(B
la
ck
 a
nd
 L
ef
f, 
19
83
) t
o 
de
te
rm
in
e 
af
fin
ity
 (p
K
A
) a
nd
 c
ou
pl
in
g 
ef
fic
ac
y 
(lo
g 
τ)
. 
a  N
eg
at
iv
e 
lo
ga
rit
hm
 o
f G
C
G
 c
on
ce
nt
ra
tio
n 
re
qu
ire
d 
to
 p
ro
du
ce
 a
 h
al
f-m
ax
im
al
 re
sp
on
se
 
b 
M
ax
im
al
 re
sp
on
se
 to
 G
C
G
 a
s 
pe
rc
en
ta
ge
 fo
rs
ko
lin
 re
sp
on
se
 (M
oc
k 
tra
ns
fe
ct
ed
 w
ith
 v
ec
to
r) 
c 
Th
e 
lo
w
 p
la
te
au
 o
f t
he
 fi
tte
d 
si
gm
oi
da
l d
os
e-
re
sp
on
se
 c
ur
ve
 
d 
Th
e 
di
ffe
re
nc
e 
be
tw
ee
n 
E m
ax
 a
nd
 b
as
al
 s
ig
na
llin
g 
e 
Th
e 
ne
ga
tiv
e 
lo
ga
rit
hm
 o
f f
un
ct
io
na
l a
ffi
ni
tie
s 
th
at
 d
es
cr
ib
es
 th
e 
af
fin
ity
 o
f t
he
 r
ec
ep
to
r 
w
he
n 
co
up
le
d 
to
 a
 
gi
ve
n 
si
gn
al
lin
g 
pa
th
w
ay
 g
en
er
at
ed
 th
ou
gh
 u
se
 o
f t
he
 o
pe
ra
tio
na
l m
od
el
 fo
r p
ar
tia
l a
go
ni
sm
 
f τ
 is
 th
e 
co
up
lin
g 
ef
fic
ie
nc
y 
pa
ra
m
et
er
 g
en
er
at
ed
 th
ou
gh
 u
se
 o
f t
he
 o
pe
ra
tio
na
l m
od
el
 fo
r p
ar
tia
l a
go
ni
sm
 
A
ll 
va
lu
es
 a
re
 m
ea
n 
± 
S
E
M
 e
xp
re
ss
ed
 a
s 
pe
rc
en
ta
ge
 f
or
sk
ol
in
 r
es
po
ns
e 
(M
oc
k 
tra
ns
fe
ct
ed
 w
ith
 v
ec
to
r) 
w
he
re
 n
 ≥
 5
 in
de
pe
nd
en
t e
xp
er
im
en
ta
l r
ep
ea
ts
, c
on
du
ct
ed
 in
 d
up
lic
at
e.
 
S
ta
tis
tic
al
 s
ig
ni
fic
an
ce
 (
*,
 p
<0
.0
5;
**
, 
p<
0.
01
;*
**
, 
p<
0.
00
1)
 c
om
pa
re
d 
to
 W
T 
G
C
G
R
 w
as
 d
et
er
m
in
ed
 b
y 
un
pa
ire
d 
S
tu
de
nt
’s
 t-
te
st
 (t
w
o-
ta
ile
d)
 
 
 284 
5.4.2.  An investigation into the importance of R173 in GCGR signalling 
5.4.2.1.  Cell-surface expression of R173A and R173A N174A mutants 
similar to WT GCGR 
 
We previously investigated the importance of 8 residues within the ICL1 
region of GCGR (residues G165-T172) and 10 residues of the class A A2AR 
ICL1 region (L33-N42) (see Figure 5.8 for alignment) through alanine 
substitution and cAMP accumulation assays. Although there was little effect 
on the measured cAMP response in the GCGR alanine substitution mutants 
following GCG stimulation, there were a number of inposteresting findings for 
the A2AR mutants including an enhanced constitutive activity for T41A. The 
equivalent position for T412.39 within GCGR is 2.46 and contains the highly 
conserved positively charged residue at the bottom of TM2, R1732.46.  
Here, we expanded on the initial investigation by investigating the 
importance of R1732.46 for cell-surface expression and signalling of GCGR. 
We also created an alanine substitution mutation at position N1742.47 as a 
‘safeguard’, to eliminate the polar amino acid that may contribute or substitute 
the interactions of R173A mutant. Having created this single and double 
alanine substitutions within GCGR, we first wanted to investigate the cell-
surface expression of these mutants using FACS analysis. There was found 
to be no significant difference in cell-surface expression of R173A or R173A 
N174A when compared to WT GCGR (Figure 5.19).  
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5.4.2.2.  R173A2.46 mutant shows severe reduction of GCG and 
oxyntomodulin-mediated cAMP accumulation 
 
Multiple studies have highlighted the importance of the conserved GCGR 
R1732.46 equivalent for G protein-coupling in a number of class B GPCRs 
including CGRP receptor (Conner et al., 2006) GIPR (Cordomí et al., 2015) 
and GLP-1R (Mathi et al., 1997). Having shown equivalent cell-surface 
expression of WT, single (R173A), and double (R173A N174A) TM2 mutant 
GCGR, we investigated the importance of the conserved R1732.46 residue for 
the GCGR-mediated cAMP accumulation. 
HEK 293 cells transfected with pmCherry-N1 expressing WT or mutant 
GCGR were stimulated with GCG or oxyntomodulin prior to measurement of 
cAMP accumulation. The potency of GCG was severely attenuated (~100-
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Figure 5.19. Cell-surface expression of WT, R173A and R173A N174A 
GCGR are similar in transfected HEK 293 cells, as determined by FACS 
analysis. FACS analysis was conducted 48 hours post transfection of HEK 
293 with WT or mutant GCGR containing pmCherry-N1. Anti-GCGR primary 
antibody at a 1:50 dilution, APC-conjugated IgG secondary antibody at a 1:150 
dilution. Normalised to vector transfected (0%) and WT (100%), n = 3 
independent experimental repeats. Statistical significance compared to WT 
was determined by one-way ANOVA with Dunnett’s post test. 
 
 286 
fold) in HEK 293 cells transfected with R173A when compared to WT (pEC50 
7.14 ±0.1 and 9.09 ±0.1, respectively) (Figure 5.20 A and Table 5.10), 
whereas the maximum response was unaffected. The reduced potency may 
reflect a reduced affinity to GCG, as indicated by fitting the operational model 
of agonism.  
The cAMP accumulation following oxyntomodulin stimulation was also 
attenuated. However, a full dose-response curve was not determined given 
the insufficient data points (Figure 5.20 B and Table 5.10) and a maximum 
response (50.3 ±8.3 percentage forskolin response) and a pEC50 (6.23 ±0.2) 
were predicted from the fit. We may have seen an oxyntomodulin maximum 
response equivalent to that seen in WT if we had stimulated at higher 
concentrations. Importantly, the measured responses to GCG or 
oxyntomodulin at the single and double TM2 mutants were equivalent (Figure 
5.20 A/B and Table 5.10), suggesting R173 is the amino acid responsible for 
the attenuated cAMP accumulation. With this in mind, the single mutant 
N174A was not made and only the R173A mutant was investigated further.  
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A 
 
 
 
 
 
 
 
 
 
 
 
B 
Figure 5.20. GCG and oxyntomodulin induced cAMP response is 
attenuated in R173A transfected HEK 293. HEK 293 cells transiently 
expressing pmCherry-N1 vector containing WT, R173A or R173A N174A 
GCGR (24 hours post transfection) were exposed to A) GCG or B) 
oxyntomodulin for 8 minutes and cAMP accumulation detected. All values are 
mean ± SEM expressed as percentage forskolin response (mock transfected 
with vector only) where n ≥ 5 independent experimental repeats, conducted in 
duplicate. Arrow indicated significant change (Table 5.10) between WT and 
mutant response. 
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5.4.2.3.  Molecular modelling of R173A mutants in three GCGR 
structures 
 
Modeller (version 9.18) was used to mutate specific residues within two of the 
three available protein structures of inactive GCGR for which PDB files exist; 
5XEZ (Zhang et al., 2017) and 4L6R (Siu et al., 2013). The GCGR residue 
within the thermostabalised (StaR) MK-0893-bound GCGR receptor (5ee7 
(Jazayeri et al., 2016)), R173 was mutated to alanine and therefore this 
structure was not used. The resulting PDB files were viewed in MacPyMol 
(version 1.7.4.5) and the WT (original PDB file) and modelled mutated 
receptor compared visually to assess any predicted changes in amino acid 
interactions and structure. To aid in illustration of the lost polar interactions 
within R173A when compared to WT GCGR, images generated in MacPyMol 
for full length GCGR (Zhang et al., 2017) are shown (Figure 5.21). 
The overall structure when comparing the modelled mutant to WT 
showed no differences. Although the interactions made by R173 differ 
between the two inactive GCGR structures, consistently R173 interacts with 
E406 within helix 8 (Table 5.11). This consistency indicates the importance of 
the interaction, possibly through stabilisation of the inactive GCGR structure. 
In both modelled structures, mutation of R173 results in lost interaction with 
E406. Importantly, there were no gained or lost interactions for R173A within 
the modelled R173A N174A when compared to R173A (Table 5.11). This 
further supports the conclusion that R173 is the residue responsible for the 
attenuated cAMP response to both GCG and oxyntomodulin.  
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5.4.2.4.  Summary 
 
R2.46 is highly conserved across class B GPCRs and is implicated to form part 
of the class A E/DRY motif equivalent, maintaining the receptor in the ground 
state (Vohra et al., 2013). Within the CLR it was proposed that the class B 
E/DRY equivalent is formed by the glutamate in TM3 (E2333.50) interacting 
with R1732.46 and a histidine in TM2 (H1772.50) (Vohra et al., 2013). 
Interestingly, no such interactions were found within the active or inactive 
structures of GLP-1R (Zhang et al., 2017b and Song et al., 2017, 
respectively) suggesting this may not be the case for other class B GPCRs. 
Mutations of the glutamic acid/aspartic acid within the E/DRY motif frequently 
induce constitutive activity and indicated that these residues maintain the 
receptor in the ground state (Rovati et al., 2007). However, in some receptors 
mutation of these residues do not result in constitutive activity and the E/DRY 
motif is suggested to be directly involved in the receptor conformation and G 
protein-coupling (Rovati et al., 2007).  
The findings presented here suggests that R173, although not required 
for successful GCGR trafficking, is important for the GCGR-mediated cAMP 
response, as demonstrated by the attenuated response to both GCG and 
oxyntomodulin in HEK 293 transfected with R173A. This finding is similar to 
what was previously reported for the R176A2.46 GLP-1R mutant, which 
showed a reduction in cAMP accumulation whilst maintaining WT cell-surface 
expression levels (Mathi et al., 1997).  
Modelling of the R173A and R173A, N174A GCGR mutants within two 
of the three available protein structures of inactive GCGR (Zhang et al., 2017 
and Siu et al., 2013) revealed the potentially important interaction between 
R173 and the helix 8 residue E406, which was lost within R173A (Section 
5.4.2.2). It may be that this interaction is critical for GCGR stabilisation. 
Alternatively, or in addition to, R173 may be essential for G protein-coupling. 
This latter explanation seems highly plausible given that the residue at this 
position has been demonstrated to contact the G protein within a CGRP 
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receptor model (R1732.46) (Vohra et al., 2013) and in the structure of the class 
A GPCR β2-adrenergic receptor (AR)-Gs complex (Thr682.39) (Rasmussen et 
al., 2011, PDB 3SN6). To add further weight to this explanation, within the 
solved peptide-activated rabbit GLP-1R in complex with heterotrimeric Gs, it 
was suggested that the lost interactions for R1762.46 in TM2, N4068.47 and 
E4088.49 in helix 8 caused by the outwards movement of TM6 on activation 
may be stabilised through hydrogen bonds or electrostatic interactions with 
residues of the Gαs α5-helix (Zhang et al., 2017b). Indeed, visualisation of the 
GLP-1R cryo-EM structure showed interactions between R1762.46 with 
T1752.45, H1802.43 and Q390 of Gαs α5-helix (Zhang et al., 2017b). Modelling 
of R176A2.46 GLP-1R showed lost interactions with T1752.45 and Q390 of Gαs 
α5-helix. It may be that a similar interaction of R1732.46 and Gαs α5-helix 
within GCGR is a requirement for effective G protein activation, which is thus 
attenuated on mutation to alanine. 
Interestingly, the residue present in the equivalent position of the A2AR 
(T412.39) was shown to interact with D1013.49 and R1023.50 of the E/DRY motif 
and mutation to alanine resulted in constitutive activity. Given the absence of 
an elevated basal cAMP accumulation for R173A in GCGR, it appears this 
residue is involved in GCGR activation and/or G protein-coupling rather than 
maintaining the receptor in an inactive conformation.  
 
 
5.4.3.  Investigating the importance of two conserved residues within 
helix 8 of GCGR; E406 and E410 
5.4.3.1.  Cell-surface expression of E406A and E406A E410A show 
reduced cell-surface expression  
 
We previously showed the importance of R1732.46 within GCGR for the ligand 
stimulated cAMP accumulation (Section 5.4.2.2), which may have been a 
consequence of lost contact with G protein-coupling or recognition. Within the 
inactive structures of the GCGR, R1732.46 was demonstrated to form tight 
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interactions with E4068.49 (Siu et al., 2013 and Zhang et al., 2017). E4068.49 is 
fully conserved in all class B GPCRs and may play a role in GPGR activation 
(Kirkpatrick et al., 2012) (Figure 5.22). Modelling of R173A in both structures 
demonstrated the lost interaction with E4068.49, which may result in a GCGR 
confirmation unfavorable to receptor activation or G protein-coupling. In order 
to investigate the importance of this interaction, we create a single alanine 
substitution mutation at position E4068.49. We also created an alanine 
substitution mutation at position E4108.53 as a ‘safeguard’, to eliminate the 
negative charge that may contribute or substitute the negative 
charge/interaction eliminated in the E406A mutant.  
Having created this single and double alanine substitutions within 
GCGR, we first investigated the cell-surface expression of these mutants 
using FACS analysis (Figure 5.23). There was found to be a significantly 
reduced cell-surface expression for E406A and E406A E410A (53.8 ±5.8 and 
21.5 ±1.3 percentage WT cell-surface expression, respectively), whereas 
there was no significant reduction in the cell-surface expression of E410A 
(91.4 ±9.1 percentage WT cell-surface expression). This suggesting that 
E406 is more crucial than E410 for the successful cell-surface expression of 
GCGR. Interestingly, when comparing the cell-surface expression of E406A 
and E406A E410A, the latter showed a significantly reduced expression. 
Although E410A alone has little effect on the measured GCGR cell-surface 
expression, mutation of both glutamate residues to alanine appears to impair 
the cell-surface expression of GCGR, possibly through premature 
degradation.  
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Figure 5.23. Cell-surface expression of WT and Helix 8 GCGR mutants, as 
determined by FACS analysis. FACS analysis was conducted 48 hours post 
transfection of HEK 293 with WT or mutant GCGR containing pmCherry-N1. Anti-
GCGR primary antibody at a 1:50 dilution, APC-conjugated IgG secondary antibody at 
a 1:150 dilution. Normalised to vector transfected (0%) and WT (100%), n = 3 
independent experimental repeats. Statistical significance (*, p< 0.1;**, p<0.01;***, 
p<0.001) compared to WT was determined by one-way ANOVA with Dunnett’s post 
test. 
 
Figure 5.22. GCGR family structure-based alignment of helix 8. A) GPCRdb.org 
structure-based alignment of helix 8 within the GCGR family receptors; GHRH 
receptor, GIPR, GLP-1R, GLP-2R, GCGR and the secretin receptor. B) The residue 
position within helix 8 of GCGR are given in both absolute and Class B (Wootten et 
al., 2013) numbers. Here, the two conserved glutamate residues targeted for alanine 
substitution are shown. Amino acid residues are given as the single amino acid code 
and colours illustrate residue physico-chemical properties (Table 5.1). 
A 
B 
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5.4.3.2.  Elevated basal cAMP accumulation in E406A and E406A E410A 
GCGR mutants  
 
Having shown a reduced cell-surface expression of E406A and E406A 
E410A, we investigate the consequence of these mutants on the ligand 
stimulated cAMP accumulation.  HEK 293 cells transfected with pmCherry-N1 
expressing WT or mutant GCGR were stimulated with GCG or oxyntomodulin 
prior to measurement of cAMP accumulation.  
           Consistent with previous findings in rat GCGR (Strudwick et al., 2004), 
mutation of E406 resulted enhanced basal activity to both GCG and 
oxyntomodulin stimulation when compared to WT (Figure 5.24 1A/1B and 
Table 5.12). The cAMP response in E410A showed subtle differences when 
compared to WT and with the exception of a small elevation in basal, showed 
no significant differences between any of the measured parameters (Figure 
5.24 2A/2B and Table 5.12). There was also found to be enhanced potency 
and basal cAMP response for the double helix 8 mutant (E406A E410A), but 
again only reached statistical significance for the enhanced constitutive 
activity (Figure 5.25 and Table 5.12).  
These findings suggest that E406 when mutated alone appears to 
result in a level of constitutive activity, which is enhanced further by the 
additional substitution of E410 to alanine. This finding may be interpreted as 
an ability of E410 within E406A to substitute or contribute to the lost 
interaction with R1732.46 or other amino acids, effectively maintaining the 
receptor in a relatively inactive state when compared to the double mutant. As 
we mutate both residues, this interaction may be completely lost resulting in 
enhanced constitutive activity.  In line with this, the double helix 8 mutant also 
showed a significantly elevated maximum response and efficacy for GCG, 
suggesting an enhanced ability for G protein-coupling.  
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Figure 5.24. cAMP response in WT and helix 8 GCGR mutant. HEK 293 
cells transiently expressing pmCherry-N1 vector containing 1) WT or E406A, 
2) WT or E410A GCGR (24 hours post transfection) were exposed to A) GCG 
or B) oxyntomodulin for 8 minutes and cAMP accumulation detected. All 
values are mean ± SEM expressed as percentage forskolin response (mock 
transfected with vector only) where n ≥ 5 independent experimental repeats, 
conducted in duplicate. Arrow indicates small shift in pEC50 for E406A mutant  
 
 
1A 
 
 
 
 
 
 
 
 
 
 
1B 
2A 
 
 
 
 
 
 
 
 
 
 
2B 
 
GCG 
 
 
 
 
 
 
 
 
 
 
Oxyntomodulin 
 
 
 
 
 
 
GCG 
 
 
 
 
 
 
 
 
 
 
Oxyntomodulin 
 
 
 
 
 
 298 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-12 -11 -10 -9 -8 -7 -6
-20
0
20
40
60
80
100
Log[GCG]M
cA
M
P 
Re
sp
on
se
 
(%
 F
or
sk
ol
in
)
-12 -11 -10 -9 -8 -7 -6
-20
0
20
40
60
80
100
Log[Oxyntomodulin]M
cA
M
P 
Re
sp
on
se
 
(%
 F
or
sk
ol
in
)
WT E406A, E410A
Figure 5.25. E406A E410A GCGR mutant showed a ligand-independent 
elevated basal cAMP level. HEK 293 cells transiently expressing pmCherry-
N1 vector containing WT or E406A E410A GCGR (24 hours post transfection) 
were exposed to A) GCG or B) oxyntomodulin for 8 minutes and cAMP 
accumulation detected. All values are mean ± SEM expressed as percentage 
forskolin response (mock transfected with vector only) where n ≥ 5 
independent experimental repeats, conducted in duplicate. Arrow indicate 
significant shift in pEC50 and basal cAMP accumulation (Table 5.12) for E406A 
E410A mutant when compared to WT. 
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5.4.3.3.  Molecular modelling of E406 and E410 mutants in three GCGR 
structures 
 
Modeller (version 9.18) was used to mutate E406 and E410 to alanine within 
the three available protein structures of inactive GCGR for which PDB files 
exist; 5XEZ (Zhang et al., 2017), 4L6R (Siu et al., 2013) and 5EE7 (Jazayeri 
et al., 2016). The resulting PDB files were viewed in MacPyMol (version 
1.7.4.5) and the WT and mutated receptor compared visually to assess any 
predicted changes in amino acid interactions and structure (Table 5.13). To 
aid in illustration of the lost polar interactions within the modelled E406A and 
E410A mutants when compared to WT GCGR, images generated in 
MacPyMol for full length GCGR (Zhang et al., 2017) are shown (Figure 5.14). 
There are differing interactions for E406 and E410 within the three WT 
GCGR structures. Notably however, E406 interacts with E410 in all three 
structures and R173 in both structures containing R173 (one structure lacks 
residue R173 (Jazayeri et al., 2016)).  In the modelled structures of E406A, 
whereas the interaction to E410 was maintained in all structures and did not 
depend on the presence of glutamate, the R173 interaction was lost 
(illustrated in Figure 5.14 C). This lost interaction with R173 may offer an 
explanation for the elevated basal cAMP response determined in E406A and 
E406A E410A (Table 5.12). It could be speculated that R173, now released 
from helix 8, is free to interact with the G protein in the absence of ligand 
leading to this small elevated cAMP levels. 
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5.4.3.4.  Summary  
 
Molecular modelling of the GLP-1R revealed an extensive hydrogen bond 
network in the ground state that is disrupted in the active state involving 
R1762.46, R3486.37 and helix 8 N4068.47 and E4088.49 (TM2-6-7-helix 8 network) 
(Wootten et al., 2016), which was also evident in the GCGR structure (Siu et 
al., .2013). More recently, the solved peptide-activated rabbit GLP-1R in 
complex with heterotrimeric Gs (Zhang et al., 2017) revealed receptor 
activation and outward movement of TM6 breaks these polar interactions 
within the TM2-6-7-helix 8 network and the HETX motif resulting in loss of the 
inactive state (Zhang et al., 2017). 
Mutation of R1762.46 and E4088.49 within GLP-1R were shown to reduce 
cell-surface expression to a similar extent (57-66% WT) and was suggested 
to support the role of these residues in a combined network (Wootten et al., 
2016). The results from analysis of GCGR cell-surface expression reported 
here are distinct from this finding and showed a significantly reduced 
expression for E406A8.49 but not R173A2.46 GCGR. The cell-surface 
expression of the double helix 8 mutant (E406A, E410A) was reduced to 
levels below that of the single helix 8 mutant (E406A), possibly as a result of 
significant conformational change and premature degradation.  
In addition to reducing cell-surface expression of GLP-1R, mutation of 
E4088.49 within GLP-1R was shown to reduce cAMP signalling for a number of 
peptides including GLP-1(7-36)amide suggesting the residue selectively 
couples the GLP-1R to cAMP signalling (Wootten et al., 2016). Here, despite 
the reduced cell-surface expression of E406A GCGR, there was a 
significantly elevated basal, indicating constitutive activity in E406A which 
was enhanced further by the additional substitution of E410 to alanine. This is 
consistent with previous reports in rat GCGR reporting E406A as having 
enhanced constitutive activity (Strudwick et al., 2004). These data suggest 
that E406, may be involved in maintaining the receptor in an inactive 
conformation. There was shown to be a lost interacting between E406A and 
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R173 within the modelled E406A GCGR structures (Table 5.13) and may 
result in a lost inactive state or the ability of R173 to interact with the G 
protein more freely in the absence of ligand, thereby providing an explanation 
for elevated basal cAMP level. 
Similarly, within the modelled R173A, the interaction with E406 was 
lost (Table 5.11). The finding of an attenuated cAMP response in R173A may 
suggests that the interaction with E406 is critical for GCGR ligand stimulated 
cAMP response. However, given that the E406A mutant showed little 
difference in cAMP response when compared to that of the WT, apart from an 
elevated basal cAMP level, it is more likely a reduced coupling to the G 
protein is a more plausible explanation for the attenuated cAMP response in 
R173A. Interestingly, within the solved peptide-activated rabbit GLP-1R in 
complex with heterotrimeric Gs, it was suggested that the lost interactions for 
R1762.46 in TM2, N4068.47 and E4088.39 in helix 8 caused by the outwards 
movement of TM6 on activation may be stabilised through hydrogen bonds or 
electrostatic interactions with residues of the Gs α5-helix (Zhang et al., 2017). 
Indeed, visualisation of the activated rabbit GLP-1R reveals helix 8 residue 
E4088.49 to interact with Q390 of Gαs α5-helix and two residues with the GLP-
1R itself (N4068.47 and E4128.53) with no apparent interaction with R1762.46 
(Zhang et al., 2017b). Interestingly, modelling of E408A8.49 within the GLP-1R 
structure reveals a lost interaction with Q390 of Gαs α5-helix and N4068.47 
whilst the interaction with E4128.53 was maintaining.  
The findings presented here for GCGR and those previously reported 
for GLP-1R (Wootten et al., 2016) suggest that E8.39 within helix 8 may play 
distinctly different roles between receptors within the class B GPCRs either 
through inactive state stabilisation (as seen for GCGR) or selectively coupling 
to cAMP signalling (as reported for GLP-1R (Wootten et al., 2016)). 
Nevertheless, this residue may play a similar role in both receptors but the 
mechanism is more complex than can be dissected here.  
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5.5.  Investigating pharmacological role of GCGR TM4  
 
5.5.1.  Cell-surface expression of GCGR TM4 mutants 
 
Harikumar et al., 2012 demonstrated that mutations of the hydrophopic face 
of TM4 (L256A4.55, V259A4.58 or G252A4.49, L256A4.55, V259A4.58) had 
selective effect on GLP-1R signalling, suggested to be as a result of the 
disturbed homodimerisation interface. In this work, using secondary 
messenger signalling assays, we investigated similar mutants in GCGR 
(L277A4.55, V280A4.58 or G271A4.49, L277A4.55, V280A4.58) (Figure 5.27).  
We first sought to investigate the cell-surface expression of the L277A, 
V280A (double) and G271A, L277A, V280A (triple) GCGR mutant. Here, HEK 
293T cells were transiently transfected with pmCherry-N1 expressing WT or 
mutant GCGR and cell-surface expression determined using FACS analysis. 
Confocal fluorescence microscopy images of HEK 293T cells expressing the 
mCherry-tagged WT GCGR showed localisation on the membrane surface 
(Figure 5.28 A). The localisation of mCherry-tagged double and triple mutant 
on the cell-surface appeared to be reduced in comparison to WT. This finding 
was confirmed by FACS analysis where the cell-surface expression of the 
double and triple mutant was significantly reduced (27.5 ±6.5 and 6.1 ±6.3 
percentage WT cell-surface expressing, respectively) (Figure 5.27 B).  
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A 
B 
Figure 5.27. GCGR family structure-based alignment of TM4 region. A) 
GPCRdb.org structure-based alignment of TM4 within the GCGR family 
receptors; GHRH receptor, GIPR, GLP-1R, GLP-2R, GCGR and the secretin 
receptor. B) The residue position within TM4 of GCGR are given in both 
absolute and Class B (Wootten et al., 2013) numbers. . Here, only the specific 
targeted region for alanine substitution mutation within the TM4 of GCGR are 
shown. Amino acid residues are given as the single amino acid code and 
colours illustrate residue physico-chemical properties (Table 5.1). 
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Figure 5.28. Cell-surface expression of WT and GCGR TM4 mutants. HEK 
293 cells were transfected with WT or mutant GCGR containing pmCherry-N1 
and cell surface expression determined by A) confocal fluorescence 
microscope (24 hours post transfection) and B) FACS analysis (48 hours post 
transfection); Anti-GCGR primary antibody at a 1:50 dilution, APC-conjugated 
IgG secondary antibody at a 1:150 dilution. Normalised to vector transfected 
(0%) and WT GCGR (100%), n = 3 independent experimental repeats. Yellow 
arrow indicates cell-surface localised receptor whereas white arrow indicate 
possible vesicles containing the receptor.  
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5.5.2.  cAMP response in GCGR TM4 mutants transfected HEK 293T 
cells 
 
Having shown reduced cell-surface expression of the L277A, V280A (double) 
and G271A, L277A, V280A (triple) GCGR mutants, we next sought to 
investigate the pharmacological consequence of these mutations on the 
cAMP response. Here, HEK 293T cells transiently transfected with pmCherry-
N1 expressing WT or the mutant GCGR were stimulated with GCG or 
oxyntomodulin and the cAMP accumulation detected.  
The potency and affinity of GCG was significantly reduced in HEK 
293T cells transfected with pmCherry-N1 expressing the TM4 triple mutant 
(pEC50 8.2 ±0.1 and pKA 7.58 ±0.1) but not the double mutant (pEC50 8.8 ±0.1 
and pKA 8.26 ±0.1) when compared to WT GCGR (pEC50 8.7 ±0.1 and pKA 
8.29 ±0.1) (Figure 5.29 and Table 5.14). Similarly, the potency and affinity of 
oxyntomodulin was significantly reduced for the triple mutant (pEC50 6.54 ±0.1 
and pKA 5.74 ±0.3) but not the double mutant (pEC50 6.99 ±0.1 and pKA 6.09 
±0.2) when compared to WT (pEC50 6.97 ±0.1 and pKA 6.48 ±0.1). These 
findings are in line with those previously reported for the similar TM4 GLP-1R 
mutants demonstrating attenuation (<10-fold) in potency for cAMP 
accumulation (Harikumar et al., 2012).  Given the only difference between the 
double and triple mutant is the G271A mutation, these data suggest that 
mutation of G271 is responsible for the reduced potency and affinity to both 
GCG and oxyntomodulin stimulation.  
The maximal response to GCG and oxyntomodulin for both mutants 
was increase when compared to WT. This finding is unexpected given the 
significantly reduced cell-surface expression of the mutants and suggests that 
the cAMP accumulation assay is able to detect similar maximal levels 
following GCGR stimulation despite reduced receptor cell-surface expression, 
presumably because at this level there is more receptor than effectors in the 
system.  
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Figure 5.29. Effect of TM4 mutations on the GCGR stimulated cAMP 
response in HEK 293T cells. HEK 293T cells (1,000 cells/well) 
transiently expressing pmCherry-N1 vector containing WT or alanine 
containing GCGR TM4 mutants (24 hours post transfection) were exposed 
to A) GCG or B) oxyntomodulin for 8 minutes and cAMP accumulation 
detected. All values are mean ± SEM expressed as percentage forskolin 
response (mock transfected with vector only) where n ≥ 5 independent 
experimental repeats, conducted in duplicate.  
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5.5.3.  cAMP response in GCGR TM4 mutants transfected HEK 293 cells 
 
For the purpose of experimental replication and to assess reproducibility of 
the results presented earlier (Section 5.5.2) in an alternative cell line, these 
experiments investigating the ligand stimualted cAMP accumulation for TM4 
GCGR mutant were also performed in HEK 293 cell. Similarly to what was 
previously demonstrated in HEK 293T cells, HEK 293 cells transiently 
transfected with pmCherry-N1 expressing WT or the mutant GCGR were 
stimulated with GCG or oxyntomodulin and the cAMP accumulation detected. 
Again, the potency of GCG was significantly reduced in the triple 
mutant when compared to WT (pEC50 8.05 ±0.1 and 9.09 ±0.1), but there was 
also a significantly reduced potency for the double mutant (pEC50 8.67 ±0.1) 
(Figure 5.30 1A and Table 5.15). This was also found to be the case for 
oxyntomodulin where the potency was significantly reduced for the triple 
mutant when compared to WT (pEC50 6.63 ±0.1 and 7.27 ±0.1) but the 
weaker potency in the double mutant (pEC50 7.04 ±0.1) was not significant 
(Figure 5.30 1B and Table 5.15). This reduction in potency, although greater, 
is in line with those previously reported for the similar TM4 GLP-1R mutants 
demonstrating attenuation (<10-fold) in potency for cAMP accumulation 
(Harikumar et al., 2012).   
The similar potency measured between the WT and double mutant for 
both GCG and oxyntomodulin responses in transfected HEK 293T (Table 
5.14) suggested that G271 was the amino acid responsible for the reduced 
potency in the triple mutant. However, the data acquired in HEK 293 cells 
suggests L277 or V280 may also be important in the GCGR mediated cAMP 
response. In order to confirm which amino acid is responsible for the reduced 
potency in the double mutant, the single V280A mutant was made and the 
cAMP response detected following GCG or oxyntomodulin stimulation (Figure 
5.30 2A/2B and Table 5.15). The potency of both GCG and oxyntomodulin 
was not significantly different to WT indicating that this mutation alone cannot 
account for the reduced potency measured in HEK 293 cells. Of course, 
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without making single mutants for all the amino acids within the triple mutant, 
we cannot exclude the possibility that it is the combination of mutations rather 
than one single amino acid causing the reduction in potency.  
Figure 5.30. Effect of TM4 mutations on the GCGR stimulated cAMP 
response is reproducible the in HEK 293 cells. HEK 293 cells (1000 
cells/well) transiently expressing pmCherry-N1 vector containing WT or 
alanine containing GCGR TM4 mutants (24 hours post transfection) were 
exposed to A) GCG or B) oxyntomodulin for 8 min and cAMP 
accumulation detected. All values are mean ± SEM expressed as 
percentage forskolin response (100 µM) (mock transfected with vector 
only) where n ≥ 5 independent experimental repeats, conducted in 
duplicate.  
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5.5.4. pERK1/2 response in GCGR TM4 mutants transfected HEK 293T 
cells 
 
Having shown a 10-fold reduced potency in the GCG and oxyntomodulin 
stimulated cAMP response for the triple (G271A, L277A, V280A) GCGR 
mutant in HEK 293T cells, we next looked to investigate the effect of both the 
double (L277A, V280A) and triple mutants on the pERK1/2 response. Here, 
HEK 293 cells transiently transfected with pmCherry-N1 expressing WT or 
mutant GCGR were stimulated with GCG or oxyntomodulin and the pERK1/2 
response determined.  
There was found to be negligible differences in the GCG or 
oxyntomodulin stimulated pERK1/2 response between HEK 293T cells 
transfected with WT or mutant GCGR for most of the measured parameters 
(Figure 5.31 and Table 5.16). There was however a reduced maximum 
response to GCG for both TM4 mutants which only reached significance for 
the double mutant when compared to WT GCGR (Emax 14.2 ±2.6 and 30.3 
±2.8, respectively). This was associated with a reduced coupling efficacy, 
which was only significant for the double mutant when compared to WT 
GCGR (log τ -0.72 ±0.08 and -0.35 ±0.05, respectively). Interestingly, the 
maximum pERK1/2 responses following oxyntomodulin stimulation of HEK 
293T cells transfected with either TM4 mutant appeared identical to WT 
GCGR. This finding could suggest that TM4 mutants have a reduced ability to 
transduce the GCG signal to pERK1/2 when compared to oxyntomodulin.  
It should be noted that the measured pERK1/2 responses showed 
variability between repeats and resulted in large error for the measured 
parameters. In addition, when comparing these responses to those also 
measured in HEK 293T cells (which used a higher cell count) (Section 
4.4.2.1) there was a reduced potency and maximum response, suggesting 
some variability across experiments. In addition, we may be experiencing 
some experimental limitation where we are at the lower end of the assays 
dynamic range. Nevertheless, these data suggest that these TM4 amino 
 315 
acids, within this experimental set up, appear not to play a significant role in 
the GCGR mediated pERK1/2 response.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
0 -9 -8 -7 -6 -5 -4
-10
0
10
20
30
Log[GCG]M
pE
R
K
1/
2 
R
es
po
ns
e 
(%
PM
A
)
GCG WT
GCG Double (L277A, V280A)
GCG Triple (G271A, L277A, V280A)
0 -9 -8 -7 -6 -5 -4
-10
0
10
20
30
Log[Oxyntomodulin]M
pE
R
K
1/
2 
R
es
po
ns
e 
(%
PM
A
)
Oxyntomodulin WT
Oxyntomodulin (L277A, V280A)
Oxyntomodulin (G271A, L277A, V280A)
Figure 5.31. Effect of GCGR TM4 mutants on pERK1/2 response. HEK 
293T cells (20, 000 cells/well) transiently expressing pmCherry-N1 vector 
containing WT or alanine containing GCGR TM4 mutants (48 hours post 
transfection) were exposed to GCG or oxyntomodulin for 5 min and 
pERK1/2 detected. All values are mean ± SEM expressed as percentage 
PMA response (1 µM) where n ≥ 5 independent experimental repeats, 
conducted in duplicate.  
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5.5.5.  Intracellular Ca2+ response in GCGR TM4 mutants transfected 
HEK 293T cells 
 
Previous work demonstrated that mutations of the hydrophopic face of TM4 
GLP-1R resulted in complete abrogation of the Ca2+i mobilisation response to 
GLP-1(7-36)amide (Harikumar et al., 2012). Here, we investigate the effect of 
similar mutants within GCGR on the Ca2+i response. 
HEK 293 cells (transfected with mCherry-tagged WT or mutant GCGR 
post plating) were loaded with Fluo-8, AM dye, stimulated with increasing 
concentrations of GCG or oxyntomodulin and the Ca2+i measured using a 
FlexStation® Multi-Mode Microplate Reader. There was no significant 
difference in the potency of GCG stimulated Ca2+i response in HEK 293 cells 
transfected with WT GCGR or double mutant  (pEC50 5.92 ±0.2 and 5.96 
±0.3) whereas there was a significantly reduced maximum response (Emax 
112.5 ±12.2 and 66.3 ±11.4 percentage WT response) (Figure 5.32 A and 
Table 5.17). Notably, there was a complete abolition of the measured Ca2+i in 
the triple mutant. A Ca2+i response to oxyntomodulin was only measured at 
the highest concentration (10 µM) in HEK 293T cells transfected with WT or 
double mutant and a full dose-response curve could not be fitted due to 
insufficient data points (Figure 5.32 B and Table 5.17). Nevertheless, this 
response was absent in the triple mutant.  
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Figure 5.32. Effect of GCGR TM4 mutants on Ca2+i mobilisation in 
transfected HEK 293T cells. HEK 293T cells transiently expressing 
pmCherry-N1 vector containing WT GCGR or alanine containing mutants 
(48 hours post transfection) were exposed to GCG or oxyntomodulin and 
Ca2+i mobilisation detected. All values are mean ± SEM expressed as 
change in Ca2+i (% WT GCGR response) n ≥ 5 independent experimental 
repeats, conducted in duplicate.  
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5.5.6. Molecular modelling of TM4 mutants in three GCGR structures 
 
Modeller (version 9.18) was used to model the TM4 mutates within the three 
available protein structures of inactive GCGR for which PDB files exist; 5XEZ 
(Zhang et al., 2017), 4L6R (Siu et al., 2013) and 5EE7 (Jazayeri et al., 2016). 
The resulting PDB files were viewed in MacPyMol (version 1.7.4.5) and the 
WT and mutated receptor compared visually to assess any predicted changes 
in amino acid interactions and structure (Table 5.18). 
The triple mutant (G271A, L277A, V280A) and WT structures 
completely overlaid indicating the overall structure is unaltered by these 
GCGR mutations. There were found to be some variations in interactions 
between the TM4 residues within the three structures. Interestingly, the 
modelled mutant receptors largely showed similar interactions when 
compared to WT structure with only small changes noted (Table 5.18). With 
this is mind; images of the models are not shown, as they would not be an 
informative visual aid.  
Within the full length GCGR (5XEZ), G271A showed a lost interaction 
with L268 and V280A showed a gained interaction with A283. Within the 
NNC0640 bound GCGR structure (4L6R), with the exception of G271A, which 
again showed a lost interaction with L268, there was found to be no lost or 
gained interactions for any of the other residues. Finally, MK-0893 bound 
GCGR showed no interaction changes within the modelled mutants when 
compared to the WT structure. The lost interaction between G271A and L268 
may provide an explanation for the reduced potency of the cAMP response 
and the abolished Ca2+i response in the triple GCGR mutant. However, given 
that there was shown to be small changes in the interactions within the 
modelled mutants for all three GCGR structures, it may be speculated that the 
triple mutant has altered interactions outside of the receptor itself, such as a 
reduced ability to form a dimeric interface with another GCGR.  
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5.5.7.  Summary  
 
Harikumar et al., 2012, demonstrated that mutations of the hydrophopic face 
of TM4 (L256A4.55, V259A4.58 or G252A4.49, L256A4.55, V259A4.58) within GLP-
1R resulted in <10-fold decrease in potency in the cAMP and pERK1/2 
response but a complete loss of Ca2+i response to GLP-1(7-36)amide 
stimulation. It was suggested that this TM4 region forms the primary 
dimerisation interface for GLP-1R, and mutation of these residues effectively 
disturbed the interface (Harikumar et al., 2012). Here, we report findings that 
three similar substitutions (G271A4.49, L277A4.55, V280A4.58) within the TM4 
region of GCGR showed complete abolishment of the Ca2+i response 
whereas there was only a small effect on cAMP accumulation and no 
measurable effect on the pERK1/2 response.  
The reduced potency of the cAMP response and the abolished Ca2+i 
response in the triple GCGR mutant could be explained by the reduced cell-
surface expression. Achieving similar levels of cell-surface expression to WT 
GCGR could allow the investigation into how the mutation influences 
secondary messengers levels independent of surface expression. However, 
previously tests looking at bringing the level of WT GCGR expression down to 
similar levels of the mutant GCGR through reducing DNA concentration at 
transfection was unsuccessful (Section 3.10.2). Here, DNA concentration was 
shown not to be proportional to the cell-surface expression.   
The findings presented here suggest that these TM4 amino acids, 
particularly G271, appear to be important for the Ca2+i response whereas they 
are less crucial for the cAMP and pERK1/2 response. However, it should be 
noted that these findings could reflect the sensitivity of the assays. For 
example, in the case of the cAMP response, we may have more receptor than 
effectors in the transfected HEK 293T system resulting in only a small 
reduction in potency and no effect on maximal response for the triple mutant 
when compared to WT GCGR. It could be speculated that, similar to what 
was reported for the GLP-1R, these amino acids within TM4 may be 
 324 
important in forming a dimeric interface. However, in order to test this 
hypothesis further experiments investigating dimerisation between WT GCGR 
and the TM4 mutant GCGR would need to be conducted.  
Interestingly, despite the complete abolishment of the GCG stimulated 
Ca2+i mobilisation in HEK 293T cells transfected with the triple mutant, there 
was a pERK1/2 response detected for this mutant (Figure 5.31). Through the 
used of a Gq/11 specific inhibition (YM-254890), it was previously shown that 
the GCG stimulated Ca2+i mobolisation was Gq/11-mediated (Section 4.3) and 
Gq/11 plays a role in the GCG stimulated pERK1/2 response in CHO-K1 cells 
stably expressing GCGR (Section 4.4.5). In combination with experiments 
using knockout cell lines, it was concluded that the GCG stimulated pERK1/2 
response is via a combination of Gq/11 and β-arrestin1/2 mediated pathways 
(Section 4.4.6). The findings presented here for the TM4 mutant may be in 
line with this conclusion where the pERK1/2 response determined for the TM4 
triple mutant may be attributed to a β-arrestin1/2 mediated pathway. An 
interesting follow up experiment would be to investigate the pERK1/2 
response in the Δβ-arrestin1/2 knockout cell transfected with the TM4 mutant.  
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Chapter 6.  General Discussion and Further Work 
 
 
6.1.  General Discussion 
 
The GCGR is abundantly expressed in the liver, the major site of GCG action 
(Taborsky, 2010), the kidneys and to a lesser extent in other organs such as 
the heart, endocrine pancreas (predominantly β–cells), spleen, 
gastrointestinal tract and brain (Habegger et al., 2010). Given this wide tissue 
distribution, it is not surprising GCG has a number of physiological effects 
beyond that of glucose homeostasis. Interestingly, a far more complex picture 
of the role GCG plays has emerged with this pancreatic hormone shown to 
also regulate lipid metabolism, stimulate energy expenditure and induce 
satiety, to name a few (Jones et al., 2012, Habegger et al., 2010, Day et al., 
2012). 
In the work presented here, we investigated GCGR signalling using 
multiple assays including those measuring cAMP accumulation, Ca2+i 
mobilisation and ERK1/2 activation. In addition, we identify several residues 
within various regions of GCGR required for signalling and receptor cell-
surface expression. These included the GCGR ICL1 region (G1651.63-
T1722.45), TM2 residue R1732.46, helix 8 residues E4068.49 and E4108.53 and 
three TM4 residues (G2714.49, L2774.55, V2804.58, previously suggested to 
form a homodimerisation interface in GLP-1R (Harikumar et al., 2012)). 
Consistent with previous reports (Weston et al., 2015), GCGR 
activation by GCG and oxyntomodulin resulted in increased cAMP levels in a 
number of cell lines (HEK 293, HEK 293T, CHO-K1 and Hep 3B cells). 
Interestingly, the potency of the measured response was shown to vary and 
depended on both cell type and chosen expression vector. This finding 
confirms that the absolute potency of an agonist at GPCRs is not only 
dependent on the affinity and intrinsic efficacy operating at the level of that 
particular receptor, but also on the properties of the assay system (Kenakin et 
al., 2012). With this in mind, variables including the chosen cell line, receptor 
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expression systems and assay sensitivity should be considered when 
interpreting such experimental data. 
An investigation into two potential GCGR antagonists in transfected 
HEK 293T cells revealed des-His1,[Glu9]-glucagon amide (des-His1,[Glu9]-
GCG), previously reported to act as an antagonist  (Unson et al., 1989) was a 
partial agonist at the GCGR. In contrast to previous findings (Cascieri et al., 
1999), L-168,049  was characterised as a potential competitive antagonist in 
transfected HEK 293T cells, although its yellow colour and possible 
autofluoresce may  limit its use in assays such as those based on TR-FRET. 
The characterisation of these potential GCGR antagonists was different when 
utilising Hep 3B cells, a model hepatocyte cell line, where GCGR was 
endogenously expressed. Here, des-His1,[Glu9]-GCG was characterised as a 
non-competitive antagonist and L-168,049 as a competitive antagonist. This 
discrepancy again highlights that conclusions are often dependent on the 
experimental system. In order to draw sound scientific conclusions, 
characterisation of novel ligands must be tested in multiple diverse systems.  
TH-GCG; a partial agonist of the GCGR-mediated cAMP response. 
Studies have highlighted the possibility that GCGR couples to alternative G 
proteins such as Gq/11 (Xu and Xie, 2009 and Wakelam et al., 1986). In line 
with these early reports, in addition to the classic Gs-coupled pathway, both 
GCG and oxyntomodulin were found to stimulate a Gq/11-mediated Ca2+i 
response at the GCGR. We also investigated the hypothesis that the GCG 
analogue TH-GCG, previously suggested to act at a receptor distinct from 
GCG and stimulating the production of inositol phosphates but not cAMP 
(Wakelam et al., 1986), may act as a biased agonist at the GCGR through Gq-
coupling. Contrary to previous findings (Wakelam et al., 1986, Lenzen et al., 
1990), TH-GCG was found to act as a partial agonist inducing a robust cAMP 
response, which was reduced in potency and maximal response when 
compared to GCG, in both HEK 293T cells transfected with GCGR and in 
hepatocytes freshly extracted from C57BL/6 mice. The LANCE® Ultra cAMP 
detection kit used in this study was likely to have superior sensitivity when 
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compared to the methods used for cAMP measurement in these early 
studies, offering an explanation for this discrepancy. TH-GCG failed to induce 
a detectable Ca2+i or IP1 response in GCGR expressing HEK 293T further 
contradicting the previous findings suggestion TH-GCG stimulation leads to 
inositol phospholipid breakdown (Wakelam et al., 1986, Lenzen et al., 1990). 
Assuming the correct synthesis of TH-GCG by Alta Biosciences, TH-GCG 
appears not to be a biased GCGR agonist and acts at the classical Gs-
coupled pathway. 
GCGR-mediated ERK1/2 activation. Although GCG is known to 
cause a rapid, concentration-dependent phosphorylation and activation of 
ERK1/2 (Jiang et al., 2001), extensive detail into the signalling pathways 
leading to this activation is lacking. This study provides an in-depth analysis 
of GCGR stimulated pERK1/2 activation through G protein and β-arrestin1/2 
mediated pathways (Figure 6.1). Contrary to previous findings suggesting a 
role for PKA in GCG induced ERK1/2 activation in β cells and HEK 293 cells 
(Dalle et al., 2004 and Jiang et al., 2001, respectively), treatment with the 
PKA specific inhibitor Rp-8-bromo-cAMP showed no effect on the measured 
pERK1/2 response to GCG or oxyntomodulin in GCGR stably expressing 
CHO-K1 cells. This finding suggested that the GCGR-mediated ERK1/2 
activation is independent of Gs stimulated pathway. Using the Gq/11 inhibition 
YM-254890 (Takasaki et al., 2004), the potency of the GCG stimulated 
pERK1/2 response was reduced and indicating a role for Gq/11 and thereby 
presumably Ca2+i, in the GCGR-mediated pERK1/2 response. Interestingly, 
the pERK1/2 response in GCGR transfected Gαq (ΔGαq and ΔGαs/q/12) 
knockout HEK 293 cells showed a reduction in maximum response and 
further supports this conclusion. These findings are consistent with reports 
that chelation of Ca2+i was found to reduce GCG-mediated ERK1/2 activation, 
suggesting an increase in Ca2+i is required for maximal ERK activation (Jiang 
et al., 2001, Li et al., 2006). The finding that the maximum pERK1/2 response 
to GCG was also reduced in β-arrestin1/2 knockout cells suggest that the 
GCGR-mediated pERK1/2 response is produced by a combination of Gq and 
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β-arrestin1/2 mediated pathways. Through the use of the specific Gβγ small 
molecule inhibitor gallein (Lehmann et al., 2008), this G protein-dependent 
pERK1/2 response was suggested to be independent of Gβγ-subunit. 
Interestingly however, at low concentrations of ligand (0.1 nM – 10 nM), it 
appears Gβγ inhibition causes an elevation in the basal pERK1/2 response. 
One speculation into the cause of this elevation could be the inability of the α-
subunit to re-bind the Gβγ and complete the G protein cycle, thereby 
remaining active and stimulating a single or multiple pathways leading to 
elevated basal pERK1/2.  
 
A pharmacological consequence of RAMP2-GCGR interaction. 
Similarly to other class B GPCRs, GCGR is reported to interact with RAMP2 
β-arrestin1/2 αs αq 
GCGR 
β γ 
 
+	PKA	inhibitor		 +	Gq	inhibitor		 +	Gβγ	inhibitor		 β-arres5n1/2	knockout		 
Emax	(%GCG) 
αq 
Gq	knockout		 
108.5	±6.4 
GCG 
96.2	±9.4	 
pEC50	é/	− − − − − 
114.5	±13.6	 
ê 
79.1	±13.7	 61.0	±14.8	 
ERK1/2	ac*va*on 
Figure 6.1. GCGR-mediated ERK1/2 activation. The work presented in this thesis 
suggest that the GCGR-mediated ERK1/2 activation following GCG stimulation is 
produced by a combination of Gq and β-arrestin1/2 mediated pathways. Treatment 
with the PKA inhibitor Rp-8-Br-cAMP or Gβγ inhibitor gallein showed no significant 
differences in ERK1/2 activation both in terms of maximum response (Emax 
expressed as a percentage GCG response) and pEC50 (-). Inhibition of Gq/11 through 
YM-254890 treatment showed a reduced GCG potency. Finally, utilising Gq/11 or β-
arrestin1/2 knockout cell lines transiently transfected with GCGR showed a reduced 
GCG stimulated maximal response when compared to WT.  
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(Christopoulos et al., 2003). We investigated the consequence of this 
potential RAMP2-GCGR interaction in HEK 293T cells and identified a 
RAMP2-dependent potentiation of the GCG stimulated cAMP response, 
which was independent of cell-surface expression. This finding was 
suggested to be as a result of RAMP2 increasing the ability of GCGR to 
transduce the signal following GCG stimulation, as determined by an increase 
in relative efficacy (logτ). This finding suggests that the RAMP2 expression 
profile, which is likely to vary between cell types and across time, may alter 
the activity of GCGR active ligands. Indeed, previous work has identified 
cross-reactivity of GLP-1R ligands, including GLP-1(7-36)amide and 
liraglutide at the GCGR, which was abolished by a RAMP2 interaction 
(Weston et al., 2014, Weston et al., 2015). This finding may have important 
implications in the design of GCGR targeted therapeutics. In addition, to gain 
a true picture of GCGR receptor signalling, and other class B GPCRs, it may 
be necessary to investigation the RAMP expression profile in the chosen 
cellular system. Interestingly, this finding could not be reproduced using a 
dual expression vector expressing both GCGR and RAMP2. However, 
investigation into the RAMP2 cell-surface expression suggested that RAMP2 
expression from MCS2 was reduced when GCGR was at MCS1. This latter 
finding highlighted that although in theory a 1:1 DNA ratio exists in a dual 
expression vector, this does not necessarily translate to a 1:1 protein 
expression ratio and caution should be exercised when interpreting 
experimental data acquired from using such dual expression vectors. 
The importance of the ICL1 region in GPCR signalling. A number 
of studies looking at class B GPCRs have proposed critical roles for residues 
within ICL1 including G proteins-coupling (Mathi et al., 1997, Conner et al., 
2006 and Kleinau et al., 2010), protein folding and correct transport (Thomas 
et al., 2007). In this study, we investigated the importance of the ICL1 region 
(G1651.63-T1722.45) for both GCGR cell-surface expression and signalling. 
Cell-surface expression analysis indicated the importance of a number of 
ICL1 amino acids for successful translation and/or trafficking of GCGR 
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including G165A1.63, S167A12.48, K168A12.49 and L169A12.50, which all showed 
reduced cell-surface expression when compared to WT. C1712.44 was 
implicated as a critical determinant of GCGR expression given the complete 
lack of cell-surface expression and detectable GFP. This finding was in line 
with the previous report implicating this conserved residue as a critical 
determinant of cell-surface translocation and function of the PTH1R (Thomas 
et al., 2007). An investigation into GCGR-mediated accumulation/activation of 
downstream signalling components following GCG stimulation showed 
negligible difference between WT and mutant GCGR for cAMP or pERK1/2 
responses, with the exception of C171A, which showed no detectable 
response, and G165A1.63, which showed a reduced maximal cAMP response. 
The latter finding may implicate a role for G1651.63 in the GCGR-mediated 
cAMP response, possibly through interaction with Gs protein. The mutants 
K168A12.49, L169A12.50, H170A12.51 and T172A2.45 (i.e. the residues towards 
TM2) showed a reduction in maximal Ca2+i response to GCG and, although 
the mechanism remains unclear, suggest these residues may play a role in 
signalling bias at the GCGR through Gq/11-coupling. 
The highly conserved nature of ICL1 within GPCRs, both in terms of 
length and amino acid sequence, and the availability of multiple crystal 
structures for the class A GPCR A2AR led to an similar investigation into the 
importance of ICL1 region (L331.59-N422.40) for cAMP signalling. Interestingly, 
a number of residues were identified to play a critical role in the measured 
cAMP accumulation. The ICL1 region of A2AR was found to play a bigger role 
in the cAMP response when compared to that of GCGR, highlighting a 
potential difference between GPCR classes A and B. The potency of both 
NECA and CGS 21680 was reduced in N34A1.60. Although this finding may be 
a consequence of reduced cell-surface expression, modelling of the mutant 
showed lost interactions with conserved helix 8 residues T2988.53 and 
E2948.49. This may suggest the importance of ICL1 and helix 8 interactions 
within A2AR, and potentially other GPCRs, for activation and/or signal 
transduction. Alanine substitution of L3712.50 resulted in a significantly reduced 
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potency to NECA but not CGS 21680, possibly indicating a role for L3712.50 in 
signalling bias at the A2AR. Alanine substitution of T412.39 increases the level 
of constitutive activity at the A2AR, possibly due to the loss of hydrogen bonds 
with residues implicated in the ionic lock of the A2AR including D1013.49 and 
R1023.50 of the E/DRY motif and Y11234.53 in ICL2 (Martínez-Archundia and 
Correa-Basurto, 2014). This latter finding is consistent with a number of 
reports showing an induced constitutive activity following mutations within the 
E/DRY motif of number of GPCRs including β2AR, rhodopsin receptor and 
oxytocin receptor (OTR) (Rovati et al., 2007).  
The equivalent position for A2AR T412.39 within GCGR is R1732.46, a 
highly conserved arginine across class B GPCRs. In line with a previous 
finding reported for the GLP-1R (Mathi et al., 1997), mutation of R1732.46 to 
alanine was found to have no influence on cell-surface expression whereas 
there was severely attenuated ligand stimulated cAMP accumulation. 
Modelling of this mutant revealed a lost interaction between R173A2.46 and 
helix 8 residues E4068.49 and may implicate this interaction as critical for 
GCGR stabilisation. Alternatively, or in addition, R1732.46 may be essential for 
G protein-coupling. This latter explanation seems highly feasible given this 
residue has been suggested to contact G protein in a number of GPCR 
structures (Rasmussen et al., 2011 and Zhang et al., 2017b) and within the 
modelled CGRP receptor (Vohra et al., 2013). To add further weight to this 
conclusion, modelling of R176A2.46 within the cryo-EM structure of activated 
rabbit GLP-1R in complex with heterotrimeric Gs reveals a lost interaction 
between and Q390 of Gαs α5-helix (Zhang et al., 2017b) and is likely to be the 
case for GCGR. 
Within GCGR this residue appears to be involved in activation and/or 
G protein-coupling rather than maintaining the receptor in an inactive 
conformation as was reported for the A2AR. In conclusion, the findings 
presented here suggest that the ICL1 region of GCGR or A2AR play very 
different role in receptor activity. 
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The importance of conserved helix 8 residues for GPCR function. 
There is suggested to be striking topological similarity between class A and B 
GPCRs helix 8 (Conner et al., 2008) and this region has been implicated in a 
range of functions including cell-surface expression (Timossi et al., 2004, 
Liang et al., 2017) and G protein-coupling (Delos Santos et al., 2006, Kleinau 
et al., 2010). In this study, a number of residues implicated to be important in 
receptor activity were found to interact with helix 8, particularly the fully 
conserved residue E8.49 which has been implicated in the TM2-6-7-helix 8 
network (involved in maintaining an inactive conformation) and G protein-
coupling (Liang et al., 2017). These residues included R1732.46, shown to 
interact with helix 8 residues E4068.49 (Siu et al., 2013 and Zhang et al., 
2017), and N341.60 of A2AR, shown to interact with helix 8 residue E2948.49 (Liu 
et al., 2012, Lebon et al., 2011, Lebon et al., 2015 Carpenter et al., 2016). 
Mutation of either of these residues within GCGR (R1732.46) or A2AR (N341.60) 
resulted in an attenuated ligand-dependent cAMP response.  
Interestingly, the equivalent positions for the helix 8 A2AR residues 
T2988.53 and E2948.49 are E4068.49 and E4108.53 within GCGR and may 
highlight a conserved interaction between helix 8 and the ICL1 region across 
GPCR classes. Consistent with previous findings in rat GCGR (Strudwick et 
al., 2004), and despite a reduced cell-surface expression, mutation of 
E4068.49 to alanine resulted in enhanced potency to both GCG and 
oxyntomodulin stimulation and a statistically significant constitutive activity, 
which was further enhanced by mutation of E410. It may be speculated that 
mutation of both E4068.49 and E4108.53 (which may substitute or contribute to 
the lost interaction with R1732.46 in E406A8.49) releases R1732.46, which in turn 
interact with the G protein independent of ligand. This finding is distinct from 
previous reports in GLP-1R suggesting mutation of the equivalent residue 
(E4088.49) reduce cAMP signalling (Wootten et al., 2016). Visualisation of the 
cryo-EM structure of activated rabbit GLP-1R in complex with heterotrimeric 
Gs reveals helix 8 residue E4088.49 to interact with Q390 of Gαs α5-helix with 
no apparent interaction with R1762.46 (Zhang et al., 2017b). Interestingly, 
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modelling of E408A8.49 within the GLP-1R structure reveals a lost interaction 
with Q390 of Gαs α5-helix. Therefore, whereas E8.49 within GLP-1R may be 
involved in selective coupling to cAMP signalling through G protein coupling, 
GCGR appears to be involved in maintaining the receptor in an inactive 
conformation.  
We investigated the consequence of converting the S16712.46 within 
GCGR to arginine, effectively making the ICL1 sequence (SKLH) closer to the 
consensus [K/R]KLH motif (Vohra et al., 2013). In a model of the CLR, the 
equivalent residue (K16712.48) was suggested to interact with the Gβ and 
possibly with the E8.49 (Vohra et al., 2013). Interestingly, within the modelled 
S167R12.46 GCGR mutant, there was a gained interaction with E4108.53 rather 
than E4068.49. Given the previous presented findings, a gained interaction 
between helix 8 and ICL1 would be predicted to move the receptor to a more 
inactive conformation. However, contradictory to this prediction, there 
appeared to be enhanced GCGR activity with a lost interaction with helix 8 
(as shown in E406A8.49 and E406A8.49, E410A8.53) and a small none significant 
increase in potency for both GCG and oxyntomodulin. 
GCGR TM4 residues; critical for cell-surface expression and Ca2+i 
response. Consistent with previous findings reported in GLP-1R (Harikumar 
et al., 2012), three substitution mutations within the TM4 region of GCGR 
(G2714.49, L2774.55, V2804.58) were found to selectively influence signalling 
whereby there was a complete abolishment of the Ca2+i response with only a 
small effect on cAMP accumulation and no measurable effect on the pERK1/2 
response. Whereas these mutants were reported to have no influence on 
GLP-1R cell-surface expression (Harikumar et al., 2012), we reported a 
significant reduced expression for the TM4 GCGR mutants. These findings 
suggested that this TM4 region plays an important role in successful 
translation and/or trafficking of GCGR and potentially the control of signal bias 
via altering the coupling efficiency of this receptor to a number of GCGR-
mediated pathways. Given that the lipid face of TM4 has been implicated to 
be the predominant determinant for dimerisation in a number of GPCRs 
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(Harikumar et al., 2007, Harikumar et al., 2012, Xue et al., 2015, Harikumar et 
al., 2017), it may be speculated that the abolished Ca2+i mobilisation is a 
consequence of a lost ability for GCGR to form dimers.  However, in order to 
investigate this hypothesis, dimerisation experiments would need to be 
conducted. 
Hep 3B cells; a troublesome model hepatocyte cell line. In this 
study, a number of cell lines were used which stably or transiently expressing 
the receptor of interest. As has been highlighted, the background of a cell 
type and variation between cell batches can contribute greatly to the 
experimental observations (Tilakaratne et al., 2000). With the intention to 
move into a more physiologically relevant cell line to investigation GCGR 
signalling, Hep 3B cells were characterised. These cells were demonstrated 
to endogenously express GCGR, however, the lost GCGR expression over 
passage, data variability and time constraint on ligand stimulated 
responsiveness indicated that these cells may not be the best model to 
investigate GCGR signalling.  
Concluding remarks. In this thesis, an in-depth analysis of GCGR 
signalling was conducted contributing knowledge to how this receptor 
functions in terms signalling cascades and at a structural level where a 
number of residues were implicated as important in receptor function and cell-
surface expression. The primary aim of this thesis was to expand on the 
current available knowledge on GCGR at a mechanistic, rather than 
physiological level. Evidence has suggested that GCG administration at low 
concentrations may play a role in normalising obesity-associated glucose 
intolerance, insulin resistance and dyslipidemia (Day et al., 2012, Pocai et al., 
2009). However, the risk of hyperglycemia imposed by GCG administration 
has prevented further studies in humans (Day et al., 2012) and current GCG-
based therapy is limited to acute emergency treatment of hypoglycemia in 
patients with type 1 diabetes (T1D) (Habegger et al., 2010). Alternatively, 
antagonism of GCG action may also provide a therapeutic approach to 
normalise blood glucose levels (Lotfy et al., 2014). A novel approach was 
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recently reported using a fully human antibody fused to GCG, blocking ligand 
binding, and was found to normalise blood glucose without causing 
hypoglycaemia (Okamoto et al., 2015). This study and others offering new 
insight into GCGR signalling provide the basis for advances in such 
therapeutic development.  
 
 
6.2.  Further Work 
 
In order to investigate if the abolished Ca2+i response in the GCGR TM4 
mutant is indeed a consequence of a disrupted dimerisation interface, as 
previously suggested (Harikumar et al., 2012), dimerisation experiments 
would need to be conducted. A variety of approaches exist for the exploration 
of dimerisation, including fluorescent-based methods such as FRET and 
bioluminescence resonance energy transfer (BRET) (Goddard and Watts, 
2012), co-immmunoprecipitation and functional complementation assays 
(Guo et al., 2017, Milligan and Bouvier, 2005). Although each approach has 
limitations that make the interpretation inconclusive (Guo et al., 2017), a 
combination of multiple approaches may provide a more convincing body of 
evidence in support of a potential dimerisation of GCGR and the importance 
of TM4.  
This study provides an in-depth analysis of the GCGR-mediated 
pERK1/2 response and suggests a role for both Gq and β-arrestin1/2-
mediated pathways. Interestingly, the finding that TM4 mutant GCGR showed 
a similar pERK1/2 response to WT GCGR despite an abolished Ca2+i 
response further supports this conclusion and suggests that a β-arrestin1/2-
mediated pathway may compensate for the loss of the Gq-mediated 
pathways. In order to test this hypothesis, an interesting follow up experiment 
would be to investigate the pERK1/2 response in the Δβ-arrestin1/2 knockout 
cell transfected with the TM4 mutant GCGR. In addition, it would be 
interesting to investigate if the measured pERK1/2 response in Δβ-arrestin1/2 
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HEK 293T cells transfected with GCGR could be abolished or further reduced 
by the treatment of YM-254890, thereby confirming the Gq-mediated pERK1/2 
response.  
Although not the primary aim of this work, a number of residues within 
the ICL1 region of A2AR were found to play a significant role in the NECA or 
CGS 21680 simulated cAMP response (including N34A1.60 and 37A12.50, 
which showed a reduced potency) and constitutive activity of A2AR (T41A2.39). 
This was distinct from the ICL1 region of GCGR where only one substitution 
showed a reduced cAMP accumulation following GCG stimulation (G1651.63). 
However, as was conducted for the ICL1 mutant GCGRs, an analysis of WT 
and mutant A2AR cell-surface expression must be conducted in order to 
confirm these findings are not a consequence of reduced cell-surface 
expression. Given that L3712.50 appears to play a more significant role in the 
NECA stimulated cAMP response when compared to the CGS 21680, this 
finding may indicate a role for L3712.50 in signalling bias at the A2AR. To further 
investigate this, alternative agonists for the A2AR, such as UK-432097 and 
adenosine, could be tested. In addition, given that A2AR has been reported to 
activate ERK1/2 signalling (Schulte and Fredholm, 2000, Orr et al., 2015), 
further analysis could include an investigation into the effect of these mutants 
on the pERK1/2 response to determine if this region is important in selective 
signalling.  
To expand on the findings investigating the importance of various 
GCGR residues, radioligand binding experiments should be conducted. For 
the GCGR ICL1 region, the oxyntomodulin stimulated cAMP, pERK1/2 and 
Ca2+i response could also be measured to determine if there are ligand-
dependent differences between the responses. In addition, the influence of 
helix 8 mutants on alternative signalling such as pERK1/2 and Ca2+i could 
also be investigated to indicate if this region is involved in signalling 
specificity.  
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